Drug Expenditure in Canada 1985 to 2006

National Health Expenditure Database



Canadian Institute for Health Information

Institut canadien d'information sur la santé The contents of this publication may be reproduced in whole or in part, provided the intended use is for non-commercial purposes and full acknowledgement is given to the Canadian Institute for Health Information.

Canadian Institute for Health Information 495 Richmond Road Suite 600 Ottawa, Ontario K2A 4H6

Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca

ISBN 978-1-55465-008-8 (PDF)

© 2007 Canadian Institute for Health Information

How to cite this document: Canadian Institute for Health Information, *Drug Expenditure in Canada, 1985 to 2006* (Ottawa: CIHI, 2007).

Cette publication est disponible en français sous le titre Dépenses en médicaments au Canada, de 1985 à 2006 ISBN 978-1-55465-010-1 (PDF)

Drug Expenditure in Canada, 1985 to 2006

Table of Contents

Executive Summary	i
Introduction	. 1
National Drug Expenditure Overview	. 3
The Share of Drugs in Total Health Expenditure	. 3
Total Drug Expenditure	
Total Drug Expenditure per Capita	. 6
Drug Expenditure: Prescribed and Non-prescribed Drugs	. 7
Prescribed Drug Expenditure by Source of Finance	. 8
Drug Expenditure in the Provinces and Territories	15
The Share of Drugs in Total Health Expenditure	16
Total Drug Expenditure by Source of Finance	17
Total Drug Expenditure per Capita by Source of Finance	18
Drug Expenditure by Type of Drug and by Source of Finance	19
International Comparisons	29
Comparability of Health Expenditure Across Countries	29
Share of Drugs in Total Health Expenditure	30
Share of Public Expenditure in Total Expenditure on Drugs	32
Share of Drugs in Public Expenditure on Health	34
Factors Affecting Drug Expenditure in Canada	37
Methodological Notes	43
Background	43
Data Limitations	47
Collection and Non-Response	49
Sources of Data	57
Series A-Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2006	59
Series B-Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2006	65
Series C-International Comparisons 1	19
Appendix – Comparison of Provincial and Territorial Drug Subsidy Programs	-1

Drug Expenditure in Canada, 1985 to 2006

List of Figures

Figure 1	Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2006
Figure 2	Annual Growth Rate for Total Drug Expenditure, Total Health Expenditure and Consumer Price Index (CPI), Canada, 1985 to 2006
Figure 3	Total Health Expenditure by Use of Funds, Canada, 2006 4
Figure 4	Total Drug Expenditure, Canada, 1985 to 20065
Figure 5	Total Drug Expenditure per Capita, Current and Constant Dollars, Canada, 1985 to 2006
Figure 6	Total Drug Expenditure by Type, Canada, 1985 to 2006
Figure 7	Total Drug Expenditure by Source of Finance and Type, Canada, 20049
Figure 8	Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2006
Figure 9	Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2006 10
Figure 10	Prescribed Drug Expenditure by Private-Sector Source of Finance, Canada, 1988 to 2006
Figure 11	Drug Expenditure as a Percentage of Total Health Expenditure, by Province/Territory and Canada, 1985 and 2006
Figure 12	Percentage of Total Drug Expenditure by Source of Finance, by Province/Territory and Canada 200617
Figure 13	Total Drug Expenditure per Capita by Source of Finance, by Province/Territory and Canada, 2006
Figure 14	Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure per Capita, by Province/Territory, 1985 to 2006
Figure 15	Annual Growth Rate for Prescribed Drug Expenditure, by Source of Finance, by Province/Territory, 1985 to 2006
Figure 16	Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2006
Figure 17	Drug Expenditure per Capita, Selected Countries, 1985 to 2004 31
Figure 18	Composition of Total Health Expenditure by Source of Finance
Figure 19	Patented Medicine Price Index, Consumer Price Index and Industrial Product Price Index, 1985 to 2006 (1987 = 100)

Drug Expenditure in Canada, 1985 to 2006

List of Text Tables

Table 1	Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2006	12
Table 2	Drug Expenditure Summary, by Province/Territory and Canada, 2006	15
Table 3	Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2004	31
Table 4	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2004	33
Table 5	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Reporting OECD Comparator Countries, 2004	35
Table 6	Factors That May Influence Drug Expenditure in Canada	40
Table 7	Provincial/Territorial Government Drug Expenditure Data	51
Table 8	Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2006	-2

Executive Summary

Total expenditure on drugsⁱ was \$21.8 billionⁱⁱ in 2004, and is forecast to have reached \$25.2 billion in 2006. The share of drugs in total health expenditure was 9.5% in 1985. It increased each year thereafter to reach 16.6% in 2004, and is forecast to have grown to 17.0% in 2006. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals. In 2006, drug expenditure is expected to have been the equivalent of over 57% of the amount spent on hospitals, and to have exceeded the amount spent on physicians' services.

At the national level, 2005 and 2006 forecast data indicate:

- The share of drugs in total health expenditure is forecast to have reached 17.0% in 2005 and to have remained at 17.0% in 2006.
- Total drug expenditure is forecast to have reached \$23.7 billion in 2005 and \$25.2 billion in 2006, representing annual increases of 8.7% and 6.0%, respectively.
- Total drug expenditure per capita in Canada is expected to have reached \$735 in 2005 and \$773 in 2006, representing annual rates of increase of 7.7% and 5.1%, respectively.
- Expenditure on prescribed drugs is expected to have reached \$19.7 billion in 2005 and \$21.1 billion in 2006, representing growth rates of 9.6% and 6.9%, respectively. Expenditure on non-prescribed drugs is forecast to have reached \$4.0 billion in 2005 and \$4.1 billion in 2006, representing increases of 4.4% and 2.0%, respectively.
- Public-sector expenditure on prescribed drugs is forecast to have reached \$9.2 billion in 2005 and \$9.6 billion in 2006 (Figure 7), representing annual growth rates of 9.5% and 4.7%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$10.6 billion in 2005 and \$11.5 billion in 2006, with corresponding annual growth rates of 9.7% and 8.7%.

At the provincial level, 2006 forecast data indicate:

- Total drug expenditure per capita is forecast to have ranged from \$684 in Prince Edward Island to \$811 in Ontario.
- The share of prescribed drugs in total drug expenditure is forecast to range from 81.6% in Alberta to 86.8% in Newfoundland and Labrador.
- The proportion of prescribed drugs financed by the public sector in 2006 varies across the provinces and is forecast to range from 36.5% in P.E.I. to 54.0% in Manitoba.

i. Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX) and are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups and appropriate taxes. Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs (over-the-counter drugs and personal health supplies). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

ii. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

At the international level, 2004 data among 17 Organisation for Economic Co-operation and Development (OECD) comparator countriesⁱⁱⁱ indicate:

- Canada had the third-highest level of total drug expenditure per capita after the United States and France.
- The public sector funded 37.8% of total drug expenditure in Canada. This was the fourth-lowest share ahead of Poland (36.5%), the U.S. (24.4%) and Mexico (11.6%). The share of public drug expenditure in total drug expenditure was highest in Luxembourg, at 83.7%.
- Drugs accounted for 9.6% of public-sector health expenditure in Canada. This was the fifth-lowest share ahead of Luxembourg (7.9%), Norway (6.8%), the U.S. (6.7%) and Mexico (5.2%). The share of drug expenditure in public-sector health expenditure was highest in Korea, at 25.5%.

Factors affecting drug expenditure:

 Numerous factors, many of which are interrelated, may influence drug expenditure. Since drug prices, as measured by several price indices, have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

iii. Comparator countries are Australia, Austria, Belgium, Canada, Denmark, France, Germany, Japan, Korea, Luxembourg, Mexico, Norway, Poland, Portugal, Spain, Switzerland and the United States.

Introduction

As the Romanow Commission pointed out, prescription drugs have fundamentally changed the face of health care in Canada.¹ The Commission stated that in the future, two key issues must be addressed: 1) Canadians must have access to the prescription drugs they need and 2) the integration of new prescription drugs must be accomplished in a safe and cost-effective manner.

Drug expenditure data in this report are primarily obtained from the National Health Expenditure Database (NHEX), maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1960. Drug expenditure data in NHEX are macrolevel data and do not allow for decomposition of prescription costs or drug classes.

The "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third-party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups and appropriate taxes. NHEX data do not include drug expenditure by non-Canadian residents (for example, Americans purchasing drugs via Canadian internet pharmacies). This classification system is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

Drug expenditure estimates within NHEX provide insight into total drug expenditure^{iv} by public and private payers and by type of drugs (prescribed and non-prescribed) at the provincial/territorial and national levels. All drug expenditure estimates stated in this report are in current dollars (unadjusted for inflation) unless otherwise stated.

Drug Expenditure in Canada, 1985 to 2006 is an annual publication and provides updated information on drug expenditure trends in Canada. This publication includes:

- National drug expenditure;
- Provincial and territorial drug expenditure;
- International comparisons; and
- Factors that may affect drug expenditure.

More information on drug expenditure and the methods used in the preparation of this document is available by contacting the Pharmaceuticals unit of CIHI by phone at 613-241-7860 or by email at drugs@cihi.ca.


iv. Total drug expenditure in this report includes expenditure on prescribed drugs and non-prescribed drugs. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as anti-perspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

National Drug Expenditure Overview

THE SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

■ Outlook—2005 and 2006


The share of drugs in total health expenditure is forecast to have reached 17.0% in 2005 and to have remained at 17.0% in 2006 (Figure 1).




■ Highlights—2004

Drugs have been one of the fastest-growing components of total health expenditure in Canada. From 1985 to 2004, total health spending grew at an average annual rate of 6.5%. During this period, expenditure on drugs increased at an average annual rate of 9.6% (Figure 2). In each of those years, the annual rate of growth for drugs exceeded the rate for total health expenditure.

Drug expenditure grew at an annual rate beyond what can be attributed to economy-wide inflation (as measured by the consumer price index or CPI) in every year between 1985 and 2004 (Figure 2). Total health expenditure grew at an annual rate above the rate of inflation in all years during this period with the exception of 1995 and 1996.





The NHEX provides an overview of all health spending in Canada, by spending category and source of funding. Total health expenditure comprises nine major spending categories. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals (Figure 3).


Total drug expenditure grew at a higher rate than total hospital expenditure every year between 1985 and 2004.² During this period, total drug expenditure grew at an average annual rate of 9.6%, while total hospital expenditure grew at an average annual rate of 4.8%.

See Data Table A.1.

TOTAL DRUG EXPENDITURE

■ Outlook—2005 and 2006

Total drug expenditure is forecast to have reached \$23.7 billion^v in 2005 and \$25.2 billion in 2006, representing annual increases of 8.7% and 6.0%, respectively.



v. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

■ Highlights—2004


Canada's total drug expenditure increased steadily from \$3.8 billion in 1985 to \$21.8 billion in 2004 (Figure 4). The average annual rate of growth during this period was 9.6%. Over the period 1985 to 1992, expenditure grew at an average annual rate of 12.2%. Between 1992 and 1997, annual growth rates decreased to an average of 6.0%. Drug expenditure increased by an average annual growth rate of 9.7% between 1997 and 2004, to reach \$21.8 billion.

See Data Table A.1.

TOTAL DRUG EXPENDITURE PER CAPITA

Outlook—2005 and 2006

Total drug expenditure per capita in Canada is expected to have reached \$735 in 2005 and \$773 in 2006, representing annual rates of increase of 7.7% and 5.1%, respectively.



■ Highlights—2004

Per capita drug expenditure trends are similar to those of total drug spending, reflecting a 1.1% average annual rate of growth in the overall population in Canada from 1985 to 2004. Total drug expenditure increased from \$147 per capita in 1985 to \$683 in 2004 (Figure 5). The average annual growth rate during this period was 8.4%.

Typically, expenditure is deflated by a price index to measure change in quantity. There is no authoritative composite price index for all drugs sold in Canada.^{vi} However, measuring drug expenditure in constant dollars (adjusted for inflation), using the CPI^{vii} reported by Statistics Canada, gives a sense of change in drug expenditure in the context of economywide inflation. Readers should cautiously interpret inflation-adjusted trends in expenditure, since drug-specific inflation may differ from that depending upon the broad basket of goods and services purchased by Canadians.

In terms of constant (1985) dollars, per capita drug expenditure increased from \$147 in 1985 to \$411 in 2004, reflecting an average annual growth rate of 5.6% during this period. Trends in per capita drug expenditure measured in constant dollars are similar to those of per capita drug expenditure measured in current dollars, though growth between 1985 and 2004 is less pronounced when it is considered relative to economy-wide inflation (Figure 5).

See Data Table A.2.

DRUG EXPENDITURE: PRESCRIBED AND NON-PRESCRIBED DRUGS

■ Outlook—2005 and 2006

Expenditure on prescribed drugs^{viii} is expected to have reached \$19.7 billion in 2005 and \$21.1 billion in 2006, representing growth rates of 9.6% and 6.9%, respectively. Expenditure on non-prescribed drugs is forecast to have reached \$4.0 billion in 2005 and \$4.1 billion in 2006, representing increases of 4.4% and 2.0%, respectively.

Non-prescribed drugs, which are typically financed out-of-pocket by consumers (households), include over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as anti-perspirants, dental floss and disposable diabetic syringes).^{ix} Since the NHEX consists of macro-level health expenditure data, some over-the-counter drugs and personal health supplies that are covered under some drug benefit plans^x may be counted as prescribed drug expenditure.

Prescribed drugs are expected to have accounted for 83.2% of total drug expenditure in Canada in 2005 and 83.8% in 2006. Conversely, the share of non-prescribed drugs in total drug expenditure is expected to have decreased to 16.8% in 2005 and 16.2% in 2006.


vi. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

vii. A measure of the average percentage change over time in the cost of a fixed basket of goods and services purchased by Canadian consumers.

viii. A prescribed drug is a substance considered to be a drug under the *Food and Drugs Act*, and which is sold for human use as the result of a prescription from a health professional.

ix. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

x. For example, diabetic test strips, where covered under drug benefit plans, may be included in prescribed drug expenditure, subject to source of data.



Highlights—2004

From 1985 to 2004, expenditure on prescribed drugs grew from \$2.6 billion to \$18.0 billion, at an average annual rate of 10.8%. Spending on non-prescribed drugs increased from \$1.2 billion to \$3.8 billion, at an average of 6.1% per year. During this period, with the exception of 1987 and 1994, annual growth in drug spending was higher in prescribed drugs than in non-prescribed drugs. As a result, prescribed drugs captured a larger share of total drug spending, rising from 67.5% in 1985 to 82.5% in 2004 (Figure 6).


Non-prescribed drug expenditure represented 17.5% of total drug expenditure in 2004. Over-the-counter drugs accounted for \$2.0 billion or 9.4% of total drug expenditure, and personal health supplies accounted for \$1.8 billion or 8.1% of the total.

See Data Table A.1.

PRESCRIBED DRUG EXPENDITURE BY SOURCE OF FINANCE

While non-prescribed drugs are typically financed out-of-pocket by consumers (households), multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial and federal drug subsidy programs and social security funds (such as workers' compensation boards or WCBs). In the private sector, they include private insurers and households.


For example, in 2006, \$9.6 billion in prescribed drugs are expected to have been financed by the public sector, and expenditure by the private sector is for both prescribed drugs (\$11.5 billion) and non-prescribed drugs (\$4.1 billion). In the private sector, prescribed drugs are expected to have been financed by private insurers (\$7.6 billion) and Canadian households (\$3.9 billion). Non-prescribed drugs are composed of over-the-counter drugs (\$2.2 billion) and personal health supplies (\$1.9 billion) (Figure 7).



■ Outlook—2005 and 2006


Public-sector expenditure on prescribed drugs is forecast to have reached \$9.2 billion in 2005 and \$9.6 billion in 2006 (Figure 8), representing annual growth rates of 9.5% and 4.7%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$10.6 billion in 2005 and \$11.5 billion in 2006, with corresponding annual growth rates of 9.7% and 8.7%.

The share of prescribed drug expenditure financed by the public sector is forecast to have dropped from 46.6% in 2004 to 46.5% in 2005, the first drop since 1997. It is forecast to have dropped again, to 45.6%, in 2006.



■ Highlights—2004

The intersections of the two series depicted in Figure 9 (excluding forecasts for 2005 and 2006) identify three distinct periods of growth in publicly and privately financed prescribed drug expenditure.



Between 1985 and 1992, expenditure on prescribed drugs in the public sector grew by an annual average rate of 14.6%, while this rate was 12.0% for prescribed drug expenditure financed by the private sector. Consequently, the share of prescribed drugs financed from public sources increased from 43.6% in 1985 to 47.7% in 1992.

From 1992 to 1997, spending on prescribed drugs by the private sector grew at an average annual rate of 9.1%, more than twice the 4.4% average annual rate of growth in publicly financed prescribed drug expenditure. Fiscal restraint introduced in several provinces led to negative growth in publicly financed prescribed drug expenditure in 1996. By 1997, the share of prescribed drugs financed from public sources had declined to 42.2%, below its share in 1985 (43.6%).

Between 1997 and 2004, expenditure on prescribed drugs by the public sector grew at an average annual rate of 12.8%, compared to 10.0% in the private sector. The share of prescribed drug expenditure financed by the public sector reached 46.6% in 2004.

See data tables A.1 and A.2.

Two levels of government—provincial/territorial and federal—as well as social security funds, such as workers' compensation boards and the Quebec Fonds de l'assurance-médicaments (drug insurance fund), finance spending on prescribed drugs by the public sector. Private-sector expenditure on prescribed drugs is financed by two sources: private insurers and households (out-of-pocket). Table 1 shows the distribution of prescribed drug expenditure by these sources of finance.

	1988		2006 ^f	
	(\$' millions)	(%)	(\$' millions)	(%)
Provincial/Territorial				
Governments	1,592.7	42.6	8,100.3	38.4
Federal Direct	89.3	2.4	670.6	3.2
Social Security Funds:				
Workers' Compensation Boards	20.8	0.6	147.5	0.7
Quebec Drug Insurance Fund*	N/A	N/A	700.2	3.3
Sub-total Public Sources	1,702.8	45.6	9,618.6	45.6
Private Insurers	1,130.3	30.2	7,558.3	35.8
Household (out-of-pocket)	903.7	24.2	3,913.5	18.6
Sub-total Private Sources	2,034.0	54.4	11,471.8	54.4
Total All Sources	3,736.8	100.0	21,090.3	100.0

Table 1–Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2006^{f}

* Data not available prior to January 1, 1997, when the program was first introduced in Quebec. f: Forecast

Source: Canadian Institute for Health Information.


Provincial/territorial government expenditure on prescribed drugs was almost \$1.6 billion in 1988, accounting for 42.6% of total expenditure on prescribed drugs. By 2006, provincial/ territorial government expenditure is forecast to have grown to over \$8.1 billion, while its share of total expenditure on prescribed drugs is expected to have diminished to 38.4%.

All provinces/territories provide some form of prescribed drug coverage to seniors and social assistance recipients (see the Appendix for an overview of provincial and territorial drug subsidy programs).

Federal direct expenditure was \$89.3 million in 1988, equivalent to 2.4% of total expenditure on prescribed drugs. Federal direct expenditure is forecast to have increased to \$670.6 million in 2006, representing 3.2% of total expenditure on prescribed drugs. The federal government provides drug benefits to Aboriginal Canadians (as of the end of March 2005, 764,523 Aboriginal Canadians had drug coverage through the Non-Insured Health Benefits Program of Health Canada³), veterans, members of the military and the RCMP, prisoners in federal correctional facilities and refugees.

Expenditure by social security funds was \$20.8 million in 1988, equivalent to 0.6% of total prescribed drug expenditure. In 2006, expenditure by social security funds is forecast to have reached \$847.7 million and have accounted for 4.0% of total expenditure on prescribed drugs. Social security funds figures have largely represented spending by the Quebec drug insurance fund since its institution in 1997. Quebec residents not otherwise covered by the provincial program or by private health insurance are insured by the Fund through the compulsory payment of premiums.

Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.



Expenditure on prescribed drugs by private insurers amounted to over \$1.1 billion in 1988, or 30.2% of prescribed drug expenditure. Private insurers' spending increased to over \$7.6 billion in 2006 and its share of prescribed drug expenditure increased to 35.8%. Private insurers include group and individual insurance. Many employers offer group benefit plans covering prescribed drugs for employees and their families. In some cases, individuals will continue to be covered by a group plan even after they retire.

Out-of-pocket spending by households was an estimated \$0.9 billion in 1988, representing 24.2% of total expenditure on prescribed drugs. By 2006, out-of-pocket prescribed drug expenditure is estimated to have risen to over \$3.9 billion, but its share of prescribed drug expenditure will have decreased to 18.6% (Figure 10).

See Data Table A.2.

Drug Expenditure in the Provinces and Territories

There is considerable variation in the level and growth of drug expenditure across the provinces and territories. These variations are influenced by several factors, including differences in provincial/territorial drug subsidy programs (see the Appendix for an overview of provincial and territorial drug subsidy programs), existence of private insurance coverage, age and sex distribution of provincial/territorial populations, the health needs of targeted populations and the manner in which health care is delivered (including the balance between institutional and ambulatory care).⁴ Other possible sources of variation in drug expenditure are described in the section "Factors Affecting Drug Expenditure in Canada."

Table 2 provides an overview of provincial/territorial drug expenditure forecast for 2006.

	Total Drug Exp.	Total Drug Exp. as a % of Total Health Exp.	Total Drug Exp. per Capita	Prescribed Drug Exp. per Capita	Prescribed Drug Exp. as a % of Total Drug Exp.	Public Prescribed Drug Exp. as a % of Prescribed Drug Exp.
	(\$' millions)	(%)	(\$)	(\$)	(%)	(%)
N.L.	374.9	16.5	727.74	631.34	86.8	41.5
P.E.I.	94.8	16.2	683.59	559.06	81.8	36.5
N.S.	748.5	17.4	796.64	659.88	82.8	40.9
N.B.	572.7	17.2	760.69	639.87	84.1	36.8
Que.	6,170.0	20.3	807.43	698.96	86.6	49.8
Ont.	10,286.7	17.0	811.13	674.86	83.2	43.2
Man.	816.5	14.1	690.13	578.19	83.8	54.0
Sask.	719.7	15.3	725.90	607.08	83.6	48.2
Alta.	2,343.4	14.4	711.19	580.15	81.6	49.9
B.C.	2,970.6	15.4	690.37	567.39	82.2	41.9
Υ.Τ.	20.5	9.9	659.26	519.11	78.7	66.4
N.W.T.	22.5	7.1	515.12	433.49	84.2	64.5
Nun.	14.5	4.7	479.13	397.47	83.0	64.3
Canada	25,155.4	17.0	772.89	647.99	83.8	45.6

Table 2_Drug Expenditure Summar	ry, by Province/Territory and Canada, 2006 ^f	
Table Z-Drug Experiorure Summar	Ty, by Province/Territory and Canada, 2000	

f: Forecast

Sources: Canadian Institute for Health Information, Statistics Canada.

In 2006, expenditure on drugs is forecast to have accounted for 17.0% of total health expenditure in Canada. Among the provinces and territories, the share of drugs in total health expenditure is expected to have ranged from 4.7% in Nunavut to 20.3% in Quebec.

Total drug expenditure per capita in Canada is expected to have been \$773 in 2006. Per capita spending on drugs in the provinces and territories is forecast to have ranged from \$479 by the residents of Nunavut to \$811 by the residents of Ontario.


Prescribed drugs are predicted to have accounted for 83.8% of total expenditure on drugs in Canada in 2006. Among the provinces and territories, the share of prescribed drugs in total drug expenditure is forecast to have ranged from 78.7% in the Yukon Territory to 86.8% in Newfoundland and Labrador.

In 2006, the proportion of prescribed drugs in Canada financed by the public sector is expected to have reached 45.6%. It is forecast that the Yukon had the highest proportion, at 66.4%, and P.E.I. had the lowest, at 36.5%.

THE SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

The share of drugs in total health expenditure is forecast to have been higher in 2006 than in 1985 in all provinces and territories except P.E.I., and the Northwest Territories and Nunavut (Figure 11).

It should be noted that in P.E.I., the share of drug expenditure in total health expenditure is expected to have grown between 1986 and 2006.




In 1985, expenditure on drugs accounted for 9.5% of total health expenditure in Canada. Newfoundland and Labrador, P.E.I., Nova Scotia, New Brunswick and Ontario exceeded the national average. P.E.I. had the highest share, at 18.0%, followed closely by Newfoundland and Labrador, at 16.3%, while among the other provinces and territories, shares ranged from 7.1% in the Northwest Territories and Nunavut to 12.0% in Nova Scotia and New Brunswick.

In 2006, Nova Scotia, New Brunswick, Quebec and Ontario are forecast to have had drug expenditure as a percentage of total health expenditure above the Canadian average (17.0%), with Quebec having the highest share at 20.3%. Newfoundland and Labrador, P.E.I., and the western provinces (Manitoba, Saskatchewan, Alberta and British Columbia) are expected to have been below the Canadian average, with Manitoba having the lowest share at 14.1%. The Yukon and the Northwest Territories and Nunavut are forecast to have had lower shares than the provinces, at 9.9% and 5.9%, respectively.

See data tables B.1.1 to B.13.1.


TOTAL DRUG EXPENDITURE BY SOURCE OF FINANCE


In 2006, Quebec, Manitoba, Saskatchewan, Alberta, the Yukon, the Northwest Territories and Nunavut are forecast to have had public shares of total drug expenditure that exceeded the national average (38.2%). The share of total drug expenditure funded by the public sector is expected to have ranged from 29.8% in P.E.I. to 54.2% in the Northwest Territories (Figure 12).



TOTAL DRUG EXPENDITURE PER CAPITA BY SOURCE OF FINANCE

In 2006, total drug expenditure per capita in Canada is forecast to have been \$773. Per capita drug spending financed by the public and private sectors amounted to \$296 and \$477, respectively (Figure 13).







Sources: Canadian Institute for Health Information, Statistics Canada.

In 2006, per capita spending on drugs by the public sector is forecast to have ranged from \$204 in P.E.I. to \$348 in Quebec. In the same year, it is expected that Quebec (\$348), Manitoba (\$312) and the Yukon (\$345) will have had publicly financed drug expenditure per capita above the Canadian average (\$296).

Drug expenditure per capita financed by the private sector is expected to have ranged from \$223 in Nunavut to \$527 in Nova Scotia. P.E.I. (\$480), Nova Scotia (\$527), New Brunswick (\$526) and Ontario (\$519) are forecast to have had privately financed drug expenditure per capita higher than the Canadian average (\$477).

It should be noted that, because the proportion of the population eligible for coverage by the public sector varies significantly across provinces and territories, public spending per capita by sector may or may not accurately reflect the amount spent per person eligible for coverage.

See data tables B.1.2 to B.13.2.


DRUG EXPENDITURE BY TYPE OF DRUG AND BY SOURCE OF FINANCE

Public- and Private-Sector Prescribed and Non-Prescribed Drug^{xi} Expenditure

Figure 14 illustrates provincial/territorial trends in public and private prescribed drug expenditure as well as private non-prescribed drug expenditure per capita from 1985 to 2004 and forecasts to 2006 (figures are not adjusted for inflation).

xi. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as anti-perspirants, dental floss and disposable diabetic syringes).
 For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

Figure 14—Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure per Capita, by Province/Territory, 1985 to 2006^f



f: Forecast

Sources: Canadian Institute for Health Information, Statistics Canada.




Figure 14 (cont')—Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Nx) Drug Expenditure per Capita, by Province/Territory, 1985 to 2006^f

f: Forecast

*On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Sources: Canadian Institute for Health Information, Statistics Canada.

Between 1985 and 2004, in all provinces and territories, the average annual rate of growth was higher in prescribed drug expenditure per capita (average annual growth rate ranged from 5.9% in P.E.I. to 10.7% in Quebec), than in non-prescribed drug expenditure per capita (average annual growth rate ranged from less than 0.4% in the Northwest Territories to 6.3% in Saskatchewan).

During the same period, three provinces/territories—Nova Scotia, Quebec and the Yukon experienced higher average annual growth rates for prescribed drug expenditure per capita than the Canadian average of 9.6%. Four provinces—Quebec, Ontario, Saskatchewan and Alberta—experienced higher average annual growth rates in non-prescribed drug spending per capita than the Canadian average of 4.9%.

Public- and Private-Sector Prescribed Drug Expenditure

Figure 15 illustrates provincial/territorial annual growth trends in public and private prescribed drug expenditure from 1985 to 2004, with forecasts to 2006.






Figure 15—Annual Growth Rate for Prescribed Drug Expenditure (Rx), by Source of Finance, by Province/Territory, 1985 to 2006^f

f: Forecast Source: Canadian Institute for Health Information.





*On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Source: Canadian Institute for Health Information.

f: Forecast

In the early- to mid-1990s, all provinces and territories in Canada initiated health system reforms and public expenditure restraints that affected nearly all categories of health spending. Between 1992 and 1997, each province and territory except Alberta experienced at least one year of decline in publicly financed prescribed drug expenditure.

The analysis of annual growth rates should be interpreted cautiously. Annual growth rates should be considered in the context of the level or magnitude of prescribed drug expenditure by source of finance (presented in the following section), as the understanding of the relationship between the two is necessary before interpreting the information. For instance, the level of drug expenditure in the last year of a reference period is affected by the initial level of drug expenditure and its annual growth rates over time.

Between 1985 and 2004, publicly financed prescribed drug expenditure grew at a higher average annual rate than privately financed prescribed drug expenditure in all provinces and territories except Nova Scotia, New Brunwsick, Saskatchetwan and B.C. During this period, average annual growth in public-sector prescribed drug spending ranged from 6.3% in Saskatchewan to 16.7% in the Yukon. Prescribed drug expenditure financed by the private sector grew at average annual rates ranging from 4.1% in Newfoundland and Labrador to 13.0% in Saskatchewan.

In 2006, public prescribed drug expenditure is expected to have grown in every province and territory except Ontario, where public prescribed drug expenditure is expected to have dropped by 0.4%. Nova Scotia will have experienced the highest growth rate, at 13.8%.

Public-Sector Prescribed Drug Expenditure

Figure 16 illustrates provincial/territorial trends in the share of publicly financed prescribed drug expenditure as a percentage of prescribed drug expenditure, from 1985 to 2004, with forecasts to 2006.




Figure 16—Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2006^f

f: Forecast

Source: Canadian Institute for Health Information.



Figure 16 (cont'd)—Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2006^f

f: Forecast

*On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. Source: Canadian Institute for Health Information.

Between 1985 and 2004, the share of prescribed drug expenditure financed by the public sector decreased in Nova Scotia, New Brunswick, Saskatchewan and B.C. During the same period, the share increased in the remaining provinces and territories, with increases ranging from less than four percentage points in Ontario to almost thirty-eight percentage points in the Yukon.

In 2006, the share of prescribed drug expenditure financed by the public sector in Canada is expected to have been 45.6%. This is forecast to have been exceeded by Quebec (49.8%), Manitoba (54.0%), Saskatchewan (48.2%), Alberta (49.9%), the Yukon (66.4%), the Northwest Territories (64.5%) and Nunavut (64.3%).

International Comparisons

COMPARABILITY OF HEALTH EXPENDITURE ACROSS COUNTRIES

In general, international comparisons should be interpreted with caution, as variation exists between countries with regard to reporting, inclusion and classification of health expenditure.

For the last six annual updates of the health database maintained by the OECD, member countries were asked to report health expenditure according to concepts presented in the OECD manual *A System of Health Accounts* (SHA), released in May 2000. Countries are at varying stages of reporting total health expenditure according to the boundary of health care proposed in the SHA manual. This means that data presented in *OECD Health Data 2006* are at varying levels of comparability.

This section shows health expenditure information for the 21 countries that most closely follow the health care boundary proposed in the OECD manual. The OECD states that the data for those countries are believed to be fairly comparable, although some deviations from SHA definitions may still exist among the sub-aggregate variables of total health expenditure. The 21 countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Japan, Korea, Luxembourg, Mexico, the Netherlands, Norway, Poland, Portugal, Spain, Switzerland, Turkey and the U.S.^{xii}

Level of income and institutional characteristics also cause differences in drug expenditure across countries. Drugs consumed in low- or middle-income countries often originate from more developed countries with high living standards and high labour costs. Consequently, the share of drugs in total health expenditure tends to be higher in low- or middle-income countries because of the high price of drugs relative to other health goods and services.⁵ Differences in service delivery across countries will also cause differences in the share of drugs in total health expenditure.

xii. The OECD does not provide health expenditure data by use of funds for the Czech Republic, Hungary, the Netherlands or Turkey from 2003 onward; therefore, these countries are excluded from this analysis.

SHARE OF DRUGS IN TOTAL HEALTH EXPENDITURE

The OECD maintains a comparative database on health-related statistics, including health expenditure. This database captures information on expenditure for pharmaceuticals and other medical non-durables outside an institutional setting (equivalent to drugs purchased in retail establishments in Canada). Pharmaceutical and other medical non-durables comprise prescribed drugs, over-the-counter drugs and a wide range of medical non-durables such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In 1985, drug expenditure in Canada represented 9.6%^{xiii} of total health expenditure. Korea had the largest share of drug expenditure in total health expenditure, at 32.7%, and Denmark had the lowest, at 6.6%. Canada ranked tenth among the 14 comparator countries for which data were available.^{xiv, xv}

By 2004, drug expenditure in Canada had increased its share in total health expenditure by over eight percentage points, to 17.7%. Canada ranked eighth in the share of drugs in total health expenditure. Luxembourg had the lowest share of drug expenditure in total health expenditure, at 8.5%, and Poland had the highest, at 29.6% (Table 3). Among the 17 comparator countries for which data were available, Canada ranked third in drug expenditure per capita, after the U.S. and France.

xiii. OECD data are standardized for international comparability; consequently, figures calculated from these data may differ from those calculated from the national health accounts of member countries. Specific to Canada, expenditure on health research and the training of health care workers is included in the national health accounts, but excluded from OECD health expenditure data.

xiv. The OECD did not provide data for Austria, Mexico or Poland in 1985.

xv. Of the comparator countries, only Canada, France and Korea conformed to SHA guidelines in 1985.


Country	GDP per Capita		Total Drug Expenditure per Capita		Total Health Ex per Capi		Total Drug Expenditure as a % of Total Health Expenditure		
	(CA\$, PPP)**	Rank	(CA\$, PPP)**	Rank	(CA\$, PPP)**	Rank	%	Rank	
Australia	40,716	5	500	11	3,900	8	12.8	11	
Austria	40,649	6	509	10	3,905	7	13.0	10	
Belgium *	39,226	9	427	13	3,775	10	11.3	13	
Canada	39,785	8	699	3	3,956	,956 5		8	
Denmark	40,380	7	338	15	3,601	3,601 11		16	
France	37,431	10	749	2	3,949	6	18.9	6	
Germany	36,020	12	536	6	3,804	9	14.1	9	
Japan*	36,959	11	527	8	2,789	12	18.9	6	
Korea	25,835	14	394	14	1,436	15	27.4	2	
Luxembourg	79,316	1	543	5	6,361	2	8.5	17	
Mexico	12,803	17	173	17	828	17	20.9	5	
Norway	50,894	2	469	12	4,958	4	9.5	15	
Poland	15,511	16	298	16	1,006	16	29.6	1	
Portugal	22,656	15	526	9	2,280	14	23.1	3	
Spain	32,344	13	596	4	2,618	13	22.8	4	
Switzerland	43,936	4	530	7	5,096	3	10.4	14	
United States	49,715	3	940	1	7,628	1	12.3	12	

Table 3—Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2004^{xvi}

* 2003 data, except GDP per capita, which is 2004.

** Converted to Canadian dollars using purchasing power parities (PPP) for GDP.

Source: OECD Health Data 2006, October 2006. Organisation for Economic Co-operation and Development and IRDES, Paris.



xvi. Canadian data reported by the OECD are as of October 2006. In December 2006, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2007.

Figure 17 illustrates the trends of drug expenditure per capita (CA\$, PPP)^{xvii} in five selected OECD comparator countries.^{xviii}

Between 1985 and 2004, per capita drug expenditure grew at a faster average annual rate in Canada (8.5%) than in France, Germany or Japan.^{xix} During this period, Germany experienced the lowest average annual growth rate in per capita drug expenditure (4.5%) and drug expenditure in the U.S. grew at the highest average annual rate (8.7%).

SHARE OF PUBLIC EXPENDITURE IN TOTAL EXPENDITURE ON DRUGS

The OECD database on health contains statistics on total expenditure on pharmaceutical goods and public expenditure on pharmaceutical goods. In Canada, drug expenditure by the public sector rose from 29.4% of total expenditure on pharmaceutical goods in 1985 to 37.8% in 2004.

In OECD countries, with the exception of those in North America, the entire population usually has coverage for prescribed drugs through public insurance. Most countries have formularies restricting the number of drugs covered under public insurance and impose cost sharing (deductibles, co-insurance or co-payments) with waivers for certain groups of beneficiaries.

Table 4 shows that among the 17 OECD comparator countries for which data were available in 2004, Canada ranked twelfth in public-sector drug expenditure per capita and fourteenth for share of public expenditure in total drug spending. The U.S. ranked thirteenth and sixteenth, respectively, in these two categories.

France had the highest level of public drug spending per capita (\$529) and Luxembourg had the highest public share of total drug spending (83.7%).

xvii. Although using purchasing power parity adjusted dollars (PPP\$), accounts for the relative change in inflation between countries' average annual growth rates should still be considered in the context of economy-wide inflation.

xviii. Comparator countries that are also G8 members.

xix. The OECD did not provide data for Japan in 2004.

	Public Drug Ex	penditure	Total Drug Ex	penditure	Public Drug Expenditure as a %			
Country	per Cap	ita	per Cap	ita	of Total Drug Expenditure			
	(CA\$, PPP)**	Rank	(CA\$, PPP)**	Rank	%	Rank		
Australia	280	11	500	11	56.1	11		
Austria	360	6	509	10	70.7	4		
Belgium*	331	8	427	13	77.4	2		
Canada	264	12	699	3	37.8	14		
Denmark	189	14	338	15	55.9	12		
France	529	1	749	2	70.6	5		
Germany	374	4	536	6	69.7	6		
Japan*	362	5	527	8	68.7	7		
Korea	189	14	394	14	48.0	13		
Luxembourg	455	2	543	5	83.7	1		
Mexico	20	17	173	17	11.6	17		
Norway	283	10	469	12	60.2	9		
Poland	109	16	298	16	36.5	15		
Portugal	309	9	526	9	58.6	10		
Spain	431	3	596	4	72.3	3		
Switzerland	356	7	530	7	67.2	8		
United States	229	13	940	1	24.4	16		

Table 4—Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2004^{xx}

* 2003 data

** Converted to Canadian dollars using purchasing power parities (PPP) for GDP

Source: OECD Health Data 2006, October 2006. Organisation for Economic Co-operation and Development and IRDES, Paris.

The high share of total drug expenditure financed by the public sector in some European countries (for example, Luxembourg, Belgium, Spain) reflects the inclusion of drug benefits provided through employment-related social security funds in publicly financed drug expenditure (see Data Table C.2.). These funds are social insurance programs covering the community as a whole or large sections of the community and are imposed or controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. In some European countries, expenditure by social security funds represents the major share of public expenditure on drugs (for example, 94.4% in Germany in 2001).⁶

xx. Canadian data reported by the OECD are as of October 2006. In December 2006, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2007.

By contrast, in Canada, until 1996, drug benefits under social security funds included only spending by WCBs and they represented less than 2% of public expenditure on drugs in retail establishments. Starting in 1997, they also included expenditure by the Quebec drug insurance fund. The share of social security funds in public expenditure on drugs in Canada increased from 6.0% in 1997 to 9.1% in 2004. The Quebec drug insurance fund, which is financed by the mandatory payment of premiums, covers residents not otherwise insured by the provincial program (for seniors, social assistance recipients, etc.) or by private health insurance generally offered through employment.

Group insurance plans offered by employers, unions and professional associations that resemble the European model do exist in Canada; however, since a government authority does not impose group health insurance in Canada, and policy-holders may voluntarily opt-out (except in Quebec), they are considered privately financed. Private health insurance, composed mainly of group insurance, accounted for 28.7% of total drug expenditure in retail establishments in Canada in 2004.

SHARE OF DRUGS IN PUBLIC EXPENDITURE ON HEALTH

In Canada, drugs accounted for only 3.8% of health expenditure by the public sector in 1985. This proportion increased to 9.6% in 2004, reflecting substantially higher growth in drug expenditure than in other types of public-sector health expenditure between 1985 and 2004. Among the comparator countries for which data were available^{xxi} in 1985, the share of drugs in public-sector health expenditure ranged from 2.1% in the U.S. to 30.1% in Portugal. In 2004, the share of drugs in public-sector health expenditure ranged from 5.2% in Mexico to 25.5% in Korea.

In 2004, the share of drug spending in public-sector health expenditure was lower than the share of drug spending in total health expenditure in each of the comparator countries except Austria, Belgium, Spain and Switzerland, reflecting generally higher cost sharing for drugs than for other health expenditure. In the case of Canada, the low share of drugs in total public expenditure on health (9.6% in 2004), when compared with the share of drugs in total health expenditure (17.7% in 2004), also reflects the absence of universal coverage of prescribed drugs by public insurance, while there exists universal and full coverage of medically necessary hospital and physician services.

xxi. The OECD did not provide data for Austria, Belgium, Mexico, Poland or Switzerland in 1985.

	Public Drug Exp		Public Health Ex		Public Drug Expenditure as a % of Public Health Expenditure		
Country	per Capi	ta	per Capi	ta			
	(CA\$, PPP)***	Rank	(CA\$, PPP)***	Rank	%	Rank	
Australia	280	11	2,634	10	10.6	11	
Austria	360	6	2,759	8	13.0	7	
Belgium*	331	8	2,685	9	12.3	9	
Canada	264	12	2,763	7	9.6	12	
Denmark**	189	14	N/A	N/A	N/A	N/A	
France	529	1	3,094	4	17.1	4	
Germany	374	4	2,926	6	12.8	8	
Japan*	362	5	2,272	11	15.9	5	
Korea	189	14	739	14	25.5	1	
Luxembourg	455	2	5,754	1	7.9	13	
Mexico	20	17	384	16	5.2	16	
Norway	283	10	4,139	2	6.8	14	
Poland	109	16	690	15	15.8	6	
Portugal	309	9	1,668	13	18.5	3	
Spain	431	3	1,855	12	23.3	2	
Switzerland	356	7	2,978	5	12.0	10	
United States	229	13	3,409	3	6.7	15	

Table 5—Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Reporting OECD Comparator Countries, 2004^{xxii}

* 2003 data

** OECD did not provide data on total health expenditure for Denmark from 2003 on.

*** Converted to Canadian dollars using purchasing power parities (PPP) for GDP.

Source: OECD Health Data 2006, October 2006. Organisation for Economic Co-operation and Development and IRDES, Paris.

xxii. Canadian data reported by the OECD are as of October 2006. In December 2006, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2007.

Factors Affecting Drug Expenditure in Canada

Numerous factors (see Table 6), many of which are interrelated, may influence drug expenditure. Since drug prices, as measured by several price indices,^{xxiii} have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

Although some literature exists on the effects of various factors on drug expenditure, more research is required to quantify the effect of each factor and to inform the relationship between drug expenditure and other health care spending.

The following review of some of the factors affecting drug expenditure is intended to facilitate discussion, and is not meant to be a systemic review of all relevant literature.

Cost-Related Factors

Although the ingredient prices of drugs, once on the market, are relatively stable, the introductory price and overall cost of drugs may be influenced by several factors. These factors include international pricing, inflation, changes in retail or wholesale mark-ups and other market forces. Market forces can be competitive forces (for example, the introduction of new products can increase drug expenditures while generics can decrease drug expenditure by offering a lower-priced alternative) or regulatory forces (for example, changes in price controls or extending patent legislation that prevents a less expensive alternative from coming to the market).

Quantity-Related Factors

There are many factors that can affect the quantity of drugs dispensed. The quantity can be a result of a change in the number of users or a change in the volume of drugs used.

Population-Related Factors

Population size affects the number of potential users in an area (for example, P.E.I. versus Ontario). Demographics such as age, gender and ethnic distribution, as well as changes in health status, also play a role in determining levels of drug expenditure. Changes in the health status of the population can be the result of the emergence of new diseases, epidemics and changes in the prevalence or severity of existing disease. Typically, healthier populations use fewer drugs.

xxiii. For more information on price indices, see the Data Limitations section of the Methodological Notes.

Health System–Related Factors

The health system also plays a role in drug expenditure. Changes in policies and programs, including regulations around drug plan eligibility and co-insurance; the extent of formulary listings; and the availability of and access to third-party insurance coverage can all affect drug spending.⁷ In general, the more accessible and more generous insurance coverage is, the less costly drugs are to the end consumer, and the more likely people are to consume drugs.

New Drugs

New drugs introduced to the market have an influence on drug expenditure. New drugs can result in switching between classes of drugs used to treat similar conditions (for example, switching from ranitidine to omeprazole for stomach ulcers), or switching between drugs within a class (for example, ibuprofen versus naproxen). Provided there is a difference in price, any switching will affect drug expenditure.

New drugs may be safer or have fewer potential side effects while being an alternative to, or even a replacement for, existing non-drug therapies (for example, surgery). In addition, new drugs may be used to treat or slow the progression of diseases or symptoms of diseases that were previously under-treated or untreatable (such as multiple sclerosis).

Other Factors

Aside from the development of new drugs, the pharmaceutical industry plays a role in influencing the trends in drug expenditure. Pharmaceutical companies promote their products to prescribers (for example, physicians, dentists, nurse practitioners) and pharmacists through a practice known as detailing, as well as by advertising to the general public, known as direct-to-consumer advertising (DTCA). Although regulated in Canada, Canadians are exposed to DTCA through international media.

Changes in either consumer preferences or prescribing practices can lead to changes in the amount or types of drugs dispensed. Changes in pharmaceutical care practices by pharmacists can improve a person's compliance with a treatment regimen, resulting in improved health outcomes, improved utilization of first-line therapies (thereby decreasing use of more costly alternative treatments), or decreasing the use of other health care resources which may be more costly, such as hospital visits.

What we know:

- Drug expenditure rose every year from 1985 on, with an average annual growth rate of 9.6% by 2006.
- New drugs are often being introduced at much higher prices than existing therapies.⁸
- In 2005, there were 66 new patented drugs introduced to the market for human consumption.⁹
- Since 1988, the price of patented medicines in Canada rose at a lower rate than economy-wide inflation in every year but one (1992).^{9, xxiv}
- Some new drugs have reduced overall medical expenditures.^{10, 11}
- An increasing number of drug therapies are being administered outside of the hospital setting, thereby shifting costs from hospitals^{xxv} to the community (for example, in-home cancer treatments).¹²
- The Canadian population has been growing at roughly 1.1% per year since 1985. The proportion of the population aged 65 years and older increased by one percentage point between 1995 and 2004.¹³ These changes were gradual and did not have a great impact on drug expenditure.¹⁴

What we don't know:

- Whether increases in total drug expenditure negatively or positively affect overall health outcomes.
- Will increased drug use reduce spending in other sectors of health care (for example, decreased hospitalization)?
- To what degree does each of the factors above affect both drug expenditure and the other factors?
- How does DTCA affect the market place, prescribing practices, physician-patient communication and the public's understanding of drug therapy in Canada?¹⁵

xxiv. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

xxv. Drugs paid through hospital budgets are not identified separately in the NHEX database but classified as hospital expenditure.

Table 6—Factors That May Influence Drug Expenditure in Canada

Prices

- Changes in the unit prices of drugs (both patented and non-patented)
- Changes in retail and wholesale mark-ups and professional fees
- Availability of generics
- International prices
- Inflation

Entry of New Drug Chemicals

Volume of Drug Use

- Population-Related
 - Changes in population size
 - Changes in population structure/distribution
 - Age, gender and ethnicity
 - Changes in health status of a population
 - Emergence of new diseases
 - Epidemics
 - Prevalence and severity of disease
- System-Related
 - Changes and transition associated with health system reform
 - Availability and access to third-party insurance coverage
 - Changes in policies and programs
 - The extent of formulary listings
 - Eligibility and co-payments
- Research and Technology–Related
 - New treatment approaches
 - Drugs replacing surgery
 - Drug therapy for previously untreatable or under-treated diseases
 - Availability of more and/or improved diagnostic technology
 - Outcomes research, evidence-based preventative or curative approaches in diagnosis or treatment
 - Use of programs and technology in monitoring patients
- Pharmaceutical Industry
 - Development of new drug products (for example, new strengths, new drug forms and presentations)
 - Promotion of drugs to physicians
 - Drug sampling
 - Direct-to-consumer advertising

- Practice- and People-Related (health care providers and consumers)
 - Changes in prescribing and dispensing practices
 - Number and mix of prescribers (specialists, general practitioners, nurse practitioners and others)
 - Multiple doctoring
 - Consumers' expectations and behaviours
 - Adherence to treatment

Methodological Notes

BACKGROUND

Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX), which is maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1960. Drug expenditure data in NHEX are macrolevel data and do not allow for decomposition of prescription costs or drug classes.

The "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third-party payers on their behalf, generally from community pharmacies. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, which include dispensing fees, mark-ups and appropriate taxes. NHEX data do not account for drug expenditure by non-Canadians (for example, Americans' purchases from Canadian pharmacies). The classification system employed is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

National Health Expenditure Database

The mandate of the NHEX database is twofold:

- 1. To support the development and evaluation of health programs in Canada by all levels of government and within the private sector.
- 2. To compile information on health expenditure that will accurately portray the importance of health care as a component of national expenditure.

Health Expenditure—includes any type of expenditure for which the primary objective is to improve or prevent the deterioration of health status.

This definition allows economic activities to be measured according to primary purpose and secondary effects. Activities that are undertaken with the direct purpose of improving or maintaining health are included. Other activities are not included, even though they may impact health. For example, housing and income support policies have social welfare goals as their primary purpose and are not considered to be health expenditure, yet they are recognized as powerful factors in determining population health.

Source of Finance

National health expenditure is reported based on the principle of *responsibility for payment* rather than on the source of the funds. It is for this reason, for example, that federal health transfers to the provinces/territories are included in the provincial/territorial government sector, since it is the responsibility of provincial/territorial governments to expend federal transfers on health services. The exception to this principle is that provincial/territorial government health transfers to municipal governments are included in the provincial/territorial health territorial government sector. The following figure depicts the decomposition of total health expenditure by source of finance.




Figure 18-Composition of Total Health Expenditure, by Source of Finance

Public Sector—includes health care spending by governments and government agencies. It is sub-divided into "Provincial Government Sector" and "Other Public Sector," as described below:

- 1. *The Provincial Government Sector* includes health spending from provincial/territorial government funds, federal health transfers to the provinces/territories and provincial/territorial government health transfers to municipal governments.
- 2. The *Federal Direct Sector* refers to direct health care spending by the federal government in relation to health care services for special groups, such as Aboriginals, the armed forces and veterans. Federal direct health expenditure does not include federal health transfers to the provinces.
- 3. The *Municipal Government Sector* expenditure includes health care spending by municipal governments for institutional services, public health, capital construction and equipment, and dental services provided by municipalities in the provinces of Nova Scotia, Manitoba and British Columbia. Designated funds transferred by provincial governments for health purposes are not included in the municipal sector, but are included with provincial government expenditure. Currently, no estimates of drug spending are included in this sector.
- 4. Social Security Funds are social insurance programs that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the

health care spending by workers' compensation boards (WCBs) and the drug insurance fund component of the Quebec ministère de la Santé et des Services sociaux drug subsidy program.

- Health spending by WCBs includes what the provincial boards commonly refer to as medical aid. Non-health related items often reported by the WCBs as medical aid expenditure—such as funeral expenses, travel and clothing—are removed.
- On January 1, 1997, the government of Quebec introduced a drug program that covered residents of the province who were not otherwise covered by the provincial program or by private health insurance, generally offered through employment. Drug claims for these participants of the new plan are paid from the drug insurance fund. This component of the Quebec drug program is self-funded through income-based premiums, deductibles and co-payments made by the insured.

Private Sector—includes health care spending by individuals and private sources as described below:

- Non-consumption includes non-patient revenues received by health care institutions such as donations and investment income, private spending on health-related capital construction and equipment, and health research funded by private sources. Currently, no estimates of drug spending are included in this portion of the private sector.
- 2. Out-of-pocket health expenditure made by individuals for health care goods and services.
- 3. Private health insurance includes health expenditure paid by commercial and not-forprofit insurance firms, as well as the cost of administering those claims.

Hierarchy of Classification

National health expenditure in Canada is based on a system of classification that is consistent with international standards developed by the OECD for reporting of health expenditure.^{xxvi}

National health expenditure is grouped within the broad categories of "Personal Health Care" or "Other Expenditure":

Personal health care consists of expenditure for health goods and services used by individuals.

Other health expenses consist of expenditure on behalf of society, such as public health; expenditure made as investments for purposes of future consumption, such as capital expenditure; the administrative expenses of planning and managing the health care system; and research.

xxvi. Statistics Canada (Public Institutions Division) publishes estimates of government health expenditure as part of its comprehensive reporting system of all government expenditure, the Financial Management System (FMS). The FMS public-sector health spending estimates are lower than those reported by CIHI because different classification methods are applied and a narrower definition of health expenditure is used in the FMS.

Personal health expenditure is classified within categories that describe the type of health care used. Certain categories overlap. The hierarchy of classification that is used to allocate overlapping categories of expenditure is as follows:

Institutional setting—health care services consumed in hospitals or other institutions are allocated to the institutional category if the institution purchases the services on behalf of its patients. For example, drugs paid through hospital budgets are classified as hospital expenditure. This allocates expenditure to the supplier actually paid by patients or their agents in the form of government or insurance companies. It also reflects data availability.

Self-employed provider of service—for example, all expenses of physicians' practices are considered to be expenditure for physicians services, even though some of these expenses would be for employment of other health professionals, drugs or personal health supplies.

Type of good or service-drugs and personal health supplies are examples.

One of the categories of health expenditure within NHEX is "Drugs." Other categories include: hospitals, other institutions, physicians, other professionals, capital, public health and administration, and other health spending. In NHEX, these categories are also named "Use of Funds."

Below is a description of the drug category within NHEX; it is not a definition supplied by the OECD.

Drugs—at the aggregate level, include expenditure on prescribed drugs and nonprescribed products purchased in retail stores. Estimates represent the final costs to consumers including dispensing fees, mark-ups and appropriate taxes. The breakdown in NHEX of prescribed drugs, over-the-counter drugs and personal health supplies is parallel with the breakdown in OECD. This category has been disaggregated at the "Canada" level in the data tables to provide information on the following sub-categories:

Prescribed Drugs—substances considered as drugs under the *Food and Drugs Act*, and are sold for human use as the result of a prescription from a health professional.

Non-Prescribed Drugs^{xxvii}—include two sub-components: "Over-the-Counter Drugs" and "Personal Health Supplies."

Over-the-Counter Drugs—therapeutic drug products not requiring a prescription and purchased as such.

Personal Health Supplies—include items used primarily to promote or maintain health; for example, oral hygiene products, diagnostic items such as diabetic test strips and medical items such as incontinence products.

xxvii. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

The Drug category in NHEX does not include drugs dispensed in hospitals and generally in other institutions. These are included in health expenditure figures for "hospitals" or "other institutions."

Other Terms

Gross Domestic Product (GDP)¹⁶—GDP implicit price index (in 1997 dollars) is used to compare annual percentage change of drug expenditure with inflation in the Canadian economy. GDP is the unduplicated value of production originating within the boundaries of Canada, regardless of the ownership of the factors of production.

Purchasing Power Parity (PPP)¹⁷—purchasing power parities (PPPs) are the rates of currency conversion that equalize the purchasing power of different currencies. This means that a given sum of money, when converted into different currencies at the PPPs rates, will buy the same basket of goods and services in all countries. Thus PPPs are the rates of currency conversion, which eliminate differences in price levels between countries.

DATA LIMITATIONS

Data contained in the NHEX are estimates. The data are collected from diverse sources and include varying classes of financial information. The data are collected and classified according to methods established by a review committee. CIHI analysts and external experts continue to improve the comprehensiveness, accuracy and currency of the data, in order to provide the most complete and objective estimates possible. Notwithstanding these improvements, national health expenditure data are estimates and should be used accordingly.

Most private-sector expenditure is estimated from survey data. Prior to 1996, the Family Expenditure Survey by Statistics Canada,¹⁸ an important source of private-sector data, was not carried out annually; therefore, trend data were imputed for years between surveys. Private-sector data were revised following a methodology review in the early 1990s. The revised private-sector data incorporated information estimated directly from new sources for 1988 and subsequent years. Prior years were estimated using trend data. As a result, readers should use caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

Drugs in Hospitals


The NHEX at CIHI uses a classification system that is consistent with international standards developed by the OECD for the reporting of health expenditure. Similar to the functional category "Pharmaceutical and Other Medical Non-Durables" in the OECD system of health accounts, the "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers, or third-party payers on their behalf, generally from retail outlets. Drugs in hospitals are considered as inputs (intermediate consumption) to the production of health care in hospitals. Consequently, drugs paid through hospital budgets are not identified separately in NHEX but classified as hospital expenditure. Similarly, drugs purchased by residential care facilities for their residents are classified as institutional expenditure. All expenses of physicians' and dentists' practices, including

drugs, are considered to be expenditure for physicians' and dentists' services. Some drug expenditure is also included in the NHEX category of public health (for example, vaccines).

While the above hierarchy of classification is essential in allocating overlapping categories of expenditure, it also reflects data availability. For example, data on expenditure by provincial/ territorial governments are usually extracted from provincial/territorial government public accounts. In the accounts, it is generally not possible to isolate drug spending from other categories of expenditure within program areas (for example, hospitals, public health). While there exist other possible data sources, the use of a single data source for the different categories of provincial government health expenditure—such as the provincial/territorial public accounts. has the major advantage of minimizing the risk of double counting.

Measuring Drug Prices

There is no authoritative composite price index for all drugs sold in Canada. The difficulty lies in the fact that traditional statistical measurement considers the price of tablets or capsules rather than measuring the nature of the product itself (that is, its therapeutic properties). In pure economic terms, the price of a drug is the price per unit of health gain attained. From a practical perspective, however, people buy tablets, capsules or other forms of medication, some of which may contain multiple active ingredients.



There are several commonly accepted price indices that can potentially be used to measure shifts in drug prices at the retail level. These include the consumer price index (CPI), the pharmaceutical component of the industrial product price index (IPPI [pharma]) and the patented medicine price index (PMPI). Each index is built upon a unique set of assumptions pertaining to inclusion criteria, definitions, updating and weighting methodologies. As a result, these indices produce differing results (Figure 19).

It is important to determine whether two different products with similar therapeutic elements used to treat similar health conditions are essentially different. Several price indices assume they are different products. The consequence is that when new products enter the market, price indices do not compare their prices to existing products; they are simply added to the basket of goods.

COLLECTION AND NON-RESPONSE

The definitions and methods used in the preparation of this document are for the most part based on those adopted in 1994 by the National Health Expenditure Methodology Review Committee. This committee included representation from Health Canada, Statistics Canada, the Quebec ministère de la Santé et des Services sociaux, the Canadian Medical Association and the Canadian Healthcare Association. Some of the recommendations for change made during that process are still under development.

General Methods

The following is intended as a general overview of the methods applied to calculate estimates of drug expenditure in Canada. More detailed information can be obtained by contacting the National Health Expenditures program area by phone at 613-241-7860, by fax at 613-241-8120 or by email at nhex@cihi.ca.

Provincial/Territorial Government

Provincial/territorial government expenditure principally includes drugs that are dispensed through provincial/territorial drug subsidy programs (see Appendix). These drug expenditure data are extracted predominantly from audited and consolidated provincial/territorial documents detailing provincial government expenditure (Table 7).

Provincial/territorial government drug spending figures include spending by the provincial/ territorial ministry responsible for health as well as by other departments that may provide drug coverage. CIHI's estimates of provincial and territorial government drug expenditure were submitted to provincial and territorial departments of health for review.

Provincial/territorial government figures identified as forecasts are based on the growth rates of major programs reported in provincial and territorial government main estimates and budgets.

Province/		
Territory		Description
Newfoundland and Labrador	Drug Expenditure Data Source	Drug expenditure data are collected from the Provincial Public Accounts Volume III, Consolidated Revenue Fund supplementary statements and schedules for three drug programs: indigents, seniors and the special drug programs.
Prince Edward Island	Drug Expenditure Data Source	The Drug Cost Assistance Program is reported under the Provincial Pharmacy program in the Queens Region Health and Community Services operating statement, which is reported in P.E.I. Provincial Public Accounts Volume II.
Nova Scotia	Drug Expenditure Data Source	Drugs data are extracted from three sources: the N.S. Supplementary Estimates Details, special tabulations from the N.S. Seniors' Pharmacare Program and the N.S. Department of Community Services, Income Assistance and Employment Support Services.
New Brunswick	Drug Expenditure Data Source	Drugs data are provided through special reports from the Department of Health and Community Services and the Department of Human Resources. A small component of drug expenditure by the provincial government is from the N.B. Public Accounts Volume 2 under Payments to Vendors and Grants and Contribution Payments.
Quebec	Drug Expenditure Data Source	Provincial government expenditure is extracted from volume 2 of the Quebec provincial public accounts. Spending on drugs by the provincial government is represented by total transfers of Program 5, Régie de l'assurance maladie du Québec (RAMQ), for "médicaments et services pharmaceutiques." See also the section, below, on Social Security Funds and the Quebec drug insurance fund.
Ontario	Drug Expenditure Data Source	Data are collected from volume 1 of the Ontario Provincial Public Accounts. Information is collected for the drug programs provided by the Ministry of Health and Long-Term Care (Ontario Drug Benefit Program, Trillium Drug Program, Special Drug Program) and by the Ministry of Community and Social Services, under Social Assistance and Employment under the Adult and Children's Service Program.
Manitoba	Drug Expenditure Data Source	Data are from Manitoba Health's pharmacare program under the Health Services Insurance Fund, Pharmacare Program. Data are also collected from the annual report of the Manitoba Department of Family Services under Income Assistance of the Employment and Income Assistance Program.
Saskatchewan	Drug Expenditure Data Source	Data sources include the Saskatchewan Public Accounts Volume 2 and the Saskatchewan Health Annual Statistical Report for the Drug Plan and Extended Benefits Branch. Data are collected for the Saskatchewan Prescription Drug Plan from their annual report. A total for the Supplementary Health Program (SHP) is also extracted from the annual report. The distribution of detailed expenditure of the Supplementary Health Programs provided in the Statistical Report for the Drug Plan and Extended Benefits is applied to the total for the SHP extracted from the public accounts. One of the components of the SHP that is also collected is "non-formulary drugs." Drug expenditure amounts are collected under the Ministry of Social Services in the Supplier Payments section of the public accounts.

 Table 7-Provincial/Territorial Government Drug Expenditure Data

Province/ Territory		Description
Alberta	Drug Expenditure Data Source	Drug expenditure data from Alberta Health and Wellness are extracted from its annual report. Detailed claims summary data are provided by Alberta Blue Cross Non-Group Benefits. The largest single expenditure component of Alberta Blue Cross Non-Group Benefits are drug benefits. The detailed claims distribution is applied to the total for Blue Cross Non-Group Benefits under Practitioner Services, extracted from the annual report of the Ministry of Health and Wellness.
		Drug expenditure information is also collected from Children's Services, the Department of Community Development and the Department of Human Resources and Employment. Drug expenditure amounts are compiled from various income assistance programs, including Income Support to Individuals and Families, Social Support to Individuals and Families, and Services to Persons with Disabilities.
British Columbia	Drug Expenditure Data Source	Data are received in the Financial Management Reports (FMRs) from the Ministry of Health Services. Control totals for major programs are from the public accounts. With few exceptions, expenditure items from the FMRs sum to the control totals. The Ministry of Health Services administers drug subsidization for all targeted groups (seniors, income assistance recipients and families) under the Medical Services Program.
Yukon Territory	Drug Expenditure Data Source	Control totals on major programs are extracted from the Yukon Public Accounts. Additional details are in a special tabulation provided by the territorial Ministry of Health and Social Services on spending for pharmacare, prescription drugs, under the Chronic Disease Program and Extended Health Benefits for Seniors.
Northwest Territories	Drug Expenditure Data Source	Drug expenditure data are provided by the Finance Division of the Department of Health and Social Services under the Extended Health Benefits of the Supplementary Health Programs.
Nunavut	Drug Expenditure Data Source	The government of Nunavut is unable to provide drug expenditure amounts to CIHI. The method used to estimate expenditure in Nunavut was to allocate the same proportion that drugs were in the Northwest Territories of the aggregate of individual programs in the N.W.T. that make up Supplementary Health Benefits Program in Nunavut.

 Table 7—Provincial/Territorial Government Drug Expenditure Data (cont'd)

Federal Direct

Prescribed drug data are derived from information provided by federal government organizations supplemented with information from the National Public Accounts. Federal government health care spending is generally provided according to the province in which the expenditure was made. Some data, however, are provided only at the national level; in these cases it is distributed by the appropriate provincial or territorial population.

Social Security Funds

Social security funds are financially autonomous social insurance schemes that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms by which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by WCBs and the drug insurance fund component of the Quebec ministère de la Santé et des Services sociaux drug subsidy program. **Workers' Compensation Boards**—Prescribed drug expenditure for the WCBs and the Commission de la santé et de la sécurite du travail du Québec are collected through special tabulations from contacts in each provincial or territorial WCB.

Quebec Drug Insurance Fund—On January 1, 1997, the Quebec ministère de la Santé et des Services sociaux, through the Régie de l'assurance maladie du Québec (RAMQ), introduced a universal drug program that covered residents of the province who were not otherwise covered by the provincial program or by private health insurance generally offered through employment. Drug claims for these participants are paid from the drug insurance fund. This fund is self-financed through the compulsory payment of premiums generally by the self-employed and employees of organizations that do not offer private drug insurance as a benefit of employment.

Data for this component of the provincial drug program are compiled by subtracting the amount for "Médicaments et services pharmaceutiques" paid on behalf of the RAMQ by the provincial government and reported in the Quebec Public Accounts from the total amount of the program reported in the RAMQ annual report; essentially, subtracting the amount of the Quebec drug subsidy program funded by the province from the overall claims of the RAMQ, leaving the portion of the program that is self-financed.

Private Sector

Private-sector drug data were revised in 1995 following a methodology review that began in the early 1990s. Private-sector data under the revised methodology incorporated information estimated directly from new sources for 1988 and subsequent years. Expenditure amounts prior to 1988 were estimated using trend data. Therefore, readers should exercise caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

The recommendations pertaining to prescribed and non-prescribed drugs that were ultimately implemented included the following:

- Data on drug benefits paid by private insurers were to be estimated based on information provided by the Canadian Life and Health Insurance Association (CLHIA) and from surveys of non-profit insurers.
- Out-of-pocket expenditure on prescribed drugs were to be estimated from Statistics Canada's Family Expenditure in Canada survey (FAMEX), re-named in 1997 to the Survey of Household Spending (SHS).
- Non-prescribed drug estimates would include two components, over-the-counter drugs and personal health supplies. Estimates would be based on information from the market research firm A. C. Nielsen.

As part of the original agreement with the not-for-profit insurance firms that provide data to NHEX, the administrators of NHEX agreed not to report the components of the private sector—insurance and out-of-pocket expenditure—at the provincial/territorial level. The purpose was to protect the proprietary nature of the information of the not-for-profit insurance firms. Consequently, CIHI only reports the private-sector sum of components by province, and the out-of-pocket and insurance components of the private sector, at the national level.

The data sources and methodologies related to these recommendations are described below.

Health Insurance drug claims paid are collected from eight not-for-profit insurance companies and the CLHIA. The CLHIA data are based on its survey of member companies. Currently, drug spending that may occur by insurance companies providing casualty insurance is not included in the estimates.

Out-of-pocket prescribed drug expenditure is based on purchased data from the SHS, formerly the FAMEX, fielded by Statistics Canada. Specifically, average household costs associated with question 14, in section "P" of the SHS, relating to medicines, drugs and pharmaceutical products **prescribed by a doctor** are the basis of the estimates. The average household expenditure of prescribed drugs is multiplied by the number of estimated households reported in the survey.

The SHS is an annual survey, which began in 1996. Prior to 1996, full surveys that included both urban and rural areas were carried out in 1986 and 1992. In 1990, a survey was conducted that included only metropolitan areas. In years when complete surveys were carried out, data are available for the 10 provinces and for 17 urban centres. The urban centres include Yellowknife and Whitehorse, which are used to derive estimates of expenditure in the territories. Metropolitan expenditure per household tends to be somewhat higher than provincial estimates. All relevant categories were updated in complete survey years. In years when only urban surveys were carried out, the percentage changes in urban expenditure within each province or territory were used to update category estimates from complete survey years. Between 1992 and 1996, when no surveys were conducted, historical provincial growth rates of the SHS variables of drug and drug sundries were used to impute missing years.

The non-prescribed drug estimate is based on data from the market research firm A. C. Nielsen, which tracks consumer sales of non-prescribed drugs sold in Canada at retail. Each year, A. C. Nielsen reports retail sales data for two consistent years for more than 48 non-prescribed drug categories. Data are reported by sales channel,^{xxviii} total dollar sales volume and by regional sales distribution for five regions that include nine provinces. Newfoundland and Labrador and the territories are not included. The data are processed by classifying the non-prescribed drug categories as either over-the-counter drugs or personal health supplies. Regional sales amounts are separated into nine provinces, and estimates

xxviii. As a general rule, Statistics Canada definitions govern the classification of stores by class of trade. Sales channels include Drug Stores; Food Stores with Pharmacies; Grocery Banners; Mass Merchandiser and Warehouse Clubs, which are estimated from A. C. Nielsen's household panel data.

for Newfoundland and Labrador and the territories are calculated using provincial distributions of "Direct Costs for Health Care" from the SHS. Appropriate provincial and federal sales taxes are incorporated into the estimates.

The following list provides the various drug classes that are supplied to CIHI by A. C. Nielsen. The choice of classes to be included in the non-prescribed drug expenditure estimate and the classification according to which drugs are included as over-the-counter or personal health supplies was made by the NHEX Drug Expenditure Review Committee during the NHEX methodology review and adopted in 1995.

Over-the-Counter Drugs	Personal Health Supplies
Analgesic rubs	Adhesive bandages and dressing strips
Anti-fungals (external)	Anti-perspirants
Athletes' foot products (included in	Artificial sweeteners
anti-fungals in later years)	Athletic supports/braces
Cold remedies	Condoms
Cough remedies	Contact lens preparations
Diarrhea remedies	Cotton swabs
Dietary aids	Cover and tape products
Headache remedies	Dental floss
Headache remedies-Child's acetaminophen	Dentrifice
Hemorrhoidal remedies	Denture adhesives
Infant feeding products	Denture cleansers
Laxatives	Diabetic test strips
Medical nutritional supplements	Disposable diabetic syringes
Milk-intolerant products	Elastic bandages
Nasal preparations	Eye drops and lotions
Oral backache remedies	Feminine hygiene products
Pediculicides	Fever thermometers
Personal lubricants	Incontinence products
Pre-menstrual products	Medical supports/braces
Sleeping aids	Oral antiseptics
Throat remedies	Pregnancy test kits
Topical wound care	Sanitary pads
Upset stomach remedies	Selected hot/cold compress
Vitamins-Children's	Selected insoles
Vitamins-Adult's	Tampons
Wart removers	Toothbrushes (includes denture brushes)

Calculation Methods

Calculation of Average Annual Rate of Growth

The average annual rate of growth is the constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. The formula used to calculate the average annual rate of growth is:

= (e (In(value at end of period) - In(value at beginning of period))/(T-1)) - 1

Where the constant e equals 2.718, which is the base of the natural logarithm, and T equals the number of years in the period.

Calculation of Calendar Year

Some information sources provide data in fiscal years. Calendar year data were derived by adding $\frac{3}{4}$ of one fiscal year to $\frac{1}{4}$ of the previous fiscal year.

Calculation of per Capita Dollars

Per capita expenditure was calculated using the most recent revised population estimates and forecasts from the Demography Division of Statistics Canada. These take into account the results of the census adjustment for net census under-count, non-permanent residents and returning Canadians.

Calculation of Total Health Expenditure

"Total Health Expenditure" refers to the sum of the public and the private sectors. "Canada" refers to the sum of the 10 provinces and three territories. "Canada Average" is the sum of provincial and territorial expenditure divided by the sum of provincial and territorial data of another variable, such as population.

Calculation of Deflated Drug Expenditure per Capita Using CPI

Where drug expenditure per capita is presented in constant 1985 dollars, constant dollar drug expenditure per capita was calculated using the CPI, provided by Statistics Canada. A more complete explanation of the methodology for calculating the consumer price index is available from Statistics Canada.¹⁹

Forecasting Methods

Provincial government-sector drug spending forecasts are based on the growth rates of drug subsidy programs of provincial health departments reported in provincial main estimates and budgets. In the case of territorial government forecasts of the Northwest Territories and Nunavut, estimates were based on amounts reported in their main estimates. In other sectors, the figures for these two territories were calculated by developing a forecast for the Northwest Territories, including Nunavut. The share of Nunavut spending in the last year of actual data of the combined total of the Northwest Territories and Nunavut was used as a proxy to break out the forecasts for the Northwest Territories and Nunavut.

Forecasts for the federal direct, WCBs and the private sector were entirely based on econometric analysis of time series trends. For each series, up to 40 different univariate forecasting specifications were evaluated, and the best one (based on the root mean square error of prediction) was selected. The functional forms studied included the exponential smoothing family (simple, double, Holt, Brown, Winters, damped trend, etc.); time trends; ARIMA specifications; etc. Logarithmic transformations were used when the data warranted their use.

Forecasts of health expenditure are identified in the figures by special symbols and in the data tables by the letter "f."

SOURCES OF DATA

Drug expenditure estimates, from the NHEX, are compiled based on information from the following sources.

Provincial Government Sector

- Provincial public accounts and main estimates
- Provincial departments of health annual reports and statistical supplements, where available
- Annual reports of various foundations, agencies and commissions
- Special tabulations and specific information from various provincial departments reporting health expenditure

Federal Direct Sector

- Public Accounts of Canada
- Special tabulations and information from:
 - Health Canada
 - Veterans Affairs Canada
 - Department of National Defence
 - Solicitor General of Canada
 - Statistics Canada
 - Citizenship and Immigration Canada

Social Security Funds Sector

- Special tabulations on medical aid spending provided by the provincial and territorial WCBs
- Annual reports of provincial and territorial WCBs
- Annual report of the RAMQ

Private Sector

- Private insurance component
 - The not-for-profit portion is captured from special tabulations provided by the not-for-profit insurance companies
 - The commercial portion is captured by a special tabulation provided by the CLHIA
- Out-of-pocket component
 - SHS, Statistics Canada (formerly the FAMEX)
 - Over-the-Counter Drugs and Personal Health Supplies—Market Review of Selected Drug Categories at Retail, a special tabulation purchased from A. C. Nielsen Canada

Economic and Demographic Data

- Gross domestic product
 - 1985 to 2005: purchased from National Accounts and Environment Division, Statistics Canada
 - 2006: purchased from the Conference Board of Canada (GDP growth rates)
- Population: purchased from the Demography Division, Statistics Canada
- Price Indices:
 - PMPI from Patented Medicine Prices Review Board
 - CPI and IPPI, purchased from the Prices Division, Statistics Canada

Series A

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2006

Table A.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Canada, 1985 to 2006

-	Public			Prescribed Drugs Private				Non-Prescribed Drugs Private (Out-of-Pocket)				
Year	Provincial/ Territorial	Federal _	Social Secu WCB	rity Funds Drug Insurance Funds	Sub-Total Public	Insurers (\$ milli	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
-		50.0							0.500.5			
1985 1986	1,048.1 1,240.6	58.0 63.3	12.6 15.2		1,118.7 1,319.2			1,447.7 1,698.8	2,566.5 3,018.0			1,235.9 1,399.0
1987	1,406.7	68.2	17.8		1,492.7			1,800.4	3,293.1			1,621.7
1988	1,592.7	89.3	20.8		1,702.8	1,130.3	903.7	2,034.0	3,736.8			1,784.9
1989	1,838.0	110.0	22.9		1,970.9	1,260.6	1,031.4	2,292.0	4,262.9			1,975.6
1990	2,120.2	130.3	27.5		2,278.0	1,466.8	1,127.0	2,593.9	4,871.8			2,058.7
1991 1992	2,428.0 2,710.7	145.6 159.7	33.2 38.1		2,606.7 2,908.5	1,671.5 1,947.3	1,190.4 1,244.9	2,861.9 3,192.3	5,468.7 6,100.7	1,290.0	 1,128.1	2,236.6 2,418.1
1993	2,817.0	187.6	40.2		3,044.9	2,089.3	1,469.4	3,558.7	6,603.5	1,373.0	1,203.1	2,576.0
1994	2,845.0	207.1	35.5		3,087.6	2,105.2	1,568.2	3,673.3	6,760.9	1,387.7	1,288.9	2,676.6
1995	3,099.7	227.8	37.8		3,365.3	2,350.1	1,683.6	4,033.8	7,399.0	1,389.4	1,314.2	2,703.6
1996	3,053.4	234.0	41.4		3,328.8	2,476.6 2,785.2	1,796.7	4,273.3 4,933.2	7,602.1	1,417.2	1,338.8	2,756.0 2,877.5
1997 1998	3,140.3 3,475.9	252.5 283.7	42.7 47.9	172.0 218.2	3,607.6 4,025.8	3,220.5	2,148.0 2,223.0	4,933.2 5,443.5	8,540.8 9,469.3	1,469.9 1,557.3	1,407.6 1,509.7	2,877.5 3,067.0
1999	3,939.6	321.0	53.7	264.0	4,578.3	3,387.0	2,302.0	5,689.0	10,267.3	1,675.6	1,576.7	3,252.3
2000	4,594.8	343.3	64.8	332.3	5,335.3	3,866.8	2,562.5	6,429.3	11,764.6	1,717.7	1,605.0	3,322.7
2001	5,267.9	392.0	75.8	379.9	6,115.6	4,489.0	2,613.5	7,102.5	13,218.1	1,792.2	1,654.0	3,446.3
2002 2003	5,911.2	447.9	86.5	450.4	6,896.1 7,670.6	5,009.4	2,934.4	7,943.9 8,812.1	14,839.9	1,888.9	1,712.5	3,601.4
2003 2004	6,464.8 7,098.2	508.1 528.6	102.8 121.1	595.0 642.2	8,390.0	5,656.2 6,255.1	3,155.9 3,364.8	9,619.9	16,482.7 18,009.8	1,942.2 2,048.2	1,714.5 1,770.9	3,656.6 3,819.1
2005 f	7,799.5	595.8	133.5	656.7	9,185.6	6,879.2	3,671.0	10,550.2	19,735.8	2,147.3	1,838.6	3,985.8
2006 f	8,100.3	670.6	147.5	700.2	9,618.6	7,558.3	3,913.5	11,471.8	21,090.3	2,152.6	1,912.5	4,065.1
-						(annual percent	tage change)					
1985												
1986	18.4	9.2	20.9		17.9			17.3	17.6			13.2
1987 1988	13.4 13.2	7.7 30.9	16.9 16.6		13.2 14.1			6.0 13.0	9.1 13.5			15.9 10.1
1989	15.4	23.2	10.0		15.7	11.5	14.1	12.7	14.1			10.7
1990	15.4	18.4	20.0		15.6	16.4	9.3	13.2	14.3			4.2
1991	14.5	11.7	20.8		14.4	14.0	5.6	10.3	12.3			8.6
1992	11.6	9.7	14.8		11.6	16.5	4.6	11.5	11.6			8.1
1993 1994	3.9 1.0	17.5 10.4	5.7 -11.9		4.7 1.4	7.3 0.8	18.0 6.7	11.5 3.2	8.2 2.4	6.4 1.1	6.6 7.1	6.5 3.9
1995	9.0	10.0	6.5		9.0	11.6	7.4	9.8	9.4	0.1	2.0	1.0
1996	-1.5	2.7	9.6		-1.1	5.4	6.7	5.9	2.7	2.0	1.9	1.0
1997	2.8	7.9	3.3		8.4	12.5	19.6	15.4	12.3	3.7	5.1	4.4
1998 1999	10.7 13.3	12.4 13.1	12.0 12.1	26.8 21.0	11.6 13.7	15.6 5.2	3.5 3.6	10.3 4.5	10.9 8.4	5.9 7.6	7.3 4.4	6.6 6.0
2000 2001	16.6 14.6	7.0 14.2	20.8 17.0	25.9 14.3	16.5 14.6	14.2 16.1	11.3 2.0	13.0 10.5	14.6 12.4	2.5 4.3	1.8 3.1	2.2 3.7
2002	12.2	14.3	14.1	18.6	12.8	11.6	12.3	11.8	12.3	5.4	3.5	4.5
2003	9.4	13.4	18.8	32.1	11.2	12.9	7.5	10.9	11.1	2.8	0.1	1.5
2004	9.8	4.0	17.8	7.9	9.4	10.6	6.6	9.2	9.3	5.5	3.3	4.4
2005 f	9.9	12.7	10.3	2.3	9.5	10.0	9.1	9.7	9.6	4.8	3.8	4.4
2006 f	3.9	12.6	10.4	6.6	4.7	9.9 tage share of to	6.6 tal drug exper	8.7	6.9	0.2	4.0	2.0
- 1985	27.6	1.5	0.3		29.4			38.1	67.5			32.5
1986	28.1	1.4	0.3		29.9			38.5	68.3			31.7
1987 1988	28.6 28.8	1.4 1.6	0.4 0.4		30.4 30.8	 20.5	 16.4	36.6 36.8	67.0 67.7			33.0 32.3
1989	28.8	1.8	0.4		30.8	20.5	16.4	36.8	68.3			32.3
1990	30.6	1.9	0.4		32.9	21.2	16.3	37.4	70.3			29.7
1991	31.5	1.9	0.4		33.8	21.2	15.4	37.1	71.0			29.0
1992	31.8	1.9	0.4		34.1	22.9	14.6	37.5	71.6	15.1	13.2	28.4
1993 1994	30.7 30.1	2.0 2.2	0.4 0.4		33.2 32.7	22.8 22.3	16.0 16.6	38.8 38.9	71.9 71.6	15.0 14.7	13.1 13.7	28.1 28.4
1995 1996	30.7 29.5	2.3 2.3	0.4 0.4		33.3 32.1	23.3 23.9	16.7 17.3	39.9 41.3	73.2 73.4	13.8 13.7	13.0 12.9	26.8 26.6
1997	27.5	2.2	0.4	1.5	31.6	24.4	18.8	43.2	74.8	12.9	12.3	25.2
1998	27.7	2.3	0.4	1.7	32.1	25.7	17.7	43.4	75.5	12.4	12.0	24.5
1999	29.1	2.4	0.4	2.0	33.9	25.1	17.0	42.1	75.9	12.4	11.7	24.1
2000	30.5	2.3	0.4	2.2	35.4	25.6	17.0	42.6	78.0	11.4	10.6	22.0
2001 2002	31.6 32.1	2.4 2.4	0.5 0.5	2.3 2.4	36.7 37.4	26.9 27.2	15.7 15.9	42.6 43.1	79.3 80.5	10.8 10.2	9.9 9.3	20.7 19.5
2002	32.1	2.4	0.5	3.0	38.1	28.1	15.7	43.8	81.8	9.6	8.5	18.2
2004	32.5	2.4	0.6	2.9	38.4	28.7	15.4	44.1	82.5	9.4	8.1	17.5
2005 f	32.9	2.5	0.6	2.8	38.7	29.0	15.5	44.5	83.2	9.1	7.8	16.8
2006 f	32.2	2.7	0.6	2.8	38.2	30.0	15.6	45.6	83.8	8.6	7.6	16.2
f-Foreca:	st										So	urce: CIHI, 2006

	Expen	diture on Dri	ugs by Type, b	y Source of Fin	ance, and a	s a Share of Public	c, Private and	Table A.1	- art 2		
		Tota	• • • •	•		2006 (continued)	Share of Drugs in Public, Private and				
	Public	All Drugs Private	Total	Hea Public	Ith Expenditure Private	Total		Ith Expenditures Private	Total		
Year	-		(\$ milli	ions)			(perce	ntage share)			
1985 1986	1,118.7	2,683.6 3,097.9	3,802.3	30,094.9 32,528.6	9,746.9 10,808.7	39,841.7	3.7 4.1	27.5 28.7	9.! 10.:		
1987	1,319.2 1,492.7	3,422.2	4,417.1 4,914.9	35,054.7	11,733.5	43,337.3 46,788.2	4.1	29.2	10.		
1988	1,702.8	3,818.9	5,521.7	38,162.8	12,796.4	50,959.2	4.5	29.8	10.8		
1989	1,970.9	4,267.7	6,238.5	41,911.1	14,184.3	56,095.5	4.7	30.1	11.1		
1990	2,278.0	4,652.5	6,930.5	45,445.5	15,577.1	61,022.6	5.0	29.9	11.4		
1991 1992	2,606.7 2,908.5	5,098.5 5,610.4	7,705.3 8,518.8	49,382.2 51,693.8	16,906.9 18,112.0	66,289.1 69,805.7	5.3 5.6	30.2 31.0	11.6 12.2		
1993	3,044.9	6,134.7	9,179.6	51,979.7	19,578.1	71,557.7	5.9	31.3	12.8		
1994	3,087.6	6,349.9	9,437.5	52,598.7	20,486.8	73,085.4	5.9	31.0	12.9		
1995	3,365.3	6,737.3	10,102.6	52,790.6	21,285.3	74,075.9	6.4	31.7	13.6		
1996 1997	3,328.8 3,607.6	7,029.3 7,810.7	10,358.1 11,418.3	52,877.1 55,301.7	21,819.7 23,433.8	74,696.8 78,735.5	6.3 6.5	32.2 33.3	13.9 14.5		
1998	4,025.8	8,510.5	12,536.3	59,403.1	24,715.5	84,118.6	6.8	34.4	14.9		
1999	4,578.3	8,941.3	13,519.5	63,243.3	26,918.4	90,161.7	7.2	33.2	15.0		
2000	5,335.3	9,752.0	15,087.2	69,156.9	28,986.9	98,143.8	7.7	33.6	15.4		
2001 2002	6,115.6 6 896 1	10,548.8 11 545 3	16,664.3 18 441 3	74,913.7	32,044.4 34,944.0	106,958.2 114 912 4	8.2 8.6	32.9 33.0	15.6 16.0		
2002	6,896.1 7,670.6	11,545.3 12,468.7	18,441.3 20,139.3	79,968.4 86,571.0	34,944.0 36,811.0	114,912.4 123,382.0	8.6 8.9	33.0	16.0		
2004	8,390.0	13,439.0	21,829.0	92,140.7	39,239.4	131,380.2	9.1	34.2	16.6		
2005 f	9,185.6	14,536.1	23,721.6	98,063.7	41,772.6	139,836.3	9.4	34.8	17.0		
2006 f	9,618.6	15,536.9	25,155.4	104,016.9	43,997.2	148,014.1	9.2	35.3	17.0		
	-,	,	(annual percent		,	,					
1985											
1986	17.9	15.4	16.2	8.1	10.9	8.8					
1987 1988	13.2 14.1	10.5 11.6	11.3 12.3	7.8 8.9	8.6 9.1	8.0 8.9					
1989	15.7	11.8	13.0	9.8	10.8	10.1					
1990	15.6	9.0	11.1	8.4	9.8	8.8					
1991	14.4	9.6	11.2	8.7	8.5	8.6					
1992 1993	11.6 4.7	10.0 9.3	10.6 7.8	4.7 0.6	7.1 8.1	5.3 2.5					
1994	1.4	3.5	2.8	1.2	4.6	2.1					
1995	9.0	6.1	7.0	0.4	3.9	1.4					
1996 1997	-1.1	4.3	2.5	0.2 4.6	2.5	0.8 5.4					
1998	8.4 11.6	11.1 9.0	10.2 9.8	4.6 7.4	7.4 5.5	5.4 6.8					
1999	13.7	5.1	7.8	6.5	8.9	7.2					
2000	16.5	9.1	11.6	9.4	7.7	8.9					
2001	14.6	8.2	10.5	8.3	10.5	9.0					
2002 2003	12.8 11.2	9.4 8.0	10.7 9.2	6.7 8.3	9.0 5.3	7.4 7.4					
2004	9.4	7.8	8.4	6.4	6.6	6.5					
2005 f	9.5	8.2	8.7	6.4	6.5	6.4					
2006 f	4.7	6.9	6.0	6.1	5.3	5.8					
	(percentag	e share of total d	rug expenditure)								
1985	29.4	70.6	100.0								
1986 1987	29.9 30.4	70.1 69.6	100.0 100.0								
1987	30.4 30.8	69.6	100.0								
1989	31.6	68.4	100.0								
1990	32.9	67.1	100.0								
1991	33.8	66.2	100.0								
1992 1993	34.1 33.2	65.9 66.8	100.0 100.0								
1994	32.7	67.3	100.0								
1995	33.3	66.7	100.0								
1996	32.1	67.9	100.0								
1997 1998	31.6 32.1	68.4 67.9	100.0 100.0								
1999	33.9	66.1	100.0								
2000	35.4	64.6	100.0								
2001	36.7	63.3	100.0								
2002 2003	37.4 38.1	62.6 61.9	100.0 100.0								
2003	38.4	61.6	100.0								
2005 f	38.7	61.3	100.0								
2006 f	38.2	61.8	100.0								
f-Forecast								Source	: CIHI, 2006		

Table A.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Canada, 1985 to 2006

-			Public		Prescribed Drugs Private						Non-Prescribed Drugs Private (Out-of-Pocket)		
(ear	Provincial/ Territorial	Federal _	Social Security WCB	/ Funds Drug nsurance Funds	Sub-Total Public	Insurers (\$ per c.	Out-of- Pocket	Sub-total Private	Total Prescribed Drugs	Over- the Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs	
-	40.56	2.24	0.49		43.29			56.02	99.31			47.82	
986	47.53	2.43	0.58		50.54			65.09	115.63			53.60	
987 988	53.18 59.44	2.58 3.33	0.67 0.78		56.44 63.55	42.18	33.72	68.07 75.91	124.51 139.46			61.32 66.61	
989	67.37	4.03	0.84		72.24	46.21	37.81	84.01	156.25			72.42	
990	76.55	4.70	0.99		82.24	52.96	40.69	93.65	175.89			74.33	
991 992	86.62 95.56	5.19 5.63	1.18 1.34		92.99 102.53	59.63 68.65	42.47 43.89	102.10 112.53	195.09 215.07	45.48	 39.77	79.79 85.24	
993	98.22	6.54	1.40		102.55	72.84	51.23	12.53	230.23	47.87	41.95	89.81	
994	98.11	7.14	1.22		106.47	72.59	54.08	126.67	233.14	47.85	44.45	92.30	
995	105.78	7.78	1.29		114.85	80.20	57.46	137.66	252.51	47.42	44.85	92.26	
996 997	103.12 105.00	7.90 8.44	1.40 1.43	 5.75	112.42 120.63	83.64 93.13	60.68 71.82	144.32 164.95	256.73 285.57	47.86 49.15	45.21 47.07	93.07 96.21	
998	115.26	9.41	1.59	7.24	133.49	106.79	73.71	180.51	314.00	51.64	50.06	101.70	
999	129.58	10.56	1.77	8.68	150.58	111.40	75.71	187.12	337.70	55.11	51.86	106.97	
2000	149.72	11.19	2.11	10.83	173.85	126.00	83.50	209.50	383.35	55.97	52.30	108.27	
2001 2002	169.82 188.42	12.64 14.28	2.44 2.76	12.25 14.36	197.14 219.81	144.71 159.68	84.25 93.53	228.96 253.21	426.10 473.02	57.77 60.21	53.32 54.59	111.09 114.79	
2003	204.14	16.04	3.25	18.79	242.21	178.60	99.65	278.25	520.47	61.33	54.14	115.46	
2004	222.00	16.53	3.79	20.08	262.40	195.63	105.23	300.86	563.26	64.06	55.39	119.44	
2005 f 2006 f	241.69 248.88	18.46 20.60	4.14 4.53	20.35 21.51	284.64 295.52	213.17 232.23	113.76 120.24	326.93 352.46	611.57 647.99	66.54 66.14	56.97 58.76	123.51 124.90	
						(annual percent	age change)						
1985													
1986 1987	17.2 11.9	8.1 6.3	19.7 15.4		16.8 11.7			16.2 4.6	16.4 7.7			12.1 14.4	
1988	11.8	29.2	15.1		12.6			11.5	12.0			8.6	
1989	13.3	21.0	8.1		13.7	9.5	12.1	10.7	12.0			8.7	
1990	13.6	16.7	18.2		13.8	14.6	7.6	11.5	12.6			2.6	
1991 1992	13.2 10.3	10.4 8.4	19.4 13.4		13.1 10.3	12.6 15.1	4.4 3.3	9.0 10.2	10.9 10.2			7.3 6.8	
1993	2.8	16.2	4.5		3.5	6.1	16.7	10.3	7.1	5.3	5.5	5.4	
994	-0.1	9.2	-12.8		0.3	-0.3	5.6	2.1	1.3	0.0	6.0	2.8	
995 996	7.8 -2.5	8.9 1.6	5.4 8.5		7.9 -2.1	10.5 4.3	6.3 5.6	8.7 4.8	8.3 1.7	-0.9 0.9	0.9 0.8	0.0 0.9	
997	1.8	6.8	2.2		7.3	11.3	18.4	14.3	11.2	2.7	4.1	3.4	
1998 1999	9.8 12.4	11.4 12.2	11.1 11.2	25.8 20.0	10.7 12.8	14.7 4.3	2.6 2.7	9.4 3.7	10.0 7.5	5.1 6.7	6.4 3.6	5.7 5.2	
2000 2001	15.5 13.4	6.0 13.0	19.6 15.7	24.7 13.1	15.5 13.4	13.1 14.8	10.3 0.9	12.0 9.3	13.5 11.2	1.6 3.2	0.9 1.9	1.2 2.6	
2002	11.0	13.0	12.8	17.2	11.5	10.3	11.0	10.6	11.0	4.2	2.4	3.3	
2003 2004	8.3 8.7	12.4	17.7 16.7	30.9 6.9	10.2 8.3	11.9 9.5	6.5 5.6	9.9 8.1	10.0 8.2	1.9 4.5	-0.8 2.3	0.6 3.4	
		3.0											
2005 f	8.9	11.7	9.3	1.3	8.5	9.0	8.1	8.7	8.6	3.9	2.9	3.4	
2006 f	3.0	11.6	9.5	5.7 (annu	3.8 al percentage ch	8.9 ange in excess of	5.7 f inflation in the	7.8 Canadian econ	6.0 omy)	-0.6	3.1	1.1	
1985													
1986 1987	14.4 7.1	5.3 1.6	16.9 10.6		14.0 6.9			13.4 -0.2	13.6 2.9			9.3 9.7	
1988	7.1	24.7	10.6		8.1			-0.2	7.5			4.1	
1989	8.8	16.4	3.5		9.1			6.1	7.5			4.1	
990	10.6	13.6	15.2		10.8			8.4	9.5			-0.4	
1991 1992	10.4 9.1	7.6 7.1	16.6 12.2		10.3 9.0			6.3 9.0	8.2 9.0			4.6 5.6	
1993	1.3	14.7	3.1		2.1			8.8	5.6	3.8	4.0	3.9	
994	-1.2	8.1	-13.9		-0.8			1.0	0.2	-1.1	4.9	1.7	
1995	5.5	6.5	3.0		5.5			6.3	6.0	-3.2	-1.4	-2.4	
1996 1997	-4.2 0.8	0.0 5.8	6.8 1.2		-3.8 6.3			3.2 13.3	0.0 10.2	-0.7 1.7	-0.9 3.1	-0.8 2.4	
1998	10.2	11.9	11.5	26.2	11.1			9.9	10.4	5.5	6.8	6.1	
1999	10.6	10.4	9.4	18.2	11.0			1.9	5.7	4.9	1.8	3.4	
2000	11.4	1.9	15.5	20.6	11.3			7.9	9.4	-2.5	-3.3	-2.9	
2001 2002	12.1 10.0	11.6 12.0	14.4 11.8	11.7 16.2	12.0 10.5			7.9 9.6	9.8 10.0	1.9 3.2	0.6 1.4	1.3 2.3	
2003	5.4	9.5	14.8	28.0	7.3			7.0	7.1	-1.0	-3.7	-2.3	
2004	6.1	0.3	14.0	4.2	5.6			5.4	5.5	1.8	-0.4	0.8	
2005 f	6.2	9.0	6.6	-1.3	5.8			6.0	5.9	1.2	0.2	0.8	
2006 f	1.4	10.0	7.9	4.1	2.2			6.2	4.4	-2.2	1.5	-0.5	
-Foreca	st										Sou	rce: CIHI, 2006	

Total Health Expenditures, Canada, 1985 to 2006 (continued) GDP Implicit All Drugs Health Expenditure Price Index-Canada Public Private Total Public Private Total (\$ per capita) (1997 = 100)Yea 1985 147.13 1,164.54 377.16 1,541.70 73.6 43.29 103.84 1986 50.54 118.69 169.23 1.246.25 414.11 1.660.36 75.6 56.44 1,325.38 443.63 1,769.01 1987 129.39 185.82 79.2 1988 63.55 142.52 206.07 1,424.23 477.56 1,901.79 82.8 1989 72.24 156.43 228.67 1,536.23 519.92 2,056.15 86.6 1990 82.24 167.98 250.22 1,640.78 562.40 2,203.18 89.2 1991 92 99 181 89 274 88 1 761 68 603 14 2 364 82 91.6 102.53 197.78 300.31 1,822.33 638.49 2,460.82 1992 92.8 1993 106.16 213.89 320.05 1,812.29 682.59 2,494.88 94.1 1994 106.47 218.97 325.44 1,813.80 706.46 2,520.26 95.2 1995 229.93 344.77 1.801.59 726.40 2.527.99 97.4 114.85 349.81 1996 112.42 237.39 1,785.73 736.88 2,522.61 99.0 1997 120.63 261.16 381.79 1,849.10 783.55 2,632.64 100.0 1998 133.49 282.21 415.70 1,969.79 819.56 2.789.35 99.6 444.67 2,080.11 885.36 2,965.47 1999 150.58 294.08 101.4 2000 173.85 317.77 491.62 2.253.47 944.54 3,198.01 105.5 197.14 340.05 537.19 1,032.98 3,447.90 106.9 2001 2,414.92 2,548.99 2,733.61 2002 219.81 368.00 587.82 1,113.84 3,662.83 108.0 635.93 2003 242.21 393.72 1,162.36 3,895.97 111.1 2004 262.40 420.31 682.70 2,881.71 1,227.22 4,108.92 114.1 2005 f 284.64 450.44 735.09 3,038.80 1,294.45 4,333.25 117.2 477 36 772 89 1 351 79 2006 f 295 52 3 195 86 4 547 65 119.0 (annual percentage change) 1985 14.3 1986 16.8 15.0 7.0 9.8 7.7 2.8 1987 9.0 7.1 6.5 11.7 9.8 6.3 4.7 1988 12.6 10.2 10.9 7.5 7.6 7.5 4.5 1989 13.7 9.8 11.0 7.9 8.9 8.1 4.6 1990 13.8 74 94 6.8 8 2 7.2 7.3 3.0 1991 13.1 8.3 9.9 7.4 7.2 2.8 1992 10.3 8.7 9.3 3.4 5.9 4.1 1.3 1.4 1.1 1993 3.5 8.1 6.6 -0.6 6.9 1.4 0.1 1.0 2.4 1994 0.3 1.7 3.5 1995 7.9 5.0 5.9 -0.7 2.8 0.3 2.3 1996 -2.1 -0.9 3.2 1.5 1.4 -0.2 1.7 1997 7.3 10.0 9.1 3.5 6.3 4.4 1.0 1998 10.7 8.1 8.9 6.5 4.6 6.0 -0.4 12.8 4.2 5.6 8.0 6.3 1.8 1999 7.0 2000 15.5 8.1 10.6 8.3 6.7 7.8 4.1 2001 13.4 7.0 9.3 7.2 9.4 7.8 1.4 2002 11.5 8.2 9.4 5.6 7.8 6.2 1.0 2003 10.2 7.0 8.2 7.2 4.4 6.4 2.9 2004 8.3 6.8 7.4 5.4 5.6 5.5 2.7 2005 f 8.5 7.2 7.7 5.5 5.5 5.5 2.7 2006 f 3.8 6.0 5.1 5.2 4.4 4.9 1.6 nge in xcess of inflation in the Canadia al percentage cha conomy 1985 1986 14.0 115 122 4.2 70 49 1.6 1987 2.4 6.9 4.3 5.1 1.8 1988 8.1 5.6 6.4 2.9 3.1 3.0 1989 9.1 5.2 6.4 3.3 4.3 3.6 1990 10.8 4.4 6.4 3.8 5.1 4.1 1991 10.3 5.5 7.1 4.6 4.5 4.6 1992 9.0 7.5 8.0 2.2 4.6 2.8 1993 2.1 6.7 5.1 -2.0 5.5 -0.1 1994 -0.8 1.3 0.6 -1.0 2.4 -0.1 1995 5.5 2.7 -3.0 0.5 3.6 -20 1996 1.6 -0.2 -2.6 -0.2 -3.8 -1.9 1997 6.3 9.0 8.2 2.6 5.3 3.4 1998 11.1 8.5 9.3 7.0 5.0 6.4 1999 11.0 2.4 5.2 3.8 6.2 4.5 11.3 4.0 6.5 4.2 2.6 3.7 2000 2001 12.0 5.7 7.9 5.8 8.0 6.5 2002 10.5 7.2 8.4 4.6 6.8 5.2 2003 7.3 4.1 5.3 4.4 3.5 1.5 2004 5.6 4.1 4.7 2.7 2.9 2.8 2005 f 2.8 2.8 2.8 5.8 4.5 5.0 2006 f 2.2 4.4 3.5 3.6 2.8 3.3

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and

Table A.2–Part 2

-Forecast

Series B

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2006

Table B.1.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Newfoundland, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Secu WCB	rity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year						(\$ mil	lions)					
1985 1986	18.0 21.4	2.3 2.7	0.1 0.2		20.4 24.4			82.8 51.6	103.2 76.0			24.9 28.2
1987	24.7	3.1	0.3		28.1			55.1	83.2			32.7
1988	28.2	1.6	0.4		30.2			58.7	88.9			32.3
1989	31.2	1.3	0.4		32.9			62.5	95.4			32.0
1990 1991	35.3 40.3	1.6 1.7	0.6		37.5 42.8			64.7 65.8	102.2 108.5			34.3 37.8
1991	40.3	1.7	0.8 1.1		42.8			72.9	119.5	20.6	17.9	37.8
1993	47.8	2.2	1.2		51.1			76.1	127.2	21.7	18.2	39.9
1994	52.1	2.5	1.2		55.8			77.9	133.7	21.5	18.3	39.8
1995	54.5	2.8	1.5		58.8			85.6	144.4	21.2	19.9	41.0
1996 1997	54.5 53.6	2.7 3.3	1.8 1.9		59.0 58.8			90.0 87.9	149.0 146.7	23.2 19.8	21.9 18.9	45.2 38.7
1998	56.1	3.7	2.4		62.1			93.7	155.8	21.8	21.0	42.9
1999	60.0	4.1	2.8		66.9			103.3	170.2	24.0	22.5	46.5
2000	68.0	5.8	3.8		77.6			119.9	197.5	24.7	22.2	46.9
2001 2002	77.9 86.9	6.6 7.4	4.2 5.0		88.7 99.3			129.2 150.2	217.9 249.5	24.6 25.5	22.6 23.0	47.1 48.6
2002	96.0	8.1	4.9		109.0			169.0	278.0	25.5	23.0	48.0
2004	101.7	7.8	4.9		114.4			178.4	292.8	26.4	23.1	49.5
2005 f	106.2	8.0	5.1		119.2			186.9	306.2	27.7	22.4	50.1
2006 f	121.7	8.2	5.1		135.0			190.3	325.3	26.3	23.3	49.7
						(annual percer	tage change)					
1985												
1986 1987	19.2 15.4	20.4 13.5	35.5 34.3		19.4 15.3			-37.6 6.7	-26.3 9.4			13.2 16.0
1988	13.9	-48.0	34.3 50.0		7.4			6.6	9.4 6.8			-1.0
1989	10.6	-20.2	14.5		9.0			6.6	7.4			-1.0
1990	13.4	21.5	38.7		14.0			3.4	7.1			7.1
1991	14.1	9.6	25.5		14.1			1.7	6.2			10.3
1992	8.8	-3.5	40.5		8.9			10.8	10.1	 E 4		2.0
1993 1994	8.9 9.1	31.4 12.4	9.2 7.4		9.7 9.2			4.5 2.3	6.5 5.1	5.4 -1.0	1.1 0.8	3.4 -0.2
1995	4.6	12.3	22.5		5.4			9.9	8.0	-1.6	8.6	3.1
1996	0.0	-2.7	18.8		0.4			5.1	3.2	9.7	10.3	10.0
1997	-1.6	23.0	3.4		-0.4			-2.3	-1.5	-14.7	-14.0	-14.3
1998 1999	4.6 7.0	10.5 12.0	28.6 16.0		5.6 7.7			6.5 10.3	6.2 9.3	10.1 10.1	11.5 7.0	10.8 8.6
2000	13.4	40.7	37.7					16.0	16.0	2.9		0.8
2000	13.4	40.7	8.8		16.1 14.3			7.8	10.3	-0.7	-1.4 1.7	0.8
2002	11.5	11.9	20.2		12.0			16.2	14.5	3.9	2.1	3.1
2003	10.6	8.3	-1.8		9.8			12.5	11.4	0.0	-2.6	-1.3
2004	5.9	-3.0	-1.2		4.9			5.5	5.3	3.5	2.8	3.2
2005 f	4.4	2.5	4.6		4.2			4.8	4.6	5.0	-2.9	1.3
2006 f	14.6	2.2	0.8		13.2			1.8	6.2	-5.0	4.2	-0.9
					(per	centage share of t	otal drug expe	enditure)				
1985	14.0	1.8	0.1		15.9			64.6	80.6			19.4
1986 1987	20.6 21.3	2.6 2.7	0.2 0.2		23.4 24.3			49.6 47.5	73.0 71.8			27.0 28.2
1988	23.2	1.3	0.2		24.9			48.4	73.3			26.7
1989	24.4	1.0	0.3		25.8			49.1	74.9			25.1
1990	25.9	1.2	0.4		27.5			47.4	74.9			25.1
1991	27.5	1.2	0.5		29.2			44.9	74.2			25.8
1992 1993	27.8 28.6	1.1 1.3	0.7 0.7		29.5 30.6			46.1 45.6	75.6 76.1	13.0 13.0	11.4 10.9	24.4 23.9
1994	30.0	1.3	0.7		32.2			44.9	77.1	12.4	10.5	22.9
1995	29.4	1.5	0.8		31.7			46.2	77.9	11.4	10.7	22.1
1996	28.1	1.4	0.9		30.4			46.4	76.7	12.0	11.3	23.3
1997	28.9	1.8	1.0		31.7			47.4	79.1	10.7	10.2	20.9
1998 1999	28.2 27.7	1.8 1.9	1.2 1.3		31.3 30.9			47.2 47.7	78.4 78.5	11.0 11.1	10.6 10.4	21.6 21.5
2000	27.8	2.4	1.6		31.8			49.0	80.8	10.1	9.1	19.2
2000	27.8	2.4	1.6		33.5			49.0	82.2	9.3	8.5	19.2
2002	29.2	2.5	1.7		33.3			50.4	83.7	8.6	7.7	16.3
2003	29.5 29.7	2.5	1.5 1.4		33.4			51.8 52.1	85.3 85.5	7.8	6.9 6.7	14.7 14.5
2004	29.7	2.3	1.4		33.4			52.1	85.5	7.7	6.7	14.5
2005 f	29.8	2.2	1.4		33.5			52.5	85.9	7.8	6.3	14.1
2006 f f-Forecast	32.5	2.2	1.4		36.0			50.7	86.8	7.0	6.2	13.2
			ncial-level insura									ce: CIHI, 2006.

Table B.1.1-Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Newfoundland, 1985 to 2006 (continued)

		All Drugs			Health Expenditure		Tota	rugs in Public, Priv Health Expenditu	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
/ear			(\$ m	illions)			(percentage share)	
1985	20.4	107.7	128.1	588.8	197.1	785.8	3.5	54.6	16.3
1986	24.4	79.8	104.2	642.9	169.6	812.5	3.8	47.1	12.8
1987 1988	28.1 30.2	87.8 91.0	115.9 121.2	693.6 733.8	188.0 197.1	881.6 930.9	4.1 4.1	46.7 46.2	13.1 13.0
1989	32.9	94.6	127.4	787.7	203.9	991.6	4.2	46.4	12.9
1990 1991	37.5 42.8	99.0 103.6	136.5 146.4	875.9 905.7	220.6 247.5	1,096.4 1,153.2	4.3 4.7	44.9 41.8	12.4 12.7
1992	46.6	111.4	158.0	928.3	269.1	1,197.4	5.0	41.4	13.2
1993	51.1	116.0	167.1	924.9	284.2	1,209.1	5.5	40.8	13.8
1994	55.8	117.7	173.5	948.1	299.8	1,247.9	5.9	39.3	13.9
1995	58.8	126.7	185.4	973.1	295.1	1,268.2	6.0	42.9	14.6
1996	59.0	135.2	194.1	974.4	277.5	1,251.9	6.1	48.7	15.5
1997	58.8	126.6	185.4	1,020.8	282.9	1,303.8	5.8	44.8	14.2
1998	62.1	136.5	198.6	1,107.8	324.5	1,432.3	5.6	42.1	13.9
1999	66.9	149.9	216.7	1,250.8	324.0	1,574.8	5.3	46.2	13.8
2000	77.6	166.8	244.4	1,318.7	365.9	1,684.5	5.9	45.6	14.5
2001	88.7	176.3	265.0	1,415.5	387.6	1,803.2	6.3	45.5	14.7
2002	99.3	198.7	298.0	1,510.4	419.0	1,929.3	6.6	47.4	15.4
2003 2004	109.0 114.4	216.9 227.8	326.0 342.2	1,592.2 1,630.3	466.9 493.5	2,059.2 2,123.9	6.8 7.0	46.5 46.2	15.8 16.1
2005 f	119.2	237.1	356.3	1,679.1	512.6	2,191.7	7.1	46.3	16.3
2006 f	135.0	239.9	374.9	1,745.9	522.3	2,268.1	7.7	45.9	16.5
			(appual paras	untago obongo)					
-			(annual perce	entage change)					
1985									
1986	19.4	-25.9	-18.6	9.2	-13.9	3.4			
1987 1988	15.3 7.4	9.9 3.7	11.2 4.6	7.9 5.8	10.9 4.8	8.5 5.6			
1989	9.0	3.9	5.1	7.4	3.4	6.5			
1990	14.0	4.7	7.1	11.2	8.2	10.6			
1991 1992	14.1 8.9	4.7 7.6	7.3 8.0	3.4 2.5	12.2 8.7	5.2 3.8			
1993	9.7	4.1	5.8	-0.4	5.6	1.0			
1994	9.2	1.5	3.8	2.5	5.5	3.2			
1995	5.4	7.6	6.9	2.6	-1.6	1.6			
1996	0.4	6.7	4.7	0.1	-6.0	-1.3			
1997	-0.4	-6.3	-4.5	4.8	2.0	4.1			
1998	5.6	7.8	7.1	8.5	14.7	9.9			
1999	7.7	9.8	9.1	12.9	-0.1	10.0			
2000	16.1	11.3	12.8	5.4	12.9	7.0			
2001	14.3	5.7	8.4	7.3	6.0	7.0			
2002	12.0	12.7	12.5	6.7	8.1	7.0			
2003	9.8	9.2	9.4	5.4	11.5	6.7			
2004	4.9	5.0	5.0	2.4	5.7	3.1			
2005 f	4.2	4.1	4.1	3.0	3.9	3.2			
2006 f	13.2	1.2	5.2	4.0	1.9	3.5			
20001				4.0	1.5	0.0			
-	(percent	age share of total d	rug expenditure)						
1985	15.9	84.1	100.0						
1986	23.4	76.6	100.0						
1987	24.3	75.7	100.0						
1988	24.9	75.1	100.0						
1989	25.8	74.2	100.0						
1990	27.5	72.5	100.0						
1991	29.2	70.8	100.0						
1992 1993	29.5 30.6	70.5 69.4	100.0 100.0						
1993 1994	30.6	67.8	100.0						
1995	31.7	68.3 69.6	100.0						
1996 1997	30.4 31.7	69.6 68.3	100.0 100.0						
1998	31.3	68.7	100.0						
1999	30.9	69.1	100.0						
2000			100.0						
2000 2001	31.8 33.5	68.2 66.5	100.0						
2001 2002	33.5	66.7	100.0						
2002	33.4	66.6	100.0						
2004	33.4	66.6	100.0						
			100.0						
2005 f	33.5	66.5							
2006 f	36.0	64.0	100.0						
									-
-Forecast								S	ource: CIHI, 2006

Table B.1.2—Part 1 Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Newfoundland, 1985 to 2006 Prescribed Drugs Prescribed Drugs

			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
	Provincial	Federal _	Social Secu WCB	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year				Funds		(\$ per	capita)			Drugs		
1985	31.05	3.94	0.24		35.23			142.89	178.12			42.96
1986 1987	37.19 43.00	4.77 5.42	0.32 0.44		42.28 48.86			89.58 95.77	131.86 144.63			48.89 56.82
1988	49.00	2.82	0.44		52.48			102.08	154.56			56.25
1989	54.05	2.25	0.75		57.04			108.52	165.56			55.53
1990	61.11	2.72	1.03		64.87			111.92	176.79			59.30
1991	69.56	2.97	1.30		73.83			113.48	187.30			65.26
1992	75.61	2.87	1.82		80.30			125.66	205.95	35.54	30.94	
1993 1994	82.36 90.69	3.77 4.28	1.99 2.15		88.12 97.12			131.28 135.64	219.40 232.75	37.46 37.45	31.30 31.86	
1995 1996	96.05 97.36	4.86 4.80	2.67 3.22		103.58 105.37			150.89 160.78	254.47 266.15	37.31 41.49	35.02 39.17	
1990	97.30	6.00	3.38		106.67			159.58	266.25	35.98	39.17	
1998	103.81	6.76	4.43		115.01			173.46	288.47	40.43	38.93	
1999	112.49	7.67	5.20		125.36			193.70	319.07	45.06	42.18	87.25
2000	128.84	10.90	7.24		146.98			226.98	373.96	46.85	42.00	88.85
2001	149.21	12.73	7.97		169.91			247.46	417.37	47.04	43.21	90.26
2002	167.25	14.32	9.63		191.20			289.07	480.27	49.13	44.35	93.48
2003 2004	185.26 196.65	15.54 15.11	9.48 9.38		210.28 221.14			325.95 344.80	536.22 565.94	49.22 51.06	43.26 44.57	92.48 95.63
2005 f	205.75	15.53	9.83		231.11			362.33	593.44	53.76	43.38	97.14
2006 f	236.23	15.90	9.93		262.06			369.28	631.34	51.12	45.28	96.40
						(annual percer	itage change)					
1985												
1986	19.8	21.0	36.2		20.0			-37.3	-26.0			13.8
1987	15.6	13.7	34.7		15.6			6.9	9.7			16.2
1988 1989	14.0 10.3	-48.0 -20.4	50.0 14.2		7.4 8.7			6.6 6.3	6.9 7.1			-1.0 -1.3
1990 1991	13.1 13.8	21.2 9.3	38.3 25.2		13.7 13.8			3.1 1.4	6.8 5.9			6.8 10.0
1992	8.7	-3.5	40.4		8.8			10.7	10.0			1.9
1993	8.9	31.4	9.3		9.7			4.5	6.5	5.4	1.2	3.4
1994	10.1	13.4	8.4		10.2			3.3	6.1	0.0	1.8	0.8
1995	5.9	13.7	24.1		6.7			11.2	9.3	-0.4	9.9	
1996	1.4	-1.3	20.4		1.7			6.6	4.6	11.2	11.8	
1997 1998	-0.1 6.7	25.0 12.8	5.1 31.2		1.2 7.8			-0.7 8.7	0.0 8.3	-13.3 12.4	-12.6 13.8	
1999	8.4	13.4	17.4		9.0			11.7	10.6	11.5	8.3	
2000	14.5	42.2	39.1		17.2			17.2	17.2	4.0	-0.4	1.8
2000	14.5	42.2	10.1		15.6			9.0	11.6	4.0	-0.4	
2002	12.1	12.5	20.8		12.5			16.8	15.1	4.4	2.6	
2003	10.8	8.5	-1.6		10.0			12.8	11.7	0.2	-2.5	-1.1
2004	6.2	-2.8	-1.0		5.2			5.8	5.5	3.7	3.0	3.4
2005 f	4.6	2.7	4.8		4.5			5.1	4.9	5.3	-2.7	1.6
2006 f	14.8	2.4	1.0		13.4			1.9	6.4	-4.9	4.4	-0.8
2000 1	14.0	2.4	1.0		annual percentage					4.0		0.0
1985												
1986	17.0	18.2	33.4		17.2			-40.1	-28.8			11.0
1987	10.9	9.0	29.9		10.8			2.2	4.9			11.5
1988 1989	9.4 5.7	-52.5 -25.0	45.5 9.6		2.9 4.1			2.1 1.7	2.3 2.6			-5.5 -5.8
1990 1991	10.0 11.1	18.2 6.6	35.3 22.4		10.7 11.1			0.1 -1.4	3.8 3.2			3.8 7.3
1992	7.4	-4.8	39.1		7.5			-1.4	8.7			0.6
1993	7.5	29.9	7.8		8.3			3.0	5.1	4.0	-0.3	
1994	9.0	12.3	7.3		9.1			2.2	5.0	-1.1	0.7	-0.3
1995	3.6	11.4	21.7		4.3			8.9	7.0	-2.7	7.6	2.0
1996	-0.3	-3.0	18.7		0.1			4.9	2.9	9.6	10.2	
1997	-1.1	24.0	4.1		0.2			-1.7	-1.0	-14.3	-13.6	
1998 1999	7.1 6.6	13.2 11.6	31.7 15.6		8.3 7.2			9.1 9.9	8.8 8.8	12.8 9.7	14.2 6.5	
2000 2001	10.4 14.5	38.1 15.4	35.0 8.8		13.1 14.2			13.1 7.7	13.1 10.3	-0.1 -0.9	-4.5 1.5	
2001 2002	14.5	15.4	8.8		14.2			15.8	10.3	-0.9	1.5	
2003	7.9	5.6	-4.5		7.1			9.9	8.8	-2.7	-5.4	-4.0
2004	3.5	-5.5	-3.7		2.5			3.1	2.8	1.0	0.3	0.7
2005 f	2.0	0.1	2.2		1.9			2.4	2.2	2.6	-5.3	-1.1
2006 f	13.2	0.8	-0.7		11.8			0.3	4.8	-6.5	2.8	-2.4
	2	0.0	0.7					0.0		0.0	2.0	
–Forecast												

Total Health Expenditures, Newfoundland, 1985 to 2006 (continued) GDP Implicit All Drugs Health Expenditure Price Index - Canada Public Private Total Public Private Total (\$ per capita) (1997 = 100)Yea 1985 221.08 1,356.50 73.6 35.23 185.85 1,016.34 340.16 1986 42.28 138.46 180.75 1.115.18 294.15 1,409.34 75.6 48.86 201.45 326.89 1,532.79 1987 152.59 1,205.91 79.2 1988 52.48 158.33 210.81 1,276.14 342.81 1,618.95 82.8 1989 57.04 164.05 221.09 1,366.63 353.75 1,720.39 86.6 1990 64.87 171.22 236.09 1,515.29 381.55 1,896.84 89.2 1991 73.83 178 73 252 56 1 562 86 427 13 1 989 99 91.6 80.30 192.14 272.44 1,600.38 463.99 2,064.37 92.8 1992 1993 88.12 200.04 288.16 1,594.84 489.99 2,084.83 94.1 1994 97.12 204.95 302.06 1,650.45 521.82 2,172.27 95.2 1995 103.58 223.22 326.80 519.99 2.234.86 97.4 1.714.87 1996 105.37 241.44 346.81 1,740.60 495.64 2.236.23 99.0 1997 106.67 229.78 336.45 1,852.68 513.46 2,366.13 100.0 1998 115.01 252.83 367.84 2,051.73 601.01 2.652.73 99.6 406.32 2,344.87 607.50 2,952.37 1999 125.36 280.95 101.4 146.98 315.83 462.81 2.497.29 692.87 3,190,16 105.5 2000 507.63 2,711.82 742.63 3,454.45 2001 169.91 337.72 106.9 2002 191.20 382.55 573.75 2,907.60 806.55 3,714.15 108.0 210.28 3,971.62 2003 418.43 628.71 3,071.00 900.61 111.1 2004 221.14 440.43 661.57 3,151.75 954.09 4,105.84 114.1 2005 f 231.11 459.47 690.58 3,254.33 993.43 4,247.76 117.2 2006 f 262.06 465 69 727 74 3 388 71 1 013 72 4 402 43 119.0 (annual percentage change) 1985 -25.5 1986 20.0 -18.2 9.7 -13.5 3.9 2.8 10.2 11.5 1987 15.6 11.1 8.8 4.7 8.1 1988 7.4 3.8 4.6 5.8 4.9 5.6 4.5 1989 8.7 3.6 4.9 7.1 3.2 6.3 4.6 1990 13.7 4.4 6.8 10.9 7.9 10.3 3.0 1991 13.8 4.4 7.0 3.1 11.9 4.9 2.8 1992 8.8 7.5 2.4 3.7 1.3 7.9 8.6 1.0 4.2 1993 97 4.1 5.8 -0.3 5.6 1.4 2.5 4.8 10.2 1994 3.5 6.5 1.1 1995 6.7 8.9 8.2 3.9 -0.4 2.9 2.3 1996 8.2 -4.7 0.1 1.7 6.1 1.5 1.7 1997 1.2 -4.8 -3.0 6.4 3.6 5.8 1.0 1998 7.8 10.0 9.3 10.7 17.1 12.1 -0.4 9.0 10.5 1.1 11.3 1.8 1999 11.1 14.3 2000 17.2 12.4 13.9 6.5 14.1 8.1 4.1 2001 15.6 6.9 9.7 8.6 7.2 8.3 1.4 2002 12.5 13.3 13.0 7.2 8.6 7.5 1.0 2003 10.0 9.4 9.6 5.6 11.7 6.9 2.9 2004 5.2 5.3 5.2 2.6 5.9 3.4 2.7 2005 f 4.5 4.3 4.4 3.3 4.1 3.5 2.7 2006 f 13.4 1.4 5.4 4.1 2.0 3.6 1.6 (annual pe entage change in excess of inflation in the Ca dia my) 1985 1986 172 -28.3 -21 0 6.9 -16.3 1.1 4.0 3.4 1987 10.8 5.5 6.7 6.4 1988 2.9 -0.8 0.1 1.3 0.4 1.1 1989 4.1 -1.0 0.3 2.5 -1.4 1.7 7.2 1990 10.7 1.3 3.8 7.9 4.8 1991 11.1 1.6 4.2 0.4 9.2 2.2 6.2 6.6 7.4 2.5 1992 7.5 1.1 1993 8.3 2.7 4.3 -1.8 4.2 -0.4 1994 9.1 1.4 3.7 2.4 5.4 3.1 1995 4.3 -27 0.5 6.6 5.9 16 6.5 1996 0.1 4.5 -0.2 -6.4 -1.6 1997 0.2 -5.8 -4.0 5.4 2.6 4.8 17.5 1998 8.3 10.5 9.8 11.2 12.6 1999 7.2 8.7 12.5 -0.7 9.5 9.3 2000 13.1 8.3 9.8 2.4 10.0 4.0 2001 14.2 8.3 7.2 6.9 5.6 5.8 6.5 4.0 2002 11.5 12.3 12.0 6.2 7.6 6.5 6.7 2.7 2003 7.1 8.8 2004 2.5 2.6 2.5 -0.1 3.2 0.7 2005 f 1.7 0.8 1.9 1.7 0.6 1.5 2006 f 11.8 -0.3 3.8 2.5 0.4 2.0

Table B.1.2—Part 2 Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and

Source: CIHI, 2006

-Forecast

Table B.2.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2006

-			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
-	Provincial	Federal _	Social Security WCB In	Drug surance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
_				Funds		(\$ mi	lions)			Drugs		
	1.7	0.8	0.0		2.5			19.5	22.0			10.7
	2.1 3.5	0.9 1.0	0.1 0.1		3.1 4.6			12.9 10.2	16.0 14.7			12.1 14.0
	4.6	0.6	0.1		5.3			12.4	17.7			11.8
	5.5	0.5	0.1		6.0			15.0	21.0			9.9
	6.5	0.6	0.1		7.3			18.0	25.3			10.6
	7.4	0.7	0.1		8.2			17.1	25.3			13.5
	7.6 7.5	0.7 0.8	0.4 0.3		8.6 8.6			18.8 21.8	27.5 30.5	8.6 9.0	7.8 8.4	16.4 17.4
	7.7	0.9	0.3		8.9			23.8	32.8	8.8	8.7	17.6
	8.5	1.0	0.4		9.8			28.4	38.3	8.2	8.3	16.5
	8.5	1.0	0.4		9.8			29.7	39.5	6.5	6.3	12.5
	9.1	1.0	0.4		10.6			28.8	39.4	6.8	6.9	13.
	10.4 12.0	1.2 1.4	0.5 0.6		12.2 13.9			33.0 33.6	45.1 47.6	8.3 8.7	8.5 8.5	16.1 17.2
	14.0 15.7	2.3 2.7	0.7 0.8		17.0 19.1			36.0 43.0	53.0 62.2	8.4 9.3	8.0 8.4	16.4 17.3
	16.9	2.7	0.7		20.3			38.1	58.4	10.0	9.0	19.0
	18.4	2.9	0.7		22.0			43.7	65.7	10.2	9.0	
	19.9	2.9	0.7		23.4			47.8	71.2	10.3	8.9	19.2
	21.9	3.2	0.7		25.8			48.8	74.6	9.8	8.4	18.2
	23.9	3.6	0.8		28.3			49.3	77.5	9.0	8.3	17.3
-						(annual percer	ntage change)					
	27.8	16.1	44.0		24.4			-34.1	-27.5			13.2
	63.7 32.4	12.6 -40.9	39.7 20.2		48.5 16.1			-21.0 21.5	-7.6 19.8			16.0 -16.1
	17.9	-17.4	0.9		13.7			21.5	19.1			-16.1
	19.8	30.7	20.5		20.7			19.8	20.1			7.5
	13.5	7.0	-0.4		12.7			-4.7	0.3			27.3
	2.5	-4.5	218.0		5.2			10.0	8.5			21.5
	-1.7 2.8	24.8 12.0	-13.7 -1.5		-0.3 3.5			15.9 9.2	10.8 7.6	4.9 -2.0	7.8 3.7	6.3 0.7
	10.2	8.6	9.8		10.0			19.2	16.7	-7.3	-5.1	-6.2
	0.0	-3.8	4.4		-0.2			4.3	3.2	-20.7	-24.1	-22.4
	7.4	8.3	14.7		7.8			-3.0	-0.3	4.9	9.2	
	14.6 14.7	16.2 14.0	21.0 11.9		15.1 14.5			14.5 2.0	14.6 5.4	21.2 5.8	23.2 0.1	22.: 3.0
	16.8 12.4	66.4 16.8	26.3 4.4		22.1 12.6			7.2 19.4	11.6 17.2	-3.7 10.5	-6.0 5.3	-4.8
	7.7	0.7	-9.4		6.0			-11.5	-6.1	7.8	7.2	
	9.2	6.4	-1.6		8.4			14.8	12.6	1.5	-0.1	0.1
	7.7	0.4	-2.8		6.5			9.3	8.3	1.1	-0.6	0.3
	10.2	11.6	7.6		10.3			2.2	4.9	-4.2	-6.4	-5.2
	9.3	11.3	7.2		9.4			0.9	3.9	-9.1	-0.4	-5.1
-					(per	centage share of t	otal drug expe	enditure)				
	5.1	2.3	0.1		7.6			59.7	67.3			32.
	7.6 12.1	3.2 3.5	0.2 0.3		11.0 15.9			45.9 35.3	56.9 51.3			43.1 48.1
	15.7	2.0	0.3		18.1			42.0	60.0			40.0
	17.6	1.6	0.3		19.6			48.5	68.1			31.9
	18.2	1.8	0.3		20.3			50.1	70.4			29.6
	19.1	1.8	0.3		21.2			44.1	65.2			34.8
	17.3	1.5	0.9 0.7		19.7			42.9	62.6 63.6	19.6	17.8	37.4 36.4
	15.6 15.3	1.7 1.8	0.7		18.0 17.7			45.6 47.4	65.1	18.8 17.5	17.6 17.3	30.4
			0.7		17.9			52.0	69.9			
	15.5 16.2	1.8 1.8	0.7		17.9			52.0 56.8	75.5	15.0 12.4	15.1 12.0	30. 24.
	17.1	2.0	0.8		19.9			54.3	74.2	12.8	13.0	25.8
	16.9 18.5	1.9 2.1	0.9 0.9		19.7			53.3	73.0	13.3	13.7	27.0 26.0
					21.5			51.9	73.4	13.5	13.1	
	20.1	3.3	1.1		24.5			51.9	76.4	12.1	11.5	23.
	19.7 21.8	3.3 3.5	1.0 0.9		24.0 26.2			53.9 49.2	77.9 75.4	11.6 13.0	10.5 11.6	22. 24.
	21.7	3.4	0.8		25.9			51.5	77.4	12.0	10.6	22.
	22.0	3.2	0.7		25.9			52.8	78.8	11.4	9.9	21.
	23.6	3.5	0.8		27.8			52.6	80.4	10.6	9.0	19.
	25.2	3.8	0.8		29.8			51.9	81.8	9.4	8.8	18.
ast												

Table B.2.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2006 (continued)

		All Drugs			alth Expenditure			ugs in Public, Priva Health Expenditure	
-	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ons)				ercentage share)	
1985	2.5	30.2	32.7	128.3	52.9	181.2	1.9	57.1	18.0
1986 1987	3.1 4.6	25.0 24.2	28.0 28.8	138.0 149.7	49.6 53.3	187.6 202.9	2.2 3.1	50.3 45.4	15.0 14.2
1988	5.3	24.1	29.4	163.0	56.5	219.5	3.3	42.6	13.4
1989	6.0	24.9	30.9	174.4	64.9	239.3	3.5	38.3	12.9
1990 1991	7.3 8.2	28.6 30.6	35.9 38.8	186.3 203.8	70.0 76.8	256.2 280.6	3.9 4.0	40.9 39.9	14.0 13.8
1992	8.6	35.2	43.9	209.2	85.8	295.0	4.1	41.1	14.9
1993 1994	8.6 8.9	39.3 41.4	47.9 50.3	218.2 217.0	93.5 96.3	311.7 313.3	4.0 4.1	42.0 43.0	15.4 16.1
1995 1996	9.8 9.8	44.9 42.4	54.7 52.3	222.8 233.0	104.3 105.8	327.1 338.8	4.4 4.2	43.1 40.1	16.7 15.4
1997	10.6	42.5	53.0	229.9	110.1	340.0	4.6	38.6	15.6
1998 1999	12.2 13.9	49.7 50.8	61.8 64.8	245.5 259.0	113.1 119.0	358.6 378.0	5.0 5.4	43.9 42.7	17.2 17.1
2000	17.0	52.4	69.4	278.1	123.5	401.6	6.1	42.5	17.3
2000	19.1	60.7	79.9	329.0	145.7	474.7	5.8	42.5	16.8
2002	20.3	57.1	77.4	366.8	145.1	511.9	5.5	39.3	15.1
2003 2004	22.0 23.4	62.9 67.0	84.9 90.4	381.0 377.5	159.8 158.6	540.8 536.0	5.8 6.2	39.3 42.2	15.7 16.9
2005 f	25.8	67.0	92.8	397.0	165.1	562.1	6.5	40.6	16.5
2006 f	28.3	66.5	94.8	417.0	169.1	586.1	6.8	39.3	16.2
2000 1	20.3	00.5	(annual percenta		109.1	560.1	0.8	35.3	10.2
1985									
1986	24.4	-17.3	-14.2	7.6	-6.3	3.5			
1987 1988	48.5 16.1	-3.1 -0.3	2.6 2.3	8.5 8.9	7.4 6.2	8.2 8.2			
1989	13.7	3.1	5.0	7.0	14.8	9.0			
1990	20.7	14.9	16.0	6.8	7.7	7.0			
1991	12.7	7.2	8.3	9.4	9.8	9.5			
1992 1993	5.2 -0.3	15.1 11.4	13.0 9.1	2.7 4.3	11.6 9.0	5.1 5.7			
1994	3.5	5.4	5.1	-0.6	3.0	0.5			
1995	10.0	8.4	8.7	2.7	8.3	4.4			
1996 1997	-0.2 7.8	-5.5 0.0	-4.5 1.5	4.6 -1.3	1.4 4.1	3.6 0.4			
1998	15.1	17.0	16.6	6.8	2.7	5.5			
1999	14.5	2.3	4.7	5.5	5.2	5.4			
2000	22.1	3.1	7.2	7.4	3.8	6.2			
2001 2002	12.6 6.0	15.8 -6.0	15.0 -3.1	18.3 11.5	18.0 -0.4	18.2 7.8			
2003	8.4	10.1	9.7	3.9	10.1	5.7			
2004	6.5	6.5	6.5	-0.9	-0.8	-0.9			
2005 f	10.3	0.1	2.7	5.2	4.1	4.9			
2006 f	9.4	-0.7	2.1	5.0	2.4	4.3			
-	(percentag	je share of total drug	g expenditure)						
1985	7.6	92.4	100.0						
1986 1987	11.0 15.9	89.0 84.1	100.0 100.0						
1988	18.1	81.9	100.0						
1989	19.6	80.4	100.0						
1990 1991	20.3 21.2	79.7 78.8	100.0 100.0						
1992	19.7	80.3	100.0						
1993	18.0	82.0	100.0						
1994	17.7	82.3	100.0						
1995 1996	17.9 18.8	82.1 81.2	100.0 100.0						
1997	19.9	80.1	100.0						
1998 1999	19.7 21.5	80.3 78.5	100.0 100.0						
2000 2001	24.5 24.0	75.5 76.0	100.0 100.0						
2002	26.2	73.8	100.0						
2003 2004	25.9 25.9	74.1 74.1	100.0 100.0						
2004 2005 f	23.3	74.1	100.0						
2006 f	29.8	70.2	100.0						
									urce: CIHI, 2006.

Table B.2.2—Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2006

			Public		Prescribe	ed Drugs	Drivete				Prescribed D	0
	Provincial	Federal _	Social Secur WCB	ity Funds Drug Insurance	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Po Personal Health Supplies	<u>cket)</u> Total Non-Presc. Drugs
ear				Funds		(\$ per	capita)			Drugs		
985	13.08	6.01	0.33		19.42			152.95	172.37			83.63
986	16.61	6.94	0.47		24.02			100.25	124.27			94.14
987	27.17	7.80	0.66		35.62			79.09	114.72			109.04
988 989	35.77 41.92	4.59 3.77	0.79 0.79		41.15 46.48			95.54 115.34	136.69 161.82			90.98 75.80
990	50.03	4.91	0.95		55.88			137.70	193.59			81.2
991 992	56.89 58.12	5.26 5.01	0.94 2.99		63.09 66.12			131.41 144.08	194.50 210.20	65.73	 59.68	103.6 125.4
993	56.53	6.18	2.56		65.27			165.28	230.55	68.24	63.70	131.9
994	57.56	6.86	2.49		66.91			178.75	245.65	66.21	65.44	131.6
995	62.95	7.39	2.72		73.06			211.56	284.62	60.91	61.67	122.5
996	62.35	7.04	2.81		72.20			218.51	290.71	47.84	46.35	94.1
997	66.82	7.61	3.21		77.64			211.50	289.13	50.05	50.46	100.5
998	76.76	8.86	3.90		89.52			242.67	332.19	60.77	62.32	123.0
999	87.75	10.07	4.35		102.17			246.71	348.88	64.10	62.19	126.2
000	102.36	16.74	5.48		124.58			264.09	388.67	61.64	58.37	120.0
001 002	114.85 123.41	19.53 19.63	5.72 5.17		140.10 148.21			314.79 278.01	454.89 426.22	68.03 73.20	61.36 65.64	129.3 138.8
002	134.37	20.82	5.08		160.27			318.39	478.65	73.20	65.37	139.4
004	144.18	20.83	4.91		169.92			346.45	516.37	74.56	64.73	139.2
005 f	158.65	23.19	5.28		187.13			353.34	540.46	71.27	60.50	131.7
006 f	172.60	25.71	5.63		203.94			355.12	559.06	64.53	60.00	124.5
						(annual percer	ntage change)					
985												
986	27.0	15.4	43.2		23.7			-34.5	-27.9			12.0
987	63.5	12.4	39.5		48.3			-21.1	-7.7			15.
988 989	31.7 17.2	-41.2 -17.9	19.5 0.3		15.5 13.0			20.8 20.7	19.2 18.4			-16. -16.
990	19.3	30.2	20.1		20.2			19.4	19.6			7. 27.
991 992	13.7 2.2	7.2 -4.8	-0.2 216.8		12.9 4.8			-4.6 9.6	0.5 8.1			27.
993	-2.7	23.5	-14.6		-1.3			14.7	9.7	3.8	6.7	5.3
994	1.8	10.9	-2.4		2.5			8.1	6.6	-3.0	2.7	-0.2
995	9.4	7.8	9.0		9.2			18.4	15.9	-8.0	-5.8	-6.9
996	-0.9	-4.7	3.4		-1.2			3.3	2.1	-21.5	-24.8	-23.2
997 998	7.2 14.9	8.0 16.5	14.4 21.3		7.5 15.3			-3.2 14.7	-0.5 14.9	4.6 21.4	8.9 23.5	6.
999	14.9	13.6	11.5		14.1			1.7	5.0	5.5	-0.2	22.
000	16.7	66.2	26.2		21.9			7.0	11.4	-3.8	-6.1	
D00 D01	10.7	16.7	4.3		12.5			19.2	17.0	-3.8	-6.1	-5.0
002	7.5	0.5	-9.6		5.8			-11.7	-6.3	7.6	7.0	7.3
003	8.9	6.1	-1.8		8.1			14.5	12.3	1.2	-0.4	0.4
004	7.3	0.0	-3.2		6.0			8.8	7.9	0.7	-1.0	-0.
005 f	10.0	11.4	7.4		10.1			2.0	4.7	-4.4	-6.5	-5.4
006 f	8.8	10.8	6.7		9.0			0.5	3.4	-9.5	-0.8	-5.
					(annual percentage	change in excess	of inflation in	the Canadian e	conomy)			
985												
986 987	24.2 58.8	12.6 7.7	40.4 34.8		20.9 43.6			-37.3 -25.8	-30.7 -12.4			9.1 11.1
988	27.2	-45.7	15.0		11.0			16.3	14.6			-21.
989	12.6	-22.4	-4.3		8.4			16.2	13.8			-21.
990	16.3	27.2	17.1		17.2			16.4	16.6			4.
991	10.9	4.4	-3.0		10.1			-7.3	-2.3			24.
992	0.9	-6.1	215.6		3.5			8.4	6.8			19.
993 994	-4.2	22.1	-16.1		-2.7			13.3	8.2	2.4	5.3	3.
	0.7	9.8	-3.5		1.4			7.0	5.5	-4.1	1.6	-1.
995	7.0	5.5	6.7		6.9			16.0	13.5	-10.3	-8.1	-9.
996 997	-2.6 6.2	-6.4 7.1	1.7 13.4		-2.8 6.5			1.6 -4.2	0.5 -1.5	-23.1 3.6	-26.5 7.9	-24. 5.
97	15.3	16.9	21.7		15.7			-4.2	15.3	21.9	23.9	5. 22.
99	12.5	11.8	9.7		12.3			-0.1	3.2	3.7	-2.0	0.
00	12.5	62.1	22.1		17.8			2.9	7.3	-7.9	-10.2	-9.
001	10.8	15.3	3.0		11.1			17.8	15.7	9.0	3.8	6.
002	6.5	-0.5	-10.6		4.8			-12.7	-7.3	6.6	6.0	6.
)03)04	6.0 4.6	3.2 -2.7	-4.7 -5.9		5.2 3.3			11.6 6.1	9.4 5.2	-1.7 -2.0	-3.3 -3.7	-2. -2.
005 f	7.4	8.7	4.8		7.5			-0.7	2.0	-7.1	-9.2	-8.
006 f Forecast	7.2	9.2	5.1		7.4			-1.1	1.8	-11.1	-2.4	-7.

		Total He		Hea	alth Expenditure		GDP Implicit Price Index – Canada
-	Public	Private	Total	Public	Private	Total	<u></u>
r _			(\$ per ca	ipita)			(1997 = 100)
5	19.42	236.58	256.00	1,004.74	414.66	1,419.40	73.6
6	24.02	194.39	218.41	1,074.57	386.13	1,460.70	75.6
57	35.62	188.13	223.76	1,164.10	414.24	1,578.34	79.2
18 19	41.15 46.48	186.53 191.20	227.67 237.68	1,260.71 1,340.84	437.42 499.18	1,698.12 1,840.01	82.8 86.6
90	55.88	218.96	274.84	1,426.83	535.91	1,962.74	89.2
91 92	63.09 66.12	235.04 269.50	298.14 335.62	1,563.81 1,599.57	589.69 655.88	2,153.50 2,255.45	91.6 92.8
93	65.27	297.22	362.49	1,651.43	707.51	2,358.94	94.1
94	66.91	310.40	377.30	1,626.43	722.12	2,348.55	95.2
95	73.06	334.14	407.20	1,657.77	775.94	2,433.70	97.4
96	72.20	312.70	384.90	1,716.36	779.25	2,495.61	99.0
97	77.64	312.00	389.64	1,689.18	808.82	2,498.01	100.0
98	89.52	365.75	455.28	1,807.78	832.78	2,640.56	99.6
99	102.17	373.00	475.17	1,900.33	873.12	2,773.45	101.4
00	124.58	384.11	508.69	2,037.89	904.73	2,942.62	105.5
01 02	140.10	444.18	584.28	2,407.05	1,066.30	3,473.35	106.9
02 03	148.21 160.27	416.85 457.83	565.06 618.10	2,678.41 2,775.01	1,059.89 1,164.09	3,738.29 3,939.11	108.0 111.1
04	169.92	485.74	655.66	2,737.95	1,150.26	3,888.21	114.1
05 f	187.13	485.11	672.24	2,874.29	1,195.68	4,069.97	117.2
16 f	203.94	479.65	683.59	3,006.37	1,218.97	4,225.34	119.0
-				nnual percentage change			
85 86				 7.0		2.9	
87	23.7 48.3	-17.8	-14.7 2.4	8.3	7.3	8.1	2.8 4.7
88	15.5	-0.9	1.7	8.3	5.6	7.6	4.5
89	13.0	2.5	4.4	6.4	14.1	8.4	4.6
90	20.2	14.5	15.6	6.4	7.4	6.7	3.0
91	12.9	7.3	8.5	9.6	10.0	9.7	2.8
92	4.8	14.7	12.6	2.3	11.2	4.7	1.3
93	-1.3	10.3	8.0	3.2	7.9	4.6	1.4
94	2.5	4.4	4.1	-1.5	2.1	-0.4	1.1
95	9.2	7.6	7.9	1.9	7.5	3.6	2.3
96 07	-1.2	-6.4	-5.5	3.5	0.4	2.5	1.7
97 98	7.5 15.3	-0.2 17.2	1.2 16.8	-1.6 7.0	3.8 3.0	0.1 5.7	1.0 -0.4
99	14.1	2.0	4.4	5.1	4.8	5.0	1.8
00	21.9	3.0	7.1	7.2	3.6	6.1	4.1
01	12.5	15.6	14.9	18.1	17.9	18.0	1.4
02	5.8	-6.2	-3.3	11.3	-0.6	7.6	1.0
03	8.1	9.8	9.4	3.6	9.8	5.4	2.9
04	6.0	6.1	6.1	-1.3	-1.2	-1.3	2.7
05 f	10.1	-0.1	2.5	5.0	3.9	4.7	2.7
06 f	9.0	-1.1	1.7	4.6	1.9	3.8	1.6
001	3.0			inflation in the Canadian		5.0	1.0
85							
85 86	20.9			 4.1	 -9.7	 0.1	
87	43.6	-8.0	-2.3	3.6	2.5	3.3	
88	11.0	-5.4	-2.8	3.8	1.1	3.1	
89	8.4	-2.1	-0.2	1.8	9.6	3.8	
90	17.2	11.5	12.6	3.4	4.3	3.6	
91	10.1	4.6	5.7	6.8	7.3	7.0	
92 93	3.5	13.4	11.3	1.0	10.0	3.5	
93 94	-2.7 1.4	8.8 3.3	6.6 3.0	1.8 -2.6	6.4 1.0	3.1 -1.5	
95 96	6.9 -2.8	5.3 -8.1	5.6 -7.1	-0.4 1.9	5.1 -1.2	1.3 0.9	
96 97	-2.8 6.5	-8.1 -1.2	-7.1	-2.6	-1.2 2.8	-0.9	
98	15.7	17.7	17.3	7.5	3.4	6.1	
99	12.3	0.2	2.6	3.3	3.0	3.2	
00	17.8	-1.1	3.0	3.1	-0.5	2.0	
01	11.1	14.3	13.5	16.8	16.5	16.7	
02	4.8	-7.2	-4.3	10.3	-1.6	6.6	
03	5.2	6.9	6.5	0.7	6.9	2.5	
04	3.3	3.4	3.4	-4.0	-3.9	-4.0	
05 f	7.5	-2.8	-0.1	2.3	1.3	2.0	
					0.0	2.2	
6 f	7.4	-2.7	0.1	3.0	0.3	2.2	

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and

Source: CIHI, 2006.

Table B.2.2–Part 2

Table B.3.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Secur WCB	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year				Funds		(\$ mil	lions)			Drugs		
1985	45.5	2.3	0.2		48.0			38.7	86.7			61.1
1986	53.1	2.4	0.2		55.7			59.6	115.3			69.2
1987 1988	62.3 72.2	2.6 3.4	0.2 0.3		65.1 76.0			67.7 74.8	132.8 150.8			80.2 78.9
1989	82.1	4.2	0.3		86.6			82.5	169.1			77.7
1990	83.0	5.0	0.3		88.3			96.0	184.2			79.3
1991	83.0	5.6	0.5		89.1			106.2	195.3			80.6
1992	89.0	5.9	0.5		95.4			118.4	213.8	48.7	44.3	
1993 1994	88.5 83.2	6.8 7.3	0.6 0.6		95.9 91.1			132.7 137.8	228.6 228.9	51.3 49.9	47.9 49.3	
1995	83.9	8.9	0.7		93.5			148.7	242.2	45.9	46.5	
1995	83.3	8.4	0.7		93.5			148.7	242.2	45.9 51.6	46.5	
1997	86.8	9.8	0.7		97.3			170.5	267.9	47.0	47.4	94.3
1998	99.5	14.4	0.8		114.7			198.7	313.4	52.4	53.7	106.1
1999	110.7	14.8	1.1		126.5			201.5	328.0	53.1	51.5	
2000 2001	117.3	18.8	1.4		137.4			227.3 247.5	364.7 400.4	52.9	50.1	103.0 110.5
2001 2002	128.7 140.8	22.3 24.2	1.9 2.2		152.9 167.2			247.5	449.5	58.1 62.3	52.4 55.9	
2003	156.2	25.9	2.5		184.6			299.5	484.1	65.9	58.1	124.0
2004	170.0	26.4	3.0		199.4			324.5	523.9	69.2	60.0	129.2
2005 f	190.9	28.6	3.4		222.9			347.8	570.7	69.3	58.8	128.1
2006 f	218.2	31.7	3.8		253.6			366.4	620.0	68.7	59.8	128.5
						(annual percer	itage change)					
1985 1986	 16.7	3.8	 16.4		 16.1			 54.0	33.0			 13.2
1987	17.2	8.3	4.2		16.8			13.6	15.1			16.0
1988	16.0	32.7	48.7		16.8			10.4	13.5			-1.6
1989	13.7	21.9	-7.8		14.0			10.4	12.2			-1.6
1990	1.0	20.1	6.4		1.9			16.3	8.9			2.1
1991 1992	0.1 7.2	12.4 5.3	41.5 2.6		0.9 7.1			10.6 11.5	6.0 9.5			1.7 15.4
1992	-0.5	15.4	2.0		0.6			11.5	6.9	5.2	8.1	6.6
1994	-6.0	6.6	6.1		-5.0			3.9	0.1	-2.7	3.0	
1995	0.8	21.6	15.7		2.6			7.9	5.8	-7.9	-5.7	-6.8
1996	-0.7	-5.0	5.2		-1.1			7.2	4.0	12.5	7.7	
1997 1998	4.2 14.5	16.2 47.4	-1.0 16.2		5.3 17.9			7.0 16.5	6.4 17.0	-9.1 11.5	-5.4 13.4	-7.2 12.4
1999	11.3	2.5	27.0		10.3			1.4	4.7	1.3	-4.1	-1.5
2000	5.9	27.1	28.6		8.6			12.8	11.2	-0.3	-2.7	-1.5
2001	9.8	18.6	39.0		11.3			8.9	9.8	9.8	4.6	7.3
2002 2003	9.4 10.9	8.6	18.0 12.3		9.4 10.4			14.0 6.1	12.2	7.2 5.7	6.6	
2003	8.8	7.0 2.0	12.3		8.0			8.4	7.7 8.2	5.0	4.0 3.3	
2005 f	12.3	8.4	12.0		11.8			7.2	8.9	0.2	-2.1	-0.9
2006 f	14.3	10.6	13.2		13.8			5.3	8.6	-0.8	1.7	
					(per	centage share of t	otal drug expe	enditure)				
1985	30.8	1.5	0.1		32.5			26.2	58.7			41.3
1986 1987	28.8 29.2	1.3 1.2	0.1 0.1		30.2 30.5			32.3 31.8	62.5 62.3			37.5 37.7
1988	31.5	1.5	0.1		33.1			32.5	65.6			34.4
1989	33.3	1.7	0.1		35.1			33.4	68.5			31.5
1990	31.5	1.9	0.1		33.5			36.4	69.9			30.1
1991	30.1	2.0	0.2		32.3			38.5	70.8			29.2
1992 1993	29.0 27.0	1.9 2.1	0.2 0.2		31.1 29.3			38.6 40.5	69.7 69.8	15.9 15.6	14.4 14.6	30.3 30.2
1994	25.4	2.2	0.2		27.8			42.0	69.8	15.2	15.0	
1995	25.1	2.6	0.2		27.9			44.5	72.4	13.7	13.9	27.6
1996	23.6	2.4	0.2		26.2			45.1	71.2	14.6	14.2	28.8
1997	24.0	2.7	0.2		26.9			47.1	74.0	13.0	13.1	26.0
1998 1999	23.7 25.6	3.4 3.4	0.2 0.2		27.4 29.3			47.4 46.6	74.7 75.8	12.5 12.3	12.8 11.9	25.3 24.2
2000 2001	25.1 25.2	4.0 4.4	0.3 0.4		29.4 29.9			48.6 48.5	78.0 78.4	11.3 11.4	10.7 10.3	
2002	24.8	4.3	0.4		29.5			49.7	79.2	11.0	9.8	20.8
2003	25.7	4.3	0.4		30.4			49.3	79.6	10.8	9.6	
2004	26.0	4.0	0.5		30.5			49.7	80.2	10.6	9.2	
2005 f	27.3	4.1	0.5		31.9			49.8	81.7	9.9	8.4	
2006 f f-Forecast	29.1	4.2	0.5		33.9			48.9	82.8	9.2	8.0	17.2
			cial-level insuran									ce: CIHI, 2006

Table B.3.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2006 (continued)

		ll Drugs			h Expenditure			Ith Expenditures	
		Private	Total	Public	Private	Total		Private	Total
Year			(\$ millio	ns)			(perce	ntage share)	
1985	48.0	99.8	147.8	947.2	285.3	1,232.5	5.1	35.0	12.0
1986 1987	55.7 65.1	128.8 147.9	184.5 213.0	1,023.2 1,165.5	353.7 395.0	1,376.9 1,560.6	5.4 5.6	36.4 37.4	13.4 13.6
1988	76.0	153.7	229.7	1,165.0	420.3	1,585.2	6.5	36.6	14.5
1989	86.6	160.2	246.8	1,281.5	470.3	1,751.8	6.8	34.1	14.1
1990	88.3	175.3	263.5	1,376.6	490.4	1,866.9	6.4	35.7	14.1
1991 1992	89.1 95.4	186.8 211.4	275.9 306.8	1,451.2 1,477.0	518.8 554.5	1,970.0 2,031.6	6.1	36.0 38.1	14.0 15.1
1992	95.9	231.8	306.8	1,445.5	579.5	2,025.0	6.5 6.6	40.0	16.2
1994	91.1	237.0	328.1	1,413.1	608.3	2,021.4	6.4	39.0	16.2
1995	93.5	241.1	334.6	1,440.0	619.4	2,059.4	6.5	38.9	16.2
1996	92.5	261.1	353.5	1,438.2	648.6	2,086.9	6.4	40.2	16.9
1997 1998	97.3 114.7	264.9 304.7	362.2 419.5	1,669.3 1,786.8	692.3 755.1	2,361.6 2,541.9	5.8 6.4	38.3 40.4	15.3 16.5
1999	126.5	306.0	432.5	1,899.7	764.0	2,663.7	6.7	40.1	16.2
2000	137.4	330.3	467.7	1,968.4	843.4	2,811.8	7.0	39.2	16.6
2001	152.9	358.0	510.9	2,082.7	913.9	2,996.6	7.3	39.2	17.0
2002 2003	167.2 184.6	400.4 423.5	567.6 608.1	2,269.5 2,491.3	1,032.4 1,111.9	3,301.9 3,603.1	7.4 7.4	38.8 38.1	17.2 16.9
2004	199.4	453.7	653.1	2,594.4	1,131.3	3,725.7	7.7	40.1	17.5
2005 f	222.9	475.9	698.8	2,830.5	1,179.0	4,009.5	7.9	40.4	17.4
2006 f	253.6	494.9	748.5	3,071.1	1,232.7	4,303.7	8.3	40.1	17.4
20001	20010	10110	(annual percenta		1,202.7	1,00017	0.0	1011	
1985				ge change/					
1985	16.1	29.1	24.9	8.0	24.0	11.7			
1987	16.8	14.9	15.4	13.9	11.7	13.3			
1988 1989	16.8 14.0	3.9 4.2	7.8 7.5	-0.1 10.0	6.4 11.9	1.6 10.5			
1990 1991	1.9 0.9	9.4 6.6	6.8 4.7	7.4 5.4	4.3 5.8	6.6 5.5			
1992	7.1	13.2	11.2	1.8	6.9	3.1			
1993 1994	0.6 -5.0	9.6 2.2	6.8 0.1	-2.1 -2.2	4.5 5.0	-0.3 -0.2			
1995 1996	2.6 -1.1	1.7 8.3	2.0 5.7	1.9 -0.1	1.8 4.7	1.9 1.3			
1997	5.3	1.5	2.5	16.1	6.7	13.2			
1998 1999	17.9 10.3	15.1 0.4	15.8 3.1	7.0 6.3	9.1 1.2	7.6 4.8			
2000 2001	8.6 11.3	7.9 8.4	8.1 9.2	3.6 5.8	10.4 8.4	5.6 6.6			
2002	9.4	11.8	11.1	9.0	13.0	10.2			
2003	10.4	5.8	7.1	9.8	7.7	9.1			
2004	8.0	7.1	7.4	4.1	1.7	3.4			
2005 f	11.8	4.9	7.0	9.1	4.2	7.6			
2006 f	13.8	4.0	7.1	8.5	4.6	7.3			
	(percentage sh	nare of total drug e	expenditure)	_					
1985	32.5	67.5	100.0						
1986 1987	30.2 30.5	69.8 69.5	100.0 100.0						
1987 1988	30.5 33.1	69.5 66.9	100.0						
1989	35.1	64.9	100.0						
1990	33.5	66.5	100.0						
1991	32.3	67.7	100.0						
1992 1993	31.1 29.3	68.9 70.7	100.0 100.0						
1994	27.8	72.2	100.0						
1995	27.9	72.1	100.0						
1996	26.2	73.8	100.0						
1997 1998	26.9 27.4	73.1 72.6	100.0 100.0						
1999	29.3	70.7	100.0						
2000	29.4	70.6	100.0						
2001	29.9	70.1	100.0						
2002 2003	29.5 30.4	70.5 69.6	100.0 100.0						
2003 2004	30.4 30.5	69.6 69.5	100.0						
2005 f	31.9	68.1	100.0						
2006 f	33.9	66.1	100.0						
f-Forecast								Sour	ce: CIHI, 2006.

Table B.3.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal	Social Secur WCB	Drug Insurance	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Po Personal Health Supplies	<u>cket)</u> Total Non-Presc. Drugs
Year				Funds		(\$ per	capita)			Drugs		
1985	51.41	2.59	0.21		54.21			43.74	97.94			69.01
1986	59.72	2.67	0.24		62.63			67.05	129.68			77.77
1987 1988	69.69 80.51	2.88 3.81	0.25 0.37		72.82 84.68			75.80 83.31	148.61 167.99			89.77 87.95
1989	90.89	4.61	0.34		95.83			91.30	187.13			85.92
1990 1991	91.20 90.73	5.50 6.14	0.36 0.50		97.05 97.37			105.50 116.04	202.55 213.41			87.16 88.07
1991	96.80	6.44	0.50		103.75			128.74	232.49	53.01	48.13	101.14
1993	95.81	7.39	0.61		103.82			143.56	247.38	55.48	51.79	107.28
1994	89.76	7.86	0.65		98.27			148.69	246.96	53.79	53.16	106.95
1995	90.40	9.54	0.75		100.69			160.23	260.92	49.45	50.07	99.52
996	89.46	9.03	0.78		99.28			171.12	270.39	55.45	53.72	109.17
997	93.13	10.48	0.78		104.39			182.88	287.28	50.37	50.79	101.16
998	106.74	15.46	0.90		123.11			213.19	336.30	56.19	57.63	113.82
1999	118.53	15.82	1.14		135.49			215.75	351.24	56.81	55.12	111.93
2000	125.55	20.11	1.47		147.13			243.42	390.56	56.64	53.64	110.28
2001	138.03	23.89	2.05		163.96			265.49	429.45	62.31	56.20	118.51
2002	150.66	25.89	2.41		178.95			302.01	480.96	66.67 70.35	59.79	126.46
2003 2004	166.82 181.31	27.64 28.17	2.70 3.21		197.16 212.69			319.91 346.18	517.06 558.87	70.35 73.77	62.09 64.04	132.44 137.81
2005 f	203.54	30.51	3.60		237.65			370.88	608.53	73.86	62.70	136.56
2006 f	232.18	33.69	4.06		269.93			389.95	659.88	73.14	63.62	136.76
						(annual percer	(and change)					
1005												
1985 1986	 16.2	3.3	 15.8		 15.5			 53.3	32.4			 12.7
1987	16.7	7.8	3.7		16.3			13.0	14.6			15.4
1988	15.5	32.1	48.1		16.3			9.9	13.0			-2.0
1989	12.9	21.0	-8.5		13.2			9.6	11.4			-2.3
1990	0.3	19.3	5.8		1.3			15.6	8.2			1.4
1991	-0.5	11.7	40.7		0.3			10.0	5.4			1.0
1992	6.7	4.8	2.1		6.5			10.9	8.9			14.8
1993	-1.0	14.8	19.7		0.1			11.5	6.4	4.7	7.6	6.1
1994	-6.3	6.3	5.7		-5.3			3.6	-0.2	-3.1	2.6	-0.3
1995	0.7	21.4	15.6		2.5			7.8	5.7	-8.1	-5.8	-6.9
1996	-1.0	-5.3	4.8		-1.4			6.8	3.6	12.1	7.3	9.7
1997	4.1	16.0	-1.1		5.2			6.9	6.2	-9.2	-5.5	-7.3
1998	14.6	47.5	16.3 26.7		17.9 10.1			16.6	17.1	11.6	13.5	12.5 -1.7
1999	11.0	2.3	20.7		10.1			1.2	4.4	1.1	-4.3	-1.7
2000	5.9	27.1	28.5		8.6			12.8	11.2	-0.3	-2.7	-1.5
2001	9.9	18.8	39.3		11.4			9.1	10.0	10.0	4.8	7.5
2002	9.1	8.4	17.7		9.1			13.8	12.0	7.0	6.4	6.7
2003 2004	10.7 8.7	6.8 1.9	12.1 19.1		10.2 7.9			5.9 8.2	7.5 8.1	5.5 4.9	3.8 3.1	4.7 4.1
	0.7		13.1		7.5				0.1	4.9	3.1	4.1
2005 f	12.3	8.3	12.0		11.7			7.1	8.9	0.1	-2.1	-0.9
2006 f	14.1	10.4	13.0		13.6			5.1	8.4	-1.0	1.5	0.1
				(annual percentage	change in excess	of inflation in	the Canadian e	conomy)			
1985												
1986	13.4	0.5	13.0		12.7			50.5	29.6			9.9
1987	11.9	3.1	-1.0		11.5			8.3	9.9			10.7
1988	11.0	27.6	43.6		11.8			5.4	8.5			-6.5
1989	8.3	16.4	-13.1		8.6			5.0	6.8			-6.9
1990	-2.7	16.3	2.7		-1.8			12.5	5.2			-1.6
1991	-3.3	9.0	37.9		-2.4			7.2	2.6			-1.7
1992	5.4	3.6	0.9		5.3			9.7	7.7			13.6
1993	-2.5	13.4	18.2		-1.4			10.1	5.0	3.2	6.2	4.6
1994	-7.4	5.2	4.6		-6.4			2.5	-1.3	-4.1	1.5	-1.4
1995	-1.6	19.1	13.3		0.1			5.4	3.3	-10.4	-8.2	
1996	-2.7	-7.0	3.1		-3.1			5.1	2.0	10.5	5.6	8.0
1997	3.1	15.1	-2.1		4.2			5.9	5.3	-10.2	-6.5	-8.3
1998 1999	15.0 9.2	48.0 0.5	16.7 24.9		18.4 8.2			17.0 -0.6	17.5 2.6	12.0 -0.7	13.9 -6.2	13.0 -3.5
2000	1.8	23.0	24.4		4.5			8.7	7.1	-4.4	-6.8	-5.6
2001 2002	8.6 8.1	17.4 7.4	37.9 16.7		10.1 8.1			7.7 12.8	8.6 11.0	8.6 6.0	3.4 5.4	6.1 5.7
2002	7.8	3.9	9.2		7.3			3.0	4.6	2.6	1.0	1.8
2004	6.0	-0.8	16.4		5.2			5.5	5.4	2.2	0.4	1.4
2005 f	9.6	5.7	9.3		9.1			4.5	6.2	-2.5	-4.7	-3.6
2006 f	12.5	8.8	11.4		12.0			3.5	6.8	-2.6	-0.1	-1.5
f—Forecast												
	ntiality precludes r	oporting area !-	aial laval incurre-	oo data							C	ce: CIHI, 2006.

Public Private Total If portaginal If portaginal If portaginal If portaginal If portaginal If portaginal Total If portaginal If portaginal Portagina Portagina			All Drugs		He	alth Expenditure		GDP Imp Price Index –
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	_	Public		Total			Total	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $				16	nita)			(1997 - 100)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	-							
72.82 155.57 233.39 1,204.53 442.14 1,746.68 72.2 86.68 171.23 253.49 1,204.53 442.14 1,746.68 72.2 97.37 204.11 301.48 1,653.68 566.34 2,152.41 91.65 97.37 204.11 301.48 1,653.68 566.34 2,152.41 91.64 98.27 255.64 355.64 1,553.63 677.32 2,119.72 92.4 99.28 200.29 375.57 1,164.13 696.40 2,240.62 90.00 103.39 240.44 384.31 1,907.16 74.24 2,240.62 90.00 123.11 327.09 445.12 1,107.40 810.28 2,127.68 90.60 138.44 327.69 433.17,900.84 2,107.72 90.24 2,240.62 1101.14 127.18 356.71 796.64 2,337.49 90.14 3,343.24 100.1 127.69 43.276.02 3,717.81 2,666.3 3,747.04 <								73.6
84.68 171.22 255.94 1,288.16 488.22 1,786.48 88.6 97.05 192.66 287.71 1,151.31 530.08 2.052.39 89.2 97.05 192.66 289.71 1,151.31 530.08 2.052.39 89.2 103.75 228.84 333.62 1,000.22 003.06 2.218.75 98.2 103.82 228.54 338.64 1,641.41 897.36 2.218.75 98.2 103.89 228.72 380.44 1,611.41 897.36 2.218.76 98.2 103.89 228.70 380.44 1,131.10 72.44 2.239.26 190.0 123.19 284.04 388.43 1.709.15 72.46 2.249.23 190.0 123.13 327.69 486.16 2.017.72 981.61 3.017.88 1005.5 179.96 428.44 607.44 2.424.25 1,141.70 3.33.82 100.60 179.79 428.45 1,101.77 2.31.35.65 1,111.11 111								
98.83 177.23 272.06 1,117.87 520.32 1,138.19 98.65 97.37 204.11 001.46 1,455.86 566.64 2,152.81 91.6 103.82 220.84 354.66 1,164.33 627.19 2,191.52 98.2 103.82 220.84 354.66 1,164.43 627.19 2,191.52 98.4 198.22 226.75 300.44 1,151.41 667.35 2,218.76 97.4 192.2 220.24 378.67 1,164.13 664.04 2,249.26 90.10 103.31 224.04 384.41 1,150.15 742.46 2,233.61 90.16 114.13 353.27 464.15 2,400.72 90.14 3,213.85 100.5 1167.06 3,444.24 110.170 3,333.32 111.14 111.12 12.6 47.7 1163 3,43.41 2,428.56 1,311.90 4,560.40 1111.1 212.65 50.7.45 744.09 3,210.71 110.70 3,333.								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
97.37 200.11 301.48 1.585.86 560.54 2.102.01 305 2.200.72 392.6 392.8 103.82 200.84 334.66 1.064.23 000.71 32.101.52 300.44 1.551.41 0.67.35 2.218.76 39.4 39.2 200.24 373.57 1.044.13 0.94.42 2.240.21 390.0 10.99 229.76 300.44 1.551.41 0.67.35 2.218.76 39.4 39.2 200.29 373.57 1.044.13 0.94.42 2.240.21 390.0 10.21 10.10 10.2 2.21 10.10 10.2 1.017.50 3.842.42 101.4 10.10 10.2 1.017.50 3.842.42 101.4 10.10 10.2 1.017.50 3.842.42 101.4 11.1 12.2 0.9 483.99 0.90.68 2.267.31 1.20.69 1.30.340.2 11.1 1.2 2.2 4.3 0.95.6 1.2 1.1 1.2 1.2 1.9 1.4 1.2 1.2 1.9 1.2 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0								
103.75 229.88 333.62 1.060.22 603.05 2.200.26 92.4 98.27 2265.64 353.91 1.324.47 666.25 2.100.72 99.2 90.28 2205.29 379.57 1.544.13 666.25 2.207.82 99.0 103.37 220.29 379.57 1.544.13 666.40 2.240.52 99.0 103.39 286.04 388.43 1.707.18 742.42 2.522.81 100.0 123.11 327.01 450.12 1.317.40 810.22 2.777.68 198.6 136.49 327.69 465.18 2.007.72 90.316 3.010.88 1005.9 136.43 33.69 547.95 2.260.74 1.187.50 3.849.24 111.1 127.2 96.453.99 666.68 2.777.35 1.206.69 3.974.64 111.1 127.2 269.35 526.71 7.96.44 3.266.50 1.31.90 4.560.40 114.2 237.65 507.45 745.09 3.017.97 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
98.27 255.64 35.91 1,22.47 656.25 2,18.76 974 99.26 229.075 360.44 1,551.41 66735 2,218.76 974 99.28 280.29 379.57 1,50.15 7424 2,22.52.61 100.0 123.11 327.01 450.12 1,107.10 810.28 2,727.68 976 135.49 327.69 463.18 2,003.29 981.13 2,822.42 101.4 147.13 355.71 500.84 2,107.72 903.16 3,010.88 106.5 163.68 383.99 547.99 2,223.74 980.14 3,21.88 106.9 178.85 428.48 607.42 2,428.56 1,104.76 3,533.32 106.0 197.16 452.35 649.51 2,600.74 1,167.50 3,848.24 111.1 227.69 483.99 666.88 2,767.35 1,206.89 3,974.04 114.1 127.69 483.99 666.88 2,767.35 1,206.89 3,974.04 114.1 127.65 507.45 745.09 3,017.97 1,27.05 4,275.02 117.2 269.93 526.71 796.64 3,265.50 1,311.90 4,580.40 1130								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		135.49	327.69	403.18	2,034.29	818.13	2,852.42	101.4
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
212.69 483.99 696.68 2,77.35 1,266.69 3,974.04 114.1 237.65 507.45 745.09 3,017.97 1,257.05 4,275.02 117.2 269.93 526.71 796.64 3,268.50 1,311.90 4,50.04 118.0 Immund percentage change)								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								
269.93 52.67.1 79.64 3,286.0 1,31.90 4,500.0 119.0 Interventage charge $\overline{1.5}$ <		212.69	483.99	696.68	2,767.35	1,206.69	3,974.04	114.1
269.93 52.67.1 79.64 3,286.0 1,31.90 4,500.0 119.0 Interventage charge $\overline{1.5}$ <		237.65	507.45	745.09	3.017.97	1,257.05	4,275.02	117 2
Lanual percentage change n								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		269.93	526.71				4,580.40	119.0
16.5 28.6 24.3 7.5 23.4 11.2 12.8 4.7 16.3 3.4 7.4 0.5 5.9 1.1 4.5 13.2 3.5 6.7 9.2 11.1 9.7 4.6 1.3 8.7 6.1 6.7 3.6 5.9 3.0 0.3 5.9 4.1 4.8 5.2 4.9 2.8 0.1 9.1 6.3 2.2.6 4.0 0.8 1.1 2.5 1.6 1.8 1.8 1.7 1.7 2.3 1.4 7.9 5.3 -0.5 4.4 1.0 1.7 5.2 1.3 2.3 15.9 6.6 13.0 1.0 1.4 7.9 5.3 -0.5 4.4 1.0 1.7 5.2 1.3 2.3 1.5 1.6 1.8 1.7 1.4 9.8 7.1 9.1 7.7 0.4 10.1 0.2 2.9 6.1 1.0 4.6 1.8 1.4 9.4	_				nnual percentage chang			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $					 7 E			
16.3 3.4 7.4 0.5 5.9 1.1 9.7 4.6 13.3 8.7 6.1 6.7 3.6 5.9 3.0 0.3 5.9 4.1 4.8 5.2 4.9 2.8 6.5 12.6 10.7 1.3 6.4 2.6 1.3 0.1 9.1 6.3 -2.6 4.0 0.8 1.4 5.3 1.9 0.2 -2.5 4.6 0.5 1.1 2.5 1.6 1.8 1.8 1.7 1.7 2.3 5.2 1.3 2.3 15.9 6.6 13.0 1.0 1.1 0.1 0.2 2.9 6.1 1.0 4.6 1.8 8.6 7.9 8.1 3.6 10.4 5.6 1.1 1.4 1.4 8.6 9.4 6.0 8.5 6.7 1.4 1.4 8.6 9.4 6.0 8.5 6.7 1.4 1.4 8.6 9.9 8.3 4.4 7.1 1.6								
13.2 3.5 6.7 9.2 11.1 9.7 4.6 1.3 8.7 6.1 6.7 3.6 5.9 3.0 6.5 12.6 10.7 1.3 6.4 2.6 1.3 6.5 12.6 10.7 1.3 6.4 2.6 1.4 5.3 1.9 -0.2 -2.5 4.6 -0.5 1.1 2.5 1.6 1.8 1.8 1.7 1.7 2.3 7.9 15.1 15.9 7.1 9.1 7.7 -0.4 10.1 0.2 2.9 6.1 1.0 4.6 1.8 8.6 7.9 8.1 3.6 10.4 5.6 1.1 10.2 5.6 6.9 9.6 7.5 8.9 2.9 7.9 7.0 7.3 4.0 1.6 3.3 2.7 11.6 0.9 8.3 4.4 7.6 2.7 1.6 12.2 2.6 6.9 8.3 4.1 1.1 1.6 11.4 8								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
6.5 12.6 10.7 1.3 6.4 2.6 1.3 0.1 9.1 6.2 2.5 4.6 0.5 1.1 2.5 1.6 1.8 1.7 1.7 2.3 1.1 2.5 1.6 1.8 1.6 1.4 1.0 1.7 2.3 1.4 7.9 5.3 0.05 4.4 1.0 1.7 1.7 2.3 1.6 1.8 1.6 1.4 1.0 1.7 0.4 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.1 <								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
4.5.3 1.9 0.2 -2.5 4.6 -0.5 1.1 2.5 1.6 1.8 1.8 1.7 1.7 2.3 1.4 7.9 5.3 -0.5 4.4 1.0 1.7 5.2 1.3 2.3 15.9 6.6 13.0 10.0 17.9 15.1 15.9 7.1 9.1 7.7 0.4 10.1 0.2 2.9 6.1 1.0 4.6 1.8 8.6 7.9 8.1 3.6 10.4 5.6 4.1 9.1 11.6 10.9 8.7 12.7 9.9 1.0 10.2 5.6 6.9 9.6 7.5 8.9 2.7 11.7 4.8 6.9 9.1 4.2 7.6 2.7 11.7 4.8 6.9 9.1 4.2 7.6 2.7 11.2 7.7 7.5 7.5 8.6 6.4 1.1 1								
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$								
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$								
5.2 1.3 2.3 15.9 6.6 13.0 1.0 17.9 15.1 15.9 7.1 6.1 1.0 4.6 1.8 8.6 7.9 8.1 3.6 10.4 5.6 4.1 11.4 8.6 7.9 8.1 3.6 10.4 5.6 4.1 9.1 11.6 10.9 8.7 12.7 9.9 10.0 10.2 5.6 6.9 9.6 7.5 8.9 2.9 7.9 7.0 7.3 4.0 1.6 3.3 2.7 11.7 4.8 6.9 8.1 4.2 7.6 2.7 13.6 3.8 6.9 8.3 4.4 7.1 1.6 convertige change in excess of inflation in the Canadian economy								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		8.6	7.9	8.1	3.6	10.4	5.6	4.1
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		11.4	8.6	9.4	6.0	8.5		1.4
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		9.1			8.7			
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								
13.63.86.98.34.47.11.6(annual percentage change in excess of inflation in the Canadian economy) 12.7 25.721.54.720.68.411.59.610.28.66.48.111.81.12.8-5.01.4-3.48.61.12.14.76.55.2-1.85.73.13.70.62.9-2.43.21.32.02.42.15.311.49.40.05.11.4-1.47.74.94.02.6-2.2-6.40.8-1.3-3.63.5-1.60.1-0.7-0.5-0.6-0.6-0.6-3.16.23.6-2.12.7-0.74.20.31.314.95.612.018.415.616.37.59.68.18.2-1.61.14.3-0.82.84.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.47.3 <td></td> <td>7.9</td> <td>7.0</td> <td>7.3</td> <td>4.0</td> <td>1.6</td> <td>3.3</td> <td>2.7</td>		7.9	7.0	7.3	4.0	1.6	3.3	2.7
13.63.86.98.34.47.11.6(annual percentage change in excess of inflation in the Canadian economy) 12.7 25.721.54.720.68.411.59.610.28.66.48.111.81.12.8-5.01.4-3.48.61.12.14.76.55.2-1.85.73.13.70.62.9-2.43.21.32.02.42.15.311.49.40.05.11.4-1.47.74.94.02.6-2.2-6.40.8-1.3-3.63.5-1.60.1-0.7-0.5-0.6-0.6-0.6-3.16.23.6-2.12.7-0.74.20.31.314.95.612.018.415.616.37.59.68.18.2-1.61.14.3-0.82.84.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.44.53.84.0-0.56.31.510.17.28.14.67.25.47.3 <td></td> <td>11 7</td> <td>1 0</td> <td>6.9</td> <td>0.1</td> <td>1.0</td> <td>76</td> <td>2 7</td>		11 7	1 0	6.9	0.1	1.0	76	2 7
Image: Another of the sector								2.7
12.7 25.7 21.5 4.7 20.6 8.4 11.5 9.6 10.2 8.6 6.4 8.1 11.8 -1.1 2.8 -5.0 1.4 -3.4 8.6 -1.1 2.1 4.7 6.5 5.2 -1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3		13.6	3.8	6.9	8.3	4.4	7.1	1.6
12.7 25.7 21.5 4.7 20.6 8.4 11.5 9.6 10.2 8.6 6.4 8.1 11.8 -1.1 2.2 8.6 6.4 8.1 11.8 -1.1 2.1 4.7 6.5 5.2 -1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 7.7 1.7 8.9 7.7 1.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6	_		(annual percentag	e change in excess of	inflation in the Canadia	n economy)		
11.5 9.6 10.2 8.6 6.4 8.1 11.8 -1.1 2.8 -5.0 1.4 -3.4 8.6 -1.1 2.1 4.7 6.5 5.2 -1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
11.8 -1.1 2.8 -5.0 1.4 -3.4 8.6 -1.1 2.1 4.7 6.5 5.2 -1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
8.6 -1.1 2.1 4.7 6.5 5.2 -1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6								
-1.8 5.7 3.1 3.7 0.6 2.9 -2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6								
-2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9		8.6	-1.1	2.1	4.7	6.5	5.2	
-2.4 3.2 1.3 2.0 2.4 2.1 5.3 11.4 9.4 0.0 5.1 1.4 -1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9		-1.8	5.7	3.1	3.7	0.6	2.9	
5.3 11.4 9.4 0.0 5.1 1.4 1.4 7.7 4.9 4.0 2.6 -2.2 6.4 0.8 1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
-1.4 7.7 4.9 -4.0 2.6 -2.2 -6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
-6.4 0.8 -1.3 -3.6 3.5 -1.6 0.1 -0.7 -0.5 -0.6 -0.6 -0.6 -3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
-3.1 6.2 3.6 -2.1 2.7 -0.7 4.2 0.3 1.3 14.9 5.6 12.0 18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$								
18.4 15.6 16.3 7.5 9.6 8.1 8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
8.2 -1.6 1.1 4.3 -0.8 2.8 4.5 3.8 4.0 -0.5 6.3 1.5 10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
4.53.84.0-0.56.31.510.17.28.14.67.25.48.110.69.97.711.78.97.32.74.06.74.66.05.24.34.61.3-1.10.69.12.24.36.41.54.9								
10.1 7.2 8.1 4.6 7.2 5.4 8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
8.1 10.6 9.9 7.7 11.7 8.9 7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
7.3 2.7 4.0 6.7 4.6 6.0 5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
5.2 4.3 4.6 1.3 -1.1 0.6 9.1 2.2 4.3 6.4 1.5 4.9								
9.1 2.2 4.3 6.4 1.5 4.9								
		5.2	4.3	4.6	1.3	-1.1	0.6	
		9.1	2.2	4.3	6.4	1.5	4.9	
12.0 2.2 5.3 6.7 2.8 5.5								
		12.0	2.2	5.3	6.7	2.8	5.5	

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and

Table B.3.2–Part 2

Table B.4.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Secur WCB	ity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year						(\$ mil	lions)					
1985 1986 1987 1988	33.9 39.6 46.2 48.5	1.7 1.8 1.9 2.7	0.1 0.2 0.2 0.2	 	35.7 41.5 48.4 51.4			38.8 45.6 56.1 61.4	74.4 87.1 104.5 112.7			48.4 54.8 63.6 61.6
1989 1990	52.7 58.3	3.1 3.7	0.3 0.4		56.0 62.4			67.1 80.3	123.1 142.7			59.6 61.0
1991 1992 1993 1994	62.4 60.0 56.8 56.0	4.1 4.2 5.2 5.7	0.4 0.5 0.6 0.6		67.0 64.8 62.5 62.3			88.8 102.2 111.3 118.4	155.8 167.0 173.8 180.7	35.6 37.0 35.9	 32.3 34.5 35.5	71.5
1995 1996 1997 1998	58.3 54.8 56.1 62.1	6.4 6.4 7.1 8.6	0.6 0.7 0.7 0.9		65.4 61.9 64.0 71.6			127.8 126.7 143.9 149.7	193.1 188.6 207.9 221.3	33.1 31.6 42.2 40.6	33.5 30.6 42.6 41.6	62.3 84.7
1999 2000 2001 2002	69.0 78.4 90.1 101.3	10.8 14.2 17.2 18.8	1.1 1.4 1.7 2.1		80.8 94.0 109.0 122.2			167.0 187.7 218.9 241.9	247.8 281.6 327.9 364.1	45.5 45.5 44.7 47.9	44.1 43.1 40.3 43.0	
2003 2004	112.3 124.4	21.0 21.6	2.6 3.3		135.9 149.3			271.4 276.1	407.2 425.4	48.5 50.1	42.8 43.5	91.4 93.6
2005 f 2006 f	139.1 147.6	23.4 25.2	3.7 4.3		166.2 177.1			285.5 304.7	451.7 481.8	48.4 47.5	41.1 43.4	89.4 91.0
						(annual percer	ntage change)					
1985 1986 1987 1988	 16.9 16.8 5.0	 7.6 9.3 36.1	 14.5 15.9 18.5		 16.4 16.4 6.3			 17.6 23.0 9.3	 17.1 19.9 7.9	 		 13.2 16.0 -3.1
1989 1990	8.6 10.7	17.3 18.6	15.6 56.5		9.1 11.4			9.3 19.7	9.2 15.9			-3.1
1991 1992 1993 1994	7.0 -3.9 -5.4 -1.4	12.5 2.0 22.5 10.6	11.2 24.7 3.7 5.4	 	7.4 -3.4 -3.5 -0.4			10.6 15.1 8.9 6.4	9.2 7.1 4.1 4.0	 3.9 -2.8	 6.8 2.9	
1995 1996 1997 1998 1999	4.2 -6.0 2.5 10.7 11.0	11.6 0.1 11.0 21.1 25.2	8.4 13.1 0.1 19.3 23.4	 	4.9 -5.2 3.3 12.0 12.9	 	 	7.9 -0.8 13.6 4.0 11.6	6.9 -2.3 10.2 6.4 12.0	-8.0 -4.4 33.5 -3.8 12.0	-5.7 -8.5 38.9 -2.1 6.0	-6.4 36.1 -3.0
2000 2001 2002 2003 2004	13.6 14.9 12.5 10.8 10.8	31.9 20.8 9.3 11.7 3.1	28.3 25.8 19.0 25.8 25.2		16.2 16.0 12.1 11.2 9.9			12.4 16.6 10.5 12.2 1.8	13.6 16.4 11.0 11.8 4.5	0.1 -1.8 7.1 1.3 3.2	-2.3 -6.5 6.5 -0.3 1.5	-4.1 6.8 0.6
2005 f	11.8	8.1	13.9		11.3			3.4	6.2	-3.4	-5.5	-4.4
2006 f	6.1	8.0	15.2		6.5 (pe	 rcentage share of t	 otal drug exp	6.7 enditure)	6.6	-1.7	5.8	1.7
1985 1986 1987 1988 1988	27.6 27.9 27.5 27.8 28.8	1.3 1.3 1.2 1.5 1.7	0.1 0.1 0.1 0.1 0.1	 	29.0 29.2 28.8 29.5 30.7	 	 	31.6 32.1 33.4 35.2 36.7	60.6 61.4 62.2 64.7 67.4	 	 	39.4 38.6 37.8 35.3 32.6
1990 1991 1992 1993	28.6 28.1 25.5 23.1	1.8 1.9 1.8 2.1	0.2 0.2 0.2 0.2	 	30.6 30.2 27.6 25.5			39.4 40.0 43.5 45.4	70.1 70.2 71.1 70.9	 15.2 15.1	 13.8 14.1	29.1
1994 1995 1996	22.2 22.5 21.8	2.3 2.5 2.6	0.2 0.2 0.3		24.7 25.2 24.7			47.0 49.2 50.5	71.7 74.4 75.2 71.0	14.2 12.7 12.6	14.1 12.9 12.2	24.8
1997 1998 1999 2000	19.2 20.5 20.4 21.2	2.4 2.8 3.2 3.8	0.2 0.3 0.3 0.4	 	21.9 23.6 24.0 25.4	 		49.2 49.3 49.5 50.7	71.0 72.9 73.5 76.1	14.4 13.4 13.5 12.3	14.5 13.7 13.1 11.6	27.1 26.5
2001 2002 2003	21.8 22.3 22.5	4.2 4.1 4.2	0.4 0.5 0.5		26.4 26.9 27.2			53.0 53.2 54.4	79.4 80.0 81.7	10.8 10.5 9.7	9.8 9.4 8.6	20.6 20.0 18.3
2004 2005 f 2006 f	24.0 25.7 25.8	4.2 4.3 4.4	0.6 0.7 0.7		28.8 30.7 30.9			53.2 52.8 53.2	82.0 83.5 84.1	9.7 8.9 8.3	8.4 7.6 7.6	16.5
f-Forecast	ntiality precludes r				30.0			00.2	54.1	0.0		ce: CIHI, 2006

Table B.4.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2006 (continued)

		II Drugs			h Expenditure			Ith Expenditures	
_		Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ns)			(perce	entage share)	
1985	35.7	87.2	122.9	752.2	274.1	1,026.2	4.7	31.8	12.0
1986	41.5	100.4	142.0	805.3	285.9	1,091.1	5.2	35.1	13.0
1987 1988	48.4 51.4	119.7 122.9	168.1 174.3	888.9 961.0	305.1 330.5	1,194.0 1,291.5	5.4 5.3	39.2 37.2	14.1 13.5
1989	56.0	126.7	182.8	1,047.7	352.4	1,400.1	5.3	36.0	13.1
1990	62.4	141.2	203.7	1,136.1	397.4	1,533.5	5.5	35.5	13.3
1991	67.0	154.9	221.9	1,186.9	442.4	1,629.3	5.6	35.0	13.6
1992	64.8	170.1	234.9	1,233.1	466.7	1,699.8	5.3	36.4	13.8
1993 1994	62.5 62.3	182.8 189.8	245.3 252.1	1,236.1 1,272.2	503.0 519.4	1,739.1 1,791.6	5.1 4.9	36.3 36.5	14.1 14.1
1995 1996	65.4 61.9	194.3 189.0	259.6 250.9	1,323.0 1,325.3	495.0 487.1	1,818.0 1,812.4	4.9 4.7	39.2 38.8	14.3 13.8
1997	64.0	228.7	292.7	1,305.7	549.1	1,854.8	4.9	41.6	15.8
1998	71.6	231.9	303.5	1,370.6	547.3	1,917.9	5.2	42.4	15.8
1999	80.8	256.6	337.4	1,469.5	604.6	2,074.1	5.5	42.4	16.3
2000	94.0	276.3	370.3	1,580.0	638.7	2,218.6	5.9	43.3	16.7
2001 2002	109.0 122.2	304.0 332.8	412.9 455.0	1,740.0 1,833.2	729.5 783.6	2,469.5 2,616.8	6.3 6.7	41.7 42.5	16.7 17.4
2003	135.9	362.7	498.6	1,954.3	831.9	2,786.1	7.0	43.6	17.9
2004	149.3	369.7	519.0	2,122.2	861.8	2,984.0	7.0	42.9	17.4
2005 f	166.2	375.0	541.2	2,254.6	889.4	3,144.1	7.4	42.2	17.2
2006 f	177.1	395.7	572.7	2,392.6	937.5	3,330.1	7.4	42.2	17.2
20001	177.1	000.7	(annual percenta		007.0	0,000.1	7.4	72.2	17.2
1985									
1986	16.4	15.2	15.6	7.1	4.3	6.3			
1987	16.4	19.2	18.4	10.4	6.7	9.4			
1988 1989	6.3 9.1	2.7 3.1	3.7 4.8	8.1 9.0	8.3 6.6	8.2 8.4			
1990					12.8				
1990	11.4 7.4	11.5 9.6	11.4 9.0	8.4 4.5	12.0	9.5 6.2			
1992	-3.4	9.8	5.8	3.9	5.5	4.3			
1993 1994	-3.5	7.4 3.9	4.4 2.8	0.2	7.8 3.3	2.3 3.0			
	-0.4			2.9					
1995 1996	4.9 -5.2	2.4 -2.7	3.0 -3.4	4.0 0.2	-4.7 -1.6	1.5 -0.3			
1997	-5.2	21.0	16.6	-1.5	12.7	2.3			
1998	12.0	1.4	3.7	5.0	-0.3	3.4			
1999	12.9	10.6	11.2	7.2	10.5	8.1			
2000	16.2	7.7	9.7	7.5	5.6	7.0			
2001 2002	16.0 12.1	10.0 9.5	11.5 10.2	10.1 5.4	14.2 7.4	11.3 6.0			
2002	11.2	9.0	9.6	6.6	6.2	6.5			
2004	9.9	1.9	4.1	8.6	3.6	7.1			
2005 f	11.3	1.4	4.3	6.2	3.2	5.4			
2006 f	6.5	5.5	5.8	6.1	5.4	5.9			
20001		hare of total drug		0.1	0.4	0.0			
1985	29.0	71.0	100.0	_					
1986	29.2	70.8	100.0						
1987	28.8	71.2	100.0						
1988 1989	29.5 30.7	70.5 69.3	100.0 100.0						
1990 1991	30.6 30.2	69.4 69.8	100.0 100.0						
1992	27.6	72.4	100.0						
1993	25.5	74.5	100.0						
1994	24.7	75.3	100.0						
1995	25.2	74.8	100.0						
1996	24.7	75.3	100.0						
1997 1998	21.9 23.6	78.1 76.4	100.0 100.0						
1999	24.0	76.0	100.0						
2000	25.4	74.6	100.0						
2001	26.4	73.6	100.0						
2002	26.9	73.1	100.0						
2003 2004	27.2 28.8	72.8 71.2	100.0 100.0						
2005 f	30.7	69.3	100.0						
2006 f	30.9	69.1	100.0						

Table B.4.2-Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2006

					Prescribe	ed Drugs	D 1				Prescribed D	
	Provincial	Federal _	Public Social Securi WCB	ty Funds Drug nsurance Funds	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	<u>e (Out-of-Po</u> Personal Health Supplies	<u>cket)</u> Total Non-Presc. Drugs
r				Funds		(\$ per	capita)			Drugs		
5	46.80	2.29	0.19		49.28			53.60	102.88			66.89
6 7	54.59 63.50	2.46 2.68	0.22 0.25		57.26 66.43			62.92 77.12	120.18 143.55			75.59 87.33
B	66.43	3.63	0.30		70.36			84.01	154.37			84.30
9	71.66	4.23	0.34		76.23			91.22	167.45			81.12
C	78.82	4.99	0.53		84.34			108.44	192.78			82.40
1	83.75	5.57	0.59		89.90			119.11	209.01			88.62
2 3	80.19 75.83	5.66 6.92	0.73 0.75		86.57 83.50			136.60 148.60	223.17 232.11	47.57 49.37	43.20 46.09	90.77 95.47
4	74.59	7.64	0.79		83.03			157.80	240.84	47.88	47.33	95.21
5	77.65	8.52	0.86		87.02			170.11	257.14	44.02	44.57	88.59
6	72.83	8.51	0.97		82.31			168.45	250.76	42.03	40.72	82.75
7	74.59	9.45	0.97		85.01			191.27	276.28	56.07	56.54	112.62
B 9	82.80 91.89	11.47 14.36	1.16 1.43		95.43 107.68			199.42 222.50	294.85 330.18	54.09 60.57	55.47 58.77	109.57 119.34
D 1	104.41 120.09	18.94 22.90	1.84 2.31		125.19 145.31			250.06 291.92	375.25 437.23	60.66 59.62	57.44 53.78	118.10 113.40
2	135.05	25.01	2.75		162.81			322.44	485.25	63.84	57.25	121.09
3	149.49	27.91	3.46		180.86			361.25	542.11	64.60	57.01	121.61
4	165.44	28.74	4.33		198.51			367.15	565.66	66.59	57.81	124.40
5 f	185.01	31.08	4.93		221.02			379.69	600.72	64.33	54.61	118.94
6 f	195.98	33.52	5.67		235.17			404.70	639.87	63.14	57.69	120.82
						(annual perce	atago chango)					
5												
6	16.6	7.4	14.3		16.2			17.4	16.8			13.0
7	16.3	8.9	15.5		16.0			22.6	19.4			15.5
В	4.6	35.6	18.1		5.9			8.9	7.5			-3.5
9	7.9	16.6	14.8		8.3			8.6	8.5			-3.8
0	10.0	17.8	55.5		10.6			18.9	15.1			1.6
1 2	6.3 -4.3	11.6 1.6	10.4 24.3		6.6 -3.7			9.8 14.7	8.4 6.8			7.6 2.4
3	-5.4	22.4	3.6		-3.5			8.8	4.0	3.8	6.7	5.2
4	-1.6	10.4	5.2		-0.6			6.2	3.8	-3.0	2.7	-0.3
5	4.1	11.5	8.3		4.8			7.8	6.8	-8.1	-5.8	-7.0
6 7	-6.2 2.4	-0.1 11.0	12.9 0.1		-5.4 3.3			-1.0 13.5	-2.5 10.2	-4.5 33.4	-8.6 38.8	-6.6 36.1
B	11.0	21.4	19.6		12.3			4.3	6.7	-3.5	-1.9	-2.7
9	11.0	25.2	23.4		12.8			11.6	12.0	12.0	5.9	8.9
C	13.6	31.9	28.3		16.3			12.4	13.6	0.1	-2.3	-1.0
1	15.0	20.9	25.9		16.1			16.7	16.5	-1.7	-6.4	-4.0
2	12.5	9.2	18.9		12.0			10.5	11.0	7.1	6.5	6.8
3 4	10.7 10.7	11.6 3.0	25.7 25.0		11.1 9.8			12.0 1.6	11.7 4.3	1.2 3.1	-0.4 1.4	0.4 2.3
5 f		8.2	13.9		11.3			3.4	6.2	-3.4		
	11.8										-5.5	-4.4
6 f	5.9	7.8	15.1		6.4			6.6	6.5	-1.9	5.6	1.6
					(annual percentage	change in excess	of inflation in					
5 6	 13.8	4.6	 11.5		 13.4			 14.6	 14.0			 10.2
7	11.6	4.2	10.7		11.3			17.8	14.7			10.2
В	0.1	31.1	13.6		1.4			4.4	3.0			-8.0
9	3.3	12.0	10.3		3.8			4.0	3.9			-8.3
0	7.0	14.8	52.5		7.6			15.8	12.1			-1.5
1 2	3.5 -5.5	8.9 0.3	7.6 23.0		3.8 -5.0			7.1 13.4	5.7 5.5			4.8 1.2
3	-6.9	21.0	2.2		-5.0			7.3	2.6	2.3	5.3	3.7
4	-2.7	9.3	4.1		-1.7			5.1	2.7	-4.1	1.6	-1.4
5	1.8	9.1	6.0		2.5			5.5	4.4	-10.4	-8.2	-9.3
6	-7.9	-1.8	11.2		-7.1			-2.7	-4.2	-6.2	-10.3	-8.3
7 B	1.4 11.4	10.0 21.8	-0.9 20.1		2.3 12.7			12.6 4.7	9.2 7.2	32.4 -3.1	37.9 -1.5	35.1 -2.3
9	9.2	21.8	20.1		12.7			9.8	10.2	-3.1	-1.5	-2.3
0	9.5	27.8	24.2		12.2			8.3	9.5	-4.0	-6.4	-5.1
1	9.5 13.7	19.6	24.2		14.7			15.4	15.2	-4.0	-0.4	-5.3
2	11.5	8.2	17.9		11.0			9.5	10.0	6.1	5.5	5.8
3 4	7.8 8.0	8.7 0.3	22.8 22.3		8.2 7.1			9.1 -1.1	8.8 1.7	-1.7 0.4	-3.3 -1.3	-2.5 -0.4
5 f	9.2	5.5	11.2		8.7			0.8	3.5	-6.1	-8.2	-7.0
6 f precast	4.3	6.2	13.5		4.8			5.0	4.9	-3.5	4.0	0.0

Table B.4.2–Part 2

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2006 (continued)

		All Drugs			Health Expenditure		GDP Implicit Price Index—Canada	
-	Public	Private	Total	Public	Private	Total		
ar _			(\$ per ca	pita)			(1997 = 100)	
985	49.28	120.48	169.76	1,039.3		1,418.05	73.6	
986 987	57.26 66.43	138.51 164.45	195.77 230.88	1,110.4 1,221.2		1,504.71 1,640.40	75.6 79.2	
988	70.36	168.31	238.67	1,315.8	30 452.46	1,768.26	82.8	
89	76.23	172.34	248.57	1,425.0	479.28	1,904.32	86.6	
90	84.34	190.84	275.18	1,535.0		2,071.96	89.2	
991 992	89.90 86.57	207.73 227.37	297.63 313.94	1,592.0 1,648.3		2,185.39 2,272.21	91.6 92.8	
93	83.50	244.07	327.57	1,650.7		2,322.46	94.1	
94	83.03	253.01	336.05	1,695.7	79 692.35	2,388.13	95.2	
95	87.02	258.70	345.73	1,761.6		2,420.84	97.4	
196 197	82.31	251.20	333.51	1,761.6		2,409.10	99.0	
97 98	85.01 95.43	303.88 308.99	388.90 404.42	1,735.0 1,826.1		2,464.74 2,555.34	100.0 99.6	
99	107.68	341.84	449.52	1,957.7		2,763.16	101.4	
000	125.19	368.15	493.34	2,105.1		2,956.15	105.5	
001	145.31	405.33	550.64	2,320.3		3,293.21	106.9	
002 003	162.81 180.86	443.53 482.86	606.34 663.72	2,443.1 2,601.4		3,487.53 3,708.84	108.0 111.1	
004	198.51	491.56	690.07	2,821.8		3,967.65	114.1	
005 f	221.02	498.63	719.66	2,998.1	14 1,182.74	4,180.89	117.2	
06 f	235.17	525.52	760.69	3,177.8	30 1,245.21	4,423.01	119.0	
-			(a)	nnual percentage c				
985 986	16.2	15.0	15.3		.8 4.1	6.1	2.8	
987	16.0	18.7	17.9	10		9.0	4.7	
988 989	5.9 8.3	2.4 2.4	3.4 4.1		.7 7.9 .3 5.9	7.8 7.7	4.5 4.6	
990	10.6	10.7	10.7		.7 12.0	8.8	3.0	
991	6.6	8.9	8.2	3	.7 10.5	5.5	2.8	
992	-3.7	9.5 7.3	5.5		.5 5.1 .2 7.7	4.0	1.3	
993 994	-3.5 -0.6	7.3	4.3 2.6		0.2 7.7 0.7 3.1	2.2 2.8	1.4 1.1	
95	4.8	2.2	2.9	3	.9 -4.8	1.4	2.3	
996	-5.4	-2.9	-3.5	0	-1.8	-0.5	1.7	
997 998	3.3 12.3	21.0 1.7	16.6 4.0		.5 12.7 .2 -0.1	2.3 3.7	1.0 -0.4	
999	12.3	10.6	4.0		.2 -0.1	8.1	-0.4	
000	16.3	7.7	9.7		.5 5.7	7.0	4.1	
001	16.1	10.1	11.6	10	.2 14.3	11.4	1.4	
002	12.0	9.4	10.1		.3 7.3	5.9	1.0	
)03)04	11.1 9.8	8.9 1.8	9.5 4.0		.5 6.0 .5 3.5	6.3 7.0	2.9 2.7	
005 f	11.3	1.4	4.3		.2 3.2	5.4	2.7	
06 f	6.4	5.4 (annual percentag	5.7 Je change in excess of		a.0 5.3 5.3 5.3	5.8	1.6	
- 85 86								
986 987	13.4 11.3	12.2 14.0	12.5 13.2		.0 1.3 .2 1.6	3.3 4.3		
988	1.4	-2.2	-1.1	3	.2 3.4	3.3		
989	3.8	-2.2	-0.4		.7 1.4	3.1		
990 991	7.6	7.7	7.7		.7 9.0 .0 7.7	5.8 2.7		
991 992	3.8 -5.0	6.1 8.2	5.4 4.2		.0 7.7 2.3 3.9	2.7		
993	-5.0	5.9	2.9	-1	.3 6.2	0.8		
94	-1.7	2.6	1.5		.6 2.0	1.7		
95	2.5	-0.1	0.5		.5 -7.1	-1.0		
996 997	-7.1 2.3	-4.6 20.0	-5.2 15.6		.7 -3.5 2.5 11.7	-2.2 1.3		
98	12.7	2.1	4.4	5	.7 0.4	4.1		
99	11.0	8.8	9.3	5	.4 8.6	6.3		
00	12.2	3.6	5.6		1.6	2.9		
001 002	14.7 11.0	8.7 8.4	10.3 9.1		8.9 13.0 4.3 6.4	10.0 4.9		
02	8.2	6.0	6.6			4.9 3.5		
004	7.1	-0.9	1.3		0.8	4.3		
005 f	8.7	-1.2	1.6	3	0.6	2.7		
		3.8	4.1	4	.4 3.7	4.2		
006 f	4.8	0.0	4.1		.4 5.7	7.2		

Table B.5.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985 to 2006

			Public		Prescribe	_	Private			Privat	Prescribed D te (Out-of-Po	cket)
	Provincial	Federal _	Social Secu WCB	urity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
ar						(\$ mi	llions)			- 5-		
85	250.4	7.4	2.1		260.0			342.6	602.6			230.5
86 87	291.2 333.8	8.1 8.8	2.7 3.2		301.9 345.8			463.0 466.6	764.9 812.4			261.0 302.7
88	333.8	10.7	3.2		398.0			523.3	921.4			366.9
89	437.1	12.8	3.5		453.4			582.4	1,035.8			444.8
90	502.9	15.3	4.2		522.4			638.9	1,161.2			468.3
91	604.0	16.7	4.9		625.6			709.4	1,335.0			534.5
92	650.5	18.1	5.1		673.7			770.9	1,444.6	306.5	264.2	
93	686.1	21.1	5.0		712.3			882.3	1,594.6	312.4	280.8	593.1
94	742.1	23.0	5.6		770.7			898.5	1,669.2	310.5	306.6	617.1
95	807.0	24.1	6.3		837.4			1,005.9	1,843.3	318.6	314.5	633.2
96	734.5	24.0	6.9		765.4			1,079.9	1,845.2	306.0	314.6	
97	697.7	26.0	7.4	172.0	903.1			1,227.2	2,130.2	278.2	294.6	572.8
98 99	775.0 917.0	29.5 34.4	8.1 9.3	218.2 264.0	1,030.8			1,228.4	2,259.2	296.1 318.0	316.7 332.4	612.7 650.5
					1,224.7			1,433.5	2,658.2			
00	1,113.9	35.0	11.1	332.3	1,492.4			1,612.8	3,105.2	306.1	324.3	630.4
01 02	1,296.9 1,422.3	38.4 44.7	13.5 15.4	379.9 450.4	1,728.6 1,932.8			1,752.2 1,968.7	3,480.8 3,901.6	324.3 335.4	331.7 340.6	655.9 676.0
02	1,521.7	50.7	18.0	450.4 595.0	2,185.4			2,083.2	4,268.6	337.6	340.0	678.0
04	1,651.4	53.5	21.1	642.2	2,368.2			2,356.1	4,724.3	358.1	352.4	710.4
05 f	1,760.8	60.1	23.0	656.7	2,500.7			2,518.8	5,019.5	409.9	385.1	795.0
06 f	1,865.5	67.4	25.4	700.2	2,658.4			2,682.7	5,341.2	417.3	411.5	828.9
						(annual percer	ntage change)					
85												
86	16.3	8.4	27.3		16.1			35.1	26.9			13.2
87	14.6	9.1	19.2		14.5			0.8	6.2			16.0
88 89	15.1 13.8	21.6 20.0	1.0 7.2		15.1 13.9			12.2 11.3	13.4 12.4			21.2 21.2
90	15.0	19.2	20.8		15.2			9.7	12.1			5.3
91 92	20.1 7.7	9.4	16.6		19.8 7.7			11.0	15.0			14.1 6.8
92 93	5.5	8.2 16.7	3.3 -0.1		5.7			8.7 14.4	8.2 10.4	 1.9	 6.3	
94	8.2	8.7	11.7		8.2			1.8	4.7	-0.6	9.2	
95	8.7	5.0	12.1		8.7			11.9	10.4	2.6	2.6	2.6
96	-9.0	-0.7	9.7		-8.6			7.4	0.1	2.6 -4.0	0.0	
97	-5.0	8.5	6.2		18.0			13.6	15.4	-9.1	-6.4	-7.7
98	11.1	13.4	10.0	26.8	14.1			0.1	6.1	6.4	7.5	
99	18.3	16.6	15.1	21.0	18.8			16.7	17.7	7.4	5.0	6.2
00	21.5	1.9	19.7	25.9	21.9			12.5	16.8	-3.8	-2.5	-3.1
01	16.4	9.6	20.8	14.3	15.8			8.6	12.1	5.9	2.3	
02	9.7	16.6	14.3	18.6	11.8			12.4	12.1	3.4	2.7	3.1
03	7.0	13.4	17.1	32.1	13.1			5.8	9.4	0.7	-0.1	0.3
04	8.5	5.5	17.3	7.9	8.4			13.1	10.7	6.0	3.5	
05 f	6.6	12.4	9.0	2.3	5.6			6.9	6.2	14.5	9.3	11.9
06 f	5.9	12.0	10.3	6.6	6.3			6.5	6.4	1.8	6.9	4.3
					(per	centage share of t	otal drug expe	enditure)				
85	30.1	0.9	0.3		31.2			41.1	72.3			27.7
86	28.4	0.8	0.3		29.4			45.1	74.6			25.4
87	29.9	0.8	0.3		31.0			41.8	72.9			27.1
88	29.8	0.8	0.3		30.9			40.6	71.5			28.5
89	29.5	0.9	0.2		30.6			39.3	70.0			30.0
90	30.9	0.9	0.3		32.1			39.2	71.3			28.7
91	32.3	0.9	0.3		33.5			37.9	71.4			28.6
92 93	32.3 31.4	0.9 1.0	0.3 0.2		33.4 32.6			38.3 40.3	71.7 72.9	15.2 14.3	13.1 12.8	28.3 27.1
93 94	31.4	1.0	0.2		33.7			39.3	73.0	13.6	12.8	27.1
95 96	32.6 29.8	1.0 1.0	0.3 0.3		33.8 31.0			40.6 43.8	74.4 74.8	12.9 12.4	12.7 12.8	25.6 25.2
97	25.8	1.0	0.3	6.4	33.4			45.4	78.8	10.3	10.9	21.2
98	27.0	1.0	0.3	7.6	35.9			42.8	78.7	10.3	11.0	21.3
99	27.7	1.0	0.3	8.0	37.0			43.3	80.3	9.6	10.0	19.7
00	29.8	0.9	0.3	8.9	40.0			43.2	83.1	8.2	8.7	16.9
01	31.4	0.9	0.3	9.2	41.8			42.4	84.1	7.8	8.0	15.9
02	31.1	1.0	0.3	9.8	42.2			43.0	85.2	7.3	7.4	14.8
03	30.8	1.0	0.4	12.0	44.2			42.1	86.3	6.8	6.9	13.7
04	30.4	1.0	0.4	11.8	43.6			43.4	86.9	6.6	6.5	13.1
05 f	30.3	1.0	0.4	11.3	43.0			43.3	86.3	7.0	6.6	13.7
06 f	30.2	1.1	0.4	11.3	43.1			43.5	86.6	6.8	6.7	13.4
Forecast												

Table B.5.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985 to 2006 (continued)

		Т	otal Health Exp	enditures, Que	bec, 1985 to	2006 (continu		ugs in Public, Priva	te and
	Public	All Drugs Private	Total	He Public	alth Expenditure Private	Total		Health Expenditure Private	
Year			(\$ milli	ons)			(p	ercentage share)	
1985	260.0	573.1	833.0	7,927.6	2,104.4	10,031.9	3.3	27.2	8.3
1986 1987	301.9 345.8	724.0 769.3	1,025.9	8,051.3 8,636.4	2,486.1 2,632.2	10,537.4 11,268.6	3.7 4.0	29.1 29.2	9.7
1988	398.0	890.3	1,115.1 1,288.3	9,428.4	2,850.8	12,279.2	4.0	31.2	9.9 10.5
1989	453.4	1,027.2	1,480.7	10,108.6	3,181.7	13,290.3	4.5	32.3	11.1
1990	522.4	1,107.1	1,629.5	10,814.1	3,497.4	14,311.5	4.8	31.7	11.4
1991	625.6	1,243.8	1,869.5	11,815.3	3,819.3	15,634.6	5.3	32.6	12.0
1992	673.7	1,341.6	2,015.3	12,234.5	4,141.5	16,376.1	5.5	32.4	12.3
1993 1994	712.3 770.7	1,475.4 1,515.6	2,187.7 2,286.3	12,459.6 12,674.4	4,444.6 4,637.2	16,904.2 17,311.6	5.7 6.1	33.2 32.7	12.9 13.2
1995 1996	837.4 765.4	1,639.1 1,700.5	2,476.5 2,465.9	12,708.9 12,254.7	4,647.8 4,711.9	17,356.7 16,966.5	6.6 6.2	35.3 36.1	14.3 14.5
1997	903.1	1,800.0	2,703.0	13,083.0	4,960.8	18,043.8	6.9	36.3	15.0
1998	1,030.8	1,841.2	2,871.9	14,286.9	4,984.4	19,271.3	7.2	36.9	14.9
1999	1,224.7	2,084.0	3,308.7	14,474.8	5,534.9	20,009.7	8.5	37.7	16.5
2000	1,492.4	2,243.2	3,735.6	15,552.5	5,890.3	21,442.8	9.6	38.1	17.4
2001	1,728.6	2,408.1	4,136.7	16,852.6	6,548.7	23,401.3	10.3	36.8	17.7
2002	1,932.8	2,644.7	4,577.5	17,705.4	7,067.6	24,772.9	10.9	37.4	18.5
2003 2004	2,185.4 2,368.2	2,761.2 3,066.5	4,946.6 5,434.7	18,589.3 19,780.0	7,506.1 7,811.8	26,095.5 27,591.8	11.8 12.0	36.8 39.3	19.0 19.7
2005 f	2,500.7	3,313.8	5,814.5	20,829.4	8,221.6	29,051.0	12.0	40.3	20.0
2006 f	2,658.4	3,511.6	6,170.0	21,766.1	8,614.5	30,380.6	12.2	40.8	20.3
1985			(annual percent	age change)					
1986	16.1	26.3	23.2	1.6	18.1	5.0			
1987	14.5	6.3	8.7	7.3	5.9	6.9			
1988 1989	15.1 13.9	15.7 15.4	15.5 14.9	9.2 7.2	8.3 11.6	9.0 8.2			
1990 1991	15.2 19.8	7.8 12.3	10.0 14.7	7.0 9.3	9.9 9.2	7.7 9.2			
1992	7.7	7.9	7.8	3.5	8.4	4.7			
1993 1994	5.7 8.2	10.0 2.7	8.6 4.5	1.8 1.7	7.3 4.3	3.2 2.4			
1995	8.7	8.1	8.3	0.3	0.2	0.3			
1996	-8.6	3.7	-0.4	-3.6	1.4	-2.2			
1997	18.0	5.8	9.6	6.8	5.3	6.3			
1998 1999	14.1 18.8	2.3 13.2	6.2 15.2	9.2 1.3	0.5 11.0	6.8 3.8			
2000 2001	21.9 15.8	7.6 7.4	12.9 10.7	7.4 8.4	6.4 11.2	7.2 9.1			
2002	11.8	9.8	10.7	5.1	7.9	5.9			
2003	13.1	4.4	8.1	5.0	6.2	5.3			
2004	8.4	11.1	9.9	6.4	4.1	5.7			
2005 f	5.6	8.1	7.0	5.3	5.2	5.3			
2006 f	6.3	6.0	6.1	4.5	4.8	4.6			
	(percentage	e share of total dru	g expenditure)						
1985	31.2	68.8	100.0						
1986	29.4	70.6	100.0						
1987 1988	31.0 30.9	69.0 69.1	100.0 100.0						
1988	30.9	69.1 69.4	100.0						
1990	32.1	67.9	100.0						
1990	32.1	66.5	100.0						
1992	33.4	66.6	100.0						
1993	32.6	67.4	100.0						
1994	33.7	66.3	100.0						
1995 1996	33.8 31.0	66.2 69.0	100.0 100.0						
1997	33.4	66.6	100.0						
1998	35.9	64.1	100.0						
1999	37.0	63.0	100.0						
2000	40.0	60.0	100.0						
2001	41.8	58.2	100.0						
2002	42.2	57.8	100.0						
2003 2004	44.2 43.6	55.8 56.4	100.0 100.0						
2005 f		57.0							
	43.0		100.0						
2006 f	43.1	56.9	100.0						
f-Forecast								So	urce: CIHI, 2006

Table B.5.2-Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Quebec, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
-	Provincial	Federal _	Social Secur WCB	ity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
-				Funds		(\$ per	capita)			Drugs		
	37.57	1.12	0.32		39.00			51.40	90.40			34.58
	43.40 49.21	1.20 1.30	0.40 0.47		45.00 50.98			69.01 68.80	114.02 119.78			38.91 44.62
	56.16	1.56	0.47		58.20			76.52	134.72			53.65
	63.09	1.85	0.50		65.44			84.06	149.50			64.20
	71.80	2.18	0.60		74.58			91.21	165.80			66.86
	85.50	2.37	0.69		88.56			100.41	188.97			75.65
	91.52	2.55	0.71		94.78			108.46	203.23	43.12	37.17	80.29
	95.89 103.18	2.95 3.20	0.71 0.78		99.55 107.16			123.31 124.94	222.86 232.10	43.65	39.24 42.63	82.89 85.80
										43.17		
	111.78 101.35	3.34 3.31	0.88 0.96		116.00 105.61			139.34 149.01	255.33 254.62	44.13 42.23	43.57 43.42	87.70 85.65
	95.91	3.57	1.01	23.65	124.14			168.69	292.83	38.24	43.42	78.74
	106.22	4.04	1.11	29.91	141.28			168.37	309.65	40.58	43.40	83.98
	125.22	4.69	1.27	36.05	167.23			195.75	362.98	43.43	45.40	88.83
	151.41	4.76	1.51	45.17	202.85			219.22	422.07	41.61	44.07	85.68
	175.33	5.19	1.82	51.36	233.69			236.88	470.57	43.84	44.84	88.68
	191.02	6.01	2.07	60.49	259.59			264.41	524.00	45.04	45.74	90.78
	203.06 218.80	6.77 7.09	2.40 2.80	79.39 85.08	291.63 313.77			277.98 312.15	569.61 625.92	45.06 47.44	45.42 46.69	90.47 94.13
	231.74	7.92	3.03	86.43	329.12			331.50	660.62	53.95	50.68	104.63
	244.12	8.82	3.32	91.63	347.89			351.07	698.96	54.61	53.85	108.47
						(annual percer	tage change)					
•												
	15.5	7.7	26.4		15.4			34.3	26.1			 12.5
	13.4	7.9	17.9		13.3			-0.3	5.1			14.7
	14.1	20.6	0.1		14.1			11.2	12.5			20.2
	12.3	18.4	5.8		12.4			9.8	11.0			19.7
	13.8	17.9	19.5		14.0			8.5	10.9			4.1
	19.1	8.4	15.6		18.7			10.1	14.0			13.2
	7.0	7.6	2.6		7.0			8.0	7.5			6.1
	4.8 7.6	15.9 8.2	-0.8 11.2		5.0 7.6			13.7 1.3	9.7 4.1	1.2 -1.1	5.6 8.6	3.2 3.5
	8.3 -9.3	4.6 -1.1	11.7 9.2		8.2 -9.0			11.5 6.9	10.0 -0.3	2.2 -4.3	2.2 -0.3	2.2 -2.3
	-5.4	8.0	5.8		17.5			13.2	15.0	-4.5	-6.7	-2.3
	10.8	13.1	9.7	26.5	13.8			-0.2	5.7	6.1	7.2	6.7
	17.9	16.2	14.6	20.5	18.4			16.3	17.2	7.0	4.6	5.8
	20.9	1.4	19.1	25.3	21.3			12.0	16.3	-4.2	-2.9	-3.5
	15.8	9.0	20.1	13.7	15.2			8.1	11.5	5.4	1.7	3.5
	8.9	15.8	13.5	17.8	11.1			11.6	11.4	2.8	2.0	2.4
	6.3	12.7	16.4	31.2	12.3			5.1	8.7	0.0	-0.7	-0.3
	7.8	4.7	16.4	7.2	7.6			12.3	9.9	5.3	2.8	4.0
	5.9	11.6	8.3	1.6	4.9			6.2	5.5	13.7	8.6	11.2
	5.3	11.4	9.6	6.0	5.7			5.9	5.8	1.2	6.3	3.7
				(;	annual percentage	change in excess	of inflation in	the Canadian e	conomy)			
	12.7	4.9	23.6		12.6			31.5	23.3			9.7
	8.7	3.2	13.1		8.5			-5.1	0.3			10.0
	9.6 7.8	16.0 13.9	-4.4 1.2		9.6 7.9			6.7 5.3	8.0 6.4			15.7 15.1
	10.8	14.9	16.4		10.9			5.5	7.9			1.1
	16.3 5.8	5.7 6.3	12.9 1.4		16.0 5.8			7.3 6.8	11.2 6.3			10.4 4.9
	3.3	14.5	-2.2		3.6			12.3	8.2	-0.2	4.1	1.8
	6.5	7.1	10.1		6.5			0.2	3.0	-2.2	7.5	2.4
	6.0	2.2	9.3		5.9			9.2	7.7	-0.1	-0.1	-0.1
	-11.0	-2.7	7.6		-10.6			5.3	-1.9	-6.0	-2.0	-4.0
	-6.4	7.0	4.8		16.6			12.2	14.0	-10.4	-7.7	-9.1
	11.2 16.1	13.5 14.4	10.1 12.8	26.9 18.7	14.2 16.6			0.2 14.5	6.2 15.4	6.5 5.2	7.6 2.8	7.1 4.0
	16.8	-2.7	15.0	21.2	17.2			7.9	12.2	-8.3	-7.0	-7.6
	14.4 8.0	7.6 14.8	18.8 12.5	12.3 16.8	13.9 10.1			6.7 10.6	10.1 10.4	4.0 1.8	0.4 1.0	2.1 1.4
	3.4	9.8	13.5	28.3	9.4			2.2	5.8	-2.9	-3.6	-3.2
	5.1	2.0	13.8	4.5	4.9			9.6	7.2	2.6	0.1	1.3
	3.3	9.0	5.7	-1.1	2.2			3.5	2.9	11.1	5.9	8.5
	3.7	9.8	8.0	4.4	4.1			4.3	4.2	-0.4	4.7	2.1
	5.7	5.0	0.0	4.4	4.1			4.5	4.2	-0.4	4.7	2.1

	Т	otal Health Exp	enditures, Quel	bec, 1985 to	2006 (conti	nued) GDP Implicit
 Public	All Drugs Private	Total	He	ealth Expenditure Private	Total	Price Index – Canac
		(\$ per ca	apita)			(1997 = 100)
 39.00	85.97	124.97	1,189.31	315.70	1,505.01	73.6
45.00 50.98	107.92 113.42	152.93 164.40	1,200.16 1,273.33	370.59 388.08	1,570.76 1,661.41	75.6 79.2
58.20	130.18	188.37	1,378.61	416.85	1,795.46	82.8
65.44	148.26	213.70	1,458.95	459.21	1,918.16	86.6
74.58 88.56	158.07 176.07	232.66 264.62	1,544.02 1,672.46	499.35 540.63	2,043.36 2,213.09	89.2 91.6
94.78 99.55	188.75 206.20	283.53 305.75	1,721.23 1,741.32	582.66 621.16	2,303.89 2,362.48	92.8 94.1
107.16	210.74	317.90	1,762.32	644.78	2,407.10	95.2
116.00	227.04	343.03	1,760.37	643.79	2,404.16	97.4
105.61 124.14	234.66 247.43	340.27 371.57	1,691.02 1,798.45	650.19 681.93	2,341.22 2,480.38	99.0 100.0
141.28 167.23	252.35 284.58	393.63 451.81	1,958.19 1,976.54	683.17 755.79	2,641.36 2,732.33	99.6 101.4
202.85	304.91	507.75	2,113.96	800.64	2,914.60	105.5
233.69	325.55	559.25	2,278.30	885.32	3,163.62	106.9
259.59 291.63	355.19 368.45	614.78 660.08	2,377.92 2,480.57	949.21 1,001.63	3,327.12 3,482.20	108.0 111.1
313.77	406.28	720.05	2,620.66	1,034.98	3,655.64	114.1
329.12	436.13	765.25	2,741.39	1,082.05	3,823.43	117.2
347.89	459.54	807.43	2,848.37	1,127.31	3,975.68	119.0
			nnual percentage chang			
 15.4	25.5	22.4	0.9	 17.4	4.4	 2.8
13.3 14.1	5.1 14.8	7.5 14.6	6.1 8.3	4.7 7.4	5.8 8.1	4.7 4.5
12.4	13.9	13.4	5.8	10.2	6.8	4.6
14.0 18.7	6.6 11.4	8.9 13.7	5.8 8.3	8.7 8.3	6.5 8.3	3.0 2.8
7.0	7.2	7.1	2.9	7.8	4.1	2.8
5.0 7.6	9.2 2.2	7.8 4.0	1.2 1.2	6.6 3.8	2.5 1.9	1.4 1.1
8.2	7.7	7.9	-0.1	-0.2	-0.1	2.3
-9.0 17.5	3.4 5.4	-0.8 9.2	-3.9 6.4	1.0 4.9	-2.6 5.9	1.7 1.0
13.8	2.0	5.9	8.9	0.2	6.5	-0.4
18.4	12.8	14.8	0.9	10.6	3.4	1.8
21.3 15.2	7.1 6.8	12.4 10.1	7.0 7.8	5.9 10.6	6.7 8.5	4.1 1.4
11.1	9.1	9.9	4.4	7.2	5.2	1.0
12.3 7.6	3.7 10.3	7.4 9.1	4.3 5.6	5.5 3.3	4.7 5.0	2.9 2.7
4.9	7.3	6.3	4.6	4.5	4.6	2.7
5.7	5.4	5.5	3.9	4.2	4.0	1.6
	(annual percentag	ge change in excess of	inflation in the Canadia			
 12.6	 22.7	 19.6	 -1.9	 14.6	 1.6	
8.5	0.4	2.8	1.4	0.0	1.0	
9.6 7.9	10.3 9.3	10.1 8.9	3.7 1.3	2.9 5.6	3.5 2.3	
10.9	3.6	5.8	2.8	5.7	3.5	
16.0 5.8	8.6 5.9	11.0 5.9	5.6 1.7	5.5 6.5	5.5 2.8	
3.6	7.8	6.4	-0.3	5.2	1.1	
6.5	1.1	2.9	0.1	2.7	0.8	
5.9 -10.6	5.4 1.7	5.6 -2.5	-2.4 -5.6	-2.5 -0.7	-2.5 -4.3	
16.6 14.2	4.5 2.4	8.2 6.4	5.4 9.3	3.9 0.6	5.0 6.9	
16.6	11.0	13.0	-0.9	8.8	1.6	
17.2	3.0	8.3	2.9	1.8	2.6	
13.9 10.1	5.4 8.1	8.8 8.9	6.4 3.4	9.2 6.2	7.2 4.2	
9.4 4.9	0.8 7.6	4.5 6.4	1.4 3.0	2.6 0.6	1.8 2.3	
2.2	4.7	3.6	2.0	1.9	1.9	
4.1	3.8	3.9	2.0	2.6	2.4	
	0.0	0.0	2.0	2.0	<u> </u>	

Table B.6.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985 to 2006

			Public		Prescribe		Private			Privat	Prescribed D te (Out-of-Po	cket)
	Provincial	Federal _	Social Secu WCB	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
				Funds		(\$ mil	lions)			Drugs		
	399.4	13.8	7.2		420.5			579.4	999.9			487.9
	481.2	14.5	8.8		504.5			706.8	1,211.2			552.4
	574.4	15.4	10.1		599.9			748.2	1,348.1			640.6
	663.8	24.5	12.0		700.4			845.3	1,545.6			711.0
	749.5	30.7	13.5		793.8			951.9	1,745.7			789.2
	881.2	36.2	16.2		933.6			1,089.7	2,023.3			816.5
	1,012.7	37.9	20.2		1,070.8			1,201.1	2,271.9			883.5
	1,183.6	41.0	23.3		1,247.8			1,376.9	2,624.8	521.5	455.3	976.7
	1,248.0 1,235.8	46.7 50.7	24.2 18.5		1,318.9 1,305.1			1,482.1 1,508.7	2,801.0 2,813.7	558.9 577.9	478.5 516.1	1,037.5 1,094.0
	1,379.6	52.9	19.5		1,452.0			1,660.0	3,112.0	578.4	528.8	1,107.2
	1,362.7 1,417.2	53.9 57.6	21.6 22.3		1,438.2 1,497.0			1,735.3 2,103.4	3,173.5 3,600.5	599.6 662.8	540.5 603.4	1,140.1 1,266.2
	1,568.2	65.9	22.5		1,658.1			2,466.3	4,124.4	700.0	646.0	1,346.0
	1,727.0	73.7	25.4		1,826.2			2,387.7	4,213.9	748.6	679.7	1,428.2
	1,983.4 2,264.1	72.6 83.0	31.1 35.4		2,087.0 2,382.4			2,719.9 3,016.0	4,807.0 5,398.4	777.9 797.0	699.8 719.6	1,477.7 1,516.6
	2,599.1	94.5	41.4		2,735.0			3,344.4	6,079.4	848.0	740.5	1,510.0
	2,894.3	106.6	51.9		3,052.8			3,766.1	6,818.8	859.6	728.3	1,587.9
	3,210.1	108.8	63.3		3,382.1			4,031.7	7,413.8	901.7	750.1	1,651.7
f	3,523.3	118.1	71.7		3,713.1			4,459.5	8,172.5	934.4	770.5	1,704.9
f	3,490.9	127.5	80.6		3,698.9			4,859.6	8,558.5	929.1	799.2	1,728.2
	3,430.3	127.5	00.0		3,030.3			4,000.0	0,000.0	323.1	755.2	1,720.2
						(annual percer						
	20.5	 4.8	20.8		20.0			22.0	 21.1			 13.2
	19.4	5.9	15.2		18.9			5.9	11.3			16.0
	15.6	59.4	19.2		16.7			13.0	14.6			11.0
	12.9	25.3	12.6		13.3			12.6	12.9			11.0
	17.6	18.0	19.8		17.6			14.5	15.9			3.5
	14.9	4.8	24.4		14.7			10.2	12.3			8.2
	16.9	8.0	15.4		16.5			14.6	15.5			10.6
	5.4	13.9	3.9		5.7			7.6	6.7	7.2	5.1	6.2
	-1.0	8.7	-23.3		-1.0			1.8	0.5	3.4	7.8	5.4
	11.6	4.3	5.1		11.3			10.0	10.6	0.1	2.5	1.2
	-1.2	1.8	10.9		-1.0			4.5	2.0	3.7	2.2	3.0
	4.0	7.0	2.9		4.1			21.2	13.5	10.5	11.6	11.1
	10.7	14.4	7.4		10.8			17.3	14.6	5.6	7.1	6.3
	10.1	11.9	6.3		10.1			-3.2	2.2	6.9	5.2	6.1
	14.8	-1.6	22.3		14.3			13.9	14.1	3.9	3.0	3.5
	14.2	14.3	13.8		14.2			10.9	12.3	2.5	2.8	2.6
	14.8	13.9	17.0		14.8			10.9	12.6	6.4	2.9	4.7
	11.4 10.9	12.8 2.0	25.2 22.0		11.6 10.8			12.6 7.1	12.2 8.7	1.4 4.9	-1.6 3.0	0.0 4.0
f	9.8	8.6	13.3		9.8			10.6	10.2	3.6	2.7	3.2
f	-0.9	8.0	12.3		-0.4			9.0	4.7	-0.6	3.7	1.4
					(per	centage share of t	otal drug expe	enditure)				
	26.8	0.9	0.5		28.3			38.9	67.2			32.8
	27.3	0.8	0.5		28.6			40.1	68.7			31.3
	28.9	0.8	0.5		30.2			37.6	67.8			32.2
	29.4	1.1	0.5		31.0			37.5	68.5			31.5
	29.6	1.2	0.5		31.3			37.6	68.9			31.1
	31.0	1.3	0.6		32.9			38.4	71.2			28.8
	32.1	1.2	0.6		33.9			38.1	72.0			28.0
	32.9	1.1	0.6		34.6			38.2	72.9	14.5	12.6	27.1
	32.5 31.6	1.2	0.6 0.5		34.4 33.4			38.6	73.0	14.6	12.5	27.0 28.0
		1.3	0.5		33.4			38.6	72.0	14.8	13.2	28.0
	32.7	1.3	0.5		34.4			39.3	73.8	13.7	12.5	26.2
	31.6	1.2	0.5		33.3			40.2	73.6	13.9	12.5	26.4
	29.1 28.7	1.2 1.2	0.5 0.4		30.8 30.3			43.2 45.1	74.0 75.4	13.6 12.8	12.4 11.8	26.0 24.6
	30.6	1.2	0.4		32.4			43.1	74.7	13.3	11.8	24.0
	31.6	1.2	0.5		33.2			43.3	76.5	12.4	11.1	23.5
	31.0	1.2	0.5		34.5			43.5	78.1	12.4	10.4	23.5
	33.9	1.2	0.5		35.7			43.6	79.3	11.1	9.7	20.7
	34.4	1.3	0.6		36.3			44.8	81.1	10.2	8.7	18.9
	35.4	1.2	0.7		37.3			44.5	81.8	9.9	8.3	18.2
f	35.7	1.2	0.7		37.6			45.1	82.7	9.5	7.8	17.3
f	33.9	1.2	0.8		36.0			47.2	83.2	9.0	7.8	16.8
	55.5	1.2	0.0		30.0			47.Z	00.2	5.0	1.0	10.0
ecast												

Table B.6.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985 to 2006 (continued) Share of Drugs in Public, Private and

				Use	lth Europeiture			in Public, Privat	
-	Public	All Drugs Private	Total	Public	Ith Expenditure Private	Total	Public	alth Expenditure Private	s Total
Year			(\$ millio	ns)			(perce	entage share)	
1985	420.5	1,067.2	1,487.7	10,443.3	3,999.5	14,442.8	4.0	26.7	10.3
1986	504.5	1,259.2	1,763.7	11,730.2	4,367.1	16,097.2	4.3	28.8	11.0
1987 1988	599.9 700.4	1,388.9 1,556.3	1,988.8 2,256.7	13,011.9 14,497.9	4,854.5 5,321.9	17,866.4 19,819.8	4.6 4.8	28.6 29.2	11.1 11.4
1989	793.8	1,741.1	2,534.9	16,093.9	5,876.9	21,970.8	4.9	29.6	11.5
1990	933.6	1,906.2	2,839.8	17,332.8	6,466.2	23,799.1	5.4	29.5	11.9
1991	1,070.8	2,084.6	3,155.4	19,156.1	7,038.2	26,194.3	5.6	29.6	12.0
1992	1,247.8	2,353.7	3,601.5	20,058.0	7,573.7	27,631.8	6.2	31.1	13.0
1993 1994	1,318.9 1,305.1	2,519.6 2,602.7	3,838.5 3,907.7	19,880.5 20,071.3	8,253.2 8,702.3	28,133.7 28,773.5	6.6 6.5	30.5 29.9	13.6 13.6
1995 1996	1,452.0 1,438.2	2,767.2 2,875.4	4,219.2 4,313.6	19,946.2 20,092.0	9,374.4 9,613.7	29,320.6 29,705.7	7.3 7.2	29.5 29.9	14.4 14.5
1997	1,497.0	3,369.7	4,866.7	20,513.9	10,266.5	30,780.4	7.2	32.8	15.8
1998	1,658.1	3,812.3	5,470.4	22,066.3	11,035.4	33,101.7	7.5	34.5	16.5
1999	1,826.2	3,815.9	5,642.1	23,378.2	12,006.2	35,384.4	7.8	31.8	15.9
2000	2,087.0	4,197.7	6,284.7	26,001.0	12,927.7	38,928.7	8.0	32.5	16.1
2001 2002	2,382.4 2,735.0	4,532.7 4,932.9	6,915.1 7,667.9	27,652.8 29,671.1	14,152.3 15,767.6	41,805.1 45,438.7	8.6 9.2	32.0 31.3	16.5 16.9
2002	3,052.8	4,932.9 5,354.0	8,406.8	33,281.8	16,446.7	49,728.5	9.2	31.3	16.9
2004	3,382.1	5,683.4	9,065.5	35,699.7	17,598.4	53,298.1	9.5	32.3	17.0
2005 f	3,713.1	6,164.3	9,877.4	37,853.8	18,886.0	56,739.7	9.8	32.6	17.4
2006 f	3,698.9	6,587.8	10,286.7	40,459.2	19,901.1	60,360.3	9.1	33.1	17.0
1985			(annual percenta	ge change) 					
1985	20.0	18.0	18.6	12.3	9.2	11.5			
1987	18.9	10.3	12.8	10.9	11.2	11.0			
1988	16.7	12.1	13.5	11.4	9.6	10.9			
1989	13.3	11.9	12.3	11.0	10.4	10.9			
1990	17.6	9.5	12.0	7.7	10.0	8.3			
1991 1992	14.7 16.5	9.4 12.9	11.1 14.1	10.5 4.7	8.8 7.6	10.1 5.5			
1993	5.7	7.0	6.6	-0.9	9.0	1.8			
1994	-1.0	3.3	1.8	1.0	5.4	2.3			
1995	11.3	6.3	8.0	-0.6	7.7	1.9			
1996	-1.0	3.9	2.2	0.7	2.6	1.3			
1997 1998	4.1 10.8	17.2 13.1	12.8 12.4	2.1 7.6	6.8 7.5	3.6 7.5			
1999	10.8	0.1	3.1	5.9	8.8	6.9			
2000	14.3	10.0	11.4	11.2	7.7	10.0			
2001	14.2	8.0	10.0	6.4	9.5	7.4			
2002	14.8	8.8	10.9	7.3	11.4	8.7			
2003 2004	11.6 10.8	8.5 6.2	9.6 7.8	12.2 7.3	4.3 7.0	9.4 7.2			
2005 f	9.8	8.5	9.0	6.0	7.3	6.5			
2006 f	-0.4 (percentage	6.9 share of total drug	4.1 expenditure)	6.9	5.4	6.4			
1985	28.3	71.7	100.0	_					
1986	28.6	71.4	100.0						
1987 1988	30.2	69.8	100.0						
1988	31.0 31.3	69.0 68.7	100.0 100.0						
1990	32.9	67.1	100.0						
1990	32.9 33.9	67.1	100.0						
1992	34.6	65.4	100.0						
1993	34.4	65.6	100.0						
1994	33.4	66.6	100.0						
1995 1996	34.4 33.3	65.6 66.7	100.0 100.0						
1990	30.8	69.2	100.0						
1998	30.3	69.7	100.0						
1999	32.4	67.6	100.0						
2000	33.2	66.8	100.0						
2001	34.5	65.5	100.0						
2002 2003	35.7 36.3	64.3 63.7	100.0 100.0						
2000	37.3	62.7	100.0						
2005 f	37.6	62.4	100.0						
2006 f	36.0	64.0	100.0						
								e	ırce: CIHI, 2006.
-Forecast								Sou	arce: CIHI, 2006.

Table B.6.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Ontario, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
	Provincial	Federal _	Social Security WCB In	/ Funds Drug surance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Year				i unus		(\$ per o	capita)			Diugs		
1985	42.96	1.49	0.78		45.23			62.31	107.54			52.47
1986 1987	50.99 59.56	1.54 1.59	0.93 1.05		53.45 62.20			74.88 77.58	128.33 139.78			58.53 66.43
1988	67.45	2.49	1.22		71.16			85.88	157.04			72.24
1989	74.16	3.04	1.34		78.53			94.18	172.71			78.08
1990	85.57	3.52	1.58		90.66			105.82	196.48			79.29
1991	97.11	3.64	1.93		102.68			115.18	217.86			84.72
1992	111.98	3.88	2.20		118.06			130.27	248.33	49.33	43.07	92.41
1993 1994	116.76 114.23	4.37 4.69	2.26 1.71		123.39 120.64			138.67 139.46	262.06 260.09	52.29 53.42	44.77 47.71	97.06 101.12
1995 1996	125.99 122.95	4.83 4.86	1.78 1.95		132.60 129.76			151.60 156.57	284.20 286.34	52.82 54.10	48.29 48.77	101.11 102.87
1997	126.21	5.13	1.98		133.33			187.33	320.66	59.03	53.74	112.77
1998	137.96	5.80	2.10		145.87			216.97	362.84	61.58	56.83	118.41
1999	150.09	6.41	2.21		158.71			207.51	366.22	65.06	59.07	124.13
2000	169.73	6.21	2.66		178.60			232.76	411.37	66.57	59.89	126.46
2001	190.30	6.97	2.97		200.24			253.50	453.74	66.99	60.49	127.47
2002 2003	214.77 236.09	7.81 8.70	3.42 4.23		226.00 249.01			276.35 307.19	502.35 556.21	70.07 70.12	61.19 59.40	131.26 129.52
2003	258.72	8.77	5.10		272.59			324.94	597.53	72.67	60.45	133.13
2005 f	280.93	9.41	5.72		296.07			355.58	651.64	74.50	61.44	135.94
2006 f	275.26	10.05	6.35		291.67			383.19	674.86	73.26	63.01	136.27
						(annual percer						
1985 1986	 18.7	3.3	 19.0		 18.2			20.2	 19.3			 11.6
1987	16.8	3.6	12.8		16.4			3.6	8.9			13.5
1988	13.2	56.2	16.8		14.4			10.7	12.3			8.8
1989	9.9	22.0	9.6		10.4			9.7	10.0			8.1
1990	15.4	15.8	17.6		15.4			12.4	13.8			1.5
1991	13.5	3.5	22.8		13.3			8.8	10.9			6.9
1992 1993	15.3 4.3	6.5 12.6	13.8 2.7		15.0 4.5			13.1 6.4	14.0 5.5	6.0	 3.9	9.1 5.0
1994	-2.2	7.4	-24.2		-2.2			0.6	-0.8	2.2	6.6	4.2
1995	10.3	3.1	3.9		9.9			8.7	9.3	-1.1	1.2	
1996	-2.4	0.6	9.6		-2.1			3.3	0.8	2.4	1.0	1.7
1997 1998	2.7 9.3	5.6 13.0	1.6 6.1		2.7 9.4			19.6 15.8	12.0 13.2	9.1 4.3	10.2 5.7	9.6 5.0
1999	8.8	10.5	5.0		8.8			-4.4	0.9	5.6	3.9	4.8
2000	13.1	-3.1	20.4		12.5			12.2	12.3	2.3	1.4	1.9
2001	12.1	12.3	11.8		12.0			8.9	10.3	0.6	1.0	0.8
2002	12.9	12.0	15.1		12.9			9.0	10.7	4.6	1.2	
2003	9.9	11.4	23.6		10.2			11.2	10.7	0.1	-2.9	-1.3
2004	9.6	0.8	20.6		9.5			5.8	7.4	3.6	1.8	2.8
2005 f	8.6	7.4	12.1		8.6			9.4	9.1	2.5	1.6	2.1
2006 f	-2.0	6.8	11.1		-1.5			7.8	3.6	-1.7	2.6	0.2
					annual percentage)	change in excess of	of inflation in	the Canadian e	conomy)			
1985												
1986 1987	15.9 12.1	0.5 -1.1	16.2 8.0		15.4 11.6			17.4 -1.1	16.5 4.2			8.8 8.7
1988	8.7	51.6	12.3		9.9			-1.1	7.8			4.2
1989	5.4	17.4	5.0		5.8			5.1	5.4			3.5
1990	12.4	12.8	14.6		12.4			9.3	10.7			-1.5
1991	10.7	0.7	20.0		10.5			6.1	8.1			4.1
1992	14.1	5.3	12.6		13.7			11.8	12.7			7.8
1993 1994	2.8 -3.3	11.2 6.3	1.3 -25.3		3.1 -3.3			5.0 -0.5	4.1 -1.8	4.6 1.1	2.5 5.5	3.6 3.1
1995 1996	8.0 -4.1	0.7 -1.1	1.5 7.9		7.6 -3.8			6.4 1.6	6.9 -0.9	-3.4 0.7	-1.1 -0.7	-2.3 0.1
1996	-4.1	4.6	0.6		-3.8			1.6	-0.9	8.1	-0.7 9.2	
1998	9.7	13.4	6.6		9.8			16.3	13.6	4.8	6.2	5.4
1999	7.0	8.7	3.2		7.0			-6.2	-0.9	3.8	2.1	3.0
2000	9.0	-7.2	16.3		8.4			8.1	8.2	-1.8	-2.7	-2.2
2001	10.8	10.9	10.4		10.8			7.6	8.9	-0.7	-0.4	-0.6
2002 2003	11.9 7.0	11.0 8.5	14.1 20.7		11.9 7.3			8.0 8.3	9.7 7.8	3.6 -2.8	0.2 -5.8	
2003	6.9	-1.9	17.9		6.8			3.1	4.7	-2.8	-5.8	-4.2
2005 f	5.9	4.7	9.5		6.0			6.8	6.4	-0.1	-1.0	-0.5
2000 1												
2006 f –Forecast	-3.6	5.2	9.5		-3.1			6.2	2.0	-3.3	1.0	-1.4

					ario, 1985 to		GDP Implicit
Public	:	All Drugs Private	Total	He Public	alth Expenditure Private	Total	Price Index – Canada
			(\$ per ca	pita)			(1997 = 100)
	45.23	114.79	160.01	1,123.23	430.17	1,553.40	73.6
	53.45 62.20	133.42 144.01	186.87 206.21	1,242.85 1,349.18	462.71 503.36	1,705.55 1,852.54	75.6 79.2
	71.16	158.13	229.28	1,473.03	540.72	2,013.75	82.8
	78.53	172.26	250.79	1,592.27	581.43	2,173.70	86.6
	90.66 02.68	185.11 199.90	275.77 302.58	1,683.15 1,836.97	627.92 674.92	2,311.07 2,511.89	89.2 91.6
1	18.06	222.68	340.74	1,897.67	716.54	2,614.22	92.8
	23.39 20.64	235.73 240.58	359.12 361.22	1,860.01 1,855.31	772.16 804.41	2,632.17 2,659.72	94.1 95.2
	32.60	252.71	385.31	1,821.57	856.11	2,677.68	97.4
1:	29.76	259.44	389.20	1,812.86	867.42	2,680.28	99.0
	33.33 45.87	300.11 335.39	433.43 481.25	1,826.98 1,941.26	914.34 970.82	2,741.32 2,912.08	100.0 99.6
	58.71	331.64	490.35	2,031.76	1,043.44	3,075.20	101.4
	78.60	359.22	537.83	2,225.09	1,106.31	3,331.40	105.5
	00.24 26.00	380.97 407.61	581.21 633.61	2,324.22 2,451.74	1,189.51 1,302.89	3,513.73 3,754.63	106.9 108.0
2	49.01	436.72	685.73	2,714.76	1,341.54	4,056.30	111.1
	72.59	458.07	730.66	2,877.30	1,418.39	4,295.69	114.1
	96.07	491.52	787.58	3,018.30	1,505.89	4,524.19	117.2
2	91.67	519.46	811.13	3,190.28	1,569.24	4,759.52	119.0
			(a	nnual percentage chang	e)		
	18.2	16.2	16.8	10.6	7.6	9.8	2.8
	16.4 14.4	7.9 9.8	10.4 11.2	8.6 9.2	8.8 7.4	8.6 8.7	4.7 4.5
	10.4	8.9	9.4	8.1	7.5	7.9	4.6
	15.4	7.5	10.0	5.7	8.0	6.3	3.0
	13.3 15.0	8.0 11.4	9.7 12.6	9.1 3.3	7.5 6.2	8.7 4.1	2.8 1.3
	4.5	5.9	5.4	-2.0	7.8	0.7	1.4
	-2.2	2.1	0.6	-0.3	4.2	1.0	1.1
	9.9 -2.1	5.0 2.7	6.7 1.0	-1.8 -0.5	6.4 1.3	0.7 0.1	2.3 1.7
	2.7	15.7	11.4	0.8	5.4	2.3	1.0
	9.4 8.8	11.8 -1.1	11.0 1.9	6.3 4.7	6.2 7.5	6.2 5.6	-0.4 1.8
	12.5	8.3	9.7	9.5	6.0	8.3	4.1
	12.1	6.1	8.1	4.5	7.5	5.5	1.4
	12.9 10.2	7.0 7.1	9.0 8.2	5.5 10.7	9.5 3.0	6.9 8.0	1.0 2.9
	9.5	4.9	6.6	6.0	5.7	5.9	2.3
	8.6	7.3	7.8	4.9	6.2	5.3	2.7
	-1.5	5.7	3.0	5.7	4.2	5.2	1.6
			-	inflation in the Canadia		<u> </u>	
	 15.4	 13.4	 14.0	 7.8	 4.8	 7.0	
	11.6	3.2	5.6	3.8	4.0	3.9	
	9.9 5.8	5.3 4.4	6.7 4.8	4.7 3.5	2.9 3.0	4.2 3.4	
	12.4	4.4	6.9	2.7	5.0	3.3	
	10.5	5.2	7.0	6.4	4.7	5.9	
	13.7 3.1	10.1 4.4	11.3 4.0	2.0 -3.4	4.9 6.3	2.8 -0.8	
	-3.3	1.0	-0.5	-1.4	3.1	-0.1	
	7.6	2.7	4.3	-4.2	4.1	-1.7	
	-3.8 1.8	1.0 14.7	-0.7 10.4	-2.1 -0.2	-0.4 4.4	-1.6 1.3	
	9.8	12.2	11.5	6.7	6.6	6.7	
	7.0	-2.9	0.1	2.9	5.7	3.8	
	8.4 10.8	4.2 4.7	5.6 6.7	5.4 3.1	1.9 6.2	4.2 4.1	
	11.9	6.0	8.0	4.5	8.5	5.9	
	7.3 6.8	4.2 2.2	5.3 3.9	7.8 3.3	0.1 3.0	5.1 3.2	
	6.0	4.6	5.1	2.2	3.5	2.7	
	-3.1	4.1	1.4	4.1	2.6	3.6	

Table B.7.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985 to 2006

Image Image <th< th=""><th></th><th></th><th></th><th>Public</th><th></th><th>Prescribe</th><th>ed Drugs</th><th>Private</th><th></th><th></th><th></th><th>Prescribed D te (Out-of-Po</th><th></th></th<>				Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
Yar		Provincial	Federal _	WCB	Drug Insurance		Insurers*			Prescribed	the- Counter	Health	Non-Presc.
1986 44.6 7.2 0.4 - 42.2 - - 61.2 110.4 - - - 0 0 1987 42.3 7.7 0.4 - 0.40 - - 0.40 10.5 - - - - 0.7 0 <th0< th=""><th>Year</th><th></th><th></th><th></th><th>Funas</th><th></th><th>(\$ mil</th><th>lions)</th><th></th><th></th><th>Drugs</th><th></th><th></th></th0<>	Year				Funas		(\$ mil	lions)			Drugs		
1897 423 77 0.4 504 613 112.3 7 1900 426 13.8 0.7 67.3 68.2 102.1 77.3 1900 45.5 13.8 0.7 67.3 68.2 102.1 68.2 102.2 68.2 102.2 101.4 108.1 10.4 10.2 101.4 108.2 10.4 4.0													61.0
1989 47.6 9.3 0.5 - 57.2 - - 74.0 125.5 - - . 75.0 1980 44.5 11.5 0.7 - 62.9 - - 62.9 148.1 - - - 72.9 1980 44.5 11.6 0.7 - 80.7 - - 10.8 20.0 50.4 44.8 9.9 1981 46.1 2.1.0 0.8 - 10.0 - - 118.5 20.0 44.0 41.0 9.9 1986 79.6 0.7 - 10.0 20.0 - - 118.0 20.0 10.0<													69.1
1989 455 11.5 0.6 - 7.7 7													75.4
1919 65.4 116.2 0.7 - 72.4 - - - 01.6 10.2 - - - - 01.6 10.2 01.4 4.6 00 1914 0.1 24.6 0.0 - 100.5 - - 10.6 100.5 - - 10.6 256.3 40.6 47.3 90 1916 72.6 22.6 0.0 - 100.2 - - 163.4 266.3 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 10.0 40.7 40.0 40.7 10.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 10.0 40.0 10.0 40.0 10.0 40.0 10.0 40.0 10.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 40.0 <td></td> <td>70.9</td>													70.9
1919 65.4 162 0.7 - 72.4 - - - 01.6 10.2 - - - - 01.6 10.2 01.6 41.6 0.0 11944 61.1 24.6 0.8<	1990	48.5	13.8	0.7		62.9			86.2	149.1			75.3
1933 06.1 21.9 0.7 - - - - 118.5 20.0 05.4 4.1.9 26.4 4.1.9 26.4 4.1.9 26.4 4.1.9 26.4 4.1.9 26.4 4.1.9 26.5 41.5 41.7 88 1986 7.8 0.7 0.0 0.0 103.2 - - 163.4 26.6 45.0													81.5
1994 0.1 2.46 0.8 - 9.85 - - 120.1 21.6 0.40 4.7.3 0.8 1995 7.2.6 2.2.6 0.8 - 100.2 - - 183.4 2.6.7 10.0 4.7.3 0.8 1998 7.2.6 2.2.6 0.8 1.0 - 10.0 2.7.2 1.0.0 4.7.3 0.8 4.0.0													93.2
1986 78 <													92.2
1986 7.3.6 2.8.6 0.9 10.2.2 18.4. 2.8.7.7 5.1.5 47.3 8.8 1987 2.3.7 3.3.1 1.0 18.3.6 18.0.5 2.2.7.7 5.3.2 5.4.5 5.4.5 5.8.6 11.0 1989 10.6.6 3.2.4.5 1.1.0 13.3.6 2.2.5 2.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.6 5.7.7 5.7.6 6.7.7 5.7.6 6.7.7 5.7.6 6.7.7 5.7.6 6.7.7 5.7.6 7.7.7 5.7.6 6.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.7 5.7.6 7.7.7 5.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7 5.7.6 7.7.7													89.7
9999 86.9 32.7 1.0 112.6 186.0 20.65 5.4.8 60.9 100 2000 130.0 38.4 1.3 170.7 20.5.3 37.0.0 57.4 62.6 100 2000 130.0 38.4 1.3 207.0 23.4 48.7 62.6 68.6 114 2003 168.8 62.2 1.1 220.3 23.4 69.9 70.7 68.7 128 20051 262.9 75.4 2.3 90.8 23.3 69.9 70.4 60.1 130.9 20051 262.9 75.4 2.3 90.6 23.3 69.9 70.4 60.1 130.9 131.9 131.9 131.9 131.9 131.9 131.9 131.9 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>98.3</td></td<>													98.3
1999 105.6 36.9 1.1 143.6 105.5 37.42 97.4 55.6 10 2001 160.8 43.5 1.6 207.0 22.3 44.5.7 66.8 55.8 11 2004 160.8 42.0 10.2 20.4 42.7 67.4 62.6 48.0 17 2004 124.6 60.7 2.4 20.2 22.4 67.4 67.7 12 2006 / 24.6 60.7 2.4 20.4 60.1 7.0													88.7
2020 10.0 84.4 1.3 170.7 20.3 47.0 67.4 63.0 110 2001 188.6 52.0 1.7 243.3 280.4 442.7 66.6 64.8 173 2004 224.6 65.3 2.3 302.2 277.2 67.9 68.7 17.0 67.7 68.0 125 2006 f 20.4 66.7 2.4 302.2 277.2 69.4 7.7 67.7 67.0 17 12 2006 f 20.4 66.7 2.4 306.5 13.7 68.0 1897 21.4 19.4 2.5 15.0 12.5 68.0 1898 4.4 2.4 19.4 2.5 10.1 117.7													102.7
2001 100.8 44.5 1.6 207.0 212.3 419.3 00.8 53.6 114 2002 127.0 60.7 2.1 280.4 280.4 46.5 56.3 120 2006 / 22.8 62.5 2.3 280.4 284.5 68.4 170 0.6 130 2006 / 22.8 7.8 7.8 7.8 0.84.6 284.3 684.9 70.4 60.1 130 2006 / 22.8 7.8 7.4 -													
2020 198.6 62.0 1.7 243.3 238.4 82.7 66.6 177 2020 224.6 65.3 2.2 302.2 277.2 69.7 68.6 125 2020 f 224.7 66.7 2.4 306.6 214.6 69.4 0.7.7 69.7 61.7 125 2020 f 226.7 7.8 2.3 306.5 314.6 69.4 7.7 69.7 61.7 12 2020 f 226.7 7.8 7.4 314.5 69.4 7.7 69.7 <td></td> <td>110.0</td>													110.0
2030 217.7 60.7 2.1 200.4 266.7 97.1 64.5 65.8 120 2006 f 222.9 75.4 2.3 360.6 284.3 68.4 70.7 61.7 130 2006 f 230.4 86.7 2.4 360.5 284.3 68.4 70.7 61.7 132 1985													114.4
2005 I 262.9 75.4 2.3 - 340.8 - - 244.3 634.9 70.4 60.1 102 2006 I 260.4 86.7 2.4 - 360.5 - - 314.5 684.1 70.7 61.7 122 1985 - 10.1 10.7 - - - - - - - - - - - -	2003	217.7								547.1			120.8
2804 2807 2.4 - 280.5 - - 314.5 684.1 70.7 61.7 122 Innum prectage darge Innum prectage darge 1986 6.6 11.1 22.4 7.4 - - - 13.3 - - - 15.8 1988 6.6 11.1 22.4 7.4 0.0 - - 0.1 15.7 - - - 16.8 1989 6.5 19.7 10.1 - 9.3 - - 10.1 15.7 - - - 16.8 1980 6.5 19.7 10.1 - 9.3 - - 11.2	2004	234.6	65.3	2.3		302.2			277.2	579.4	67.7	58.0	125.8
Interesting change 1985	2005 f	262.9	75.4	2.3		340.6			294.3	634.9	70.4	60.1	130.5
ness 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 101 117 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 118 <t< td=""><td>2006 f</td><td>280.4</td><td>86.7</td><td>2.4</td><td></td><td>369.5</td><td></td><td></td><td>314.5</td><td>684.1</td><td>70.7</td><td>61.7</td><td>132.4</td></t<>	2006 f	280.4	86.7	2.4		369.5			314.5	684.1	70.7	61.7	132.4
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$							(annual nercer	(anne change)					
1966 6.6 11.1 23.4 7.4 13.3 13.3 1987 12.2 7.4 10.2 13.6 10.1 1.7 15.6 1980 6.5 19.7 16.1 9.3 11.2 12.8 <	1005												
1987 2.2 7.4 10.2 19.6 10.1 1.7.7 16 1989 4.1 24.1 8.5 0.5 10.1 17.7 6.5 1990 6.5 17.7 1.1 9.3 16.0 12.5 6.5 1991 14.3 17.8 7.1 15.0 6.6 10.6 -2.3 0.6 18.9 1992 2.2 14.4 17.9 2.0.9 18.6 10.6 12.5 4.6 19.9 3.0 -1.9 1.6 0.3 1.9 1.6 0.5 13.3 9.9 1.6 0.3 1.1 6.3 1.3 1.5 1.6 6.5 1.6 1.6 1.5 1.3 1.5 1.6 0.2 2.2 2.2 1.6 1.6 1.5 1.5 1.6 0.2 2.2													13.2
1989 4.1 2.4.1 8.5 0.5 15.0 15.7 15.0 1991 14.3 17.8 7.1 15.0 61.1 12.5 16.1 1992 22.3 14.4 17.9 20.9 61.6 10.6 12.5 16.1 1993 0.1 17.9 -10.4 20.9 16.6 10.6 12.5 15.0 11.5 0.0 0.0 0.0 <td>1987</td> <td>22.2</td> <td>7.4</td> <td>10.2</td> <td></td> <td>19.6</td> <td></td> <td></td> <td>-9.3</td> <td>1.7</td> <td></td> <td></td> <td>16.0</td>	1987	22.2	7.4	10.2		19.6			-9.3	1.7			16.0
1990 6.5 19.7 16.1 15.0 15.0 15.0 1992 12.3 14.4 17.9 20.9 6.1 12.5 14 1993 0.1 17.9 10.4 3.6 6.1 12.5 14 1994 -10.2 12.1 5.3 25.2 14.6 18.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9													-5.9
19191 14.3 17.8 7.1 15.0 11.2 12.8 84 1932 0.1 17.9 -10.4 3.6 16.6 10.6 2.3 0.6 1.4 1934 -10.2 13.3 9.2 25.2 14.6 18.9 2.9 1.3 9.3 13.3 9.2 2.7 14.2 5.7 15.0 16.6 15.3 13.3 9.3 11.8 7.4 7.4 7.4 14.2 5.7 15.0 16.6 15.3 13.3 9.3 13.3 9.3 13.3 9.3 13.3 9.3 13.3 9.3 13.3 14.3 14.3 13.3 15.3 14.3 14.3 13.3 15.3 14.3 15.3 14.3 15.3 14.3 14.3 13.3 13.0 12.2 13.3 14.3 13.3 13.0 12.2 12.3 14.3 13.3 14.3 14.3 14.3 14.3 1													-5.9
1992 22.9 14.4 17.9 20.9 -6.1 12.5 194 1994 -10.2 12.1 5.3 4.7 8.9 3.0 -1.9 1.5 0 0 1995 30.2 12.1 5.3 4.7 1.6 1.0 6.3 1.0 0 0 0 0 0 0.1 9.4 7.0 1.4 1.1 6.3 1.3 9 9 1.3 7 1.2 5.7 15.0 16.6 16 11.3 7 1.2 5.7 15.0 16.6 16 12.3 1.0 1.3 1.0 <													6.2
1983 -0.1 17.9 -10.4 3.6 16.6 10.6 2.3 0.6 -1.9 1994 -10.2 12.1 5.3 4.7 14.6 18.9 2.9 1.9 2.9 1.9 2.9 1.9 2.9 1.8 14.6 18.9 2.9 1.8 1.9 2.9 1.8 1.6 1.6 1.8 1.7 1.4 4.7 1.8 1.7 1.9 1.6 1.8 1.9 2.9 2.7 2.0 1.8 1.9 2.2 2.0 4.5 4.7 3.4 4.6 1.6 1.8 1.7 1.6 4.7 3.4 4.4 2.0 2.2 2.0 4.0 4.0 2.0 1.7 1.6 4.7 3.4 1.1 3.0 2.7 2.2 2.0 4.7 3.4 1.1 3.0 2.7 2.2 2.0 4.0 3.5 3.3 2.0 2.7 7.2 2.0 4.0 3.5 3.1 1.0<													8.2 14.4
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	1993	-0.1				3.6			16.6	10.6		0.6	-1.0
1986 -7.3 2.8 4.7 4.6 10.4 4.1 6.3 13.3 9 1987 0.1 9.6 7.9 13.7 14.2 9.7 11.8 7.6 99 1989 16.5 7.4 2.5 13.7 1.4.5 7.7 9.9 0.2 2.7 18.0 16.0 16.7 7.9 1.6.7 7.9 1.6.7 7.7 3.4 11.5 1.5.9 2.0 4.4 2004 16.7 7.7 9.6 7.7 11.4 15.3 3.0 2.7 2.2 2.0 4.0 3.5 3.3 3.0 2.7 2.0 4.0 3.5 3.3 3.0 2.7 2.0 4.0 3.5 3.3 3.0 2.7 2.0 4.0 3.5 3.3 3.0 2.7 1.0 3.0 2.7 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0	1994	-10.2	12.1	5.3		-4.7			8.9	3.0	-1.9	1.6	-0.3
1997 -0.1 9.6 7.9 2.7 1.2 9.7 11.8 -7.6 -9.9 1999 22.9 9.7 13.8 119.2 12.2 5.7 15.0 16.6 15 1999 22.9 9.7 13.8 118.2 13.7 16.0 4.7 3.4 4.4 2001 22.8 16.0 18.0 17.6 13.7 16.0 4.7 3.4 4.4 2003 17.9 16.7 7.9 17.6 13.3 3.0 2.2 2.2 2004 7.7 7.7 9.6 7.7 4.0 5.9 5.1 3.1 3.0 2.7 2.2 2004 7.7 7.7 9.6 7.7 4.0 5.9 7.1 4.6 9.7 0.4 2.7 1 2005 f 12.1 15.3 3.1													-2.4
1988 16.5 7.4 2.5 7 15.0 16.6 15 2000 24.0 4.0 20.6 18.8 3.4 11.5 5.9 2.0 4 2001 22.8 16.0 18.0 21.3 3.4 11.5 5.9 2.0 4 2001 22.8 16.0 18.0 21.3 12.8 15.1 3.0 2.2 2 2003 14.8 16.7 19.9 15.3 14.4 13.3 3.0 2.7 2 2004 7.7 7.7 9.6 7.7 6.9 7.7 0.4 2.7 1 2005 f 12.1 15.3 3.1 12.7 6.9 7.7 0.4 2.7 1 12.6 6.7 15.1 4.9 23.5 37.4 61.9 39													9.6 -9.8
2000 24.0 4.0 20.6 18.8 13.7 16.0 4.7 3.4 4.4 2001 22.8 16.0 18.0 21.3 3.4 11.5 5.9 2.0 4.4 201 17.9 16.7 7.9 17.6 11.4 13.3 3.0 2.7 22 2003 14.8 16.7 19.9 15.3 4.0 5.9 5.1 3.1 4 2005 f 12.1 15.3 3.1 12.7 6.9 7.7 0.4 2.7 1 2005 f 12.1 15.3 3.1 8.5 6.9 7.7 0.4 2.7 1 2005 f 12.1 15.3 3.1 8.5 8.0 6.1 8.0 8.1 8.0 6.1 9.0													15.8
2001 22.8 16.0 18.0 21.3 3.4 11.5 5.9 2.0 4 2002 17.9 16.7 7.9 17.6 -12.8 15.1 3.0 2.2 22 2004 7.7 7.7 9.6 7.7 4.0 5.9 5.1 3.1 4 2005 f 12.1 15.3 3.1 12.7 6.9 7.7 0.4 2.7 1 2006 f 6.7 15.1 4.9 8.5 6.9 7.7 0.4 2.7 1 1985 20.3 4.1 0.2 24.5 37.4 61.9 88 1986 20.3 4.1 0.2 24.5 32.2 56.4 38 1986 22.4 5.7 0.3 28.5 38	1999	22.9	9.7	13.8		19.2			-4.5	4.7	5.9	-0.2	2.9
2002 17.9 16.7 7.9 17.6 12.8 15.1 3.0 2.2 2 2003 14.8 16.7 19.9 15.3 12.1 15.3 3.1 7.7 4.0 5.9 5.1 3.1 2006 1 12.1 15.3 3.1 12.7 6.9 7.7 0.4 2.7 1 2006 1 6.7 15.1 4.9 8.5 6.9 7.7 0.4 2.7 1 (pretrating share of total drug expenditure) 188 23.7 4.6 0.3 28.5 38.0 61.5 33 1980 22.4 5.7 0.3 28.0 3	2000	24.0	4.0	20.6		18.8			13.7	16.0	4.7	3.4	4.1
2003 14.8 16.7 19.9 15.3 11.4 13.3 3.0 2.7 2 2004 7.7 7.7 9.6 7.7 4.0 5.9 5.1 3.1 4.3 2006 f 12.1 15.3 3.1 12.7 6.2 9.6 4.0 3.5 3.1 2006 f 6.7 15.1 4.9 8.5 6.9 7.7 0.4 2.7 1 Uprotentage share of total drug expenditure 1986 13.3 4.0 0.2 28.5 38.0 61.5 38.0 61.5 38.0 61.5 38.0 61.5 38.0 61.5 39.0 62.5 38.4 66.4 38.4 66.1 38.4 66.1													4.0
2004 7.7 7.7 9.6 7.7 4.0 5.9 5.1 3.1 4 2005 f 12.1 15.3 3.1 12.7 6.2 9.6 4.0 3.5 3.3 2006 f 6.7 15.1 4.9 8.5 6.2 9.6 4.0 0.2 7 terrentage share of total durg werter 1885 20.3 4.1 0.2 23.5 38.0 61.5 38.9 1986 20.3 4.0 0.2 26.5 38.0 61.5 38.9 1987 22.0 4.0 0.3 28.5 38.4 66.4 32 39.9 21.6 61.3 38.4 66.4 32 39.9 39.1 1.0 38.4 66.4													2.6 2.9
2006 f 6.7 15.1 4.9 8.5 6.9 7.7 0.4 2.7 1 Iprecentage share of total drug expenditure 1985 20.3 4.1 0.2 24.5 37.4 61.9 38 1986 19.3 4.0 0.2 26.2 38.0 61.5 48 1987 22.3 4.6 0.3 28.5 33.9 62.5 31 1989 22.4 6.7 0.3 28.0 38.4 66.4 31 1991 22.2 6.5 0.3 29.0 38.4 66.4 32 1992 24.1 6.6 0.3 31.0													4.1
2006 f 6.7 15.1 4.9 8.5 6.9 7.7 0.4 2.7 1 Iprecentage share of total drug expenditure 1985 20.3 4.1 0.2 24.5 37.4 61.9 38 1986 19.3 4.0 0.2 26.2 38.0 61.5 48 1987 22.3 4.6 0.3 28.5 33.9 62.5 31 1989 22.4 6.7 0.3 28.0 38.4 66.4 31 1991 22.2 6.5 0.3 29.0 38.4 66.4 32 1992 24.1 6.6 0.3 31.0	2005 f			3.1						9.6	4.0	35	3.8
Iperentage share of total drug expenditure) 1985 20.3 4.1 0.2 24.5 38.0 61.5 38.0 1986 19.3 4.0 0.2 23.5 38.0 61.5 38.4 1987 22.0 4.0 0.2 28.5 33.9 62.5 37 1989 22.4 5.7 0.3 28.3 38.4 66.4 37 1990 21.6 6.1 0.3 28.0 38.4 66.4 32 1991 22.2 6.5 0.3 28.0 38.4 66.4 32 1991 22.6 7.3 0.2 31.3													
1985 20.3 4.1 0.2 24.5 37.4 61.9 38 1986 19.3 4.0 0.2 23.5 38.0 61.5 38 1987 22.0 4.0 0.2 28.5 32.2 58.4 31 1988 23.7 4.6 0.3 28.3 33.9 62.5 31 1989 22.4 5.7 0.3 28.0 36.8 65.1 31 1990 21.6 6.1 0.3 28.0 36.4 67.4 31 36.0 67.4 31 199 199 24.6 7.7 1.8 14.7	2006 f	6.7	15.1	4.9						1.1	0.4	2.7	1.5
1986 19.3 4.0 0.2 23.5 38.0 61.5 38.1 1987 22.0 4.0 0.2 26.2 32.2 58.4 4.1 1988 23.7 4.6 0.3 28.5 38.8 65.1 37.4 1990 21.6 6.1 0.3 28.0 38.4 66.4 33.9 1991 22.2 6.5 0.3 29.0 38.4 67.4 33.9 1991 22.6 7.3 0.2 31.0 39.3 69.4 16.7 13.8 29 193 194 19.9 8.0 0.3 28.1 42.8 74.1 13.9 12.1 25 1996 20.2 7.8 0.2 28.3						(per	centage share of t	otal drug expe	enditure)				
1987 22.0 4.0 0.2 26.2 32.2 58.4 41 1988 23.7 4.6 0.3 28.5 33.9 62.5 34 1990 21.6 6.1 0.3 28.3 36.8 66.1 33.9 1990 21.6 6.1 0.3 28.0 38.4 66.4 32 1991 22.2 6.5 0.3 29.0 38.4 66.4 32 1992 24.1 6.6 0.3 30.1 36.0 67.0 18.3 14.7 33 1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 27.8													38.1
1988 23.7 4.6 0.3 28.5 33.9 62.5 37 1990 21.6 6.1 0.3 28.0 38.4 66.1 34 1990 21.6 6.1 0.3 28.0 38.4 66.4 33 1991 22.2 6.5 0.3 31.0 38.4 66.4 32 1992 24.1 6.6 0.3 30.1 39.3 69.4 16.7 13.9 30 1993 22.6 7.3 0.2 30.1 42.0 70.1 16.1 13.8 29 1994 19.9 8.0 0.2 28.1 42.8 74.1 13.9 12.1 25 1996 20.2 7.8 0.2 29.2													38.5 41.6
1990 21.6 6.1 0.3 28.0 38.4 66.4 32 1991 22.2 6.5 0.3 29.0 38.4 67.4 32 1992 24.1 6.6 0.3 30.1 39.3 69.4 16.7 13.9 30 1993 22.6 7.3 0.2 30.1 39.3 69.4 16.7 13.9 30 1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 28.3 44.8 73.1 14.0 13.0 26 1996 20.2 7.8 0.2 29.2 48.9 76.7 11.8 11.5 23 1997 19.3 8.2 0.3 29.2 <td></td> <td>37.5</td>													37.5
1991 22.2 6.5 0.3 29.0 38.4 67.4 32 1992 24.1 6.6 0.3 31.0 36.0 67.0 18.3 14.7 33 1992 24.6 7.3 0.2 30.1 39.3 69.4 16.7 13.9 30 1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 28.3 42.8 74.1 13.9 12.1 25 1996 20.2 7.8 0.2 28.3 48.9 76.7 11.8 15.0 26 1997 19.3 8.2 0.3 29.2 48.9 76.7 11.8 10.6 22.4 24 1999 24.6 8.6 0.3 35.1	1989	22.4	5.7	0.3		28.3			36.8	65.1			34.9
1992 24.1 6.6 0.3 31.0 36.0 67.0 18.3 14.7 33 1993 22.6 7.3 0.2 30.1 39.3 69.4 16.7 13.9 30 1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 31.3 42.8 74.1 13.9 12.1 25 1996 20.2 7.8 0.2 28.3 48.9 76.7 11.8 11.5 23 1997 19.3 8.2 0.3 29.2 45.8 75.1 12.6 12.4 24 1999 24.6 8.6 0.3 39.4 42.0 75.4 11.8 10.8 22 2000 26.9 7.9 0.3 38.8	1990	21.6	6.1	0.3		28.0			38.4	66.4			33.6
1993 22.6 7.3 0.2 30.1 39.3 69.4 16.7 13.9 30 1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 31.3 42.8 74.1 13.9 12.0 26 1996 20.2 7.8 0.2 28.3 44.8 73.1 14.0 13.0 26 1997 19.3 8.2 0.3 27.8 48.9 76.7 11.8 11.5 23 1998 20.8 8.2 0.2 29.2 45.8 75.1 12.6 12.4 24 1999 24.6 8.6 0.3 35.1 42.0 77.4 11.8 10.8 22 2001 30.1 8.3 0.3 40.5													32.6
1994 19.9 8.0 0.3 28.1 42.0 70.1 16.1 13.8 29 1995 23.0 8.0 0.2 31.3 42.8 74.1 13.9 12.1 25 1996 20.2 7.8 0.2 28.3 44.8 73.1 14.0 13.0 26 1997 19.3 8.2 0.2 28.3 48.9 76.7 11.8 11.5 23 1998 20.8 8.2 0.2 29.2 45.8 75.1 12.6 12.4 24 1999 24.6 8.6 0.3 33.4 42.0 75.4 12.8 11.8 24 2000 26.9 7.9 0.3 35.1 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 40.5													33.0 30.6
1996 20.2 7.8 0.2 28.3 44.8 73.1 14.0 13.0 26 1997 19.3 8.2 0.3 27.8 48.9 76.7 11.8 11.5 23 1998 20.8 8.2 0.2 29.2 48.9 76.7 11.8 11.5 23 1999 24.6 8.6 0.3 33.4 42.0 75.4 12.8 11.8 24 2000 26.9 7.9 0.3 35.1 39.8 78.6 11.4 10.0 21 2001 30.1 8.3 0.3 42.0 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 42.0 39.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>29.9</td></td<>													29.9
1996 20.2 7.8 0.2 28.3 44.8 73.1 14.0 13.0 26 1997 19.3 8.2 0.3 27.8 48.9 76.7 11.8 11.5 23 1998 20.8 8.2 0.2 29.2 48.9 76.7 11.8 11.5 23 1999 24.6 8.6 0.3 33.4 42.0 75.4 12.8 11.8 24 2000 26.9 7.9 0.3 35.1 39.8 78.6 11.4 10.0 21 2001 30.1 8.3 0.3 42.0 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 42.0 39.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 <td< td=""><td>1995</td><td>23.0</td><td>8.0</td><td>0.2</td><td></td><td>31.3</td><td></td><td></td><td>42.8</td><td>74 1</td><td>13.9</td><td>12 1</td><td>25.9</td></td<>	1995	23.0	8.0	0.2		31.3			42.8	74 1	13.9	12 1	25.9
1998 20.8 8.2 0.2 29.2 45.8 75.1 12.6 12.4 24 1999 24.6 8.6 0.3 33.4 42.0 75.4 12.8 11.8 24 2000 26.9 7.9 0.3 35.1 42.2 77.4 11.8 10.8 22 2001 30.1 8.3 0.3 38.8 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 42.0 9.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.9 39.3 82.2 9.6 8.2 17 2005 f 34.3 9.8 0.3 45.3 38.5 <td< td=""><td>1996</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>26.9</td></td<>	1996												26.9
1999 24.6 8.6 0.3 33.4 42.0 75.4 12.8 11.8 24 2000 26.9 7.9 0.3 35.1 42.2 77.4 11.8 10.8 22 2001 30.1 8.3 0.3 38.8 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 40.5 39.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.0 39.3 82.2 9.6 8.2 17 2004 33.3 9.8 0.3 44.5 38.5 82.9 9.2 7.9 17 2005 f 34.3 9.8 0.3 45.3 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>23.3</td></t<>													23.3
2000 26.9 7.9 0.3 35.1 42.2 77.4 11.8 10.8 22 2001 30.1 8.3 0.3 38.8 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 40.5 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.9 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.9 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.9 39.3 82.2 9.6 8.2 17 2005 f 34.3 9.8 0.3 45.3 38.5 82.9 9.2 7.9 17 2006 f 34.3 10.6 0.3 45.3													24.9 24.6
2001 30.1 8.3 0.3 38.8 39.8 78.6 11.4 10.0 21 2002 31.6 8.7 0.3 40.5 39.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 39.9 80.4 10.4 9.1 19 2004 33.3 9.3 0.3 42.9 39.3 82.2 9.6 8.2 17 2005 f 34.3 9.8 0.3 44.5 38.5 82.9 9.2 7.9 17 2006 f 34.3 10.6 0.3 45.3 38.5 83.8 8.7 7.6 16 f – Forecast 38.5 83.8 8.7 7.6 16													
2002 31.6 8.7 0.3 40.5 39.9 80.4 10.4 9.1 19 2003 32.6 9.1 0.3 42.0 39.9 81.9 9.7 8.4 18 2004 33.3 9.3 0.3 42.0 39.3 82.2 9.6 8.2 17 2005 f 34.3 9.8 0.3 44.5 38.5 82.9 9.2 7.9 17 2006 f 34.3 10.6 0.3 45.3 38.5 83.8 8.7 7.6 16 f – Forecast 38.5 83.8 8.7 7.6 16													22.6 21.4
2003 32.6 9.1 0.3 42.0 39.9 81.9 9.7 8.4 18 2004 33.3 9.3 0.3 42.9 39.3 82.2 9.6 8.2 17 2005 f 34.3 9.8 0.3 44.5 38.5 82.9 9.2 7.9 17 2006 f 34.3 10.6 0.3 45.3 38.5 83.8 8.7 7.6 16 f – Forecast 38.5 83.8 8.7 7.6 16													19.6
2005 f 34.3 9.8 0.3 44.5 38.5 82.9 9.2 7.9 17 2006 f 34.3 10.6 0.3 45.3 38.5 83.8 8.7 7.6 16 f-Forecast	2003	32.6	9.1	0.3		42.0			39.9	81.9	9.7	8.4	18.1
2006 f 34.3 10.6 0.3 45.3 38.5 83.8 8.7 7.6 16 f-Forecast	2004	33.3	9.3	0.3		42.9			39.3	82.2	9.6	8.2	17.8
f-Forecast	2005 f	34.3	9.8	0.3		44.5			38.5	82.9	9.2	7.9	17.1
	2006 f	34.3	10.6	0.3		45.3			38.5	83.8	8.7	7.6	16.2
* Note: Confidentiality precludes reporting provincial-level insurance data. Source: CIHI, 200													

Table B.7.1–Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985 to 2006 (continued) Share of Drugs in Public, Private and Total Health Expenditures All Drugs Health Expenditure Public Private Total Public Private Total Public Private Total Year (\$ millions) (percentage share) 1985 415.6 1,726.5 39.2 121.0 160.2 1,310.9 3.0 29.1 9.3 1986 42.2 137.3 179.4 1,425.8 463.9 1,889.7 3.0 29.6 9.5 1,530.2 1987 50.4 141.9 192.4 449.9 1,980.2 31.5 9.7 3.3 9.7 1988 57.3 143.4 200.7 1,634.3 435.4 2,069.6 3.5 32.9 1989 57.6 145.8 203.4 1,773.2 484.2 2,257.4 3.2 30.1 9.0 1990 62.9 161.5 224.4 1,951.1 533.2 2,484.3 3.2 30.3 9.0 1991 724 177.3 249 6 2 006 0 570.0 2,576.0 3.6 31.1 9.7 87.5 282.3 2,099.3 602.6 2,701.9 4.2 194.8 32.3 10.4 1992 1993 90.7 210.8 301.5 2,088.9 660.2 2,749.1 4.3 31.9 11.0 1994 86.5 221.0 307.5 2,115.7 686.4 2,802.0 4.1 32.2 11.0 2,179.4 2,185.3 11.9 1995 108.3 237.7 346.0 733.3 2,912.7 5.0 32.4 1996 103.2 261.8 365.0 783.6 2,968.9 4.7 33.4 12.3 845.5 3,097.4 4.7 1997 106.0 275.4 381.4 2,251.9 32.6 12.3 1998 120.5 291.7 412.2 2,388.6 900.0 3,288.6 5.0 32.4 12.5 974.2 429.9 3,689.1 29.4 1999 143.6 286.2 2.714.9 5.3 11.7 2000 170.7 315.3 486.0 3.005.3 1.047.4 4.052.7 5.7 30.1 12.0 2001 207.0 533.7 3,184.5 4,325.9 326.7 1,141.4 6.5 28.6 12.3 2002 243.3 356.8 600.2 3,366.5 1,219.7 4,586.2 7.2 29.3 13.1 2003 280.4 387.5 667.9 3.654.1 1,270.3 4,924,4 7.7 30.5 13.6 2004 302.2 403.0 705.2 3,897.1 1,328.4 5,225.5 7.8 30.3 13.5 2005 f 340.6 424.8 765.4 4,143.8 1,365.5 5,509.3 8.2 31.1 13.9 2006 f 369.5 447 0 816 5 4 366 3 1.432.2 5 798 5 85 31.2 14 1 (annual percentage change) 1985 1986 7.4 13.5 12.0 8.8 11.6 9.5 1987 19.6 3.4 7.2 7.3 -3.0 4.8 1988 13.6 1.1 4.4 6.8 -3.2 4.5 1989 0.5 1.7 1.4 8.5 11.2 9.1 1990 9.3 10.7 10.3 10.0 10.1 10.1 2.8 4.7 3.7 4.9 1991 15.0 9.8 11.2 6.9 20.9 9.9 1992 13.1 5.7 1993 3.6 8.2 6.8 -0.5 9.6 1.7 1994 -4.7 4.9 2.0 1.3 4.0 1.9 1995 25.2 7.6 12.5 3.0 6.8 3.9 1996 -4.6 10.1 5.5 0.3 6.9 1.9 1997 2.7 5.2 4.5 3.0 7.9 4.3 5.9 -1.9 1998 13.7 8.1 6.1 6.4 6.2 19.2 13.7 8.2 12.2 1999 4.3 2000 18.8 10.2 13.1 10.7 7.5 9.9 2001 21.3 3.6 9.8 6.0 9.0 6.7 2002 17.6 9.2 12.5 5.7 6.9 6.0 2003 15.3 8.6 11.3 8.5 4.1 7.4 4.6 2004 7.7 4.0 5.6 6.7 6.1 5.4 2005 f 12.7 8.5 6.3 2.8 5.4 2006 f 8.5 5.2 6.7 5.4 4.9 5.2 (percentage share of total drug expenditure) 75.5 1985 24.5 100.0 1986 23.5 76.5 100.0 1987 26.2 73.8 100.0 28.5 100.0 1988 71.5 1989 28.3 71.7 100.0 1990 28.0 72.0 100.0 1991 29.0 71.0 100.0 69.0 1992 31.0 100.0 30.1 69.9 100.0 1993 1994 28.1 71.9 100.0 1995 31.3 68.7 100.0 1996 28.3 71.7 100.0 1997 27.8 100.0 72.2 1998 29.2 70.8 100.0 1999 33.4 66.6 100.0 2000 35.1 64.9 100.0 61.2 59.5 2001 38.8 100.0 40.5 100.0 2002 2003 42.0 58.0 100.0 2004 42.9 57.1 100.0 2005 f 44.5 55.5 100.0 2006 f 45.3 54.7 100.0 Source: CIHI, 2006 f-Forecast

91

Table B.7.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Manitoba, 1985 to 2006

			Public		Prescribe	d Drugs	Private				Prescribed D e (Out-of-Po	
	Provincial	Federal _	Social Security WCB	y Funds Drug surance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
Y ear				- unuo		(\$ per o	capita)			Brago		
1985	29.98	6.00	0.28		36.26			55.40	91.67			56.35
1986 1987	31.68 38.48	6.60 7.05	0.34 0.38		38.62 45.91			62.48 56.33	101.10 102.25			63.26 72.94
1988	43.10	8.42	0.47		51.99			61.78	113.77			68.38
1989	41.26	10.44	0.51		52.20			67.91	120.11			64.25
1990	43.87	12.47	0.59		56.92			77.93	134.85			68.11
1991	49.95	14.63	0.63		65.21			86.34	151.55			73.41
992	61.22	16.69	0.74		78.65			91.33	169.98	46.32	37.42	83.73
1993 1994	60.90 54.43	19.59 21.86	0.66 0.69		81.15 76.99			106.06 114.94	187.21 191.92	45.06 44.00	37.46 37.86	82.52 81.86
1995 1996	70.49	24.65 25.22	0.75 0.78		95.89			131.08	226.97	42.51	36.96	79.48 86.70
1996	65.03 64.88	25.22	0.78		91.03 93.31			144.10 164.30	235.13 257.61	45.01 39.64	41.69 38.45	78.09
1998	75.51	29.60	0.86		105.97			166.11	272.09	45.52	44.77	90.29
1999	92.43	32.32	0.98		125.72			158.03	283.75	48.00	44.50	92.50
2000	114.11	33.47	1.17		148.75			178.93	327.68	50.06	45.82	95.88
2001	139.70	38.69	1.38		179.77			184.40	364.18	52.81	46.57	99.38
2002	164.09	45.00	1.48		210.57			207.17	417.74	54.19	47.43	101.62
2003 2004	187.42 200.45	52.23 55.84	1.77 1.92		241.42 258.21			229.56 236.88	470.98 495.09	55.51 57.89	48.48 49.60	103.99 107.49
2005 f	223.26	64.00	1.97		289.22			249.93	539.16	59.82	51.03	110.86
2006 f	236.99	73.29	2.06		312.34			265.84	578.19	59.76	52.18	111.94
						(annual percer	itage change)					
1985												
1986	5.6	10.1	22.4		6.5			12.8	10.3			12.3
1987 1988	21.5 12.0	6.8 19.4	9.5 24.8		18.9 13.2			-9.8 9.7	1.1 11.3			15.3 -6.3
1989	-4.3	23.9	8.3		0.4			9.9	5.6			-6.0
1990	6.3		15.9		9.0				12.3			
1990	13.9	19.5 17.3	6.8		14.6			14.8 10.8	12.3			6.0 7.8
1992	22.6	14.1	17.5		20.6			5.8	12.2			14.1
1993	-0.5	17.4	-10.8		3.2			16.1	10.1	-2.7	0.1	-1.4
1994	-10.6	11.6	4.8		-5.1			8.4	2.5	-2.4	1.1	-0.8
1995	29.5	12.7	8.7		24.6			14.0	18.3	-3.4	-2.4	-2.9
1996 1997	-7.7	2.3	4.2 7.8		-5.1			9.9	3.6	5.9	12.8	9.1
1997	-0.2 16.4	9.4 7.3	2.4		2.5 13.6			14.0 1.1	9.6 5.6	-11.9 14.8	-7.8 16.4	-9.9 15.6
1999	22.4	9.2	13.3		18.6			-4.9	4.3	5.5	-0.6	2.5
2000	23.5	3.5	20.1		18.3			13.2	15.5	4.3	3.0	3.6
2001	23.5	15.6	17.6		20.9			3.1	11.1	5.5	1.6	3.7
2002	17.5	16.3	7.5		17.1			12.3	14.7	2.6	1.8	2.3
2003	14.2	16.1	19.3		14.7			10.8	12.7	2.4	2.2	2.3
2004	7.0	6.9	8.8		7.0			3.2	5.1	4.3	2.3	3.4
2005 f	11.4	14.6	2.4		12.0			5.5	8.9	3.3	2.9	3.1
2006 f	6.2	14.5	4.4		8.0			6.4	7.2	-0.1	2.2	1.0
20001	0.2	14.5			annual percentage					0.1	2.2	1.0
1985												
1986	2.8	7.3	19.6		3.7			10.0	7.5			9.5
987	16.7	2.0	4.8		14.1			-14.6	-3.6			10.6
1988 1989	7.5 -8.8	14.9 19.4	20.2 3.8		8.7 -4.2			5.1 5.3	6.7 1.0			-10.8 -10.6
1990	3.3	16.4	12.9		6.0			11.7	9.3			3.0
1991 1992	11.1 21.3	14.6 12.8	4.0 16.3		11.8 19.4			8.0 4.5	9.6 10.9			5.0 12.8
1993	-2.0	16.0	-12.2		1.7			4.5	8.7	-4.2	-1.3	-2.9
994	-11.7	10.5	3.7		-6.2			7.3	1.4	-3.5	0.0	-1.9
1995	27.2	10.4	6.3		22.2			11.7	15.9	-5.7	-4.7	-5.2
1996	-9.4	0.6	2.6		-6.7			8.3	1.9	4.2	11.1	7.4
1997	-1.2	8.4	6.8		1.5			13.0	8.6	-12.9	-8.8	-10.9
1998 1999	16.8 20.6	7.7 7.4	2.8 11.5		14.0 16.8			1.5 -6.7	6.1 2.5	15.3 3.6	16.9 -2.4	16.1 0.6
2000 2001	19.4 21.1	-0.6 14.3	16.0 16.2		14.2 19.5			9.1 1.7	11.4 9.8	0.2 4.1	-1.2 0.3	-0.5 2.3
2001	16.5	14.3	6.5		19.5			1.7	9.8 13.7	4.1	0.3	2.3
2003	11.3	13.2	16.4		11.8			7.9	9.9	-0.5	-0.7	-0.6
2004	4.3	4.2	6.1		4.3			0.5	2.4	1.6	-0.4	0.7
2005 f	8.7	12.0	-0.2		9.4			2.9	6.2	0.7	0.2	0.5
2006 f	4.5	12.9	2.8		6.4			4.8	5.6	-1.7	0.6	-0.6
	-	-	-		-							
-Forecast												

Table B.7.2–Part 2

		All Drugs		Ца	alth Expenditure		Pri
-	Public	Private	Total	Public	Private	Total	
			(\$ per ca	pita)			
-	36.26	111.76	148.02	1,211.28	383.98	1,595.25	
	38.62	125.74	164.36	1,306.04	424.97 409.78	1,731.01	
	45.91 51.99	129.27 130.16	175.18 182.14	1,393.62 1,482.95	395.06	1,803.40 1,878.01	
9	52.20	132.15	184.35	1,606.82	438.77	2,045.59	
	56.92	146.04	202.96	1,764.67	482.25	2,246.92	
	65.21 78.65	159.76 175.06	224.97 253.71	1,807.82 1,886.70	513.71 541.56	2,321.53 2,428.27	
2	81.15	188.58	269.73	1,869.05	590.76	2,459.81	
ŀ	76.99	196.79	273.78	1,883.55	611.07	2,494.62	
	95.89 91.03	210.56 230.81	306.44 321.84	1,930.11 1,926.73	649.44 690.93	2,579.55 2,617.66	
6 7	93.31	242.39	335.70	1,982.07	744.21	2,726.28	
8	105.97	256.40	362.37	2,099.82	791.23	2,891.05	
99	125.72	250.53	376.26	2,376.29	852.73	3,229.01	
0 1	148.75 179.77	274.81 283.78	423.56 463.56	2,619.32 2,766.07	912.83 991.39	3,532.15 3,757.46	
2	210.57	308.80	519.36	2,913.23	1,055.51	3,968.74	
03	241.42	333.55	574.97	3,145.64	1,093.58	4,239.22	
04	258.21	344.37	602.58	3,330.20	1,135.18	4,465.37	
05 f	289.22	360.79	650.01	3,519.00	1,159.59	4,678.59	
6 f	312.34	377.78	690.13	3,690.54 nnual percentage change	1,210.53	4,901.07	
-							
5 6	6.5	12.5	11.0	7.8	10.7	8.5	
7	18.9	2.8	6.6	6.7	-3.6	4.2	
8 9	13.2 0.4	0.7 1.5	4.0 1.2	6.4 8.4	-3.6 11.1	4.1 8.9	
5	9.0	10.5	10.1	9.8	9.9	9.8	
1	14.6	9.4	10.8	2.4	6.5	3.3	
	20.6	9.6	12.8	4.4	5.4	4.6	
3	3.2 -5.1	7.7 4.4	6.3 1.5	-0.9 0.8	9.1 3.4	1.3 1.4	
5	24.6	7.0	11.9	2.5	6.3	3.4	
6	-5.1	9.6	5.0	-0.2	6.4	1.5	
7	2.5	5.0	4.3	2.9	7.7	4.1	
8 9	13.6 18.6	5.8 -2.3	7.9 3.8	5.9 13.2	6.3 7.8	6.0 11.7	
D	18.3	9.7	12.6	10.2	7.0	9.4	
1	20.9	3.3	9.4	5.6	8.6	6.4	
)2	17.1	8.8	12.0	5.3	6.5	5.6	
)3)4	14.7 7.0	8.0 3.2	10.7 4.8	8.0 5.9	3.6 3.8	6.8 5.3	
5 f	12.0	4.8	7.9	5.7	2.2	4.8	
ð f	8.0	4.7 (annual percentag	6.2 ge change in excess of	4.9 inflation in the Canadiar	4.4 n economy)	4.8	
5							
6	3.7	9.7	8.2	5.0	7.9	5.7	
7 3	14.1 8.7	-1.9 -3.8	1.8 -0.5	2.0 1.9	-8.3 -8.1	-0.6 -0.4	
9	-4.2	-3.0	-3.4	3.8	6.5	4.4	
D	6.0	7.5	7.1	6.8	6.9	6.8	
1	11.8	6.6	8.1	-0.3	3.8	0.6	
2 3	19.4 1.7	8.3 6.3	11.5 4.9	3.1 -2.4	4.2 7.6	3.3 -0.1	
3 4	-6.2	3.3	0.4	-2.4 -0.3	2.3	-0.1	
5	22.2	4.7	9.6	0.1	3.9	1.1	
6	-6.7	7.9	3.4	-1.8	4.7	-0.2	
7	1.5	4.0	3.3	1.9	6.7	3.2	
98 99	14.0 16.8	6.2 -4.1	8.4 2.0	6.4 11.4	6.8 6.0	6.5 9.9	
0							
1	14.2 19.5	5.6 1.9	8.5 8.1	6.1 4.2	2.9 7.3	5.3 5.0	
2	16.1	7.8	11.0	4.3	5.5	4.6	
13 14	11.8 4.3	5.1 0.6	7.8 2.1	5.1 3.2	0.7 1.1	3.9 2.6	
05 f	9.4	2.1	5.2	3.0	-0.5	2.1	
06 f	6.4	3.1	4.6	3.3	2.8	3.2	

Table B.8.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2006

					Prescribe	ed Drugs					Prescribed D	<u> </u>
P	rovincial	Federal	Public Social Secu WCB	Drug	Sub-Total Public	Insurers*	Private Out-of- Pocket	Sub-Total Private	Total Prescribed	Over- the-	te (Out-of-Po Personal Health	Total Non-Presc.
				Insurance Funds					Drugs	Counter Drugs	Supplies	Drugs
						(\$ mil	ions)					
	67.6 81.1	6.3 7.1	0.1 0.1		74.0 88.3			26.8 33.8	100.8 122.1			35.3 40.0
	67.8	7.1	0.1		75.7			42.5	118.2			40.0
	63.0	9.7	0.3		73.1			53.5	126.5			58.3
	74.8	12.2	0.2		87.2			67.3	154.5			73.2
	88.7	14.5	0.3		103.5			79.5	183.0			74.4
	93.5	16.8	0.3		110.6			89.2	199.8			73.0
	85.0 57.8	19.0 22.4	0.3 0.4		104.3 80.6			99.5 126.7	203.8 207.3	40.6 49.9	35.6 44.9	
	56.2	25.0	0.4		81.6			141.3	222.9	48.8	45.5	
	63.8	28.0	0.5		92.2			146.8	239.0	47.4	44.7	92.1
	66.6	28.8	0.8		96.2			140.0	244.3	44.7	44.8	
	69.3	31.2	0.8		101.3			161.2	262.5	45.8	47.3	93.1
	78.9	33.7	0.9		113.6			167.4	280.9	44.6	46.7	91.3
	89.1	38.8	1.1		129.0			174.0	303.0	49.6	48.7	
	100.2	42.3	1.3		143.8			185.6	329.4	52.8	51.0	
	116.3 133.9	48.1 55.2	1.6 1.9		165.9 191.0			216.1 222.5	382.1 413.6	54.3 55.5	50.5 51.3	104.8 106.8
	151.4	62.5	2.2		216.1			252.3	468.4	54.2	50.0	
	168.1	64.9	2.5		235.5			274.1	509.6	56.9	51.8	108.8
	187.2	74.1	2.7		264.0			294.4	558.4	59.0	53.6	112.6
	203.7	83.6	3.0		290.3			311.6	601.9	61.1	56.7	117.8
						(annual percen	tage change)					
						(unndu poroon						
	20.0	13.1	2.4		19.3			25.8	21.1			13.2
	-16.4	8.9	42.4		-14.2			25.8	-3.2			16.0
	-7.1	26.1	58.9		-3.5			25.8	7.0			25.6
	18.7	25.3	-28.9		19.4			25.8	22.1			25.6
	18.7	18.6	9.8		18.6			18.2	18.5			1.6
	5.4	16.1	5.4		6.9			12.2	9.2			-1.9
	-9.1 -32.0	12.9 18.1	20.3 32.9		-5.7 -22.7			11.5 27.3	2.0 1.7	 22.7	26.3	4.5 24.4
	-2.8	11.7	-2.2		1.3			11.5	7.5	-2.1	1.3	
	13.6	11.7	16.1		13.0			3.9	7.2	-2.9	-1.9	-2.5
	4.4	3.0	63.1		4.3			0.9	2.2	-2.3	0.4	
	4.0	8.3	4.3		5.3			8.8	7.4	2.5	5.5	4.0
	13.9	8.1	9.6		12.1			3.9	7.0	-2.6	-1.2	
	12.9	15.1	22.0		13.6			3.9	7.8	11.2	4.1	7.6
	12.4	9.0	16.4		11.4			6.7	8.7	6.5	4.9	
	16.1 15.1	13.8 14.9	18.5 20.9		15.4 15.1			16.4 3.0	16.0 8.2	2.7 2.3	-1.0 1.5	
	13.1	13.1	14.4		13.1			13.4	13.2	-2.3	-2.5	
	11.0	3.8	17.3		9.0			8.6	8.8	5.0	3.7	
	11.3	14.3	5.4		12.1			7.4	9.6	3.6	3.4	3.5
	8.8	12.8	13.7		10.0			5.8	7.8	3.6	5.8	
	0.0	12.0	13.7						7.0	3.0	5.6	4.7
					(per	centage share of to	otal drug expe	nditure)				
	49.6	4.6	0.1		54.4			19.7	74.1			25.9
	50.0 41.2	4.4 4.7	0.1 0.1		54.5 46.0			20.8 25.8	75.3 71.8			24.7 28.2
	34.1	5.3	0.2		39.5			28.9	68.5			31.5
	32.8	5.4	0.1		38.3			29.5	67.9			32.1
	34.5	5.6	0.1		40.2			30.9	71.1			28.9
	34.3	6.2	0.1		40.5			32.7	73.3			26.7
	30.3	6.8	0.1		37.2			35.5	72.8	14.5	12.7	27.2
	19.1 17.7	7.4 7.9	0.1 0.1		26.7 25.7			41.9 44.5	68.6 70.3	16.5 15.4	14.9 14.4	31.4 29.7
	19.3 19.9	8.4 8.6	0.2		27.9 28.8			44.3 44.4	72.2 73.2	14.3 13.4	13.5 13.4	27.8 26.8
	19.5	8.8	0.2		28.5			45.3	73.8	12.9	13.4	
	21.2	9.1	0.2		30.5			45.0	75.5	12.0	12.6	
	22.2	9.7	0.3		32.2			43.4	75.5	12.4	12.1	24.5
	23.1	9.8	0.3		33.2			42.8	76.0	12.2	11.8	24.0
	23.9	9.9	0.3		34.1			44.4	78.5	11.1	10.4	21.5
	25.7	10.6	0.4		36.7			42.8	79.5	10.7	9.9	20.5
	26.4 27.2	10.9 10.5	0.4 0.4		37.7 38.1			44.1 44.3	81.8 82.4	9.5 9.2	8.7 8.4	18.2 17.6
	27.9	11.0	0.4		39.3			43.9	83.2	8.8	8.0	16.8
	28.3	11.6	0.4		40.3			43.3	83.6	8.5	7.9	16.4
	20.0											

All Drage Number Number Total Total Total Total Number Ver Component Component			Total	Health Expend	litures, Saskatc	hewan, 1985	5 to 2006 (con		ugs in Public, Priva	te and
Ner (p.mlos) (p.exerup. here) 1986 24.0 6.2.1 13.6 1.56.5 32.7 1.22.8 6.2 1.6.5 30.9 1987 23.1 11.7 14.8.4 1.56.5 32.7 1.22.8 6.2 1.6.5 30.9 1988 23.1 11.7 1.84.6 1.92.5 40.0 2.22.2 6.3 30.4 11.1 1989 10.0.6 10.2 2.2.7 1.92.5 40.0 2.22.2 6.3 30.4 11.0 1989 10.0.6 10.2 2.2.7 1.92.5 40.0 2.22.2 4.0 30.4 10.0 30.4 10.0 30.4 10.0 30.4 10.0 30.0 10.0 2.0.5 2.40.5 10.0 30.0 10.0		Public		Total			Total	Total	Health Expenditure	es
1986 24.0 40.1 134.1 1,195.5 333.2 1,50.4 4.2 106.5 6.2 1989 70.3 88.9 164.6 1,272.2 396.5 1,272.8 4.6 2.0 4.6 3.0 1.2 1.2 2.0 4.6 3.0 1.2 4.6 3.0 1.2 4.6 3.0 1.2 4.6 3.0 1.1 1.1 1.0 4.6 2.0 4.6 3.0 1.1 1.1 1.0 1.0 4.6 3.0 1.1 1.1 1.0 <td< th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td<>										
1886 1897 1 </td <td>Year</td> <td></td> <td></td> <td>(\$ millio</td> <td>ons)</td> <td></td> <td></td> <td>(p</td> <td>ercentage share)</td> <td></td>	Year			(\$ millio	ons)			(p	ercentage share)	
1997 775 10.9 1.6.5 2.2.6 3.6.5 1990 1.7.2 1.7.7 1.8.8.8 1.4.8.7 1.8.7.9 1.6.5 2.2.6 3.0.1 1.1 1990 1.7.0 1.7.8.8 1.7.9.2 1.4.9.7 2.3.9.2 1.4.9 3.0.1 1.1<	1985			136.1	1,195.5					8.9
9888 731 1117 104.6 1.466.3 386.3 1.857.6 5.0 0.0.2 10.1 9899 101.6 103.8 175.2 14.44 227.7 1.257.2 4.20 2.057.2 4.8 32.4 11.4 9890 101.8 175.8 220.1 1.797.3 4.00.1 2.257.2 4.8 32.4 11.4 9890 00.4 221.5 302.1 1.727.8 97.4 2.305.4 4.6 300.1 1.73 9891 01.6 227.5 327.3 1.727.8 97.4 2.305.4 4.6 300.1 1.3 9892 01.3 226.7 377.3 1.779.8 90.6 2.273.4 4.6 39.6 1.3 9890 113.3 226.7 377.3 2.105.8 90.6 2.273.8 4.7 3.0 1.3 9900 113.8 226.7 377.3 2.105.8 90.6 2.773.8 4.0 3.0 1.3 9000 113.8 226.7 377.3 2.06.8 1.077.4 4.077.7 1.6 3.0 1.03.6 1.077.4 4.077.7 1.6 3.0 1.03.6 1.077.7 4.0 3.0 1.03.6 1.077.7 <td>1986</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>9.5</td>	1986									9.5
990 1005 1539 272 1.7221 4001 2.7222 6.8 33.0 11.1 992 164.3 175.8 2001 1.935 606.3 2.355.4 5.7 3.7 1.7 993 164.3 175.8 2001 1.935 606.3 2.355.4 5.7 3.7 1.7 994 18.4 2.27 31.2 1.778 602.4 2.487.5 5.1 2.86 1.37 995 62.2 22.7 33.2 1.142.2 62.0 2.487.5 5.1 2.76 1.37 1.47 1.80 1.37 1.33<	1988									
1991 110.6 162.2 272.8 1.02.89 400.9 2.316.9 6.0 3.0 11.6 1994 10.4.3 173.0 1.1 1.728 173.0 2.322.4 4.6 30.0 13.3 1996 92.2 220.6 311.1 1.728.6 603.6 2.324.6 5.1 36.0 13.4 1996 92.2 227.4 333.6 1.662.3 625.0 2.497.3 5.1 36.0 13.4 1997 10.13 2.42.7 333.6 1.662.3 625.0 2.497.3 5.1 37.4 13.4 1998 112.0 2.27.2 2.77.0 2.653.1 5.1 1.77.0 1.33.4 110.0 2.20.4 2.247.4 801.0 1.07.2 4.63.2 7.7 8.0 39.2 1.33.4 2001 166.8 2.20.9 110.7 3.615.0 1.07.2 4.63.4 8.0 39.2 15.3 2004 2.27.1 3.03.0 1.03.4 4.83.4 8.0 39.2 15.3 2005 1.0.7 4.7<	1989	87.2	140.4	227.7		423.7		5.4	33.1	11.1
1992 00.4.3 172.8 240.1 1.1115 505.8 2.25.4 4.2 30.8 4.3 30.8 4.3 30.8	1990									
1983 80.6 221.5 302.1 1,272.8 974.1 2,01.9 4,2 8.8 13.3 1984 61.6 223.7 31.7.1 1,120.8 61.6 24.99.5 6.1 8.4 13.6 1986 62.2 2.38.8 33.1.1 1,120.8 61.6 2.49.9.5 6.1 8.4 13.4 13.6 62.4 2.21.0.1 66.8 4.77.3 6.1 8.4 13.4 13.6 62.4 2.21.0.1 66.8 4.77.3 6.0 7.7.3 13.6 0000 11.8 2.22.2 4.12.2 2.24.04 7.61 3.14.7 6.0 7.7.3 13.6 0001 12.0 12.22.2 4.21.6 2.29.0.2 4.29.0 7.6 6.0 7.7.4 13.6 0002 12.6.1 3.66.4 7.7.6 7.7.7 3.06.0 7.6 7.7.7 7.6 7.7.7 7.6 7.7.7 7.6 7.7.7 7.6 7.7.7 7.7.7 7.6 7.7.7 7.7.7 7.7.7 7.7.7 7.7.7 7.7.7 7.7.7 7.7.7 7.7.7										
9996 92.2 22.8 53.1 1.420.8 1988 2.495.5 5.1 98.6 19.4 9997 10.3 24.2 38.6 1.976.1 077.0 2.653.1 5.1 37.6 13.4 9997 10.3 24.2 38.6 1.976.1 077.0 2.653.1 5.1 37.6 13.4 9997 10.3 24.2 38.6 1.976.1 077.5 3.477.7 6.4 37.6 13.4 9001 116.8 250.5 43.3 2.203.1 777.5 3.477.7 7.6 36.5 14.4 9002 116.1 326.4 2.690.7 07.3 3.620.7 7.6 36.5 14.4 9002 116.1 326.4 2.690.7 07.3 3.620.7 7.6 36.5 14.6 9002 126.1 326.4 1.070.7 4.172.7 7.6 37.8 110.3 9002 13.8 1.010.8 1.071.7 4.172.7 7.6 37.8 110.3 9004 1.02 1.01.7 1.01.7 4.172.7 7.6 37.8 110.3 9005 1.03 1.01.7 1.01.7 4.17.7 1.01.7 1.01.7 1.01.7 <t< td=""><td>1993</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	1993									
1986 0.2, 27,6 333,6 1,462,3 625,0 2,467,3 5,2 35,0 1,4 1997 101,3 224,2 45,1 2,174,1 97,7 2,633,1 5,1 37,6 14,4 1999 110,0 224,2 45,1 2,213,4 97,8 13,3 45,2 97,9 13,8 2000 115,8 220,3 448,0 2,281,2 97,3 3,462,0 44,37,7 7,0 36,8 14,4 2001 116,0 320,8 48,60 2,281,7 7,0 36,6 14,3 2004 224,6 224,0 67,0 3,38,0 1,09,0 4,97,7 2,63 37,8 14,6 2004 220,3 424,4 7,10 3,38,0 1,09,0 4,97,7 3,0 38,0 1,11,0 1986 1- 110,0 110,0 13,4 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 114,1 <td>1994</td> <td>81.6</td> <td>235.7</td> <td>317.3</td> <td>1,778.8</td> <td>603.6</td> <td>2,382.4</td> <td>4.6</td> <td>39.0</td> <td>13.3</td>	1994	81.6	235.7	317.3	1,778.8	603.6	2,382.4	4.6	39.0	13.3
1997 10.1.3 254.2 355.5 1.976.1 677.0 2.653.1 6.1 37.6 13.4 1998 12.80 27.2 401.2 2.260.4 716.1 2.265.5 5.7 37.8 13.5 0000 14.8.8 32.8.5 43.3 2.351.2 706.5 3.477.7 6.0 37.8 13.6 0000 14.8.8 32.8.5 43.2 2.72.7 3.866.7 7.6 3.477.5 7.9 3.6 14.6 0000 12.8.5 382.8 018.4 3.088.6 1.012.7 4.121.2 7.6 3.7.6 14.6 0000 + 280.3 42.9.4 71.9 3.016.0 1.078.4 4.682.4 0.0 3.9.8 15.3 1986 -<	1995									
1989 11 0.6 292.7 37.2 2.10.5 66.6 2.77.3 5.4 9.6 11.6 12 0.0 12 0.0 222.2 210.2 225.0 31.6 2.77.3 6.0 37.8 13.5 0001 16.8 320.0 44.6 2.26.1 31.6 31.6 32.6 36.0 46.1 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 14.6 36.0 16.0 36.0 16.0										
2020 1438 2929 443.2 2,281.2 707.3 3,42.2 0.0 37.8 13.8 2020 191.0 322.4 522.4 2,72.7 3,82.8 7.0 38.6 14.8 2020 121.0 322.8 121.8 31.0 1.0.72.7 4,121.2 7.8 37.8 11.0 20204 226.0 422.4 71.0 3.33.80 1.0.72.7 4,121.2 7.8 32.8 11.0 20204 226.0 422.4 716.7 3.15.0 1.072.4 4,493.4 8.0 38.8 1.5.3 20204 226.2 1.6 3.3 4.7 3.6 3.6 7.4 3.8 1.5.3 1.6 1.5	1998									
2001 165.9 20.20 26.81.5 871.3 3.452.9 6.4 36.8 14.1 2003 216.1 356.4 52.04 2.725.4 807.3 3.652.7 7.0 36.8 14.8 2003 216.1 356.5 577.6 3.667.4 7.6 36.7 11.8 2004 226.5 307.7 0.7 3.680.4 17.7 3.667.4 7.9 36.1 15.3 2005 220.3 42.4 710.7 3.615.0 1.028.6 4.37.5 7.9 36.1 15.3 1986	1999	129.0	272.2	401.2	2,250.4	718.1	2,968.5	5.7	37.9	13.5
20203 191.0 323.4 520.4 2,72.4 907.7 3,626.7 7.0 86.5 14.3 2004 236.5 382.8 618.4 3,108.5 1,012.7 4,121.2 7.6 87.8 18.0 2004 230.3 429.4 719.7 3,38.0 1,033.6 4,493.4 8.0 39.8 18.3 2006 200.3 429.4 719.7 3,08.6 1,012.7 4,469.4 8.0 39.8 18.3 2006 200.3 429.4 719.7 3,08 4,477.4 4,469.4 8.0 39.8 18.3 2007 10.7 10.0 10.4 1.4	2000									
2033 2161 3565 572.6 2.8967 37.7 3.8984 7.6 36.7 14.5 20504 235.5 382.8 618.4 3.108.6 1.012.7 4.121.2 7.8 35.7 15.5 205051 264.0 407.0 071.0 3.388.0 1.032.6 4.377.5 7.9 39.8 15.3 205051 264.0 407.0 171.7 3.615.0 1.078.4 4.60 38.8 1.53 10807 - <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>										
22061 224.0 407.0 671.0 338.0 1,038.0 4,037.6 4,00 39.0 1,53 22061 230.3 429.4 719.7 3,815.0 1,038.0 4,038.1 8.0 39.8 1,53 1985 10.3 10.7	2003	216.1	356.5	572.6	2,896.7	972.7	3,869.4	7.5	36.7	14.8
20261 202.3 429.4 719.7 2,615.0 1,728.4 4,893.4 6,0 39.8 15.3 1985 10.3 15.7 19.0 10.9 13.4 11.4	2004									15.0
Interpretable base 1995	2005 f									
1986 1987 1-2 205 1.6 3.5 4.7 13.8 1989 1-4 2.5.7 2.3.2 11.0 14.7 11.7 1989 1-4 2.5.7 2.3.2 11.0 14.7 11.7 1991 6.8 5.4 6.0 2.1 6.7 3.0 1982 2.5.7 8.4 2.7 -0.5 3.0 0.2 1983 2.2.7 2.60 7.9 -5.0 13.5 -1.0 1984 1.3 6.4 5.8 6.1 8.3 6.7 1985 13.0 1.3 4.3 2.4 2.5 2.4 1986 1.2.1 1.8 4.7 6.4 -1.1 4.5 1987 5.3 7.0 6.8 6.1 8.3 6.7 1988 12.1 1.8 4.7 6.4 -1.1 4.5 1989 13.6 5.2 7.8 7.3 7.2 7.0 2000 11.4 6.3 8.7 7.4 2.7 7.0 2001 15.1 10.9 12.4 8.4 13.7 8.7 <td>2006 f</td> <td>290.3</td> <td>429.4</td> <td></td> <td></td> <td>1,078.4</td> <td>4,693.4</td> <td>8.0</td> <td>39.8</td> <td>15.3</td>	2006 f	290.3	429.4			1,078.4	4,693.4	8.0	39.8	15.3
1986 19.3 18.7 19.0 10.9 13.4 11.4 1987 14.2 20.5 18.3 3.7 14.4 11.7 1989 3.45 25.7 12.3 7.0 4.6 4.0 1989 18.8 8.6 13.0 10.0 8.6 8.7 1980 18.8 8.6 13.0 10.0 8.6 8.7 1981 6.9 5.4 2.7 -0.5 3.0 0.2 1982 -5.7 8.4 2.7 -0.5 3.0 0.2 1984 1.3 6.4 5.0 3.0 6.7 8.4 1985 13.0 1.3 4.3 0.5 6.1 8.3 6.7 1986 1.3.0 1.3 4.3 0.5 6.1 8.3 6.7 1987 5.3 7.0 6.4 7.1 7.0 7.0 1989 12.8 5.7 7.3 8.3 3.7 7.2 2000 11.4 6.3 6.0 7.3 6.3 6.7 6.2 2005 f 12.1 6.3 6.5 7.4 2.7 6.2 2005 f 12.1 6.3 6.										
1987 -1.4.2 2.0.5 1.6 3.5 4.7 3.8 1989 3.6 2.5.7 12.3 7.0 6.8 4.0 1989 19.4 2.5.7 2.2.2 11.0 14.7 11.7 1981 6.9 5.4 6.0 2.1 6.7 3.0 0.2 1983 -2.2.7 2.6.0 7.9 -6.0 13.3 -1.0 1984 1.3 6.4 5.0 3.0 5.1 3.5 1985 13.0 1.3 4.3 2.4 2.5 2.4 1987 5.3 1.0 6.8 6.1 8.0 2.0 1987 5.3 1.0 6.8 6.7 6.0 1989 13.4 6.3 8.0 6.4 3.7 6.0 2000 1.4 1.9 1.2.5 7.3 8.3 7.0 7.0 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 1.2.1 6.3 8.5 7.4 7.2										
1989 19.4 2.5.7 2.2.2 11.0 14.7 11.7 1990 1.6.9 5.4 0.0 8.6 0.2 1991 1.5.7 8.4 2.7 2.60 7.9 3.0 1993 2.2.7 2.60 7.9 3.0 3.5 3.0 1994 1.3 6.4 5.0 3.5 3.5 1995 1.3.1 1.3 4.3 2.4 2.5 2.4 1996 1.3.3 0.5 0.8 6.1 8.3 6.7 1997 5.3 7.0 0.5 6.1 8.3 6.7 1998 1.3.1 8.4.7 7.0 7.2 7.0 2000 11.4 6.3 8.0 7.3 4.5 2001 15.4 10.9 12.4 8.4 13.7 8.7 2002 15.1 2.6 6.9 7.3 4.1 6.5 2003 13.1 8.2 10.0 6.3 7.9 7.2 2004 1.0 5.5 7.3 8.3 3.7 7.2 2005 f 1.2.1 6.3 8.5 7.4 2.7 6.2 2006 f 1.2.1 <	1987				3.5					
1980 18.6 9.6 13.0 10.0 8.6 9.7 1982 5.7 5.4 6.7 6.5 3.0 0.2 1984 1.3 6.4 5.0 3.0 5.1 3.5 1985 13.0 1.3 4.3 2.4 2.5 2.4 1986 13.0 1.3 4.3 2.4 2.5 2.4 1987 4.3 -0.5 0.8 6.7 6.0 1989 1.5 5.2 7.8 7.0 7.2 7.0 1989 13.6 5.2 7.8 7.0 7.2 7.0 2000 1.4 6.3 8.0 5.8 6.7 6.0 2001 1.5.4 10.9 1.2.4 8.4 1.3.7 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 1.2.1 6.3 8.5 7.4 2.7 6.2 2005 f 1.2.1 6.3 8.5 7.4 2.7 6.2 2005 f 1.0.0 5.5 7.3 8.3 7.7 7.2 1985 54.4 55 100.0 5.8 5.7 5.7	1988									
1991 6.9 5.4 6.0 2.1 6.7 3.0 1993 22.7 28.0 7.9 6.0 13.6 1.0 1993 1.3 6.4 5.0 13.6 1.0 1995 13.0 1.3 4.3 2.4 2.6 2.4 1995 13.0 1.3 4.3 2.4 2.6 2.4 1995 13.0 1.3 4.3 2.4 2.6 2.4 1995 13.0 1.3 4.3 2.4 2.6 2.4 1997 5.3 7.0 6.5 6.1 8.3 6.7 6.0 2000 11.4 6.3 8.0 7.3 4.1 6.5 2001 15.4 10.9 7.3 4.1 6.5 2002 15.1 2.6 6.9 3.6 3.7 6.7 2004 9.0 7.4 8.0 7.3 6.7 6.2 2005 f 10.5 10.0 7.3 4.1 6.5 1987 4.6.5 5.0 <td></td>										
1983 2.2.7 2.6.0 7.9 -6.0 13.5 -1.0 1994 1.3 6.4 5.0 5.1 3.5 1995 1.3.0 1.3 4.3 2.4 2.5 2.4 1997 5.3 7.0 6.6 6.1 8.3 6.7 1998 1.1 1.8 4.7 6.4 -1.1 4.5 1999 13.6 5.2 7.8 7.0 7.2 7.0 2000 11.4 6.3 8.0 5.8 6.7 6.7 2001 15.4 1.0.3 1.6 7.3 7.3 7.9 2002 15.1 2.6 6.3 5.6 3.4 5.0 2004 10.0 5.5 7.3 8.3 3.7 7.2 2005 f 12.1 6.3 8.5 7.4 6.5 7.3 8.3 3.7 1989 38.3 61.7 100.0 5.5 7.3 8.3 3.7 7.2 1989 38.3 61.7 100.0 5.5 7.3 8.3 3.7 7.2 1989 38.3 61.7 100.0 5.5 7.3 8.3 3.7 7.2 <	1990									
1994 1.3 6.4 5.0 3.0 5.1 3.5 1996 1.3.0 1.3 4.3 2.4 2.5 2.4 1997 5.3 7.0 6.5 6.6 8.3 6.7 1998 1.2.1 1.6 4.8 1.1 4.5 1999 1.5.6 5.2 7.8 7.0 7.2 2000 11.4 6.3 8.0 6.8 6.7 6.0 2001 15.4 10.9 12.4 8.4 13.7 9.7 2002 15.1 2.6 6.9 3.4 5.0 2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 6.7 2005 f 10.0 5.5 7.3 8.3 3.7 7.2 2006 f 10.0 5.5 7.3 8.3 3.7 7.2 2006 f 10.0 5.5 7.3 8.3 3.7 7.2 1986 5.4 4.5.6 100.0 100.0 100.0 1987 4.6.0 5.0 100.0 100.0 100.0 1989 3.5 6.7.1 100.0	1992									
1995 13.0 1.3 4.3 2.4 2.5 2.4 1996 4.3 0.5 0.8 2.3 1.0 2.0 1997 5.3 7.0 6.5 6.1 8.3 6.7 1998 12.1 1.8 4.7 6.4 -1.1 4.5 2000 11.4 6.3 8.0 5.8 6.7 6.0 2001 15.4 0.9 12.4 8.4 13.7 9.7 2002 15.1 2.6 6.9 5.6 3.4 5.0 2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 10.0 5.5 7.3 8.3 3.7 7.2 1985 54.4 45.6 100.0 19.9 19.9 19.9 1985 54.5 100.0 19.9 19.0 19.9 19.9 1986 55.5 100.0 19.0 19.9 19.9 19.9 1987 54.5 100.0 19.9 19.0 19.9 19.9 1988 36.3 61.7 100.0 19.9 19.9 <td>1993 1994</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1993 1994									
1996 4.3 0.5 0.8 2.3 1.0 2.0 1997 5.3 7.0 6.5 6.1 8.3 6.7 1998 1.2.1 1.8 4.7 6.4 7.0 7.2 2000 11.4 6.3 8.0 5.8 6.7 8.0 2001 15.1 2.2 6.9 6.3 8.7 8.7 2002 15.1 2.2 6.9 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 12.1 6.3 8.5 7.4 2.7 6.2 2004 9.0 7.4 8.0 3.7 7.2 2005 12.1 6.3 8.5 0.7 8.2 2006 10.0 5.5 7.3 8.3 3.7 7.2 1985 54.4 45.5 100.0 1989 8.3 61.7 100.0 1986 54.5 100.0 1989 3.6 17.1 100.0 1987 4.6 54.5 100.0 1989 19.5 10.0										
1988 12.1 1.8 4.7 6.4 -1.1 4.5 1989 13.6 5.2 7.8 7.0 7.0 2000 11.4 6.3 8.0 5.8 6.7 6.0 2001 15.4 10.9 12.4 8.4 13.7 9.7 2002 15.1 2.6 6.9 5.6 3.4 5.0 2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 12.1 6.3 8.5 7.4 2.7 6.2 2006 f 10.0 5.5 7.3 8.3 3.7 7.2 Interreture ture ture ture ture ture ture	1996									
1999 13.6 5.2 7.8 7.0 7.2 7.0 2000 11.4 6.3 8.0 5.8 6.7 6.0 2001 15.1 2.6 6.9 5.6 3.4 5.0 2004 9.0 7.4 8.0 7.3 4.1 6.5 2004 9.0 7.4 8.0 7.4 6.7 2004 9.0 7.4 8.0 7.4 6.7 2004 10.0 5.5 7.3 8.3 3.7 7.2 2004 10.0 5.5 7.3 8.3 3.7 7.2 1985 54.4 45.6 100.0 10.0 10.0 10.0 1986 54.4 45.6 100.0 10.0 10.0 10.0 1987 46.0 54.0 100.0 10.0 10.0 10.0 1988 38.3 61.7 100.0 1989 2.5 7.1 100.0 1989 22.6 7.7.3 100.0 10.0 10.0 10.0 1989 22.6 7.7.3 100.0 10.0 10.0 1989 22.6 7.7.3 100.0 10.0 1989	1997									
2001 15.4 10.9 12.4 8.4 13.7 9.7 2002 15.1 2.6 6.9 5.6 3.4 5.0 2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 12.1 6.3 8.5 7.4 2.7 6.2 2006 f 10.0 5.5 7.3 8.3 3.7 7.2 Image: Share of total drug expenditure 1985 54.4 45.6 100.0 1986 54.5 45.5 100.0 1987 46.0 54.0 100.0 1988 38.3 61.7 100.0 1989 38.3 61.7 100.0 1981 40.5 59.5 100.0 1982 37.2 62.8 100.0 1984 25.7 74.3 100.0 1985 27.9 7.1 100.0 1986 28.5 71.5 100.0 1987 28.5 71.5 100.0 1988 30.5 69.5 100.0 1989 32.2 67.8 100.0	1998 1999									
2001 15.4 10.9 12.4 8.4 13.7 9.7 2002 15.1 2.6 6.9 5.6 3.4 5.0 2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f 12.1 6.3 8.5 7.4 2.7 6.2 2006 f 10.0 5.5 7.3 8.3 3.7 7.2 Image: Share of total drug expenditure 1985 54.4 45.6 100.0 1986 54.5 45.5 100.0 1987 46.0 54.0 100.0 1988 38.3 61.7 100.0 1989 38.3 61.7 100.0 1981 40.5 59.5 100.0 1982 37.2 62.8 100.0 1984 25.7 74.3 100.0 1985 27.9 7.1 100.0 1986 28.5 71.5 100.0 1987 28.5 71.5 100.0 1988 30.5 69.5 100.0 1989 32.2 67.8 100.0										
2003 13.1 8.2 10.0 6.3 7.9 6.7 2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 f1 12.1 6.3 8.5 7.4 2.7 6.2 2006 f1 10.0 5.5 7.3 8.3 3.7 7.2 Intercentage share of total drug expenditure 1985 54.4 45.6 100.0 1986 54.4 45.6 100.0 1987 100.0 1987 46.0 54.0 100.0 1988 38.3 61.7 100.0 1988 38.3 61.7 100.0 1992 37.2 62.8 100.0 1984 25.7 74.3 100.0 1994 25.7 74.3 100.0 1984 25.7 74.3 100.0 1994 25.7 74.3 100.0 1985 27.9 7.1 100.0 1995 28.6 71.5 100.0 1984 25.7 74.3 100.0 1995 28.6 71.5 100.0 1985 28.6 71.5 100.0 1995 28.6 100.0 1986 28.6 71.6 100.0 </td <td>2001</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	2001									
2004 9.0 7.4 8.0 7.3 4.1 6.5 2005 fi 12.1 6.3 8.5 7.4 2.7 6.2 2006 fi 10.0 5.5 7.3 8.3 3.7 7.2 Importance share of total drug expenditure 1986 54.4 54.5 100.0 1987 46.0 54.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1989 40.5 59.5 100.0 1989 30.2 59.8 100.0 1989 26.7 73.3 100.0 1989 25.7 74.3 100.0 1989 25.5 71.6 100.0 1989 26.5 71.6 100.0 1989 26.5 71.6 100.0 1989 32.2 67.8 100.0 1989 32.2 67.8 100.0 2001 <	2002									
20061 10.0 5.5 7.3 8.3 3.7 7.2 Ipprentage share of total drug expenditure) 1985 54.4 45.6 100.0 1986 54.5 45.5 100.0 1987 46.0 54.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1989 38.3 61.7 100.0 1989 38.3 61.7 100.0 1981 40.5 59.8 100.0 1982 32.7 73.3 100.0 1984 25.7 74.3 100.0 1985 28.8 71.2 100.0 1986 28.8 71.2 100.0 1987 28.5 71.5 100.0 1989 30.5 68.5 100.0 1989 30.5 68.5 100.0 1989 38.1 61.9 100.0 2001 34.1	2003 2004									
Ippendiculation Ippendiculation 1985 54.4 45.6 100.0 1986 54.5 45.5 100.0 1987 56.0 50.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1989 38.3 61.7 100.0 1990 40.5 59.5 100.0 1982 37.2 62.8 100.0 1984 25.7 74.3 100.0 1985 27.9 72.1 100.0 1986 28.8 71.2 100.0 1987 28.5 71.5 100.0 1989 30.5 69.5 100.0 1989 32.2 67.8 100.0 2001 34.1 66.9 100.0 2002 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 39.3 60.7 100.0	2005 f	12.1	6.3	8.5	7.4	2.7	6.2			
Ippendiculation Ippendiculation 1985 54.4 45.6 100.0 1986 54.5 45.5 100.0 1987 56.0 50.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1989 38.3 61.7 100.0 1990 40.5 59.5 100.0 1982 37.2 62.8 100.0 1984 25.7 74.3 100.0 1985 27.9 72.1 100.0 1986 28.8 71.2 100.0 1987 28.5 71.5 100.0 1989 30.5 69.5 100.0 1989 32.2 67.8 100.0 2001 34.1 66.9 100.0 2002 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 39.3 60.7 100.0										
1986 54.5 45.5 100.0 1987 46.0 54.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1990 40.2 59.8 100.0 1991 40.5 59.5 100.0 1992 37.2 62.8 100.0 1993 26.7 73.3 100.0 1994 25.7 74.3 100.0 1995 27.9 7.2 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 1999 32.2 67.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2002 36.7 63.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2004										
1986 54.5 45.5 100.0 1987 46.0 54.0 100.0 1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1990 40.2 59.8 100.0 1991 40.5 59.5 100.0 1992 37.2 62.8 100.0 1993 26.7 73.3 100.0 1994 25.7 74.3 100.0 1995 27.9 7.2 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2002 36.7 63.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2004	1985	54.4	45.6	100.0						
1988 39.5 60.5 100.0 1989 38.3 61.7 100.0 1990 40.2 59.8 100.0 1991 40.5 59.5 100.0 1992 37.2 62.8 100.0 1994 26.7 73.3 100.0 1995 27.9 72.1 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.6 69.5 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2005 f 39.3 60.7 100.0 2005 f 39.3 60.7 100.0	1986	54.5	45.5	100.0						
1989 38.3 61.7 100.0 1990 40.2 59.8 100.0 1991 40.5 59.5 100.0 1992 37.2 62.8 100.0 1993 26.7 73.3 100.0 1994 25.7 74.3 100.0 1995 27.9 72.1 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2005 f 39.3 60.7 100.0										
199140.559.5100.0199237.262.8100.0199326.773.3100.0199425.774.3100.0199527.972.1100.0199628.871.2100.0199728.571.5100.0199830.569.5100.0199932.267.8100.0200033.266.8100.0200134.165.9100.0200236.763.3100.0200337.762.3100.0200438.161.9100.02005 f39.360.7100.02006 f40.359.7100.0	1989									
1992 37.2 62.8 100.0 1993 26.7 73.3 100.0 1994 25.7 74.3 100.0 1995 27.9 72.1 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2005 f 39.3 60.7 100.0	1990	40.2	59.8	100.0						
1993 26.7 73.3 100.0 1994 25.7 74.3 100.0 1995 27.9 72.1 100.0 1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2005 f 40.3 59.7 100.0	1991									
199425.774.3100.0199527.972.1100.0199628.871.2100.0199728.571.5100.0199830.569.5100.0199932.267.8100.0200033.266.8100.0200134.165.9100.0200236.763.3100.0200337.762.3100.0200438.161.9100.02005 f39.360.7100.02006 f40.359.7100.0										
1996 28.8 71.2 100.0 1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	1994									
1997 28.5 71.5 100.0 1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	1995	27.9	72.1	100.0						
1998 30.5 69.5 100.0 1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	1996									
1999 32.2 67.8 100.0 2000 33.2 66.8 100.0 2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0										
2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	1999									
2001 34.1 65.9 100.0 2002 36.7 63.3 100.0 2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	2000	33.2	66.8	100.0						
2003 37.7 62.3 100.0 2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0	2001	34.1	65.9	100.0						
2004 38.1 61.9 100.0 2005 f 39.3 60.7 100.0 2006 f 40.3 59.7 100.0										
2006 f 40.3 59.7 100.0	2003									
	2005 f	39.3	60.7	100.0						
	2006 f	40.3	59.7	100.0						

Table B.8.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2006

			Public		Prescribe	d Drugs	Private			Non-Prescribed Drugs Private (Out-of-Pocket)			
	Provincial	Federal _	Social Security WCB	Funds Drug surance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs	
Year				runus		(\$ per o	capita)			Diugs			
1985	65.90	6.11	0.14		72.15			26.16	98.31			34.43	
1986 1987	78.76 65.64	6.89 7.48	0.14 0.20		85.79 73.32			32.80 41.13	118.59 114.45			38.85 44.90	
1988	61.28	9.47	0.32		71.08			52.00	123.08			56.67	
1989	73.37	11.97	0.23		85.58			66.00	151.57			71.80	
1990	88.11	14.37	0.26		102.73			78.97	181.70			73.85	
1991	93.26	16.75	0.27		110.29			89.00	199.30			72.76	
1992	84.66	18.90	0.33		103.88			99.15	203.03	40.47	35.45	75.92	
1993 1994	57.37 55.63	22.26 24.80	0.44 0.43		80.07 80.85			125.84 139.94	205.90 220.79	49.53 48.37	44.64 45.12	94.17 93.49	
1995 1996	62.89 65.33	27.57 28.25	0.49 0.80		90.94 94.39			144.72 145.37	235.66 239.76	46.73 43.82	44.05 44.00	90.78 87.82	
1990	68.04	30.62	0.83		99.49			145.37	257.80	43.82	44.00	91.42	
998	77.57	33.12	0.91		111.61			164.51	276.12	43.82	45.92	89.74	
1999	87.81	38.23	1.12		127.15			171.45	298.60	48.87	47.95	96.82	
2000	99.38	41.95	1.31		142.64			184.19	326.83	52.40	50.65	103.05	
2001	116.26	48.10	1.56		165.92			216.10	382.02	54.25	50.52	104.77	
2002	134.44	55.48	1.90		191.82			223.47	415.28	55.73	51.52	107.25	
2003 2004	152.26 169.08	62.85 65.23	2.18 2.55		217.28 236.87			253.67 275.64	470.95 512.51	54.52 57.25	50.29 52.15	104.81 109.39	
2005 f	188.28	74.55	2.69		265.53			296.16	561.68	59.32	53.91	113.23	
2006 f	205.41	84.34	3.07		292.81			314.27	607.08	61.64	57.18	118.82	
						(annual percer	tage change)						
1985 1986	 10 E		2.1					25.4	20.6			 12.8	
1985	19.5 -16.7	12.7 8.5	41.9		18.9 -14.5			25.4	-3.5			12.6	
1988	-6.6	26.6	59.6		-3.1			26.4	7.5			26.2	
1989	19.7	26.4	-28.3		20.4			26.9	23.2			26.7	
1990	20.1	20.0	11.1		20.0			19.7	19.9			2.8	
1991	5.9	16.6	5.9		7.4			12.7	9.7			-1.5	
1992	-9.2	12.8	20.1		-5.8			11.4	1.9			4.3	
1993 1994	-32.2 -3.0	17.8 11.4	32.6 -2.4		-22.9 1.0			26.9 11.2	1.4 7.2	22.4 -2.3	25.9 1.1	24.0 -0.7	
1995 1996	13.1 3.9	11.1 2.5	15.6 62.3		12.5 3.8			3.4 0.5	6.7 1.7	-3.4 -6.2	-2.4 -0.1	-2.9 -3.3	
1997	4.1	8.4	4.4		5.4			8.9	7.5	2.6	5.6	4.1	
1998	14.0	8.2	9.7		12.2			3.9	7.1	-2.5	-1.2	-1.8	
1999	13.2	15.4	22.3		13.9			4.2	8.1	11.5	4.4	7.9	
2000	13.2	9.8	17.2		12.2			7.4	9.5	7.2	5.6	6.4	
2001	17.0	14.6	19.4		16.3			17.3	16.9	3.5	-0.3	1.7	
2002	15.6	15.3	21.4		15.6			3.4	8.7	2.7	2.0	2.4	
2003	13.3	13.3	14.6		13.3			13.5	13.4	-2.2	-2.4	-2.3	
2004	11.0	3.8	17.3		9.0			8.7	8.8	5.0	3.7	4.4	
2005 f	11.4	14.3	5.4		12.1			7.4	9.6	3.6	3.4	3.5	
2006 f	9.1	13.1	14.0		10.3			6.1	8.1	3.9	6.1	4.9	
				(annual percentage	change in excess of	of inflation in	the Canadian e	conomy)				
1985	16.7							 22.6					
1986 1987	16.7 -21.4	9.9 3.7	-0.7 37.2		16.1 -19.3			22.6 20.7	17.8 -8.2			10.0 10.8	
1988	-11.2	22.1	55.1		-7.6			21.9	3.0			21.7	
1989	15.2	21.9	-32.9		15.8			22.4	18.6			22.1	
1990	17.1	17.0	8.1		17.0			16.6	16.8			-0.2	
1991	3.1	13.8	3.1		4.6			10.0	6.9			-4.2	
992	-10.5	11.5	18.9		-7.1			10.1	0.6			3.1	
1993	-33.7	16.3	31.1		-24.4			25.5	0.0	20.9	24.5	22.6	
1994	-4.1	10.3	-3.5		-0.1			10.1	6.1	-3.4	0.0	-1.8	
1995	10.7	8.8	13.3		10.1			1.1	4.4	-5.7	-4.7	-5.2	
1996 1997	2.2 3.2	0.8 7.4	60.6 3.4		2.1 4.4			-1.2 7.9	0.1 6.5	-7.9 1.6	-1.8 4.6	-4.9 3.1	
1998	14.4	8.6	10.1		12.6			4.4	7.5	-2.1	-0.7	-1.4	
1999	11.4	13.6	20.5		12.1			2.4	6.3	9.7	2.6	6.1	
2000	9.1	5.7	13.1		8.1			3.3	5.4	3.1	1.5	2.3	
2001	15.6	13.3	18.0		15.0			16.0	15.5	2.2	-1.6	0.3	
2002	14.6	14.3	20.4		14.6			2.4	7.7	1.7	1.0	1.4	
2003 2004	10.4 8.4	10.4	11.7 14.6		10.4 6.3			10.6 6.0	10.5	-5.1	-5.3	-5.2 1.7	
.004		1.1	14.6						6.1	2.3	1.0		
								4.8	6.0				
2005 f	8.7	11.6	2.8		9.4			4.0	6.9	1.0	0.7	0.9	
	8.7 7.5	11.6	2.8 12.4		9.4 8.7			4.8	6.5	2.3	4.5	3.3	

Table B.8.2–Part 2

	All Drugs			Health Expenditure		GDP Implicit P <u>rice Index – Canada</u>
Public	Private	Total	Public	Private	Total	
		(\$ per c	apita)			(1997 = 100)
72.1	5 60.60	132.75	1,165.85	324.93	1,490.78	73.6
85.3		157.44	1,288.21		1,655.19	75.6
73.3		159.35	1,328.72		1,711.73	79.2
71.0 85.5		179.74 223.37	1,428.29 1,598.43		1,787.57 2,014.15	82.8 86.6
						89.2
102.1 110.2		255.54 272.06	1,779.42 1,824.01		2,236.27 2,313.60	89.2 91.6
103.8		278.95	1,812.37		2,316.20	92.8
80.0		300.07	1,716.06		2,286.26	94.1
80.8	233.43	314.28	1,762.05	597.86	2,359.92	95.2
90.9		326.44	1,795.42		2,405.56	97.4
94.3 99.4		327.58 349.22	1,827.39 1,941.01		2,440.67 2,605.99	99.0 100.0
111.6		365.86	2,067.33		2,725.63	99.6
127.1		395.42	2,217.77		2,925.47	101.4
142.6	4 287.24	429.88	2,362.85	760.56	3,123.41	105.5
165.9	2 320.87	486.79	2,581.17	871.23	3,452.40	106.9
191.8		522.54	2,736.70		3,641.73	108.0
217.2 236.8		575.76 621.91	2,912.66 3,126.39		3,890.69 4,144.86	111.1 114.1
265.5		674.92	3,357.69		4,403.40	117.2
292.8	433.09	725.90	3,645.98		4,733.68	119.0
			innual percentage ch			
 18	.9 18.2	 18.6	 10.5	12.9	 11.0	2.8
-14		1.2	3.1		3.4	4.7
-3	.1 26.3	12.8	7.5	-6.2	4.4	4.5
20	.4 26.8	24.3	11.9	15.7	12.7	4.6
20		14.4	11.3		11.0	3.0
7		6.5	2.5		3.5	2.8
-5 -22		2.5 7.6	-0.6 -5.3		0.1 -1.3	1.3 1.4
	.0 6.1	4.7	2.7		3.2	1.1
12	.5 0.9	3.9	1.9	2.1	1.9	2.3
	.8 -1.0	0.3	1.8		1.5	1.7
	.4 7.1	6.6	6.2		6.8	1.0
12 13		4.8 8.1	6.5 7.3		4.6 7.3	-0.4 1.8
12 16		8.7 13.2	6.5 9.2		6.8 10.5	4.1 1.4
15		7.3	6.0		5.5	1.4
13		10.2	6.4		6.8	2.9
9	.0 7.4	8.0	7.3	4.1	6.5	2.7
12	.1 6.3	8.5	7.4	2.7	6.2	2.7
10	.3 5.8	7.6	8.6	4.0	7.5	1.6
		tage change in excess o				1.0
16	.1 15.4	15.8	7.7	10.1	8.2	
-19		-3.5	-1.6		-1.3	
-7 15		8.3 19.7	3.0 7.3		-0.1 8.1	
17		11.4 3.7	8.3 -0.3		8.0 0.7	
-7	.6 3.1 .1 7.0	3.7	-0.3		-1.1	
-24		6.1	-6.8		-2.7	
-0		3.6	1.6		2.1	
10	.1 -1.4	1.5	-0.4	-0.3	-0.4	
2	.1 -2.6	-1.3	0.1	-1.2	-0.2	
	.4 6.1	5.6	5.2		5.8	
12 12		5.2 6.3	6.9 5.5		5.0 5.5	
8 15	.1 3.0 .0 10.4	4.6 11.9	2.4		2.7 9.2	
15		6.3	7.9		9.2	
10	.4 5.5	7.3	3.5	5.2	3.9	
6	.3 4.7	5.3	4.6	1.4	3.8	
9	.4 3.7	5.9	4.7	0.0	3.6	
g	.7 4.2	6.0	7.0	2.4	5.9	
					0.0	

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and

Table B.9.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Alberta, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
Provinci	ial	Federal _	Social Secu WCB	urity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Prese Drugs
				. and		(\$ mil	lions)			Diago		
	9.5 9.2	6.4 7.0	0.9		76.7			134.5 147.9	211.2 239.3			113
	33.2 95.7	7.0	1.2 1.5		91.4 104.6			147.9	239.3			128 148
	0.8.0	9.1	1.6		118.7			172.6	291.3			163
	59.7	11.1	1.8		172.7			194.5	367.2			179
17	9.5	13.2	2.2		194.9			219.0	413.9			184
	9.5 39.2	15.2	2.2		207.1			219.0	448.3			194
)5.6	17.1	3.0		225.6			256.8	482.4	103.3	91.2	192
)5.8	20.4	3.7		229.9			297.0	526.9	114.2	98.7	213
20	08.1	22.8	3.3		234.2			309.4	543.7	111.6	106.1	217
21	2.5	26.0	3.1		241.5			323.6	565.1	112.3	108.9	221
	32.6	26.3	3.5		262.4			360.2	622.6	120.5	112.5	233
	64.8	29.3	3.5		287.6			403.5	691.1	135.4	125.9	261
	8.1	32.8	4.2		315.0			430.1	745.1	143.6	135.0	278
32	28.2	41.2	5.2		374.6			494.4	869.1	156.9	136.7	293
38	37.1	45.1	5.7		437.8			556.5	994.3	164.5	150.0	314
	51.0	51.4	7.7		510.1			617.5	1,127.7	181.8	160.8	342
	5.2	57.7	8.7		581.7			686.9	1,268.6	190.7	169.6	360
58	38.2	64.9	10.2		663.2			754.3	1,417.5	209.1	177.3	386
65	53.7	67.8	10.9		732.4			800.9	1,533.3	225.0	187.2	412
77	1.5	79.1	10.9		861.4			882.6	1,743.9	230.1	194.9	425
84	9.8	92.0	11.2		953.0			958.6	1,911.6	233.1	198.7	431
						(annual percer	ntage change)					
	9.8	9.8	33.7		19.1			10.0	13.3			13
	5.1	6.1	23.4		14.5			3.5	7.7			16 10
	2.7 8.0	22.8 22.5	13.0 10.2		13.5 45.5			12.7 12.7	13.0 26.1			10
4	6.0	22.5	10.2		45.5			12.7	20.1			
	2.4	18.0	22.6		12.9			12.6	12.7			2
	5.4	16.1	19.6		6.3			10.1	8.3			4
	8.7	11.8	11.9		8.9			6.5	7.6			0
	0.1	19.6	23.9		1.9			15.7	9.2	10.6	8.3	9
	1.1	11.9	-11.4		1.9			4.2	3.2	-2.3	7.4	2
	2.1	13.7	-5.1		3.1			4.6	3.9	0.7	2.6	1
	9.5	1.3	11.9		8.6			11.3	10.2	7.3	3.3	Ę
	9.6	11.5	-0.3		9.6			12.0	11.0	12.3	11.9	1:
	9.1 8.0	11.8 25.8	21.3 22.9		9.5 18.9			6.6 15.0	7.8 16.6	6.0 9.3	7.2 1.3	1
					10.5							
	7.9	9.2	9.8		16.9			12.6	14.4	4.8	9.7	
	6.5	14.1	36.1		16.5			11.0	13.4	10.5	7.3	9
	4.2	12.2	13.6		14.0			11.2	12.5	4.9	5.4	!
	4.2 1.1	12.4 4.5	16.2 6.9		14.0 10.4			9.8 6.2	11.7 8.2	9.7 7.6	4.6 5.6	
1	8.0	16.7	0.1		17.6			10.2	13.7	2.3	4.1	3
1	0.2	16.4	2.7		10.6			8.6	9.6	1.3	1.9	1
					(per	centage share of t	otal drug expe	enditure)				
	21.4	2.0	0.3		23.7			41.5	65.1			3-
	22.6 23.6	1.9 1.8	0.3 0.4		24.9 25.8			40.3 37.7	65.1 63.4			3
	23.7	2.0	0.4		26.1			38.0	64.1			3
	29.2	2.0	0.3		31.6			35.6	67.2			3
					00.0				~~~~			
	80.0 29.5	2.2 2.4	0.4 0.4		32.6 32.3			36.6 37.6	69.2 69.9			31
	30.4	2.4	0.4		32.3			37.8	71.3	15.3	13.5	2
	27.8	2.5	0.4		31.1			40.1	71.3	15.4	13.3	2
	27.3	3.0	0.4		30.8			40.6	71.4	14.7	13.9	2
								44.0				
	27.0 27.2	3.3 3.1	0.4 0.4		30.7 30.7			41.2 42.1	71.9 72.8	14.3 14.1	13.8 13.1	2
	26.8	3.1	0.4		30.2			42.1	72.8	14.1	13.1	2
	27.2	3.2	0.4		30.8			42.0	72.8	14.2	13.2	2
	28.2	3.5	0.4		32.2			42.5	74.7	13.5	11.8	2
	29.6	3.4	0.4		33.5			42.5	76.0	12.6	11.5	24
	29.6 30.7	3.4 3.5	0.4		33.5 34.7			42.5	76.0	12.6	10.9	2
	30.7 31.6	3.5 3.5	0.5		34.7 35.7			42.0	76.7	12.4	10.9	2
	32.6	3.6	0.5		36.8			42.2	78.6	11.7	9.8	2
	33.6	3.5	0.6		37.6			41.2	78.8	11.6	9.6	2
	85.6	3.6	0.5		39.7			40.7	80.4	10.6	9.0	1
3	86.3	3.9	0.5		40.7			40.9	81.6	9.9	8.5	1:
		eporting provinc										ce: CIHI, 2

Table B.9.1–Part 2 nd as a Share of Public, Private and

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Alberta, 1985 to 2006 (continued)

			•			2006 (continued)		ugs in Public, Priva	
-	Public	All Drugs Private	Total	Public	alth Expenditure Private	Total	Public	Health Expenditure Private	Total
Year			(\$ millio	ons)			(p	ercentage share)	
1985	76.7	247.6	324.3	3,239.1	831.3	4,070.4	2.4	29.8	8.0
1986 1987	91.4 104.6	276.0 301.6	367.4 406.2	3,537.9 3,514.4	910.6 985.5	4,448.5 4,499.9	2.6 3.0	30.3 30.6	8.3 9.0
1988	118.7	335.9	454.6	3,645.6	1,184.9	4,830.6	3.3	28.3	9.4
1989	172.7	374.0	546.7	4,031.0	1,318.8	5,349.8	4.3	28.4	10.2
1990	194.9	403.4	598.3	4,326.9	1,422.5	5,749.4	4.5	28.4	10.4
1991	207.1	434.0	641.1	4,557.5	1,505.1	6,062.5	4.5	28.8	10.6
1992 1993	225.6 229.9	451.2 510.0	676.9 739.8	4,846.4 4,800.5	1,584.2 1,719.9	6,430.7 6,520.4	4.7 4.8	28.5 29.7	10.5 11.3
1994	234.2	527.1	761.4	4,527.8	1,778.0	6,305.7	5.2	29.6	12.1
1995	241.5	544.8	786.3	4,283.5	1,801.6	6,085.0	5.6	30.2	12.9
1996	262.4	593.2	855.6	4,466.5	1,846.4	6,312.9	5.9	32.1	13.6
1997	287.6	664.8	952.4	4,942.0	2,131.0	7,073.1	5.8	31.2	13.5
1998 1999	315.0 374.6	708.6 788.1	1,023.7 1,162.7	5,354.0 6,140.2	2,253.8 2,538.1	7,607.7 8,678.3	5.9 6.1	31.4 31.0	13.5 13.4
2000 2001	437.8 510.1	870.9 960.1	1,308.7 1,470.2	6,792.9 7,745.0	2,809.6 3,265.2	9,602.5 11,010.2	6.4 6.6	31.0 29.4	13.6 13.4
2002	581.7	1,047.2	1,628.9	8,470.2	3,373.7	11,843.9	6.9	31.0	13.8
2003	663.2	1,140.7	1,803.9	9,127.0	3,523.5	12,650.5	7.3	32.4	14.3
2004	732.4	1,213.1	1,945.4	9,965.0	3,867.4	13,832.4	7.3	31.4	14.1
2005 f	861.4	1,307.5	2,168.9	11,083.3	4,141.7	15,225.0	7.8	31.6	14.2
2006 f	953.0	1,390.4	2,343.4	11,852.0	4,372.7	16,224.7	8.0	31.8	14.4
-			(annual percenta	age change)					
1985									
1986	19.1	11.5	13.3	9.2	9.5	9.3			
1987 1988	14.5 13.5	9.3 11.3	10.6 11.9	-0.7 3.7	8.2 20.2	1.2 7.3			
1989	45.5	11.4	20.3	10.6	11.3	10.7			
1990	12.9	7.8	9.4	7.3	7.9	7.5			
1991	6.3	7.6	7.2	5.3	5.8	5.4			
1992	8.9	4.0	5.6	6.3	5.3	6.1			
1993 1994	1.9 1.9	13.0 3.4	9.3 2.9	-0.9 -5.7	8.6 3.4	1.4 -3.3			
1995	3.1	3.4	3.3	-5.4	1.3	-3.5			
1996 1997	8.6 9.6	8.9 12.1	8.8 11.3	4.3 10.6	2.5 15.4	3.7 12.0			
1998	9.5	6.6	7.5	8.3	5.8	7.6			
1999	18.9	11.2	13.6	14.7	12.6	14.1			
2000	16.9	10.5	12.6	10.6	10.7	10.6			
2001	16.5	10.2	12.3	14.0	16.2	14.7			
2002 2003	14.0 14.0	9.1 8.9	10.8 10.7	9.4 7.8	3.3 4.4	7.6 6.8			
2004	10.4	6.3	7.8	9.2	9.8	9.3			
2005 f	17.6	7.8	11.5	11.2	7.1	10.1			
2006 f	10.6	6.3	8.0	6.9	5.6	6.6			
		e share of total drug							
1985	23.7	76.3	100.0						
1986	24.9	75.1	100.0						
1987 1988	25.8 26.1	74.2 73.9	100.0 100.0						
1989	31.6	68.4	100.0						
1990	32.6	67.4	100.0						
1991	32.3	67.7	100.0						
1992	33.3	66.7	100.0						
1993	31.1	68.9	100.0						
1994	30.8	69.2	100.0						
1995	30.7	69.3	100.0						
1996 1997	30.7 30.2	69.3 69.8	100.0 100.0						
1998	30.8	69.2	100.0						
1999	32.2	67.8	100.0						
2000	33.5	66.5	100.0						
2001	34.7	65.3	100.0						
2002 2003	35.7 36.8	64.3 63.2	100.0 100.0						
2003	37.6	62.4	100.0						
2005 f	39.7	60.3	100.0						
2006 f	40.7	59.3	100.0						
f-Forecast								So	urce: CIHI, 2006.

				Prescribe	ed Drugs				Non-	Prescribed D	rugs
Provincial	Federal	Public Social Secu		Sub-Total	Insurers*	Private Out-of-	Sub-Total	Total	Over-	e (Out-of-Po Personal	Total
		WCB	Drug Insurance Funds	Public		Pocket	Private	Prescribed Drugs	the- Counter Drugs	Health Supplies	Non-Preso Drugs
					(\$ per	capita)					
28.91	2.65	0.37		31.93			55.96	87.89			47.0
34.23 39.32		0.48 0.60		37.59 42.96			60.86 62.87	98.44 105.83			52.0 60.9
43.98		0.67		48.36			70.31	118.67			66.
64.01	4.47	0.73		69.20			77.94	147.14			71.
70.48	5.16	0.87		76.52			86.00	162.51			72.
72.98		1.02		79.89			93.03	172.92			74.
78.09	6.48	1.13		85.70			97.53	183.24	39.22	34.62	73.8
77.14 77.07	7.65 8.46	1.38 1.21		86.18 86.74			111.35 114.58	197.53 201.32	42.82 41.33	37.01 39.28	79.8 80.6
77.70 83.81	9.50 9.49	1.13 1.25		88.33 94.55			118.34 129.79	206.67 224.34	41.08 43.44	39.81 40.53	80.8 83.9
90.05	10.37	1.22		101.64			142.56	244.20	47.85	44.49	92.3
95.90	11.31	1.45		108.66			148.33	256.98	49.52	46.55	96.0
111.14	13.97	1.74		126.85			167.42	294.27	53.14	46.29	99.4
128.81	15.00	1.88		145.69			185.19	330.88	54.73	49.90	104.6
147.55	16.82	2.52		166.89			202.01	368.91	59.46	52.62	112.0
165.33 186.15	18.51 20.53	2.81 3.22		186.65 209.90			220.43 238.73	407.08 448.63	61.19 66.19	54.41 56.12	115.0 122.3
203.99		3.39		228.52			249.91	478.43	70.20	58.40	128.0
236.87	24.27	3.34		264.49			270.99	535.47	70.65	59.84	130.4
257.91	27.92	3.39		289.22			290.92	580.15	70.76	60.29	131.0
					(annual perce	ntage change)					
18.4		32.2		17.7			8.7	12.0			11
14.9 11.9		23.2 12.1		14.3 12.6			3.3 11.8	7.5 12.1			15 9
45.5		8.4		43.1			10.9	24.0			8
10.1	15.6	20.1		10.6			10.3	10.4			0
3.5		17.5		4.4			8.2	6.4			2
7.0		10.2		7.3			4.8	6.0			-0
-1.2		22.3		0.6			14.2	7.8	9.2	6.9	8
-0.1	10.5	-12.5		0.6			2.9	1.9	-3.5	6.1	1.
0.8		-6.3		1.8			3.3	2.7	-0.6	1.4	0
7.9 7.4		10.3 -2.2		7.0 7.5			9.7 9.8	8.6 8.9	5.7 10.2	1.8 9.8	3 10
6.5		-2.2		6.9			4.0	5.2	3.5	9.8 4.6	4
15.9		20.6		16.7			12.9	14.5	7.3	-0.6	3
15.9	7.4	7.9		14.9			10.6	12.4	3.0	7.8	5
14.6		33.8		14.6			9.1	11.5	8.7	5.4	7
12.0		11.4		11.8			9.1	10.3	2.9	3.4	3
12.6		14.6		12.5			8.3	10.2	8.2	3.1	5
9.6	3.0	5.4		8.9			4.7	6.6	6.1	4.1	5
16.1	14.8	-1.5		15.7			8.4	11.9	0.6	2.5	1
8.9	15.0	1.5		9.4			7.4	8.3	0.2	0.8	0
				(annual percentage	change in excess	of inflation in	the Canadian e	conomy)			
15.6		29.4		14.9			5.9	9.2			9
10.1 7.3	1.1 17.3	18.5 7.6		9.5 8.1			-1.4 7.3	2.8 7.6			11 4
41.0		3.8		38.5			6.3	19.4			4
7.1		17.1		7.5			7.3	7.4			-2
0.8		14.8		1.6			5.4	3.6			0
5.7		8.9		6.0			3.6	4.7			-2
-2.6		20.8		-0.9			12.7	6.4	7.7	5.5	6
-1.2	9.4	-13.6		-0.4			1.8	0.8	-4.6	5.0	-0
-1.5		-8.6		-0.5			0.9	0.3	-2.9	-1.0	-2
6.2 6.5		8.6 -3.2		5.4 6.5			8.0 8.8	6.9 7.9	4.1 9.2	0.1 8.8	2 9
6.9		-3.2		7.3			4.5	5.7	3.9	5.1	4
14.1	21.7	18.8		14.9			11.1	12.7	5.5	-2.4	1
11.8		3.8		10.7			6.5	8.3	-1.1	3.7	
11.8		3.8 32.4		13.2			6.5 7.7	8.3 10.1	-1.1 7.3	3.7 4.1	
11.0		10.4		10.8			8.1	9.4	1.9	2.4	
9.7	8.0	11.7		9.6			5.4	7.3	5.3	0.2	2
6.9	0.3	2.7		6.2			2.0	4.0	3.4	1.4	2
13.5	12.1	-4.2		13.1			5.8	9.3	-2.0	-0.2	-1
		~ -								-	
7.3	13.4	-0.1		7.7			5.8	6.7	-1.5	-0.8	-1

Table B.9.2—Part 2

Γ

	All Drugs		Her	alth Expenditure		GDP Implicit Price Index – Canada
Public	Private	Total	Public	Private	Total	
		(\$ per ca	pita)			(1997 = 100)
31.93	103.03	134.95	1,347.98	345.94	1,693.92	73.6
37.59	113.54	151.13	1,455.36	374.58	1,829.95	75.6
42.96	123.86	166.81	1,443.08	404.68	1,847.76	79.2
48.36 69.20	136.84 149.90	185.20 219.10	1,485.33 1,615.48	482.78 528.50	1,968.11 2,143.98	82.8 86.6
76.52 79.89	158.36 167.40	234.87 247.29	1,698.71 1,757.86	558.47 580.52	2,257.18 2,338.38	89.2 91.6
85.70	171.37	257.08	1,840.71	601.71	2,442.42	92.8
86.18	191.18	277.36	1,799.67	644.78	2,444.45	94.1
86.74	195.19	281.92	1,676.53	658.34	2,334.87	95.2
88.33	199.23	287.56	1,566.45	658.82	2,225.27	97.4
94.55	213.76	308.31	1,609.44	665.33	2,274.78	99.0
101.64 108.66	234.91 244.40	336.55 353.05	1,746.27 1,846.54	753.00 777.31	2,499.27 2,623.85	100.0 99.6
126.85	266.85	393.70	2,079.12	859.44	2,938.56	101.4
145.69 166.89	289.82 314.09	435.51 480.99	2,260.58 2,533.75	934.98 1,068.18	3,195.56 3,601.93	105.5 106.9
186.65	336.04	522.69	2,718.01	1,082.58	3,800.59	108.0
209.90	361.04	570.94	2,888.63	1,115.16	4,003.79	111.1
228.52	378.52	607.04	3,109.41	1,206.76	4,316.16	114.1
264.49	401.47	665.96	3,403.10	1,271.70	4,674.81	117.2
289.22	421.97	711.19	3,596.95	1,327.07	4,924.02	119.0
200.22	421.07		nnual percentage change		4,024.02	110.0
17.7	10.2	12.0	8.0	8.3	8.0	2.8
14.3	9.1	10.4	-0.8	8.0	1.0	4.7
12.6	10.5	11.0	2.9	19.3	6.5	4.5
43.1	9.5	18.3	8.8	9.5	8.9	4.6
10.6	5.6	7.2	5.2	5.7	5.3	3.0
4.4 7.3	5.7 2.4	5.3 4.0	3.5 4.7	3.9 3.7	3.6 4.4	2.8 1.3
0.6	11.6	7.9	-2.2	7.2	0.1	1.3
0.6	2.1	1.6	-6.8	2.1	-4.5	1.1
1.8	2.1	2.0	-6.6	0.1	-4.7	2.3
7.0	7.3	7.2	2.7	1.0	2.2	1.7
7.5	9.9	9.2	8.5	13.2	9.9	1.0
6.9 16.7	4.0 9.2	4.9 11.5	5.7 12.6	3.2 10.6	5.0 12.0	-0.4 1.8
14.9	8.6	10.6	8.7	8.8	8.7	4.1
14.6 11.8	8.4 7.0	10.4 8.7	12.1 7.3	14.2 1.3	12.7 5.5	1.4 1.0
12.5	7.4	9.2	6.3	3.0	5.3	2.9
8.9	4.8	6.3	7.6	8.2	7.8	2.7
15.7	6.1	9.7	9.4	5.4	8.3	2.7
9.4	5.1 (annual percenta)	6.8 ge change in excess of	5.7 inflation in the Canadiar	4.4 economy)	5.3	1.6
14.9	7.4	9.2	5.2	5.5	5.2	
9.5	4.3	5.6	-5.6	3.3	-3.8	
8.1 38.5	6.0 5.0	6.5 13.7	-1.6 4.2	14.8 4.9	2.0 4.4	
7.5 1.6	2.6 3.0	4.2 2.5	2.1 0.7	2.6 1.2	2.3 0.8	
6.0	3.0	2.5	3.5	2.4	3.2	
-0.9	10.1	6.5	-3.7	5.7	-1.4	
-0.4	1.0	0.5	-7.9	1.0	-5.6	
-0.5	-0.3	-0.3	-8.9	-2.3	-7.0	
5.4	5.6	5.5	1.1	-0.7	0.6	
6.5	8.9	8.2	7.5	12.2	8.9	
7.3	4.5	5.3	6.2	3.7	5.4	
14.9	7.4	9.7	10.8	8.8	10.2	
10.7	4.5	6.5	4.6	4.7	4.6	
13.2	7.0	9.1	10.7	12.9	11.4	
10.8 9.6	6.0 4.5	7.7 6.3	6.3 3.4	0.3 0.1	4.5 2.5	
6.2	2.1	3.6	4.9	5.5	5.1	
13.1	3.4	7.1	6.8	2.7	5.7	
10.1	5.4	7.1	0.0	2.7	5.7	
7.7	3.5	5.2	4.1	2.7	3.7	

Table B.10.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Secur WCB	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year				Funds		(\$ mil	lions)			Drugs		
1985	128.5	7.8	1.4		137.7			121.1	258.8			157.7
1986	151.4	8.6	1.5		161.5			105.6	267.0			178.5
1987 1988	153.5 169.8	9.2 14.0	1.7 2.0		164.4 185.7			134.9 159.6	299.2 345.3			207.0 219.3
1989	196.5	14.0	2.0		216.7			188.9	405.6			232.3
1990	232.6		2.4		256.3				473.0			
1990	232.6	21.2 24.4	2.4		302.4			216.8 241.1	543.5			248.6 266.2
1992	311.8	26.5	3.1		341.5			268.1	609.5	149.5	134.7	284.2
1993	346.0	32.1	3.5		381.6			303.1	684.7	164.4	146.0	
1994	339.4	35.8	4.0		379.2			323.2	702.5	169.4	156.9	326.3
1995	349.5	40.5	4.2		394.1			353.5	747.6	172.3	163.8	336.0
1996	379.4	44.2	3.9		427.5			374.9	802.4	178.3	166.3	
1997	418.7	45.3	4.0		468.0			412.2	880.2	182.4	172.7	355.0
1998 1999	457.8 515.6	49.5 54.2	5.1 5.9		512.4 575.7			480.0 505.7	992.4 1,081.5	193.5 210.8	185.0 196.7	378.5 407.6
2000	595.4	58.2	6.8		660.4			570.1	1,230.5	222.0	199.6	
2001 2002	659.1 696.7	65.6 76.0	7.4 7.2		732.1 779.9			641.0 759.4	1,373.1 1,539.3	232.1 245.3	209.6 220.3	
2003	698.1	88.0	7.6		793.7			892.7	1,686.4	261.3	225.5	
2004	752.5	92.6	9.0		854.1			1,038.8	1,892.9	277.2	231.6	
2005 f	823.8	108.3	9.8		941.9			1,216.1	2,157.9	282.3	239.4	521.7
2006 f	886.8	126.4	10.6		1,023.7			1,417.7	2,441.4	283.9	245.2	529.2
						(annual percer	ntage change)					
1985												
1986	17.8	9.6	4.7		17.2			-12.8	3.2			13.2
1987	1.4	7.3	15.5		1.8			27.8	12.1			16.0
1988 1989	10.6 15.8	51.5 29.1	16.5 9.0		13.0 16.7			18.4 18.4	15.4 17.5			5.9 5.9
1990	18.3	17.9	14.0		18.2			14.7	16.6			7.1 7.1
1991 1992	18.4 13.2	14.6 9.0	10.1 16.1		18.0 12.9			11.3 11.2	14.9 12.1			6.8
1993	11.0	21.0	11.6		11.7			13.1	12.3	10.0	8.4	
1994	-1.9	11.6	14.1		-0.6			6.6	2.6	3.0	7.4	
1995	3.0	12.9	5.7		3.9			9.4	6.4	1.7	4.4	3.0
1996	8.6	9.1	-6.0		8.5			6.1	7.3	3.5	1.5	
1997	10.3	2.6	2.1		9.5			10.0	9.7	2.3	3.9	
1998	9.4	9.2	25.6		9.5			16.4	12.7	6.1	7.1	6.6
1999	12.6	9.6	17.2		12.4			5.4	9.0	9.0	6.3	7.7
2000	15.5	7.3	15.1		14.7			12.7	13.8	5.3	1.5	
2001	10.7	12.7	8.3		10.9			12.4	11.6	4.6	5.0	
2002 2003	5.7 0.2	15.8 15.8	-3.0 6.4		6.5 1.8			18.5 17.6	12.1 9.6	5.7 6.5	5.1 2.3	5.4 4.6
2003	7.8	5.1	17.9		7.6			17.0	12.2	6.1	2.3	4.0
2005 f	9.5	17.0	8.8		10.3			17.1	14.0	1.8	3.3	
2006 f	7.6	16.7	8.2		8.7			16.6	13.1	0.6	2.4	
2000 1	7.0	1017	0.2			centage share of the			1011	0.0	2.1	
1985	30.9	1.9	0.3		33.1			29.1	62.1			37.9
1986	34.0	1.9	0.3		36.2			23.7	59.9			40.1
1987	30.3	1.8	0.3		32.5			26.6	59.1			40.9
1988 1989	30.1 30.8	2.5 2.8	0.3 0.3		32.9 34.0			28.3 29.6	61.2 63.6			38.8 36.4
1990	32.2	2.9	0.3		35.5			30.0	65.5			34.5
1991 1992	34.0 34.9	3.0 3.0	0.3 0.3		37.3 38.2			29.8 30.0	67.1 68.2	 16.7	 15.1	32.9 31.8
1992	34.9	3.0	0.3		38.3			30.5	68.8	16.5	14.7	
1994	33.0	3.5	0.4		36.9			31.4	68.3	16.5	15.3	
1995	32.2	3.7	0.4		36.4			32.6	69.0	15.9	15.1	31.0
1995	32.2	3.7	0.4		36.4			32.0	70.0	15.5	14.5	30.0
1997	33.9	3.7	0.3		37.9			33.4	71.3	14.8	14.0	
1998	33.4	3.6	0.4		37.4			35.0	72.4	14.1	13.5	27.6
1999	34.6	3.6	0.4		38.7			34.0	72.6	14.2	13.2	27.4
2000	36.0	3.5	0.4		40.0			34.5	74.5	13.4	12.1	25.5
2001	36.3	3.6	0.4		40.3			35.3	75.7	12.8	11.5	24.3
2002	34.8	3.8	0.4		38.9			37.9	76.8	12.2	11.0	
2003 2004	32.1 31.3	4.1 3.9	0.4 0.4		36.5 35.6			41.1 43.3	77.6 78.8	12.0 11.5	10.4 9.6	
2005 f	30.7	4.0	0.4		35.1			45.4	80.5	10.5	8.9	
					04.5			477	00.0			
2006 f f-Forecast	29.9	4.3	0.4		34.5			47.7	82.2	9.6	8.3	17.8

Table B.10.1-Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985 to 2006 (continued)

		All Drugs			th Expenditure			Ith Expenditures	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ns)			(perce	ntage share)	
1985	137.7	278.8	416.5	3,410.1	1,227.1	4,637.3	4.0	22.7	9.0
1986 1987	161.5 164.4	284.1 341.9	445.6 506.3	3,666.0 3,895.3	1,317.2 1,444.9	4,983.3 5,340.3	4.4 4.2	21.6 23.7	8.9 9.5
1988	185.7	378.9	564.6	4,241.2	1,597.1	5,838.3	4.4	23.7	9.7
1989	216.7	421.2	637.9	4,736.0	1,773.0	6,509.0	4.6	23.8	9.8
1990	256.3	465.4	721.7	5,386.7	1,986.0	7,372.6	4.8	23.4	9.8
1991 1992	302.4 341.5	507.3 552.2	809.7 893.7	5,967.2 6,477.9	2,159.5 2,291.2	8,126.7 8,769.1	5.1 5.3	23.5 24.1	10.0 10.2
1993	381.6	613.5	995.1	6,869.8	2,427.0	9,296.8	5.6	25.3	10.2
1994	379.2	649.5	1,028.7	7,237.5	2,519.1	9,756.5	5.2	25.8	10.5
1995	394.1	689.5	1,083.6	7,538.4	2,560.6	10,099.0	5.2	26.9	10.7
1996	427.5	719.4	1,146.9	7,688.7	2,675.5	10,364.2	5.6	26.9	11.1
1997 1998	468.0 512.4	767.3 858.6	1,235.2 1,370.9	7,942.6 8,304.5	2,875.2 3,089.7	10,817.8 11,394.2	5.9 6.2	26.7 27.8	11.4 12.0
1999	575.7	913.3	1,489.0	8,969.4	3,289.7	12,259.1	6.4	27.8	12.1
2000	660.4	991.7	1,652.1	9,825.9	3,519.7	13,345.6	6.7	28.2	12.4
2001	732.1	1,082.7	1,814.8	10,820.5	3,824.5	14,644.9	6.8	28.3	12.4
2002 2003	779.9 793.7	1,225.0 1,379.5	2,004.9 2,173.2	11,478.0 11,956.0	4,160.6 4,446.1	15,638.6 16,402.1	6.8 6.6	29.4 31.0	12.8 13.2
2003	854.1	1,547.6	2,401.7	12,269.3	4,896.1	17,165.4	7.0	31.6	13.2
2005 f	941.9	1,737.8	2,679.6	12,919.1	5,286.1	18,205.1	7.3	32.9	14.7
2006 f	1,023.7	1,946.9	2,970.6	13,586.1	5,646.2	19,232.4	7.5	34.5	15.4
_			(annual percenta						
1985 1986	 17.2	 1.9	 7.0	 7.5	7.3	7.5			
1987	1.8	20.3	13.6	6.3	9.7	7.2			
1988	13.0	10.8	11.5	8.9	10.5	9.3			
1989	16.7	11.2	13.0	11.7	11.0	11.5			
1990	18.2	10.5	13.1	13.7	12.0	13.3			
1991 1992	18.0	9.0	12.2	10.8 8.6	8.7	10.2 7.9			
1992	12.9 11.7	8.9 11.1	10.4 11.3	6.0	6.1 5.9	6.0			
1994	-0.6	5.9	3.4	5.4	3.8	4.9			
1995	3.9	6.2	5.3	4.2	1.6	3.5			
1996	8.5	4.3	5.8	2.0	4.5	2.6			
1997	9.5	6.7	7.7	3.3	7.5 7.5	4.4			
1998 1999	9.5 12.4	11.9 6.4	11.0 8.6	4.6 8.0	6.5	5.3 7.6			
2000	14.7	8.6	10.9	9.5	7.0	8.9			
2001	10.9	9.2	9.8	10.1	8.7	9.7			
2002	6.5	13.1	10.5	6.1	8.8	6.8			
2003 2004	1.8 7.6	12.6 12.2	8.4 10.5	4.2 2.6	6.9 10.1	4.9 4.7			
2005 f	10.3	12.3	11.6	5.3	8.0	6.1			
2006 f	8.7	12.0	10.9	5.2	6.8	5.6			
_	(percentage s	share of total drug	expenditure)	_					
1985	33.1	66.9	100.0						
1986 1987	36.2 32.5	63.8 67.5	100.0 100.0						
1988	32.9	67.1	100.0						
1989	34.0	66.0	100.0						
1990	35.5	64.5	100.0						
1991	37.3	62.7	100.0						
1992 1993	38.2 38.3	61.8 61.7	100.0 100.0						
1993	36.9	63.1	100.0						
1995	36.4	63.6	100.0						
1996	37.3	62.7	100.0						
1997	37.9	62.1	100.0						
1998 1999	37.4 38.7	62.6 61.3	100.0 100.0						
2000	40.0	60.0	100.0						
2000	40.0	60.0 59.7	100.0						
2002	38.9	61.1	100.0						
2003	36.5	63.5	100.0						
2004	35.6	64.4	100.0						
2005 f	35.1	64.9	100.0						
2006 f	34.5	65.5	100.0						

Table B.10.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2006

			Public		Prescribe	d Drugs	Private				Prescribed D te (Out-of-Po	
	Provincial	Federal _	Social Securit WCB	Drug nsurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
ar				Funds		(\$ per (capita)			Drugs		
85	43.21	2.63	0.47		46.31			40.72	87.03			53.01
86	50.41	2.86	0.49		53.75			35.14	88.89			59.43
87 88	50.32 54.50	3.02 4.48	0.55 0.63		53.89 59.62			44.21 51.23	98.11 110.85			67.88 70.39
89	61.46	5.64	0.67		67.77			59.07	126.84			72.63
90	70.67	6.46	0.74		77.87			65.87	143.74			75.56
91	81.63	7.22	0.79		89.64			71.48	161.12			78.90
92	89.90	7.65	0.90		98.45			77.29	175.73	43.10	38.83	81.93
93	96.98	9.01	0.97		106.96			84.97	191.93	46.07	40.93	87.01
94	92.34	9.75	1.08		103.18			87.94	191.11	46.08	42.69	88.76
95	92.52	10.72	1.11		104.35			93.59	197.94	45.61	43.36	88.96
96	97.94	11.40	1.02		110.35			96.76	207.12	46.01	42.91	88.92
97 98	106.03 114.95	11.47 12.42	1.02 1.27		118.52 128.63			104.40 120.51	222.92 249.15	46.18 48.58	43.73 46.45	89.92 95.04
99	128.53	13.52	1.48		143.52			120.51	269.60	52.56	40.45	101.61
00 01	147.40 161.60	14.41 16.09	1.69 1.81		163.50 179.50			141.14 157.17	304.64 336.66	54.95 56.92	49.42 51.39	104.37 108.30
02	169.30	18.47	1.74		189.50			184.53	374.03	59.60	53.53	113.14
03	168.02	21.19	1.83		191.04			214.87	405.91	62.90	54.27	117.17
04	179.09	22.03	2.14		203.26			247.22	450.48	65.97	55.13	121.10
05 f	193.63	25.45	2.30		221.38			285.83	507.21	66.35	56.27	122.62
06 f	206.09	29.37	2.46		237.92			329.48	567.39	65.99	56.99	122.98
						(annual percer	itage change)					
85												
86	16.7	8.5	3.7		16.1			-13.7	2.1			12.1
87	-0.2	5.7	13.7		0.3			25.8	10.4			14.2
88	8.3	48.3 25.7	14.1 6.2		10.6 13.7			15.9 15.3	13.0			3.7 3.2
69	12.8	25.7	0.2		13.7			15.3	14.4			3.2
90	15.0	14.5	10.8		14.9			11.5	13.3			4.0
91 92	15.5	11.8	7.4 12.9		15.1			8.5	12.1			4.4 3.8
92	10.1 7.9	6.0 17.7	8.5		9.8 8.6			8.1 9.9	9.1 9.2	6.9	5.4	3.8 6.2
94	-4.8	8.3	10.7		-3.5			3.5	-0.4	0.0	4.3	2.0
95	0.2	9.9	2.8		1.1			6.4	3.6	-1.0	1.6	0.2
96	5.9	6.4	-8.4		5.8			3.4	4.6	0.9	-1.0	0.0
97	8.3	0.6	0.2		7.4			7.9	7.6	0.4	1.9	1.1
98 99	8.4 11.8	8.2 8.9	24.5 16.4		8.5 11.6			15.4 4.6	11.8 8.2	5.2 8.2	6.2 5.6	5.7 6.9
00	14.7	6.6	14.3		13.9			11.9	13.0	4.5	0.8	2.7
01	9.6	11.6	7.3		9.8			11.4	10.5	3.6	4.0	3.8
02 03	4.8	14.8	-3.9		5.6			17.4	11.1	4.7	4.2	4.5 3.6
03	-0.8 6.6	14.7 4.0	5.3 16.6		0.8 6.4			16.4 15.1	8.5 11.0	5.5 4.9	1.4 1.6	3.6
05 f	8.1	15.5	7.4		8.9			15.6	12.6	0.6	2.1	1.3
06 f	6.4	15.4	7.0		7.5			15.3	11.9	-0.5	1.3	0.3
05					annual percentage	-						
85 86	 13.9	 5.7	0.9		 13.3			 -16.5				 9.3
87	-4.9	1.0	9.0		-4.5			21.1	5.6			9.5
88	3.8	43.8	9.6		6.1			11.4	8.5			-0.8
89	8.2	21.2	1.6		9.1			10.7	9.9			-1.4
90	12.0	11.5	7.8		11.9			8.5	10.3			1.0
91	12.7	9.0	4.6		12.4			5.8	9.3			1.7
92	8.9	4.8	11.6		8.6			6.9	7.8			2.6
93	6.4	16.3	7.0		7.2			8.5	7.8	5.5	4.0	
94	-5.9	7.2	9.6		-4.6			2.4	-1.5	-1.1	3.2	0.9
95	-2.1	7.6	0.5		-1.2			4.1	1.2	-3.4	-0.8	
96	4.2	4.7	-10.1		4.1			1.7	3.0	-0.8	-2.7	-1.7
97 98	7.3 8.8	-0.4 8.7	-0.8 25.0		6.4 9.0			6.9 15.9	6.6 12.2	-0.6 5.6	0.9 6.7	0.1 6.1
99	10.0	7.1	14.6		9.8			2.8	6.4	6.4	3.8	5.1
00			10.2		9.8				8.9	0.4		
00	10.6 8.3	2.5 10.3	10.2 5.9		9.8 8.4			7.8 10.0	8.9 9.2	0.4	-3.3 2.6	-1.4 2.4
02	3.8	13.8	-4.9		4.6			16.4	10.1	3.7	3.2	
03	-3.6	11.9	2.5		-2.1			13.6	5.6	2.6	-1.5	0.7
04	3.9	1.3	13.9		3.7			12.4	8.3	2.2	-1.1	0.7
05 f	5.5	12.9	4.8		6.3			13.0	9.9	-2.1	-0.6	-1.4
	4.8	13.8	5.4		5.9			13.7	10.3	-2.2	-0.3	-1.3
06 f												
06 f Forecast												

Table B.10.2–Part 2

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2006 (continued)

_	Public	All Drugs	Total	Dublia	Health Expenditure	Total	Price Index – Canada
	Public	Private	Total	Public	Private	Total	
			<i>(</i> 1				(4007 400)
			(\$ per ca				(1997 = 100)
	46.31 53.75	93.73 94.57	140.04 148.32	1,146.55 1,220.34		1,559.13 1,658.82	73.6 75.6
	53.89	112.09	165.99	1,277.10		1,750.82	79.2
	59.62	121.62	181.24	1,361.3		1,874.03	82.8
	67.77	131.70	199.47	1,480.99	554.42	2,035.41	86.6
	77.87	141.42	219.29	1,636.89		2,240.37	89.2
	89.64	150.38	240.03	1,768.8		2,409.00	91.6
	98.45 106.96	159.22 171.97	257.66 278.93	1,867.66 1,925.7		2,528.24 2,606.03	92.8 94.1
	103.18	176.70	279.88	1,969.00		2,654.34	95.2
	104.35	182.55	286.90	1,995.86	6 677.94	2,673.80	97.4
	110.35	185.69	296.04	1,984.50		2,675.13	99.0
	118.52	194.32	312.84	2,011.53	3 728.17	2,739.70	100.0
	128.63	215.55	344.18	2,084.9		2,860.64	99.6
	143.52	227.68	371.21	2,236.02	2 820.10	3,056.12	101.4
	163.50	245.51	409.01	2,432.62		3,304.02	105.5
	179.50 189.50	265.47 297.66	444.97 487.16	2,653.08 2,789.04		3,590.81 3,800.01	106.9 108.0
	191.04	332.04	523.08	2,877.78		3,947.94	111.1
	203.26	368.32	571.58	2,919.9		4,085.19	114.1
	221.38	408.46	629.83	3,036.55	5 1,242.46	4,279.01	117.2
	237.92	452.46	690.37	3,157.44	4 1,312.20	4,469.63	119.0
				nnual percentage ch			
	 16.1	 0.9	5.9	6.4	4 6.3	6.4	 2.8
	0.3	18.5	11.9	4.	7 8.0	5.5	4.7
	10.6	8.5	9.2	6.0	8.2	7.0	4.5
	13.7	8.3	10.1	8.8	8 8.1	8.6	4.6
	14.9	7.4	9.9	10.		10.1	3.0
	15.1	6.3	9.5	8.		7.5	2.8
	9.8 8.6	5.9 8.0	7.3 8.3	5.0		4.9 3.1	1.3 1.4
	-3.5	2.8	0.3	2.3		1.9	1.1
	1.1	3.3	2.5	1.4	4 -1.1	0.7	2.3
	5.8	1.7	3.2	-0.0		0.0	1.7
	7.4	4.6	5.7	1.4	4 5.4	2.4	1.0
	8.5	10.9	10.0	3.		4.4	-0.4
	11.6	5.6	7.9	7.:		6.8	1.8
	13.9	7.8	10.2	8.		8.1	4.1
	9.8 5.6	8.1 12.1	8.8 9.5	9. 5.		8.7 5.8	1.4 1.0
	0.8	12.1	9.5 7.4	3.3		3.9	2.9
	6.4	10.9	9.3	1.		3.5	2.7
	8.9	10.9	10.2	4.0		4.7	2.7
	7.5	10.8 (annual percentag	9.6 ge change in excess of	4.0 Inflation in the Cana		4.5	1.6
	 13.3	 -1.9	 3.1	 3.1	 6 3.5	 3.6	
	-4.5	-1.9	3.1	-0.1		3.6 0.8	
	6.1	4.0	4.7	2.	1 3.7	2.5	
	9.1	3.7	5.5	4.:		4.0	
	11.9	4.4	6.9	7.	5 5.8	7.0	
	12.4	3.6	6.7	5.	3 3.3	4.8	
	8.6	4.6	6.1	4.		3.7	
	7.2 -4.6	6.6 1.7	6.8 -0.8	1. 1.:		1.6 0.8	
	-1.2	1.0	0.2	-1.0		-1.6	
	4.1 6.4	0.0 3.7	1.5 4.7	-2.: 0.4		-1.6 1.4	
	9.0	11.4	10.5	4.		4.9	
	9.8	3.8	6.0	5.4		5.0	
	9.8	3.7	6.1	4.	7 2.2	4.0	
	8.4	6.8	7.4	7.	7 6.3	7.3	
	4.6	11.1	8.5	4.		4.8	
	-2.1 3.7	8.7 8.2	4.5 6.6	0. -1.		1.0 0.8	
	6.3 5.9	8.2 9.2	7.5 8.0	1.: 2.:		2.1 2.9	
	5.9	9.2	0.0	2.	- 4.0	2.9	

Table B.11.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2006

-			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
-	Territorial	Federal _	Social Secu WCB	urity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
-						(\$ mil	lions)			•		
	0.2 0.3	0.3 0.3	0.0 0.0		0.5 0.7			1.3 1.2	1.8 1.9			1.3 1.3
	0.7	0.4	0.0		1.1			1.2	2.3			1.2
	1.0	0.6	0.0 0.0		1.7 2.1			1.0 1.0	2.7			1.1
	1.2	0.8							3.1			1.1
	1.3 1.6	1.0 1.2	0.0 0.0		2.3 2.8			1.0 1.2	3.3 4.0			1.0 1.3
	2.0	1.3	0.0		3.4			1.2	4.5	1.2	1.1	2.3
	2.3	1.5	0.0		3.8			2.3	6.1	1.3	1.1	2.4
	2.1	1.7	0.0		3.8			1.6	5.4	1.3	1.1	2.4
	1.5 1.5	1.8 1.9	0.0 0.0		3.4 3.4			1.7 2.2	5.1 5.6	1.3 1.6	1.2 1.5	2.5 3.0
	1.9	2.0	0.0		4.0			3.4	7.4	1.6	1.5	3.1
	2.2	2.1	0.0		4.4			2.9	7.3	1.7	1.6	3.3
	2.7	3.1	0.0		5.8			3.0	8.8	1.8	1.7	3.5
	3.3	3.0	0.1		6.4			3.2	9.6	1.8	2.1	3.8
	3.9 4.5	3.0 3.2	0.1 0.1		7.0 7.8			3.6 3.9	10.5 11.7	1.9 1.9	2.1 2.1	3.9 4.0
	5.1	3.7	0.1		8.9			4.8	13.7	2.1	1.8	3.9
	5.9	3.8	0.1		9.8			4.9	14.7	2.3	2.0	4.2
	6.2	3.9	0.2		10.3			5.2	15.5	2.4	2.0	4.4
	6.1	4.4	0.2		10.7			5.4	16.1	2.2	2.2	4.4
						(annual percer	tage change)					
-												
	53.7	10.9	-18.3		27.7			-6.2	3.5			-5.0
	126.4	6.7	32.5		65.5			-2.6	21.4			-1.6
	41.8 15.4	72.7 37.4	32.5 -42.2		51.6 23.0			-13.2 -0.3	18.0 14.1			-12.6 0.2
	5.9	17.1	98.0		10.8			-6.5	5.1			-6.2
	26.2	16.5	-54.9		21.5			-0.5	22.5			-0.2
	23.5	15.7	303.9		21.0			-4.1	13.4			77.9
	13.2 -8.4	14.3 10.1	-9.1 -3.4		13.5 -1.0			95.5 -29.3	34.5 -11.5	6.7 -1.9	2.4 -0.1	4.7 -1.1
	-26.3 -2.3	9.1 3.8	40.5 3.9		-10.1 1.1			8.0 27.6	-4.7 10.0	2.4 19.5	13.0 20.2	7.2 19.8
	26.0	7.0	4.8		15.2			55.4	31.0	3.1	3.9	3.5
	17.8	4.0	-10.8		10.4			-15.6	-1.7	3.3	4.6	3.9
	21.9	44.5	28.0		32.9			4.6	21.6	7.8	4.7	6.3
	21.4	-0.9	15.1		9.6			6.1	8.4	-1.1	22.3	10.2
	17.7 17.6	0.4 4.2	59.6 10.3		9.8 11.7			10.7 10.8	10.1 11.4	6.3 3.5	0.3 1.7	3.0 2.5
	12.1	17.9	15.7		14.5			20.7	16.6	6.2	-11.9	-3.2
	15.0	1.7	26.8		9.6			3.2	7.4	8.7	6.1	7.5
	6.2	3.8	26.8		5.6			5.8	5.6	5.0	2.0	3.6
	-2.2	12.7	13.5		3.7			4.4	3.9	-6.6	7.8	0.0
						centage share of t	otal drug expe					
-	6.7	9.5	0.3		16.6			41.3	57.8			42.2
	10.3	10.6	0.3		21.2			38.8	59.9			40.1
	20.9 27.6	10.0 16.2	0.3 0.4		31.2 44.1			33.6 27.2	64.9 71.4			35.1 28.6
	28.9	20.2	0.4		49.3			24.6	73.9			26.1
	30.0	23.1	0.4		53.5			22.6	76.1			23.9
	30.7	21.9	0.1		52.7			22.9	75.7			24.3
	29.4	19.6	0.4		49.4			17.0	66.5	17.9	15.6	33.5
	26.7 26.8	18.0 21.7	0.3 0.3		45.1 48.8			26.7 20.7	71.8 69.5	15.4 16.5	12.8 14.0	28.2 30.5
	20.0 17.2	23.9 21.9	0.5 0.4		44.3 39.6			22.6 25.4	66.9 65.0	17.1 18.0	16.0 17.0	33.1 35.0
	17.9	19.3	0.4		37.6			32.6	70.1	15.3	14.6	29.9
	21.1	20.1	0.3		41.5			27.5	69.0	15.8	15.2	31.0
	22.0	24.8	0.4		47.2			24.6	71.8	14.6	13.6	28.2
	24.5	22.6	0.4		47.5			24.0	71.5	13.2	15.3	28.5
	26.7 28.8	21.0 20.1	0.6 0.6		48.2 49.4			24.6 25.0	72.8 74.4	13.0 12.3	14.2 13.3	27.2 25.6
	28.8	20.1	0.6		49.4 50.7			25.0	74.4	12.3	10.5	25.6
	31.0	20.1	0.7		51.8			26.0	77.8	11.9	10.3	22.2
	31.3	19.8	0.8		52.0			26.1	78.1	11.9	10.0	21.9
	29.7	21.7	0.9		52.3			26.5	78.7	10.8	10.5	21.3
st	29.7 iality precludes r				52.3			26.5	78.7	10.8		21.3 ce: CIHI, 2006.

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2006 (continued) , Share of Drugs in Public, Private and Health Expenditure Total Health Expenditures All Drugs Public Private Total Public Private Total Public Private Total Year (\$ millions) (percentage share) 1985 32.9 39.7 38.9 0.5 2.6 3.2 6.8 1.6 8.0 2.5 2.4 7.4 7.9 1986 0.7 3.2 37.0 5.6 42.6 1.8 44.4 43.3 1987 3.5 39.1 5.6 44.7 2.8 1.1 2.1 45.8 8.3 1988 1.7 3.8 40.6 5.2 4.1 40.8 1989 2.1 2.1 4.2 44.2 5.3 49.5 4.7 40.3 8.5 1990 2.3 2.0 4.3 48.5 5.0 53.6 4.7 39.6 8.0 1991 28 25 5.3 56 5 61 62.6 49 41 0 84 60.6 67.5 5.6 49.7 10.1 3.4 1992 3.4 6.8 6.9 1993 3.8 4.7 8.5 69.0 10.6 79.6 5.5 44.1 10.6 1994 3.8 4.0 7.7 83.3 9.9 93.2 4.5 40.2 8.3 4.3 4.0 8.1 1995 3.4 7.7 84.4 10.5 94.8 40.8 1996 3.4 5.2 8.7 91.3 109.4 3.8 28.9 7.9 18.1 4.0 6.6 85.4 102.6 4.6 10.3 1997 10.5 17.2 38.3 1998 4.4 6.2 10.5 87.3 16.2 103.6 5.0 38.0 10.2 1999 5.8 6.5 12.3 91.8 16.8 108.5 6.3 38.8 11.3 2000 6.4 7.0 13.4 98.9 24.7 123.5 6.4 28.6 10.8 7.0 7.5 27.4 6.0 2001 14.5 115.9 27.4 143.3 10.1 2002 7.8 8.0 15.8 123.0 33.1 156.1 6.3 24.1 10.1 7.2 7.4 2003 8.9 8.7 17.6 124.5 32.1 156.6 27.0 11.2 2004 9.8 9.1 18.9 133.1 35.4 168.6 25.7 11.2 2005 f 10.3 9.6 19.9 161.5 39.2 200.6 6.4 24.4 9.9 22.9 99 2006 f 10.7 9.8 20.5 164 7 427 207 4 65 (annual percentage change) 1985 1986 27.7 -5.6 -0.1 12.3 -17.3 7.2 1987 65.5 -2.1 12.2 5.8 0.4 5.1 1988 51.6 -12.9 7.3 3.8 -7.5 2.3 1989 23.0 -0.1 10.1 9.1 1.2 8.2 1990 10.8 -6.3 2.1 9.7 -4.8 8.2 21.5 21.0 1991 25.1 23.2 16.4 20.9 16.8 38.2 7.2 14.1 1992 29.1 7.9 1993 13.5 35.3 24.5 14.0 52.5 17.9 1994 -1.0 -14.8 -8.6 20.7 -6.7 17.0 7.6 1.3 6.1 1995 -10.1 -1.1 1.8 1996 1.1 23.0 13.3 8.2 73.4 15.4 1997 15.2 25.4 21.4 -6.4 -5.3 -6.2 1998 10.4 -6.3 0.0 2.2 -5.4 0.9 5.5 32.9 16.9 5.1 3.2 1999 4.8 7.7 17.3 2000 9.6 8.3 8.9 47.2 13.8 11.0 2001 9.8 6.6 8.1 16.0 2002 11.7 6.5 9.0 6.1 20.9 8.9 2003 14.5 8.6 11.5 1.2 -2.9 0.3 2004 7.4 10.3 7.7 9.6 5.1 7.0 4.8 2005 f 5.6 5.2 21.3 10.5 19.0 2006 f 3.7 2.4 3.1 2.0 8.9 3.4 (percentage share of total drug expenditure) 1985 83.4 100.0 16.6 986 21.2 78.8 100.0 1987 31.2 68.8 100.0 44.1 55.9 100.0 1988 1989 49.3 50.7 100.0 1990 53.5 46.5 100.0 1991 52.7 47.3 100.0 1992 49.4 50.6 100.0 45.1 54.9 100.0 1993 1994 48.8 51.2 100.0 1995 44.3 55.7 100.0 1996 39.6 60.4 100.0 1997 37.6 62.4 100.0 1998 41.5 58.5 100.0 47.2 1999 52.8 100.0 47.5 2000 52.5 100.0 2001 48.2 51.8 100.0 49.4 50.6 100.0 2002 2003 50.7 49.3 100.0 2004 51.8 48.2 100.0 2005 f 52.0 48.0 100.0 2006 f 52.3 47.7 100.0

Table B.11.1–Part 2

f-Forecast

Table B.11.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2006

			Public		Prescribe	d Drugs	Private				Prescribed D e (Out-of-Po	
	Territorial	Federal _	Social Secu WCB	urity Funds Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
				Funds					Drugs	Drugs	Supplies	Drugs
Year						(\$ per						
1985 1986	8.73 13.36	12.38 13.65	0.40 0.33		21.51 27.34			53.66 50.07	75.17 77.41			54.79 51.78
1987	28.81	13.87	0.41		43.10			46.44	89.54			48.51
1988	39.46	23.14	0.53		63.12			38.94	102.06			40.97
1989	44.68	31.20	0.30		76.17			38.08	114.25			40.28
1990	46.19	35.65	0.58		82.41			34.77	117.18			36.89
1991 1992	56.02 66.44	39.91 44.31	0.25 0.97		96.18 111.72			41.78 38.47	137.95 150.19	40.52	 35.28	44.38 75.80
1993	74.64	50.24	0.87		125.74			74.59	200.34	40.32	35.83	78.72
1994	69.86	56.56	0.86		127.28			53.92	181.20	43.00	36.58	79.59
1995	50.23	60.17	1.18		111.59			56.82	168.41	42.94	40.31	83.25
1996	47.63	60.58	1.19		109.40			70.33	179.73	49.79	47.00	96.79
1997 1998	59.26 71.27	63.97 67.89	1.23 1.12		124.46 140.28			107.92 93.02	232.38	50.68 53.43	48.20 51.46	98.89 104.89
1998	87.87	99.30	1.12		188.62			93.02	233.30 287.07	58.26	51.46	104.89
2000 2001	107.91 128.25	99.59 100.91	1.69 2.73		209.19 231.89			105.64 118.12	314.83 350.02	58.29 62.54	67.49 68.33	125.78 130.87
2002	150.84	105.08	3.01		258.93			130.84	389.76	64.69	69.46	134.15
2003	166.66	122.13	3.43		292.22			155.60	447.82	67.72	60.30	128.03
2004	189.91	123.07	4.31		317.29			159.17	476.46	72.93	63.40	136.33
2005 f	200.87	127.25	5.44		333.56			167.65	501.21	76.26	64.36	140.62
2006 f	195.70	142.85	6.16		344.70			174.41	519.11	70.98	69.16	140.15
						(annual percer	tago chango)					
1005												
1985 1986	 52.9	 10.3	 -18.7		27.1			 -6.7	3.0			 -5.5
1987	115.7	1.6	26.2		57.6			-7.2	15.7			-6.3
1988	36.9	66.8	28.0		46.5			-16.2	14.0			-15.5
1989	13.2	34.8	-43.3		20.7			-2.2	12.0			-1.7
1990	3.4	14.3	93.3		8.2			-8.7	2.6			-8.4
1991	21.3	11.9	-56.6		16.7			20.1	17.7			20.3
1992 1993	18.6 12.3	11.0 13.4	287.7 -9.8		16.2 12.6			-7.9 93.9	8.9 33.4	 5.8	 1.6	70.8 3.9
1994	-6.4	12.6	-1.2		1.2			-27.7	-9.6	0.3	2.1	1.1
1995	-28.1	6.4	37.1		-12.3			5.4	-7.1	-0.1	10.2	4.6
1996	-5.2	0.7	0.8		-2.0			23.8	6.7	16.0	16.6	16.3
1997	24.4	5.6	3.5		13.8			53.5	29.3	1.8	2.6	2.2
1998 1999	20.3 23.3	6.1 46.3	-9.0 29.5		12.7 34.5			-13.8 5.8	0.4 23.0	5.4 9.0	6.7 6.0	6.1 7.5
2000 2001	22.8	0.3	16.5 61.1		10.9			7.3	9.7	0.1 7.3	23.8	11.5
2001 2002	18.9 17.6	1.3 4.1	10.3		10.9 11.7			11.8 10.8	11.2 11.4	3.4	1.2 1.7	4.0 2.5
2002	10.5	16.2	14.1		12.9			18.9	14.9	4.7	-13.2	-4.6
2004	14.0	0.8	25.6		8.6			2.3	6.4	7.7	5.1	6.5
2005 f	5.8	3.4	26.2		5.1			5.3	5.2	4.6	1.5	3.2
2006 f	-2.6	12.3	13.1		3.3			4.0	3.6	-6.9	7.5	-0.3
20001	-2.0	12.5	13.1		annual percentage					-0.5	7.5	-0.5
1985												
1986	50.1	7.5	-21.5		24.3			-9.5	0.2			-8.3
1987	110.9	-3.2	21.5		52.9			-12.0	10.9			-11.1
1988	32.4	62.3	23.5		41.9			-20.7	9.5			-20.1
1989	8.7	30.3	-47.9		16.1			-6.8	7.4			-6.2
1990	0.4	11.2	90.3		5.2			-11.7	-0.5			-11.4
1991 1992	18.5 17.3	9.2 9.8	-59.4 286.5		13.9 14.9			17.4 -9.2	15.0 7.6			17.5 69.5
1992	17.3	9.8 11.9	-11.3		14.9			-9.2 92.5	31.9	4.4	0.1	2.4
1994	-7.5	11.5	-2.3		0.1			-28.8	-10.7	-0.8	1.0	0.0
1995	-30.4	4.1	34.7		-14.7			3.0	-9.4	-2.5	7.9	2.3
1996	-6.9	-1.0	-0.9		-3.6			22.1	5.1	14.3	14.9	14.6
1997	23.4	4.6	2.5		12.8			52.5	28.3	0.8	1.6	1.2
1998 1999	20.7 21.5	6.6 44.4	-8.5 27.7		13.2 32.7			-13.4 4.0	0.8 21.2	5.9 7.2	7.2 4.2	6.5 5.7
2000 2001	18.7 17.5	-3.8 0.0	12.4 59.8		6.8 9.5			3.2	5.6 9.8	-4.0 5.9	19.7 -0.1	7.4
2001 2002	17.5 16.6	3.1	59.8 9.3		9.5 10.7			10.5 9.8	9.8 10.4	2.4	-0.1	2.7
2003	7.6	13.3	11.2		10.0			16.0	12.0	1.8	-16.1	-7.5
2004	11.3	-1.9	22.9		5.9			-0.4	3.7	5.0	2.4	3.8
2005 f	3.1	0.7	23.6		2.5			2.7	2.5	1.9	-1.1	0.5
	-4.2	10.7	11.5		1.7			2.4	2.0	-8.5	5.8	-1.9
2006 f												
f-Forecast	ntiality precludes r											ce: CIHI, 2006.

Table B.11.2—Part 2

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Yukon Territory, 1985 to 2006 (continued)

_		All Drugs			lealth Expenditure		Price Index – Canad
	Public	Private	Total	Public	Private	Total	
r _			(\$ per ca	pita)			(1997 = 100)
	21.51	108.45	129.96	1,351.18	278.89	1,630.07	73.6
6 7	27.34	101.85	129.19	1,510.29	229.51	1,739.80	75.6
	43.10	94.95 79.90	138.05	1,521.49	219.52 196.03	1,741.02	79.2 82.8
	63.12 76.17	79.90	143.03 154.53	1,524.93 1,632.10	194.61	1,720.95 1,826.71	86.6
	82.41	71.66	154.07	1,747.95	180.81	1,928.76	89.2
1 2	96.18 111.72	86.16 114.27	182.33 225.99	1,954.71 2,011.98	210.04 230.03	2,164.74 2,242.01	91.6 92.8
-	125.74	153.32	279.06	2,274.52	347.90	2,622.42	94.1
L .	127.28	133.51	260.79	2,805.59	331.74	3,137.33	95.2
	111.59	140.07	251.66	2,771.86	343.47	3,115.33	97.4
	109.40	167.12	276.53	2,908.40	577.74	3,486.13	99.0
	124.46	206.81	331.27	2,687.26	540.01	3,227.27	100.0
В	140.28	197.90	338.19	2,804.53	521.26	3,325.80	99.6
Ð	188.62	211.24	399.87	2,981.92	544.45	3,526.37	101.4
	209.19	231.42	440.61	3,250.61	810.58	4,061.19	105.5
1	231.89	248.99	480.89	3,848.40	908.18	4,756.58	106.9
2	258.93	264.99	523.92	4,082.75	1,097.93	5,180.68	108.0
3	292.22	283.62	575.84	4,070.34	1,050.94	5,121.29	111.1
4	317.29	295.50	612.79	4,315.10	1,148.67	5,463.77	114.1
f	333.56	308.27	641.84	5,210.54	1,264.12	6,474.66	117.2
f	344.70	314.56	659.26	5,297.07	1,371.60	6,668.67	119.0
-			(a	nnual percentage chan	ge) 		
	27.1	-6.1	-0.6	11.8	-17.7	6.7	2.8
	57.6	-6.8	6.9	0.7	-4.4	0.1	4.7
B 9	46.5	-15.8	3.6	0.2	-10.7	-1.2	4.5
	20.7	-1.9	8.0	7.0	-0.7	6.1	4.6
)	8.2	-8.5	-0.3	7.1	-7.1	5.6	3.0
2	16.7	20.2	18.3	11.8	16.2	12.2	2.8
	16.2	32.6	23.9	2.9	9.5	3.6	1.3
	12.6 1.2	34.2 -12.9	23.5 -6.5	13.0 23.3	51.2 -4.6	17.0 19.6	1.4 1.1
5	-12.3	4.9	-3.5	-1.2	3.5	-0.7	2.3
6 7	-2.0 13.8	19.3 23.7	9.9 19.8	4.9 -7.6	68.2 -6.5	11.9 -7.4	1.7 1.0
	13.8	-4.3	2.1	-7.6	-6.5 -3.5	-7.4 3.1	-0.4
	34.5	6.7	18.2	6.3	4.4	6.0	1.8
	10.9	9.6	10.2	9.0	48.9	15.2	4.1
	10.9	9.6 7.6	9.1	18.4	48.9	15.2	4.1
	11.7	6.4	8.9	6.1	20.9	8.9	1.0
3	12.9	7.0	9.9	-0.3	-4.3	-1.1	2.9
	8.6	4.2	6.4	6.0	9.3	6.7	2.7
f	5.1	4.3	4.7	20.8	10.1	18.5	2.7
6 f							
	3.3	2.0 (annual percenta)	2.7 ge change in excess of	1.7 inflation in the Canadi	8.5	3.0	1.6
_							
	24.3	-8.9	-3.4	9.0	-20.5	3.9	
	52.9	-11.5	2.1	-4.0	-9.1	-4.7	
	41.9 16.1	-20.4 -6.5	-0.9	-4.3	-15.2 -5.3	-5.7	
			3.5	2.5		1.6	
	5.2	-11.6	-3.3	4.1	-10.1	2.6	
	13.9	17.5	15.6	9.1	13.4	9.5	
2	14.9 11.1	31.4 32.7	22.7 22.0	1.7 11.6	8.3 49.8	2.3 15.5	
	0.1	-14.0	-7.6	22.3	-5.7	18.5	
	-14.7	2.6	-5.8	-3.5	1.2	-3.0	
	-3.6 12.8	17.6 22.8	8.2 18.8	3.3 -8.6	66.5 -7.5	10.2 -8.4	
7 3	13.2	-3.9	2.5	-8.6	-7.5 -3.0	-8.4 3.5	
)	32.7	4.9	16.4	4.5	2.6	4.2	
)	6.8	5.4	6.1	4.9	44.8	11.1	
,	9.5	6.2	7.8	4.9	44.8	15.8	
2	10.7	5.4	7.9	5.1	19.9	7.9	
3	10.0	4.1	7.0	-3.2	-7.2	-4.0	
	5.9	1.5	3.7	3.3	6.6	4.0	
5 f	2.5	1.7	2.1	18.1	7.4	15.8	
6 f							
	1.7	0.4	1.1	0.1	6.9	1.4	

Table B.12.1-Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2006

-			Public		Prescribe		Private				Prescribed D te (Out-of-Po	
-	Territorial	Federal _	Social Secu WCB	urity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Presc. Drugs
-						(\$ mil	lions)					
	1.1 1.4	2.4 2.7	0.0 0.0		3.5 4.1			2.3 2.7	5.8 6.8			4.1 4.4
	1.7	3.0	0.0		4.7			3.0	7.7			4.7
	1.9	3.2	0.0		5.1			3.4	8.6			5.1
	2.1	3.7	0.0		5.8			3.9	9.7			5.4
	2.4	4.3	0.0		6.6			3.9	10.6			5.1
	3.0 3.6	4.9 5.7	0.0 0.0		7.9 9.3			5.0 4.9	12.9 14.2	2.4	 2.1	6.0 4.5
	2.5	6.4	0.0		8.9			4.7	13.6	2.6	2.2	
	1.2	7.1	0.1		8.3			3.5	11.8	2.7	2.3	4.9
	1.1	7.7	0.1		8.9			3.8	12.6	2.7	2.5	
	1.3 1.4	8.0 8.5	0.0 0.0		9.3 9.9			3.5 4.4	12.8 14.4	2.5 2.9	2.4 2.8	4.9 5.7
	1.7	8.8	0.0		10.5			4.5	15.0	3.0	2.0	6.0
	1.8	7.6	0.0		9.4			3.3	12.7	2.2	2.1	4.3
	1.9	7.6	0.0		9.5			3.4	13.0	2.2	1.4	3.6
	2.2	8.8	0.0		11.0			3.6	14.7	2.1	1.4	3.5
	2.4 3.2	10.7 9.0	0.0 0.0		13.1 12.3			4.0 5.3	17.2 17.5	2.2 2.1	1.5 1.5	3.6 3.6
	3.2 3.6	9.0 8.1	0.0		12.3			5.3	17.5	2.1	1.5	3.6
f	3.5	8.4	0.1		12.0			6.3	18.2	2.2	1.4	3.6
f	3.5	8.6	0.1		12.2			6.7	18.9	2.1	1.5	3.6
-						(annual percer	tage change)					
	 30.3	 12.3	 -5.7		 17.7			 14.6	 16.5			 8.2
	22.0	8.5	-5.7		13.1			14.6	12.9			6.2
	12.6	6.9	67.7		9.2			15.4	11.6			8.6
	7.6	17.3	-6.6		13.5			14.2	13.8			7.2
	13.9	14.8	-0.9		14.4			0.2	8.7			-6.0
	25.2	16.0	13.9		19.2			25.8	21.7			17.8
	21.7 -31.8	14.9 13.3	1.0 27.0		17.4 -4.2			-1.1 -4.2	10.3 -4.2	 7.3	 3.0	-25.1 5.3
	-50.0	10.0	32.1		-6.5			-25.9	-13.2	2.5	4.3	3.3
	-8.1	9.1	0.9		6.5			7.8	6.9	1.8	12.3	6.6
	14.4	3.3	-15.9		4.6			-6.7	1.3	-6.5	-6.0	-6.2
	9.9	6.5	-3.6		7.0			27.0	12.4	15.5	16.3	15.9
	16.2 10.2	3.3 -13.7	1.1 -14.2		5.1 -9.9			1.6 -27.4	4.1 -15.2	4.1 -27.6	5.4 -29.6	4.8 -28.6
	6.8 13.6	-0.1 16.2	0.1 22.9		1.3 15.7			5.1 5.8	2.3 13.1	-0.2 -5.9	-32.0 2.7	-15.6 -2.5
	7.4	21.8	4.0		18.9			11.0	16.9	4.8	3.0	-2.3
	34.8	-15.7	1.7		-6.5			30.7	2.2	-3.2	1.3	-1.4
	12.8	-9.6	56.6		-3.5			1.6	-2.0	-1.9	-8.6	-4.7
f	-2.3	3.0	-14.2		1.3			16.5	6.1	5.0	2.3	3.9
f	-0.2	2.5	-1.5		1.7			7.3	3.6	-2.5	4.1	0.1
					(per	centage share of t	otal drug expe	enditure)				
-	10.9	24.5	0.2		35.6			23.4	59.0			41.0
	12.6	24.3	0.1		37.1			23.7	60.7			39.3
	13.9	23.9	0.1		38.0 37.6			24.2 25.3	62.2			37.8 37.2
	14.2 13.7	23.2 24.4	0.2 0.2		38.3			25.3	62.8 64.2			37.2
			0.2		42.4			25.1	67.5			32.5
	15.1 15.7	27.1 26.1	0.2		42.4			25.1	68.2			32.5
	19.3	30.3	0.2		49.7			26.2	75.9	12.9	11.2	
	13.4	34.9	0.2		48.6			25.6	74.1	14.1	11.8	25.9
	7.4	42.2	0.3		49.9			20.8	70.7	15.8	13.5	29.3
	6.3	43.1	0.3		49.7			21.0	70.7	15.1	14.2	
	7.3 7.1	45.0 42.2	0.2		52.5 49.5			19.8 22.1	72.3 71.7	14.3 14.5	13.5 13.8	27.7 28.3
	7.9	41.9	0.2		50.0			21.6	71.5	14.5	14.0	28.5
	10.8	44.6	0.2		55.6			19.3	74.9	13.0	12.1	25.1
	11.7	45.6	0.2		57.5			20.8	78.3	13.2	8.4	21.7
	12.2	48.3	0.2		60.7			20.1	80.8	11.3	7.9	19.2
	11.4	51.4 42.6	0.2		63.1 58.0			19.5 25.0	82.5 83.0	10.4 9.9	7.1 7.1	17.5 17.0
	15.1 17.5	42.6 39.5	0.2 0.4		58.0 57.4			25.0 26.1	83.0 83.4	9.9 10.0	7.1	17.0
f	16.2	38.5	0.3					28.7	83.7	9.9	6.4	16.3
					55.0							
f	15.7	38.3	0.3		54.2			29.9	84.2	9.4	6.5	15.8
ecast												

Table B.12.1-Part 2

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2006 (continued)

-		All Drugs			n Expenditure			Ith Expenditures	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
Year			(\$ millio	ns)			(perce	ntage share)	
1985	3.5	6.4	9.9	118.9	19.6	138.5	3.0	32.4	7.1
1986 1987	4.1 4.7	7.0 7.7	11.2 12.3	145.2 157.4	21.7 23.9	166.9 181.3	2.9 3.0	32.5 32.1	6.7 6.8
1988	5.1	8.5	13.6	183.9	23.9	211.2	2.8	31.2	6.5
1989	5.8	9.4	15.2	203.6	29.3	232.9	2.9	31.9	6.5
1990	6.6	9.0	15.7	218.5	28.4	246.8	3.0	31.9	6.4
1991	7.9 9.3	11.0 9.4	18.9 18.7	247.2 249.9	32.3 29.7	279.5 279.6	3.2 3.7	34.0	6.8 6.7
1992 1993	9.3	9.4	18.4	258.7	29.7	279.6	3.7	31.7 33.3	6.4
1994	8.3	8.4	16.7	259.5	26.6	286.2	3.2	31.5	5.8
1995	8.9	9.0	17.9	270.3	24.5	294.8	3.3	36.6	6.1
1996	9.3	8.4	17.7	265.4	26.6	291.9	3.5	31.6	6.1
1997 1998	9.9 10.5	10.1 10.5	20.1 20.9	280.9 301.3	26.2 26.2	307.1 327.5	3.5 3.5	38.7 40.0	6.5 6.4
1999	9.4	7.5	16.9	211.2	19.8	230.9	4.5	38.1	7.3
2000	9.5	7.0	16.6	194.9	20.5	215.4	4.9	34.4	7.7
2001	11.0	7.1	18.2	220.0	26.3	246.3	5.0	27.2	7.4
2002 2003	13.1 12.3	7.7 8.9	20.8 21.1	245.2 243.7	29.2 29.8	274.4 273.5	5.3 5.0	26.3 29.8	7.6 7.7
2003 2004	12.3	8.8	20.6	268.4	30.2	298.6	4.4	29.8	6.9
2005 f	12.0	9.8	21.8	275.4	32.8	308.2	4.4	30.0	7.1
2006 f	12.2	10.3	22.5	285.4	32.9	318.3	4.3	31.2	7.1
2000 1	12.2	10.3	(annual percenta		32.9	316.5	4.5	31.2	7.1
1985									
1986	17.7	10.5	13.1	22.2	10.5	20.5			
1987 1988	13.1 9.2	8.7 11.3	10.3 10.5	8.4 16.8	10.0 14.4	8.6 16.5			
1989	13.5	10.0	11.3	10.8	7.5	10.3			
1990	14.4	-3.4	3.4	7.3	-3.3	6.0			
1991	19.2	21.3	20.4	13.2	13.7	13.2			
1992	17.4	-14.2	-1.0	1.1	-7.9	0.1			
1993 1994	-4.2 -6.5	0.3 -11.2	-1.9 -8.9	3.5 0.3	-4.7 -6.1	2.7 -0.3			
1995	6.5	7.1	6.8	4.1	-7.8	3.0			
1996	4.6	-6.4	-0.9	-1.8	8.4	-1.0			
1997 1998	7.0 5.1	20.5 3.4	13.4 4.3	5.8 7.3	-1.5 0.0	5.2 6.6			
1999	-9.9	-28.1	-19.0	-29.9	-24.6	-29.5			
2000	1.3	-6.6	-2.2	-7.7	3.6	-6.7			
2001	15.7	1.5	9.7	12.9	28.4	14.4			
2002	18.9	7.6	14.4	11.4	11.2	11.4			
2003 2004	-6.5 -3.5	15.5 -0.9	1.6 -2.4	-0.6 10.1	2.0 1.4	-0.3 9.2			
2005 f	1.3	11.6	5.7	2.6	8.5	3.2			
2006 f	1.7	4.7	3.0	3.6	0.5	3.3			
		share of total drug							
1985	35.6	64.4	100.0						
1986	37.1	62.9	100.0						
1987	38.0	62.0	100.0						
1988 1989	37.6 38.3	62.4 61.7	100.0 100.0						
1990	42.4	57.6	100.0						
1991	41.9	58.1	100.0						
1992	49.7	50.3	100.0						
1993 1994	48.6 49.9	51.4 50.1	100.0 100.0						
1995 1996	49.7 52.5	50.3 47.5	100.0 100.0						
1997	49.5	50.5	100.0						
1998 1999	50.0 55.6	50.0 44.4	100.0 100.0						
2000	57.5	44.4	100.0						
2000 2001	60.7	42.5 39.3	100.0						
2002	63.1	36.9	100.0						
2003	58.0 57.4	42.0	100.0						
2004	57.4	42.6	100.0						
2005 f	55.0	45.0	100.0						
2006 f	54.2	45.8	100.0						
-Forecast									ce: CIHI, 2006

Table B.12.2–Part 1

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2006

			Public		Prescribe	ed Drugs	Private				Prescribed D e (Out-of-Po	
	Territorial	Federal _	Social Secu WCB	Drug Insurance	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
ear				Funds		(\$ per	capita)			Drugs		
985	19.87	44.58	0.30		64.76			42.52	107.28			74.63
986	25.75	49.79	0.29		75.83			48.45	124.28			80.32
987	31.22	53.68	0.30		85.21			54.27	139.47			84.79
988 989	34.75 36.51	56.71 64.93	0.50 0.46		91.96 101.90			61.91 69.02	153.87 170.93			91.01 95.30
990	40.26	72.19	0.44		112.88			66.93	179.82			86.68
991 992	48.72 57.90	80.93 90.80	0.48 0.48		130.14 149.18			81.44 78.63	211.58 227.81	38.63	33.63	98.76 72.26
993	38.77	101.02	0.60		140.39			73.95	214.34	40.71	34.01	74.73
994	18.92	108.39	0.77		128.08			53.43	181.52	40.69	34.62	75.30
995	17.01	115.69	0.76		133.46			56.36	189.82	40.52	38.04	78.56
996	19.17	117.78	0.63		137.58			51.79	189.37	37.33	35.24	72.58
997	21.03	125.16	0.60		146.79			65.59	212.38	43.00	40.90	83.91
998	24.63	130.34	0.62		155.58			67.20	222.79	45.15	43.48	88.63
999	44.84	185.89	0.87		231.61			80.63	312.24	54.01	50.56	104.57
000	48.07	186.46	0.88		235.41			85.11	320.51	54.09	34.51	88.60
001	54.18	215.04	1.07		270.29			89.29	359.58	50.51	35.15	85.66
002	57.23	257.78	1.10		316.11			97.51	413.62	52.08	35.62	87.71
003 004	75.76	213.32	1.09		290.18			125.17 125.40	415.36	49.52	35.45	84.96
	84.22	190.13	1.69		276.04				401.44	47.90	31.95	79.85
005 f	82.04	195.27	1.44		278.75			145.69	424.45	50.15	32.60	82.75
006 f	80.68	197.32	1.40		279.40			154.09	433.49	48.18	33.46	81.64
						(annual percer	tage change)					
985												
986	29.6	11.7	-6.3		17.1			14.0	15.8			7.6
987 988	21.2 11.3	7.8 5.6	6.3 65.8		12.4 7.9			12.0 14.1	12.2 10.3			5.6 7.3
989	5.1	5.6 14.5	-8.8		10.8			14.1	10.3			4.7
990	10.3	11.2	-4.0		10.8			-3.0	5.2			-9.1
991 992	21.0 18.8	12.1 12.2	10.2 -1.4		15.3 14.6			21.7 -3.4	17.7 7.7			13.9 -26.8
993	-33.0	11.3	24.8		-5.9			-6.0	-5.9	5.4	1.1	-20.0
994	-51.2	7.3	28.8		-8.8			-27.7	-15.3	-0.1	1.8	0.8
995	-10.1	6.7	-1.3		4.2			5.5	4.6	-0.4	9.9	4.3
996	12.7	1.8	-17.1		3.1			-8.1	-0.2	-0.4	-7.4	-7.6
997	9.7	6.3	-3.8		6.7			26.7	12.2	15.2	16.1	15.6
998	17.1	4.1	1.9		6.0			2.5	4.9	5.0	6.3	5.6
999	82.1	42.6	41.8		48.9			20.0	40.2	19.6	16.3	18.0
000	7.2	0.3	0.5		1.6			5.6	2.7	0.1	-31.7	-15.3
001	12.7	15.3	22.0		14.8			4.9	12.2	-6.6	1.9	-3.3
002	5.6	19.9	2.3		17.0			9.2	15.0	3.1	1.3	2.4
003	32.4	-17.2	-0.1		-8.2			28.4	0.4	-4.9	-0.5	-3.1
004	11.2	-10.9	54.3		-4.9			0.2	-3.3	-3.3	-9.9	-6.0
005 f	-2.6	2.7	-14.4		1.0			16.2	5.7	4.7	2.0	3.6
006 f	-1.7	1.0	-2.9		0.2			5.8	2.1	-3.9	2.6	-1.3
				(annual percentage	change in excess	of inflation in	the Canadian e	conomy)			
985												
986	26.8	8.9	-9.1		14.3			11.2	13.0			4.8
987 988	16.5	3.1	1.5 61.2		7.6 3.4			7.3 9.6	7.5			0.8 2.8
988 989	6.8 0.5	1.1 9.9	-13.4		3.4 6.2			9.6	5.8 6.5			2.8
990 991	7.2 18.3	8.1 9.4	-7.1 7.4		7.7 12.5			-6.1	2.2 14.9			-12.1
991	10.3	9.4 10.9	-2.6		12.5			18.9 -4.7	6.4			11.2 -28.1
993	-34.5	9.8	23.3		-7.3			-7.4	-7.4	4.0	-0.3	2.0
994	-52.3	6.2	27.7		-9.9			-28.8	-16.4	-1.2	0.7	-0.3
995	-12.4	4.4	-3.6		1.9			3.1	2.2	-2.7	7.6	2.0
996	11.0	0.1	-18.8		1.4			-9.8	-1.9	-9.5	-9.0	-9.3
997	8.7	5.3	-4.8		5.7			25.7	11.2	14.2	15.1	14.6
998	17.5	4.6	2.3		6.4			2.9	5.3	5.4	6.7	6.1
999	80.3	40.8	40.0		47.1			18.2	38.3	17.8	14.5	16.2
000	3.1	-3.8	-3.6		-2.5			1.4	-1.5	-4.0	-35.8	-19.4
001	11.4	14.0	20.6		13.5			3.6	10.8	-8.0	0.5	-4.7
002	4.6	18.9	1.3		16.0			8.2	14.0	2.1	0.3	1.4
003	29.5	-20.1	-3.0		-11.1			25.5	-2.5	-7.8	-3.4	-6.0
004	8.5	-13.6	51.6		-7.6			-2.5	-6.0	-6.0	-12.6	-8.7
	-5.3	0.0	-17.1		-1.7			13.5	3.1	2.0	-0.6	1.0
005 f												
005 f 006 f	-3.3	-0.6	-4.5		-1.4			4.2	0.5	-5.5	1.0	-2.9
	-3.3	-0.6	-4.5		-1.4			4.2	0.5	-5.5	1.0	-2.9

Table B.12.2–Part 2

Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2006 (continued)

_		All Drugs			Health Expenditure		Price Index – Canada	
	Public	Private	Total	Public	Private	Total		
ar			(\$ per ca	anita)			(1997 = 100)	
85	64.76	117.15	181.91	2,185.68	3 361.05	2,546.73	73.6	
86	75.83	128.77	204.59	2,655.45		3,052.14	75.6	
87	85.21	139.05	224.26	2,859.77		3,293.37	79.2	
88 89	91.96 101.90	152.93 164.33	244.89 266.23	3,302.40 3,570.18		3,792.49 4,084.51	82.8 86.6	
90 91	112.88 130.14	153.61 180.20	266.49 310.34	3,708.35 4,057.16		4,190.00 4,586.61	89.2 91.6	
92	149.18	150.89	300.07	4,004.30	476.22	4,480.52	92.8	
93 94	140.39 128.08	148.68 128.74	289.07 256.82	4,071.51 3,983.42		4,517.40 4,391.79	94.1 95.2	
95 96	133.46 137.58	134.92 124.36	268.38 261.95	4,060.01 3,927.17		4,428.49 4,320.58	97.4 99.0	
97	146.79	149.50	296.29	4,146.76		4,533.25	100.0	
98	155.58	155.83	311.42	4,484.12	2 389.81	4,873.92	99.6	
99	231.61	185.20	416.81	5,194.03	485.82	5,679.85	101.4	
00	235.41	173.70	409.11	4,812.89		5,318.24	105.5	
01 02	270.29 316.11	174.95 185.22	445.24 501.33	5,390.16 5,909.52		6,033.94 6,613.60	106.9 108.0	
102	290.18	210.14	500.32	5,909.52		6,475.34	108.0	
04	276.04	205.26	481.30	6,263.88		6,969.00	114.1	
005 f	278.75	228.44	507.20	6,408.00	762.66	7,170.66	117.2	
06 f	279.40	235.72	515.12	6,545.06		7,300.34	119.0	
			(a	nnual percentage ch	ange)			
85								
86 87	17.1 12.4	9.9 8.0	12.5 9.6	21.5		19.8 7.9	2.8 4.7	
187	7.9	10.0	9.0	15.5		15.2	4.7	
89	10.8	7.5	8.7	8.1		7.7	4.6	
90	10.8	-6.5	0.1	3.9	9 -6.4	2.6	3.0	
91	15.3	17.3	16.5	9.4		9.5	2.8	
92	14.6 -5.9	-16.3 -1.5	-3.3 -3.7	-1.0		-2.3	1.3	
193 194	-5.9 -8.8	-1.5	-3.7 -11.2	1. -2.2		0.8 -2.8	1.4 1.1	
95	4.2	4.8	4.5	1.9	9 -9.8	0.8	2.3	
96	3.1	-7.8	-2.4	-3.3	3 6.8	-2.4	1.7	
997	6.7	20.2	13.1	5.6		4.9	1.0	
98 99	6.0 48.9	4.2 18.8	5.1 33.8	8. ⁻ 15.8		7.5 16.5	-0.4 1.8	
000	1.6	-6.2	-1.8	-7.3		-6.4	4.1	
001	14.8	0.7	8.8	12.0		13.5	1.4	
02	17.0	5.9	12.6	9.6		9.6	1.0	
003	-8.2	13.5	-0.2	-2.4		-2.1	2.9	
004	-4.9	-2.3	-3.8	8.6	6 0.0	7.6	2.7	
005 f	1.0	11.3	5.4	2.3	3 8.2	2.9	2.7	
006 f	0.2	3.2	1.6	2.1	1 -1.0	1.8	1.6	
_		(annual percentag	ge change in excess of	inflation in the Cana	adian economy)			
185 186	 14.3	 7.1	 9.7	 18.7	 7 7.1	 17.0		
87	7.6	3.2	4.9	3.0		3.2		
88	3.4	5.5	4.7	11.0	D 8.5	10.6		
89	6.2	2.9	4.2	3.5	5 0.4	3.1		
90	7.7	-9.5	-2.9	3.0		-0.4		
91 92	12.5 13.4	14.5 -17.5	13.7 -4.6	6.0 -2.0		6.7 -3.6		
93	-7.3	-17.5	-4.0	-2.0		-0.6		
94	-9.9	-14.5	-12.3	-3.3		-3.9		
95	1.9	2.5	2.2	-0.4	4 -12.1	-1.5		
96	1.4	-9.5	-4.1	-4.9	9 5.1	-4.1		
97 98	5.7 6.4	19.2 4.7	12.1 5.5	4.6		3.9 8.0		
98 99	47.1	17.0	32.0	14.0		14.7		
00	-2.5	-10.3	-5.9	-11.4		-10.5		
01	13.5	-0.6	7.5	10.6	6 26.0	12.1		
02	16.0	4.9	11.6	8.0		8.6		
03 04	-11.1 -7.6	10.6 -5.0	-3.1 -6.5	-5.3		-5.0 4.9		
005 f	-1.7	8.6	2.7	-0.4		0.2		
005 f								
	-1.4	1.6	0.0	0.9	5 -2.6	0.2		
								Source: CI

Table B.13.1–Part 1

Expenditure on Drugs by Type, by Source of Finance, and as a Share of Public, Private and Total Health Expenditures, Nunavut, 1985 to 2006

			Public		Prescribe	a Drugs	Private				Prescribed E te (Out-of-Po	
Т	erritorial	Federal _	Social Secu WCB	rity Funds Drug Insurance Funds	Sub-Total Public	Insurers*	Out-of- Pocket	Sub-Total Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	Total Non-Pre Drugs
						(\$ mi						
	 1.0	 0.0	 0.0		 1.1			 1.3	2.4	 1.4	 1.3	
	1.2	0.2	0.0		1.4			1.5	2.8	1.5	0.9	
	1.2 1.5	0.4 0.8	0.0 0.0		1.7 2.4			1.5 2.1	3.2 4.5	1.4 1.5	1.0 1.0	
	2.1	4.1	0.0		6.3			3.3	9.6	1.4	1.0) :
	2.2	5.1	0.1		7.4			4.1	11.5	1.4	0.9	
	2.2	5.2	0.0		7.5			4.0	11.5	1.5	1.0) :
	2.3	5.4	0.0		7.7			4.3	12.0	1.5	1.0	
	2.0	0.4	0.0						12.0	1.5	1.0	· ·
						(annual percer	ntage change)					
	21.7 3.7	289.9 174.5	3.1 24.7		31.3 23.1			9.2 4.7	18.9 13.6	1.8 -4.2	-30.6 4.5	
	23.4	88.4	4.5		39.2			36.1	37.7	6.6	4.7	
	36.7	421.2	1.4		165.5			56.6	114.5	-3.6	0.9	
	6.3	22.9	57.0		17.5			24.9	20.1	-1.6	-8.3	-
	-0.1	2.6	-13.5		1.7			-2.2	0.3	5.0	3.3	
	3.5	2.5	-1.2		2.8			7.3	4.3	-2.7	3.5	-
					(per	centage share of t	otal drug expe	enditure)				
												-
	19.1	0.8	0.5		20.3			25.9	46.1	27.8	26.0	
	22.9 22.2	2.9 7.5	0.5 0.5		26.3 30.3			27.9 27.3	54.2 57.6	28.0 25.0	17.8 17.4	
	22.2	11.4	0.5		33.9			27.3	63.8	21.5	17.4	
	17.5	34.5	0.3		52.2			27.2	79.4	12.0	8.6	
	16.2	36.8	0.4		53.4			29.5	82.9	10.3	6.9	
	16.0	37.4	0.3		53.7			28.6	82.3	10.7	7.0	
	16.0	37.1	0.3		53.4			29.6	83.0	10.0	7.0	

Year 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1994 1995 1994	Public	All Drugs Private	Total (\$ millio	Public	alth Expenditure Private	Total		ugs in Public, Priva Health Expenditure Private	
985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1996 1997				Public	Private	Total	Public	Private	Total
985 986 987 988 989 990 991 992 993 994 995 994 995 996 997			(\$ millio						
986 987 988 989 990 991 992 993 994 995 994 995 996 997				ons)			(p	ercentage share)	
987 988 999 990 991 992 993 994 995 996 999									
988 989 990 991 992 993 994 995 996 997									
990 991 992 993 994 995 996 997									
1991 1992 1993 1994 1995 1996 1997									
1992 1993 1994 1995 1996 1997									
1994 1995 1996 1997									
1995 1996 1997									
1996 1997									
1997									
1999	1.1	4.1	5.2	133.6	9.0	142.5	0.8	46.0	3.6
2000 2001	1.4 1.7	3.9 3.9	5.3 5.6	159.2 173.7	9.2 10.6	168.4 184.2	0.9 1.0	42.0 37.1	3.1 3.0
2001	2.4	4.6	7.0	203.8	11.1	214.9	1.2	41.5	3.0
2003	6.3	5.7	12.0	279.2	13.2	292.4	2.3	43.5	4.1
2004	7.4	6.5	13.8	295.1	13.8	308.9	2.5	46.7	4.5
2005 f	7.5	6.5	14.0	298.2	14.1	312.3	2.5	45.7	4.5
2006 f	7.7	6.7	14.5 (annual percenta	295.7	14.9	310.6	2.6	45.4	4.7
1985									
1986									
1987 1988									
1989									
1990									
1991									
1992 1993									
1993									
1995									
1996									
1997 1998									
1999									
2000	31.3	-6.4	1.3	19.2	2.5	18.1			
2001	23.1	1.3	7.0	9.1	14.6	9.4			
2002 2003	39.2 165.5	17.7 24.6	24.2 72.4	17.3 37.0	5.0 19.1	16.6 36.1			
2004	17.5	12.3	15.0	5.7	4.4	5.6			
2005 f	1.7	0.2	1.0	1.0	2.4	1.1			
2006 f	2.8	4.4	3.5	-0.8	5.2	-0.6			
		e share of total drug		0.0	0.2	0.0			
1985				_					
1986									
1987 1988									
1989									
1990									
1991									
1992 1993									
1993									
1995									
1996									
1997 1998									
1999	20.3	79.7	100.0						
2000	26.3	73.7	100.0						
2001	30.3	69.7	100.0						
2002	33.9	66.1	100.0						
2003 2004	52.2 53.4	47.8 46.6	100.0 100.0						
2005 f	53.7	46.3	100.0						
2006 f	53.4	46.6	100.0						

DRUG EXPENDITURE IN CANADA DATA TABLES

Table B.13.2—Part 1 Expenditure on Drugs per Capita by Type, by Source of Finance, and Public, Private and Total Health Expenditures, Nunavut, 1985 to 2006 Prescribed Drugs

			Public		Prescribe	ed Drugs	Private			Non-Prescribed Private (Out-of-P			
Т	erritorial	Federal _	Social Secu WCB	urity Funds Drug Insurance Funds	Sub-Total Public	Insurers* (\$ per)	Out-of- Pocket capita)	Sub-Total Private	Total Prescribed Drugs		Over- the- Counter Drugs	Personal Health Supplies	Total Non-Pres Drugs
	36.87	1.47	0.87		39.22			49.98	89.20		53.77	50.33	104.
	43.76	5.60	0.88		50.24			53.24	103.47		53.39	34.07	87.
	44.37	15.02	1.07		60.46			54.52	114.97		50.00	34.80	84.
	53.59	27.68	1.10		82.36			72.60	154.96		52.15	35.67	87.
	72.19	142.15	1.09		215.44			112.05	327.49		49.52	35.45	84.
	75.43	171.78	1.69		248.89			137.53	386.42		47.90	31.95	79.
	74.57	174.43	1.44		250.45			133.12	383.56		49.77	32.67	82.
	76.66	177.56	1.42		255.64			141.83	397.47		48.09	33.57	81
						(annual percer	tage change)						
	18.7	280.3	0.5 22.0		28.1			6.5	16.0		-0.7	-32.3	-10
	1.4 20.8	168.4 84.3	22.0		20.3 36.2			2.4 33.2	11.1 34.8		-6.3 4.3	2.2 2.5	
	34.7	413.6	-0.1		161.6			54.3	111.3		-5.0	-0.6	
	4.5	20.8	54.3		15.5			22.7	18.0		-3.3	-9.9	-1
	-1.1	1.5	-14.4		0.6			-3.2	-0.7		3.9	2.2	:
	2.8	1.8	-1.8		2.1			6.5	3.6		-3.4	2.8	-
				(annual percentage	change in excess	of inflation in	une Canadian e	conomy)				
													-
													-
													-
													-
													-
	14.6		-3.6		24.0			2.4	11.9		-4.8	-36.4	-2
	0.0	167.0	20.6		19.0			1.0	9.8		-7.7	0.8	
	19.8	83.3	1.3		35.2			32.2	33.8		3.3	1.5	
	31.8 1.8	410.7 18.1	-3.0 51.6		158.7 12.8			51.4 20.0	108.4 15.3		-7.9 -6.0	-3.5 -12.6	
	-3.8		-17.1		-2.0			-5.9	-3.4		1.2	-0.4	
	1.2		-3.4		0.5			4.9	2.0		-5.0	1.2	

				avut, 1985 to	2000 (00	GDP Implicit
Public	All Drugs Private	Total	He Public	ealth Expenditure Private	Total	Price Index – Canada
		(\$ per ca	apita)			(1997 = 100)
						73.6
						75.6
						79.2 82.8
						86.6
						89.2
						91.6 92.8
						94.1
						95.2
						97.4 99.0
						100.0
 39.2	 2 154.08	 193.30	4,979.28	335.22	 5,314.50	99.6 101.4
50.2 60.4		190.93 199.77	5,787.57 6,175.93	335.29 375.90	6,122.86 6,551.84	105.5 106.9
82.3	160.42	242.78	7,089.84	386.25	7,476.09	108.0
215.4 248.8		412.45 466.28	9,572.75 9,945.50	453.33 465.38	10,026.08 10,410.88	111.1 114.1
240.0		466.00	9,942.66	403.38	10,414.15	117.2
255.6	223.49	479.13 (a	9,791.74 Innual percentage chang	492.80	10,284.54	119.0
						2.8 4.7
						4.5
						4.6
						3.0 2.8
						2.8
						1.4
						1.1
						2.3 1.7
						1.0
						-0.4 1.8
28		-1.2	16.2	0.0	15.2	4.1
28		4.6	6.7	12.1	7.0	4.1
36	.2 15.1	21.5	14.8	2.8	14.1	1.0
161 15		69.9 13.0	35.0 3.9	17.4 2.7	34.1 3.8	2.9 2.7
	.6 -0.8	-0.1	0.0	1.3	0.0	2.7
2		2.8 tage change in excess of	-1.5 inflation in the Canadia	4.5 In economy)	-1.2	1.6
24 19		-5.3 3.3	12.1 5.4	-4.1 10.8	11.1 5.7	
35		3.3 20.5	5.4 13.8	1.8	13.1	
158 12		67.0 10.4	32.1 1.2	14.5 0.0	31.2	
					1.1	
-2		-2.7	-2.7	-1.3	-2.6	
0	.5 2.1	1.2	-3.1	2.9	-2.8	

Series C

International Comparisons

Table C.1

The Share of Pharmaceutical Goods* in Total Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2003, 2004

1985		2003		2004	
	(%)		(%)		(%)
Korea	32.7	Slovak Republic	38.5	Poland	29.6
Portugal	25.4	Poland	30.3	Korea	27.4
Spain	20.3	Korea	27.6	Portugal	23.1
Japan	18.0	Spain	22.8	Spain	22.8
lceland	16.6	Portugal	22.5	Italy	21.1
France	16.2	Italy	21.6	Mexico	20.9
Belgium	15.7	Mexico	21.5	France	18.9
Luxembourg	14.7	Japan	18.9	Canada	17.7
United Kingdom	14.1	France	18.8	Greece	17.4
Germany	13.8	Greece	17.1	Finland	16.3
New Zealand	13.3	Canada	17.0	Iceland	14.8
Turkey	13.0	Finland	16.0	Germany	14.1
Switzerland	11.3	Germany	14.6	Austria	13.0
Ireland	9.9	Iceland	14.5	Australia	12.8
Finland	9.7	Australia	13.3	Ireland	12.4
Canada	9.6	Austria	13.1	Sweden	12.3
Netherlands	9.3	Sweden	12.6	United States	12.3
Norway	9.1	United States	12.4	Switzerland	10.4
United States	8.9	Ireland	11.8	Norway	9.5
Australia	8.1	Belgium	11.3	Denmark	9.4
Sweden	7.0	Switzerland	10.5	Luxembourg	8.5
Denmark	6.6	Denmark	10.0		
		Luxembourg	9.4		
		Norway	9.2		

*The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium:	Includes therapeutic devices.
Germany:	Includes therapeutic means and methods (external applications, physiotherapy, speech therapy, occupational therapy) and special devices such as hearing and visual aids and orthopedic devices.
Ireland:	Includes therapeutic goods.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.
Source: OECD Health Data 2006, and IRDES, Paris.	October 2006 version, Organisation for Economic Co-operation and Development

Table C.2

The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-durables*, OECD Reporting Countries, 1985, 2003, 2004

1985		2003		2004	
	(%)		(%)		(%)
Turkey	90.0	Ireland	86.2	Ireland	88.7
Luxembourg	86.0	Luxembourg	84.1	Luxembourg	83.7
New Zealand	80.4	Slovak Republic	82.7	Greece	77.9
Germany	71.9	Greece	77.6	Spain	72.3
Sweden	70.1	Belgium	77.4	Austria	70.7
France	67.1	Germany	73.9	France	70.6
Portugal	64.7	Spain	71.8	Sweden	70.0
United Kingdom	64.1	Austria	71.0	Germany	69.7
Netherlands	63.3	Sweden	70.4	Switzerland	67.2
Spain	62.5	France	70.3	Norway	60.2
Iceland	61.9	Japan	68.7	Iceland	59.2
Ireland	60.7	Switzerland	66.1	Portugal	58.6
Japan	60.6	Norway	58.8	Australia	56.1
Belgium	51.0	Portugal	58.4	Finland	56.0
Australia	46.5	Iceland	58.3	Denmark	55.9
Denmark	45.5	Denmark	57.3	Italy	50.5
Finland	44.5	Australia	56.1	Korea	48.0
Norway	43.2	Finland	53.7	Canada	37.8
Canada	29.4	Italy	49.1	Poland	36.5
Korea	11.8	Korea	45.1	United States	24.4
United States	9.3	Poland	40.5	Mexico	11.6
		Canada	38.1		
		United States	23.2		
		Mexico	10.4		

*The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium:	Includes therapeutic devices.
Germany:	Includes therapeutic means and methods (external applications, physiotherapy, speech therapy, occupational therapy) and special devices such as hearing and visual aids and orthopedic devices.
Ireland:	Includes therapeutic goods.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.
Source: OECD Health Data 2006, and IRDES, Paris.	October 2006 version, Organisation for Economic Co-operation and Development

Table C.3

The Share of Pharmaceutical Goods* in Public Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2003, 2004

1985		2003		2004	
	(%)		(%)		(%)
Portugal	30.1	Slovak Republic	36.0	Greece	25.7
Turkey	23.1	Greece	24.7	Korea	25.5
Spain	15.7	Korea	24.5	Hungary	24.6
Japan	15.4	Spain	23.3	Spain	23.3
Luxembourg	14.2	Hungary	22.5	Portugal	18.5
France	13.8	Portugal	17.9	France	17.1
Germany	12.8	Poland	17.5	Poland	15.8
New Zealand	12.3	France	16.8	Italy	14.2
Iceland	11.8	Japan	15.9	Ireland	13.8
Korea	10.8	Italy	14.4	Austria	13.0
United Kingdom	10.5	Germany	13.7	Germany	12.8
Netherlands	8.3	Austria	13.2	Switzerland	12.0
Ireland	7.9	Ireland	13.1	Finland	11.9
Finland	5.5	Belgium	12.3	Australia	10.6
Sweden	5.4	Switzerland	11.8	lceland	10.5
Australia	5.3	Finland	11.3	Sweden	10.2
Norway	4.6	Australia	11.1	Canada	9.6
Canada	3.8	Sweden	10.4	Luxembourg	7.9
Denmark	3.5	Iceland	10.1	Norway	6.8
United States	2.1	Canada	9.3	United States	6.7
		Luxembourg	8.8	Mexico	5.2
		Norway	6.5		
		United States	6.5		
		Mexico	5.1		

*The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Belgium:	Includes therapeutic devices.
Germany:	Includes therapeutic means and methods (external applications, physiotherapy, speech therapy, occupational therapy) and special devices such as hearing and visual aids and orthopedic devices.
Ireland:	Includes therapeutic goods.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.
Source: OECD Health Data 2006, and IRDES, Paris.	October 2006 version, Organisation for Economic Co-operation and Development

Appendix

Comparison of Provincial and Territorial Drug Subsidy Programs

Comparison of Provincial and Territorial Drug Subsidy Programs

Table 8 gives an overview of provincial and territorial drug subsidy programs. The table was verified for accuracy with provincial/territorial programs. Information is also available from the following websites:

British Columbia Pharmacare www.healthservices.gov.bc.ca/pharme

Alberta Prescription Drug Program www.health.gov.ab.ca/ahcip/ahcip_prescription.html

Saskatchewan Drug Plan www.health.gov.sk.ca/ps_drug_plan.html

Manitoba Pharmacare Program www.gov.mb.ca/health/pharmacare/index.html

Ontario Drug Benefits www.health.gov.on.ca/english/providers/program/drugs/odbf_mn.html

Régime général d'assurance-médicaments du Québec (RGAM) www.ramq.gouv.qc.ca/en/citoyens/assurancemedicaments/index.shtml

New Brunswick Prescription Drug Program www.gnb.ca/0212/intro-e.asp

Nova Scotia Pharmacare www.gov.ns.ca/health/pharmacare/default.htm

Prince Edward Island Pharmacy Services www.gov.pe.ca/infopei/Government/GovInfo/Health/Pharmacy Services

Newfoundland and Labrador Prescription Drug Program www.gov.nf.ca/health/nlpdp

Yukon Pharmacare www.hss.gov.yk.ca/programs/insured hearing/pharmacare/

Northwest Territories

www.hlthss.gov.nt.ca/content/About HSS/hss system.asp

Nunavut Planning Commission www.gov.nu.ca/hsssite/hssmain.shtml

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
British Columbia	Fair Pharmacare Enhanced Assistance	All families in which one or more family members were born before 1940 and are not covered by other plans	None	Based on family net income: \$0 < \$33K 1% \$33K to \$50K 2% > \$50K	Pharmacare pays 75%	1.25% < \$33K 2% \$33K to \$50K 3% > \$50K
	Fair Pharmacare	Families in which all family members were born in 1940 or later and are not covered by other plans	None	Based on family net income: \$0 < \$15K 2% \$15K to \$30K 3% > \$30K	Pharmacare pays 70%	2% <\$15K 3% \$15K to \$30K 4% >\$30K
	Pharmacare Plan B	Residents of long-term care facilities	None	None	None	N/A
	Pharmacare Plan C	B.C. Income Assistance Benefits recipients	None	None	None	N/A
	Pharmacare Plan D	Cystic fibrosis patients	None	None	None	N/A
	Pharmacare Plan F	At Home program for severely handicapped children	None	None	None	N/A
	Pharmacare Plan G	Clients of Mental Health Service Centres meeting low-income criterion	None	None	None	N/A
	Pharmacare Plan P	Palliative residents treated at home	None	None	None	N/A
Alberta	Seniors	Seniors aged 65 and older and their eligible dependants	None	None	30% of prescription to a max of \$25 per prescription plus additional cost if higher- cost product is selected	N/A
	Widows	Residents aged 55 to 64 who qualify for Alberta Widows' Pension and eligible dependants	None	None	30% of prescription to a max of \$25 per prescription plus additional cost if higher- cost product is selected	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Alberta (cont'd)	Palliative	Palliative residents treated at home	None	None	30% of prescription to a max of \$25 per prescription plus additional cost if higher- cost product is selected	The maximum amount palliative patients pay out of pocket is \$1,000
	Group 1	A universal plan available to all residents under the age of 65	Quarterly (3-month) rate is \$61.50 for singles and \$123 for families. Subsidized rates are available at \$43.05 for singles and \$86.10 for families.	None	30% of prescription to a max of \$25 per prescription plus additional cost if higher- cost product is selected	N/A
	Province-wide services	Residents with specific conditions may be eligible for high-cost drugs, mostly transplant and HIV drugs	None	None	None	N/A
	Income Support	Residents receiving social assistance and eligible dependants	None	None	\$2 per prescription for first three prescriptions each month	N/A
	Assured Income for the Severely Handicapped (AISH)	Residents receiving AISH (an income support program for adults with a permanent disability that severely impairs their ability to earn a living) and eligible dependants	None	None	\$2 per prescription for first three prescriptions each month	N/A
	Alberta Adult Health Benefit	Qualified clients leaving Income Support for work	None	None	\$2 per prescription for first three prescriptions each month	N/A
	Alberta Child Health Benefit	Children in low- income families	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Saskatchewan	Saskatchewan Drug Plan	All residents with Saskatchewan health coverage	None	Income-tested (annual threshold based on 3.4% of adjusted family income)	Income-tested (based on benefit drug costs, to help spread cost out evenly over the year)	N/A
		Seniors receiving the Saskatchewan Income Plan supplement or receiving the federal Guaranteed Income Supplement and residing in a special care home (automatically receive this deductible and co-pay but may also apply for income-tested coverage)	None	\$100 semi- annual family deductible	35% consumer co-payment after deductible has been paid	N/A
		Seniors receiving the Guaranteed Income Supplement and living in the community (automatically receive this deductible and co-pay but may also apply for income-tested coverage)	None	\$200 semi- annual family deductible (may apply for income- tested coverage)	35% consumer co- payment after deductible has been paid	N/A
	Emergency Assistance Program	Residents who require immediate treatment with covered prescription drugs and are unable to cover their share of the cost. This is a one-time benefit, and individuals are encouraged to apply for income- tested coverage for future assistance.	None	None	The level of assistance provided is in accordance with the consumer's ability to pay	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Saskatchewan (cont'd)	Family Health Benefits	Eligibility is established by the Department of Social Services, based on the number of children in the family and the family's annual income (automatically receive this deductible and co-pay but may also apply for income-tested coverage) Persons	None	\$100 semi- annual family deductible	No charge for benefit prescriptions for children; 35% consumer co- payment after deductible has been paid for adult benefit prescriptions	N/A
	Supplementary Health	nominated by Saskatchewan Social Services for special coverage, including persons on Social Assistance, wards, inmates, etc.	None	None	prescription (some drugs covered at no charge; individuals under 18 and certain other categories receive benefit prescriptions at no charge)	N/A
	Saskatchewan Aids to Independent Living (SAIL)	Persons registered under the following SAIL programs receive formulary and approved non-formulary drugs at no charge: Paraplegia Program, Cystic Fibrosis Program and Chronic End Stage Renal Disease Program	None	None	None	N/A
	Drug Plan Palliative Care Program	Residents who are in the late stages of a terminal illness	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Manitoba	Pharmacare	All provincial residents who are eligible for benefits under <i>The Prescription</i> <i>Drug Cost</i> <i>Assistance Act</i>	None	Based on total adjusted family income; 2.56% of < = \$15,000; 3.83% of \$15,000- \$40,000; 4.41% of \$40,000- \$75,000; 5% of >\$75,000; 5% of >\$75,000; credit of \$3,000 for a spouse and each dependent under 18 years; minimum of \$100 deductible is applicable to everyone	None	N/A
	Employment and Income Assistance Program	Individual Manitobans that are receiving drug benefits pursuant to the Employment and Income Assistance Program	None	None	None	N/A
	Personal Care Home	Manitoba residents of Personal Care Homes	None	None	None	N/A
	Palliative Care	Residents who are terminally ill and wish to remain at home	None	None	None	N/A

	1			(00110.)		B.4
Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Ontario	Ontario Drug Benefit Program	Seniors (aged 65 and older)	None	\$100	After deductible, up to \$6.11 per prescription	N/A
		Residents of long-term care facilities	None	None	Up to \$2 per prescription	N/A
		Residents of homes for special care	None	None	Up to \$2 per prescription	N/A
		Residents receiving professional services under the home care program	None	None	Up to \$2 per prescription	N/A
		Residents receiving social assistance	None	None	Up to \$2 per prescription	N/A
	Trillium Drug Program	Residents with high drug costs in relation to income	None	Income-based	Up to \$2 per prescription	N/A
	Special Drugs Program	Residents with valid Ontario Health Insurance. Coverage is product-specific for a limited number of diseases or conditions.	None	None	None	N/A
Quebec	Régime général d'assurance- médicaments du Québec (RGAM)	Employment assistance (welfare) recipients (EAR) and other holders of a claim slip	None	\$8.33 per month	25% of prescription costs	\$16.66 per month (no deductible or co-pay for EAR with severe employment constraints)
		Seniors (65 and over) receiving at least 94% of the maximum GIS	None	\$8.33 per month (not applicable for seniors who receive the maximum GIS [100%])	25% of prescription costs (not applicable for seniors who receive the maximum GIS [100%])	\$16.66 per month (not applicable for seniors who receive the maximum GIS [100%])
		Seniors (65 and over) receiving less than 94% of the maximum GIS (partial GIS)	\$0 to \$538 per adult per year, depending on income ^{xxix}	\$12.10 per month	29% of prescription costs	\$47.51 per month

xxix. Although, in theory, the maximum premium is \$538, the highest premium actually paid by people in this beneficiary group is \$20, because it depends on income.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Quebec (cont'd)		Seniors (65 and over) without GIS	\$0 to \$521 per adult per year, depending on income	\$12.10 per month	29% of prescription costs	\$73.42 per month
		General clientele (residents under 65 without access to a group plan)	\$0 to \$521 per adult per year, depending on income	\$12.10 per month	29% of prescription costs	\$73.42 per month
New Brunswick	Prescription Drug Program— Plan A	Seniors with GIS	None	None	\$9.05 for each prescription	\$250.00
		Seniors without GIS who qualify for benefits based on an annual income as follows: a single senior with an annual income of \$17,198 or less; a senior couple (both age ≥ 65) with a combined annual income of \$26,955 or less; a senior couple with one spouse under 65, with a combined annual income of \$32,390 or less	None	None	\$15 per prescription	N/A
	Prescription Drug Program— Plan B	Cystic fibrosis patients or patients with juvenile or infant sclerosis of the pancreas	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan E	Individuals residing in a licensed residential facility who hold a valid health card for prescription drugs issued by the Department of Family and Community Services	None	None	\$4 for each prescription	\$250

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
New Brunswick (cont'd)	Prescription Drug Program— Plan F	Individuals holding a valid health card for prescription drugs issued by the Department of Family and Community Services	None	None	\$4 per prescription for adults (18 and over) and \$2 for children (under 18 years)	\$250 per family
	Prescription Drug Program— Plan G	Special-needs children and children under the care of the Minister of Family and Community Services	None	None	None	N/A
	Prescription Drug Program— Plan H	Residents in possession of a prescription written by a neurologist for the medications Avonex, Rebif, Betaseron or Copaxone are eligible to apply for assistance	\$50 yearly registration fee	None	Income-tested (ranges from 0 to 100%)	N/A
	Prescription Drug Program— Plan R	Organ-transplant recipients who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan T	Individuals with growth hormone deficiency who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan U	Individuals who are HIV positive and are registered with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan V	Individuals who reside in a registered nursing home	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Nova Scotia	Seniors Pharmacare Program	Seniors (65 and older) receiving GIS and covered by Medical Services Insurance (MSI) and not having coverage through Veterans Affairs Canada, First Nations and Inuit Health or a private drug plan	None	None	33% prescription cost (\$30 maximum, \$3 minimum)	\$360
		Seniors (65 and older) not receiving GIS and covered by MSI and not having coverage through Veterans Affairs Canada, First Nations and Inuit Health or a private drug plan	Up to \$400 per year	None	33% prescription cost (\$30 maximum, \$3 minimum)	\$360
	Department of Community Services Programs	Eligible clients and their dependents in receipt of Income Assistance, any client and/or dependent having access to another drug plan, be it from a public or private entity, will be required to use that plan and will not be eligible for the pharmacare program	None	None	All income- assistance clients and dependents are required to co-pay a flat fee of \$5 per prescription, unless the client or dependent is eligible for co-pay exemption	N/A
	Drug Assistance for Cancer Patients	Residents having a gross family income no greater than \$15,720 per year and not eligible for coverage under other drug programs	None	None	None	N/A
	Multiple Sclerosis Drug Funding Assistance	Residents who meet established MS criteria and who do not have other drug coverage	None	None	\$9.35 per prescription	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Nova Scotia (cont'd)	Nova Scotia Diabetes Assistance Program	Residents under 65 with a valid Nova Scotia Health Card and who do not have drug coverage through Veterans Affairs Canada, First Nations and Inuit Health or any private drug plans that cover diabetes supplies, who have a confirmed diagnosis of diabetes	None	Income-based	20% of the total prescription cost	N/A
Prince Edward Island	Seniors Drug Cost Assistance Plan	Seniors 65 years of age or older and eligible for P.E.I. Medicare	None	None	First \$11 of the medication cost plus the pharmacy professional fee for each prescription	N/A
	Children-In- Care/Financial Assistance Program	Persons eligible under the <i>Welfare</i> <i>Assistance Act</i> and persons in the temporary or permanent care of the Director of Child Welfare	None	None	None	N/A
	Family Health Benefit Program	Families eligible for P.E.I. Medicare, with one or more children under 18 years of age, a total annual net family income of \$20,000 or less, and approved by the program	None	None	The pharmacy professional fee, \$7.5 for each prescription	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Prince Edward Island (cont'd)	Erythropoietin Program	Persons eligible for P.E.I. Medicare who have been diagnosed with chronic renal failure or are receiving kidney dialysis and who do not have any other drug insurance	None	None	None	N/A
	Diabetes Control Program	Persons with diabetes eligible for P.E.I. Medicare and who are registered with the program	None	None	Insulin: \$10 per 10 mL vial of insulin or box of 1.5 mL insulin cartridges; \$20 per box of 3.0 mL insulin cartridges. Oral Medications and Urine Testing Materials: \$11 per prescription. High-Cost Diabetes Medications: An income- based portion of the medication plus the dispensing fee for each high-cost medication obtained.	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Prince Edward Island (cont'd)	High Cost Drugs Program	Persons eligible for P.E.I. Medicare and approved for coverage of one or more of the medications included in the program.	None	None	Income-tested co-pay plus the pharmacy professional fee for each prescription	N/A
	Community Mental Health Program	Approved long- term psychiatric patients living in the community	None	None	None	N/A
	Sexually Transmitted Diseases (STD) Program	Persons diagnosed with sexually transmitted disease or identified contacts of a person with a sexually transmitted disease	None	None	None	N/A
	Institutional Pharmacy/ Nursing Home Program	Residents in private nursing homes eligible for coverage under the Welfare Assistance Act and regulations	None	None	None	N/A
	Disease-Specific Programs (e.g. AIDS/HIV, cystic fibrosis, growth hormone, hepatitis, tuberculosis, hairy cell leukemia, AIDS- related Kaposi's sarcoma, basal cell carcinoma, and transplant drug programs delivered through the provincial pharmacy)	Persons diagnosed with specific medical conditions or at risk for exposure to communicable diseases	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Prince Edward Island (cont'd)	Quit-Smoking Program	Persons eligible for P.E.I. Medicare and who have registered with the program	None	None	None	N/A
	Nutrition Program	Children and high-risk pregnant women diagnosed with a nutritional deficiency	None	None	None	N/A
Newfoundland and Labrador	The Senior Citizens Drug Subsidy Program	Seniors (65 and older) who are in receipt of the Guaranteed Income Supplement and who are registered for the Old Age Security benefits	None	None	Mark-up and professional fee for identified benefits	N/A
	The Income Support Program	Residents of the province who qualify for full benefit coverage under the Department of Humans Resources and Employment	None	None	None	N/A
		Residents who, due to the high cost of their medications, may qualify for drug- card-only benefits	None	None	None	N/A
	The Special Needs Program	Residents with cystic fibrosis or growth hormone deficiency	None	None	None, for identified benefits	N/A
Yukon Territory	Pharmacare	Seniors 65 years of age or older (and seniors' spouses aged 60 years and older) registered with Yukon Health Care Insurance Plan (YCHCIP) and not having coverage through First Nations and Inuit Health; Program may also include clients receiving palliative care	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Yukon Territory (cont'd)	Chronic Disease Program	Residents who have a chronic disease or a serious functional disability as provided under the Chronic Disease and Disability Benefits regulations and not having coverage through First Nations and Inuit Health (residents must use private insurance plans first); Program may also include clients receiving palliative care	None	Maximum \$250 per individual and \$500 per family (deductible may be waived, depending on income)	None	N/A
	Children's Drug and Optical Program	Children under the age of 19 years from low- income families and not having coverage through First Nations and Inuit Health	None	Maximum \$250 per child and \$500 per family (deductible may be waived, depending on income)	None	N/A
Northwest Territories	Extended Health Benefits Program for Specified Diseases	Resident, non- native or Métis, and have a specified disease condition	None	None	None	N/A
	Seniors' Benefit program	Métis and non- native residents who are 60 years of age and older	None	None	None	N/A
	Metis Health Benefits Program	Eligible Métis 59 years old and younger	None	None	None	N/A
	Indigent Health Benefits Program	Indigent individuals or families resident of the Northwest Territories, who meet the eligibility requirements according to the Indigent Health Benefits Policy	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Co-Pay	Maximum Annual Co-Pay
Nunavut	Extended Health Benefits Program	All Métis and non-Aboriginal residents, including seniors, who have a specific chronic condition or have reached the age of 60	None	None	None	N/A
	Indigent Health Benefits Program	All residents who do not have access to other programs	None	None	None	N/A

REFERENCE LIST

- 1. R. J. Romanow, *Building on Values: The Future of Health Care in Canada* (Saskatoon: Commission on the Future of Health Care in Canada, 2002).
- 2. Canadian Institute for Health Information, *National Health Expenditure Trends, 1975–2006* (Ottawa: CIHI, 2006).
- Health Canada, Non-Insured Health Benefits Program, Annual Report 2004/2005, (Ottawa: 2005).
- 4. S. Morgan, "Sources of Variation in Provincial Drug Spending," *Canadian Medical Association Journal*, 170 (3) (2004): pp. 329–330.
- 5. S. Jacobzone, Organisation for Economic Co-operation and Development, *Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals*, Labour Market and Social Policy; Occasional Papers, No. 40, (Paris: April 2000).
- 6. Natalie Zifonun, *SHA-Based Health Accounts in 13 Countries: Country Studies—Germany— National Health Accounts 2001* (OECD, August 17, 2004).
- M. Aserud et al, *Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing and Purchasing Policies (Review)*, The Cochrane Collaboration, (The Cochrane Library: John Wiley & Sons, Ltd., 2006. Issue 4), pp. 1–66, Cochrane Library Number CD005979.
- S. Morgan et al, "'Breakthrough' Drugs and Growth in Expenditure on Prescription Drugs in Canada," *British Medical Journal* 331, 7520 (October 8, 2005): pp. 815–16, [online], cited February 8, 2007, from <<u>http://www.pubmedcentral.nih.gov/</u> articlerender.fcgi?artid=1246080>, catalogue no. 38582.703866.
- Patented Medicine Prices Review Board, Patented Medicine Prices Review Board 2005 Annual Report (Ottawa: Patented Medicine Prices Review Board, 2005): pp. 1–64, [online], cited April 2005, from http://www.pmprb-cepmb.gc.ca/CMFiles/PMPRB-AR-EN38HAP-6122006-3172.pdf>.
- 10. Z. Karaca and S. Wiggins, *The Impacts of Break-Through Drug Classes on Total Health Expenditures: Empirical Evidence from the 1996–2001 Medical Expenditure Panel Surveys*, eds, Z. Karaca and S. Wiggins (Texas: A&M University, November 11, 2006): pp. 1–40, [online], cited February 14, 2007, from http://ssrn.com/abstract=947603, catalogue no. 947603.
- 11. F. R. Lichtenberg, "Are The Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS," *Health Affairs* 20, 5, (September/October 2001): pp. 241–251.
- 12. Canadian Cancer Society, A National Home Care Program, [online], cited February 9, 2007, from <<u>http://www.cancer.ca/ccs/internet/standard/</u> 0,3182,3172 335445 langld-en,00.html>.
- 13. Statistics Canada, Demography Division, *Annual Demographic Statistics 2005* (Ottawa: Statistics Canada, March 2006), catalogue no. 91-213-XIB.
- 14. S. Morgan, "Drug Spending in Canada: Recent Trends and Causes," *Medical Care* 42, 7 (July 2004): pp. 635–642, ISSN: 0025-7079/04/4207-0635.
- 15. B. Mintzes et al, "Volume IV: Pills, Persuasion and Public Health Policies," in An Assessment of the Health System Impacts of Direct-to-Consumer Advertising of Prescription Medicines (DTCA), eds. B. Mintzes, A. Kazanjian, K. Bassett, J. Lexchin (Report of an Expert Survey on Direct-to-Consumer Advertising of Prescription Drugs in Canada, the United States and New Zealand) (Vancouver, B.C., Health Policy and Research Unit, Centre for Health Services and Policy Research, June 2001), pp.1–48, [online], cited February 14, 2007, from <<u>http://www.chspr.ubc.ca/hpru/pdf/dtca-v4-expertsurvey.pdf</u>>, catalogue no. HPRU 02:4D.
- 16. Statistics Canada, *Guide to the Income and Expenditure Accounts*, catalogue 13-603E, 1996, pp. 137 and 139.
- 17. OECD Health Data 2006 (Paris: OECD, 2006).

^{18.} Statistics Canada, *Family Expenditure in Canada*, Periodical, Ottawa catalogue number 65-555-XPB.

^{19.} Statistics Canada, *Your Guide to the Consumer Price Index*, (Ottawa: Statistics Canada, 1996), pp. 7–9, [online], cited February 9, 2007, from <<u>http://www.statcan.ca/english/sdds/document/</u>2301_D6_T9_V1_E.pdf>, catalogue number 62-557-XPB.

